#version: 0.2
t h
i n
t i
r e
a n
th e</w>
e r
e n
o n
o f</w>
a r
e d</w>
r o
o n</w>
o r
i n</w>
i t
o u
a t
i s</w>
s t
an d</w>
a l
t o</w>
o r</w>
a ti
in g</w>
a c
d i
e c
e s
e r</w>
a s
a l</w>
e s</w>
a t</w>
u s
i l
o m
e l
i c
i s
a s</w>
en t
l e
s u
e n</w>
n o
a n</w>
b e</w>
s i
p ro
o l
v e</w>
T h
o s
f or</w>
a b
c on
w h
w it
d u
wit h</w>
l y</w>
no t</w>
m e
d e
en t</w>
h a
ati on</w>
ar e</w>
th at</w>
i m
ti on</w>
l o
b e
a m
r i
v er
a d
Th e</w>
l e</w>
a g
s e
s h
e d
e m
ou l
u n
e x
v i
ti on
u l
c om
o p
a p
oul d</w>
u r
c h
er e</w>
o u</w>
s .</w>
s ,</w>
l i
f f
t s</w>
t a
i t</w>
m a
c e</w>
ent s</w>
s p
in g
p ati
n e
. .
ati on
ha ve</w>
t er
t r
f or
du c
i r
p re
u m
w e
p e
y ou</w>
q u
th e
sh ould</w>
o c
p er
th er</w>
p or
c l
b y</w>
th is</w>
at ed</w>
0 0
i d
us e</w>
e .</w>
h as</w>
ou r</w>
t re
p o
m ent</w>
di c
at e</w>
p l
i g
e ,</w>
be en</w>
e t
W h
il l</w>
re d</w>
t ed</w>
w as</w>
ou n
p h
in e</w>
as e</w>
w ill</w>
a f
os e</w>
y ,</w>
it y</w>
f ro
pati ents</w>
on e</w>
re n
h e
ic h</w>
re c
fro m</w>
p a
o t
y .</w>
ti c
u d
st r
a r</w>
u ro
s y
e v
wh ich</w>
pro duc
I f</w>
i c</w>
m on
p ar
c re
ta k
j ec
m in
an y</w>
ff ec
ma y</w>
ou t</w>
t e
y our</w>
c h</w>
d er
us t</w>
su l
u t
E uro
s o</w>
con t
in f
i v
en d
o d</w>
o ther</w>
al l</w>
an c
es .</w>
.. ..
ac c
ed .</w>
r a
an d
me dic
an t</w>
) .</w>
w ere</w>
di s
c an</w>
d a
tre at
ti m
tion s</w>
v el
e ffec
r is
u t</w>
y e
w or
ti ve</w>
st e
es s</w>
o g
ab le</w>
es ,</w>
for m
es e</w>
t er</w>
us ed</w>
c a
o d
an ce</w>
o v
or e</w>
su b
I n
d er</w>
s e</w>
ar y</w>
ou r
i f</w>
lo w
en c
al ly</w>
s er
a v
th er
e p
m ust</w>
es s
o b
ag e</w>
s ec
in cre
u re
an g
pre s
i on</w>
C om
Euro pe
m ent
si on</w>
ic al</w>
b er</w>
I n</w>
th ese</w>
ou s</w>
p os
th ere</w>
w a
al so</w>
com m
th an</w>
p le
s ol
su r
m ore</w>
g h
- -
ar m
ac t
f e
t ab
s t</w>
re por
i th
i r</w>
c o
0 0</w>
ig h
d o
ti v
i ti
h y
n o</w>
the y</w>
E U
t o
m is
I t</w>
Wh at</w>
a in
al l
c ar
ar k
i d</w>
t en
Europe an</w>
r u
ro u
treat ment</w>
re g
i f
v e
t ri
medic in
as t</w>
in jec
a ,</w>
h i
U n
h o
d .</w>
u m</w>
c i
d ose</w>
ver ,</w>
f o
e t</w>
it s</w>
el l
t h</w>
ed ,</w>
d e</w>
el y</w>
sp ec
ver y</w>
min i
d oc
en ce</w>
b ut</w>
w ith
w n</w>
ta in
ye ar
on ly</w>
wh o</w>
ation s</w>
for e</w>
u c
du r
m g</w>
m il
ff ic
a st
as s
2 00
as ed</w>
per i
Y ou</w>
er s</w>
su ch</w>
ad mini
se e</w>
an ti
m o
b lo
we ver,</w>
ch il
cl ud
al s</w>
i a</w>
the ir</w>
si b
re qu
ti c</w>
f ol
s om
) ,</w>
af ter</w>
t ,</w>
g n
f i
a il
A l
tab le
el l</w>
vi r
arm ac
p en
ur e</w>
u tion</w>
g o
tr an
d o</w>
it e</w>
u di
k e</w>
u b
in to</w>
g r
k no
k s</w>
' s</w>
wh en</w>
we e
g en
t w
in ter
d ec
pl ac
m ark
F or</w>
doc t
p r
re sp
re ac
an t
u s</w>
H o
pe op
g re
u p</w>
c er
re sul
por t
.... ....
w ould</w>
p e</w>
g l
in clud
b ec
st udi
inf ec
di se
1 /</w>
tak e</w>
S t
k ing</w>
d ing</w>
m p
ex am
d os
ris k</w>
e st
c oun
ther ap
am e</w>
f ir
a d</w>
in form
in u
b o
si on
re l
t ec
m an
i on
y s
Com mis
ac t</w>
l on
be t
c ur
blo od</w>
re comm
b le
en ti
i al</w>
s ti
il l
i st
b re
at es</w>
ation .</w>
R e
n um
d ro
re duc
v is
h um
resp on
t ing</w>
fol low
1 9
g iv
ing ,</w>
cl in
chil d
( A
ing .</w>
peop le</w>
O n
EU /</w>
tion .</w>
es t</w>
ap pro
a re
dur ing</w>
de vel
y s</w>
re e</w>
F O
ph armac
ser v
me as
end ed</w>
con tain
con si
Th ere</w>
Ho wever,</w>
effec ts</w>
t .</w>
tion ,</w>
sur e</w>
ar g
A N
g h</w>
f in
f er
b in
ab out</w>
u th
b i
c le
injec tion</w>
he al
cont inu
os t</w>
tim e</w>
sec tion</w>
ne ed
c ent
w e</w>
wh at</w>
p ri
doct or</w>
as es</w>
ch ang
uth or
c or
p ec
s k
( see</w>
c an
inform ation</w>
ne w</w>
ov er</w>
num ber</w>
-- --
ac tive</w>
tw o</w>
1 0</w>
s o
n ec
f act
H A
R I
p er</w>
4 .
T I
sub st
repor t</w>
l a
d ,</w>
th ose</w>
c e
pos sib
0 .
5 0</w>
ul ar</w>
st ud
sh o
Commis sion</w>
devel op
be ing</w>
M E
at er</w>
si gn
produc t</w>
rec e
Th is</w>
tre ated</w>
su p
m g
er g
ri b
av ail
ha d</w>
giv en</w>
b ot
ar d</w>
al u
si de</w>
fir st</w>
ation ,</w>
ste m</w>
id e</w>
A n
do es</w>
the re
s el
lo w</w>
f un
be fore</w>
sul in</w>
clin ical</w>
w om
p ol
em ent</w>
r al</w>
u p
igh t</w>
or y</w>
is h
me di
table ts</w>
cont ro
tak en</w>
d s</w>
medicin al</w>
f l
admini str
ren t</w>
ati ve</w>
ac k
s en
t y
l ess</w>
som e</w>
produc ts</w>
gh t</w>
re ,</w>
l im
a .</w>
hum an</w>
ar i
we en</w>
e f
ne ed</w>
sol ution</w>
m u
m e</w>
r it
ff e
ad e</w>
in v
in e
enc y</w>
em ber</w>
a use</w>
is ed</w>
bet ween</w>
I S</w>
6 /</w>
t u
d ed</w>
c ol
if ic
- 0
re n</w>
v acc
ac k</w>
sy stem</w>
S E
im port
P ro
is ation</w>
incre ase</w>
s ame</w>
or m
g rou
an s</w>
pro vi
o x
d at
an im
m ost</w>
ag ain
at ely</w>
il ity</w>
wh ere</w>
d es
it ed</w>
with out</w>
m s</w>
o ver
t om
in t
b od
se ver
s it
re s
th en</w>
mon th
HA T</w>
00 0</w>
T el
W HAT</w>
recomm ended</w>
incre ased</w>
t ly</w>
at ing</w>
s af
pati ent
g i
com bin
par tic
m l</w>
D o</w>
/ 1
le vel
ic e</w>
ta in</w>
et y</w>
te st
f ul
ar ly</w>
a k
v er</w>
child ren</w>
c ould</w>
in sulin</w>
or s</w>
or der
in al</w>
R E
m at
com p
year s</w>
Wh y</w>
M e
is t</w>
he pati
a z
can not</w>
pro ble
ment .</w>
v en
et ing</w>
therap y</w>
includ ing</w>
di ffe
I N
ul ation</w>
th ro
o f
follow ing</w>
il y</w>
e u
d r
C h
m any</w>
FO R</w>
b en
s )</w>
mp tom
bec ause</w>
ac h</w>
or der</w>
oc i
nec ess
con di
ac h
im pa
oun d</w>
lon g
W e</w>
A L</w>
p s</w>
il e</w>
i de
g ro
e re
tak ing</w>
str uc
requ i
ev en</w>
a uthor
un der</w>
in es</w>
stud y</w>
ol og
th ree</w>
y l
studi es</w>
rece iv
On e</w>
Wh en</w>
x im
e ther</w>
us ing</w>
ser i
M ember</w>
ure s</w>
ma in
i a,</w>
s a
tiv ity</w>
tran s
m ade</w>
e y
1 0
e l</w>
/ 9
st ar
sy mptom
m it
m b
in ,</w>
c al
R O
the m</w>
r on
t y</w>
l y,</w>
hi b
exam ple
Al l</w>
O ral</w>
por t</w>
po in
ex peri
ap pe
th rou
import ant</w>
st em
P ati
ver se</w>
c ap
c ase</w>
administr ation</w>
i z
i es</w>
hy per
N e
ste red</w>
cent r
avail able</w>
E U</w>
u st
em p
su m
l ed</w>
l ab
ation al</w>
ou s
2 0
wor k</w>
f ur
re si
le .</w>
again st</w>
example ,</w>
da y</w>
tion al</w>
a th
f ic
wa y</w>
st er
tim es</w>
is ,</w>
h el
bot h</w>
Euro pe</w>
r ing
me th
kno wn</w>
i p
C on
gen er
h igh
pl ic
le ast</w>
dat a</w>
a vi
p le</w>
on d
dis order
Un ion</w>
g u
ad di
M A
wom en</w>
in dic
du l
Pati ents</w>
ob serv
h our
b as
t ur
sy stem
th em
si ve</w>
e -
fun c
di vi
1 00</w>
gr am
admini stered</w>
........ ........
ren al</w>
S T
o k
repor ted</w>
de m
n orm
1 .
there fore</w>
s w
possib le</w>
3 0</w>
qu es
m en
sever e</w>
h ol
T H
19 9
v ing</w>
u al</w>
t s.</w>
U SE
P h
S P
om e</w>
i x
b el
t al
m ents</w>
du ce</w>
ro s
anc es</w>
d g
in hib
consi de
us ion</w>
tic s</w>
di sp
s or
ent ly</w>
sign ific
heal th</w>
al ,</w>
with in</w>
un der
ig n
0 6/</w>
O N
t e</w>
ben ef
A c
c ul
v ed</w>
t en</w>
impa ir
l y
saf ety</w>
or al</w>
ffic i
p op
l ast</w>
in iti
fur ther</w>
er ,</w>
di rec
A C
wor k
w n
p i
c ell
ut e</w>
re le
pro pos
mil li
bod y</w>
w ell</w>
st o
ig h</w>
ho w</w>
e g
at t
2 .
r ate</w>
P ar
2 0</w>
e y</w>
al .</w>
op er
es s,</w>
ass oci
w ater</w>
lo c
com ple
AN D</w>
re ad
or g
er .</w>
sk in</w>
m un
i l</w>
en d</w>
f ac
po ten
dise as
2 5</w>
ve l</w>
s :</w>
E ME
3 7
w ar
ti me
ti s</w>
r ap
n on
de d.</w>
combin ation</w>
li ke</w>
tran sp
s ite</w>
po si
su g
is e</w>
ac ter
a ffec
im medi
ad verse</w>
1 2</w>
/ 0
symptom s</w>
g et</w>
d am
N o</w>
j ust</w>
f u
effec t</w>
m ic
s ing
s ?</w>
h al
e very</w>
throu gh</w>
con centr
dise ase</w>
ti es</w>
pro tec
mon it
_ _
Me dic
re at
ma in</w>
l u
se t</w>
s m
contro l
USE D</w>
tr a
reac tions</w>
p ub
oun t</w>
ma ke</w>
li st
l it
sen si
wee ks</w>
mu ch</w>
ter m</w>
hy dro
pro ce
pati ent</w>
a dul
le ,</w>
t s,</w>
pro te
level s</w>
- f
op h
n ing</w>
me tab
lo g
le vel</w>
le g
in ation</w>
c are</w>
O N</w>
ty pe</w>
n ational</w>
metab ol
y ing</w>
po w
li f
tr ac
medicin es</w>
ou t
ing s</w>
coun tri
c r
af le
s us
dec re
contain s</w>
l in
e )</w>
di st
st and
in ary</w>
h igh</w>
1 5
ex c
em b
p ack
m l
e qu
r an
im pro
/ 200
resul t</w>
d el
v alu
ca use</w>
Tel :</w>
mg /</w>
im p
c ases</w>
pa red</w>
v es</w>
inv ol
gro w
associ ated</w>
ou gh</w>
gre s
1 4</w>
t ot
du e</w>
to o</w>
spec if
i b
ap p
oc cur
l arg
wh ether</w>
th ing</w>
E R
A U
wee k
pl as
in c
ho wever,</w>
plac e
on ce</w>
ha em
ch o
ab ility</w>
a em
---- ----
hepati c</w>
ed ing</w>
N o
da ys</w>
In ter
ep t
c as
d ru
H um
som e
poten ti
h e</w>
conside red</w>
I I
v ent</w>
sub jec
heal th
sy n
pre gn
coun tr
gl y
ass ess
t ro
sy ring
e ach</w>
tec h
f il
c y
as si
1 5</w>
c all
mic ro
f a
A s</w>
ffic ul
ti l</w>
is m</w>
chang e</w>
c anc
ac hi
da ily</w>
I T</w>
subst ance</w>
u r</w>
pro c
partic ul
l os
ill ed</w>
A T
se qu
necess ary</w>
St ates</w>
C oun
wa st
di fficul
(A 4
t ell</w>
h ar
(A 5
meas ures</w>
l es</w>
l and
fo re,</w>
inhib it
EU /1
le afle
al ity</w>
pa in</w>
p end
o id</w>
milli on</w>
lon g</w>
op en
g e
en z
peri od</w>
com pared</w>
/ 00
com e</w>
I C
- 2
l am
it y.</w>
ent ,</w>
tion s.</w>
cer tain</w>
sing le</w>
resul ts</w>
ha p
per s
it y,</w>
c our
ti s
l y.</w>
appro pri
al ys
us ,</w>
divi du
b ased</w>
al low
a vir
a de
is su
con cer
in ce</w>
for m</w>
requi re
ev alu
pro f
contain ing</w>
develop ment</w>
plac e</w>
m ul
li k
inf usion</w>
at el
specif ic</w>
mark et</w>
ac y</w>
ol e</w>
f r
tion s,</w>
or t</w>
or d
month s</w>
an other</w>
T E
ye ar</w>
non -
m a</w>
in .</w>
S A
E x
A g
v it
read y</w>
ec h
5 %</w>
ex pec
di d</w>
at ory</w>
4 0</w>
sti tu
it .</w>
ar t
tot al</w>
l ish
i ve</w>
in dividu
A L
tic al</w>
in e,</w>
on g</w>
iti es</w>
f ail
da y
T reat
par t</w>
o l</w>
li c</w>
g .</w>
en sure</w>
el ine</w>
e i
dos es</w>
P RO
diffe rent</w>
condi tions</w>
D e
C I
wee k</w>
v ari
s ci
respon se</w>
po st
seri ous</w>
fo od</w>
to x
ti n</w>
ru s</w>
bi o
0 %</w>
reduc ed</w>
observ ed</w>
m al
b u
n ess</w>
ev ents</w>
ri c</w>
ma j
3 6
l or
call ed</w>
r ang
p ut</w>
ca re
Th ere
all erg
2 4</w>
s c
proble ms</w>
incre as
v ol
er i
1 )</w>
wh ite</w>
t t
s al
avi r</w>
sib le</w>
pro gres
p tion</w>
M r</w>
reduc tion</w>
re as
er al</w>
comm on</w>
vi rus</w>
medic ine</w>
% )</w>
n ed</w>
el ec
al ready</w>
1 8
poin t</w>
p at
ati c</w>
3 5
u fact
A r
vi e
s ing</w>
org an
me ans</w>
li ver</w>
d om
tri dg
ti ce</w>
ir c
H e
r y</w>
6 0</w>
ol d</w>
U C
n a
dec is
car ri
O F</w>
pres ent
is .</w>
us es</w>
u ally</w>
tre at</w>
experi ence</w>
er c
ad j
M ark
wor king</w>
wa ys</w>
un til</w>
rel ated</w>
di um</w>
bec ome</w>
hour s</w>
grou p</w>
achi ev
he ar
contro l</w>
H I
G er
min im
fu l</w>
fe w</w>
ad v
ok ine
at ed.</w>
an e
T o</w>
ti g
sec on
impair ment</w>
f our</w>
t le</w>
og en
car tridg
anim als</w>
Q u
sm all</w>
is h</w>
in k</w>
ic k
d ri
chil d</w>
H M
E n
l ine</w>
ex t</w>
est ab
reg ul
at e,</w>
patient s.</w>
e ?</w>
ade qu
sho w
de pend
F r
su ffici
re .</w>
and ,</w>
A n</w>
ren ce</w>
m ov
m ar
a x
Un ited</w>
6 .
w w
vi al</w>
s ed</w>
re s</w>
as s</w>
a in</w>
wh ile</w>
provi ded</w>
medic al</w>
lo b
ei ther</w>
di ab
ci l</w>
on s</w>
f requ
lif e</w>
do wn</w>
2 .</w>
re ad</w>
go od</w>
ent .</w>
de ter
Coun cil</w>
( C
sp e
sit u
y oun
xim ately</w>
ful ly</w>
re duce</w>
re di
k .</w>
disorder s</w>
an ts</w>
mul ti
g ra
ffic acy</w>
vir on
te e</w>
sti l
countr y</w>
at e.</w>
5 .
1 7
’ s</w>
subst ances</w>
norm al</w>
ing redi
fi ed</w>
e ver
b l
tr ain
ob jec
n am
man ag
kno w</w>
in te
d one</w>
ch em
b r
ap plic
receiv ing</w>
dis continu
N ov
p ur
olog ical</w>
ex po
sho wn</w>
pres c
ple ase</w>
ell ing</w>
Y our</w>
Mark eting</w>
FO R
ti vel
potenti al</w>
mark eting</w>
Y P
r as
pharmac okine
b ro
an i
re spec
appro ximately</w>
ter s</w>
li gh
im mun
ic i
ab sor
A d
w .</w>
syn dro
str ic
receiv ed</w>
ment ,</w>
mark et
j o
a y
A uthor
t ed.</w>
need s</w>
gl uc
c at
' .</w>
star t</w>
o e
go ing</w>
ep t</w>
Medic ines</w>
D i
(A4 -0
tr av
emp lo
ant ly</w>
C o
re st
pop ulation</w>
particul arly</w>
infec tion</w>
re se
ra di
oc c
m us
ist .</w>
id enti
ri ght</w>
need le</w>
n at
m y
ac tion</w>
Treat ment</w>
1 3
or .</w>
d ra
as k</w>
-f illed</w>
os is</w>
od .</w>
gre ater</w>
appe ar
TI ON</w>
- term</w>
t on
ren tly</w>
o ther
M r
A R
treat ment.</w>
su c
re d.</w>
bre ast
ast ro
adj ust
si mil
r ac
estab lish
cle ar</w>
cell s</w>
ab le.</w>
0 2
m ix
stil l</w>
produc tion</w>
experi enc
imp act</w>
gi ve</w>
ac tivity</w>
signific ant</w>
m or
ir e</w>
d en
D E
o m</w>
benef it</w>
ol er
g o</w>
ar acter
appropri ate</w>
th ir
ic ally</w>
er ing</w>
are a</w>
H y
v ent
sol u
sensi tivity</w>
en viron
sup port</w>
chang es</w>
1 1</w>
vir al</w>
syring e</w>
ous ly</w>
er y</w>
bo di
am in
a m</w>
P re
we ight</w>
vi a</w>
v al
t ure</w>
sti t
high er</w>
h and
fl u
U se</w>
secon d</w>
grow th</w>
disp os
ren c
p it
mo der
me an</w>
func tion</w>
f t</w>
com mon
vacc ine</w>
plas ma</w>
par ti
p es</w>
os ph
no tice</w>
le ad</w>
control led</w>
ch lor
po t
enz y
ent s.</w>
c lo
There fore,</w>
requi red</w>
prote in</w>
de mon
cur rent</w>
w at
resi st
of ten</w>
effec tiv
e p</w>
a y</w>
1 8</w>
or ing</w>
no w</w>
bel o
ation s.</w>
TH E</w>
s ince</w>
o ff
en ,</w>
ar ch</w>
1 4
ufact ure
ter inary</w>
pr im
low er</w>
effec tive</w>
demon str
B ut</w>
st at
1 2
sel f</w>
o k</w>
expec ted</w>
(A5 -0
rib ed</w>
reg ar
ion s</w>
h or
grou p
exam ple</w>
ex ist
er s.</w>
ac tiv
su ff
sci enti
pre vent</w>
li ed</w>
i a
er s,</w>
en g
pre -filled</w>
c ut
anc y</w>
O L
C YP
A D
wast e</w>
maj or</w>
individu al</w>
- 00
pres ent</w>
m ight</w>
b ur
al s.</w>
on e.</w>
no log
i ally</w>
ag es</w>
P le
Hum an</w>
tain ed</w>
simil ar</w>
sh i
f ound</w>
e fficacy</w>
cont act</w>
vi v
spec ial</w>
rele v
immedi ately</w>
ati s
se en</w>
p en</w>
doc um
com pe
carri ed</w>
c ular</w>
c ha
ar ,</w>
am ount</w>
S E</w>
Pro duc
3 .
sus pen
sug ar</w>
studi ed</w>
l at
includ ed</w>
hel p</w>
cl os
Commis sion
youn g</w>
sto p</w>
bet ter</w>
ar ound</w>
an n
Ph armac
pr in
in struc
ey e</w>
bre ast</w>
allerg ic</w>
H ol
st or
s es</w>
qu ality</w>
b ack</w>
A P
2 00</w>
t or
t em
re t
pharmac ist.</w>
larg e</w>
e vi
de fin
al low</w>
S u
L i
u e</w>
ple ment
is m
in test
f -
es s.</w>
Ple ase</w>
K ing
Com mit
vis ion</w>
t op
pub lic</w>
proce dur
ven tion</w>
ca used</w>
at ric</w>
V E
loc al</w>
h er
al ways</w>
y -
ur ing</w>
so dium</w>
l ic
f ic</w>
en ess</w>
canc er</w>
an alys
us e.</w>
r e</w>
l ing</w>
ingredi ents</w>
pro gram
hap pen
ane ous</w>
Ac cor
ta il
re con
cor rec
am p
) :</w>
list ed</w>
le ad
es pec
countri es</w>
a ver
un g
st ate</w>
pa in,</w>
es ?</w>
continu e</w>
cl es</w>
art an</w>
U K</w>
- fe
ter ms</w>
ron ic</w>
ph ys
in i
fer on</w>
expo sure</w>
ex t
ex p
ex cre
consi der
anc e,</w>
re f
at ,</w>
acc id
o wn</w>
li ght</w>
fi ve</w>
emplo y
b o</w>
anim al</w>
ag e.</w>
3 00</w>
pa th
on .</w>
n er
l and</w>
ev er</w>
diab et
c ell</w>
Accor ding</w>
st s</w>
st ri
li am
cur rently</w>
com par
al co
y ou
wn .</w>
monit oring</w>
i ver
espec ially</w>
con sum
a k</w>
Re port</w>
E X
5 0
1 6
ti vi
re d
n ext</w>
/200 1)</w>
th es
on ,</w>
des ign
ci pi
ut es</w>
ter n
partic ular</w>
leafle t</w>
in e.</w>
com it
7 /</w>
resi d
pri or</w>
pre vi
ph osph
p ass
og n
ne x</w>
y n
time .</w>
st op
in du
e di
anc e.</w>
sign s</w>
ml )</w>
k in
ic ity</w>
h ed</w>
e me
P or
I m
con f
breast -fe
aracter is
ac id</w>
V ir
1 3</w>
ou s,</w>
long er</w>
inf lu
inc id
dru g</w>
EME A</w>
ye t</w>
of f</w>
g e</w>
e :</w>
child ren
1 6</w>
year s.</w>
i red</w>
es tim
en .</w>
No t</w>
An nex</w>
3 0
evi d
co ated</w>
S ec
y t
w ,</w>
pro por
place bo
manag ement</w>
ion ,</w>
di ag
da y.</w>
author isation</w>
B e
( e.</w>
hepati tis</w>
de fic
anti -
G en
v ot
suc c
p an
int ro
hy po
ch ronic</w>
are as</w>
An y</w>
2 5
t og
ma xim
k e
iti s,</w>
intest inal</w>
ab il
__ __
PRO D
Commit tee</w>
0 )</w>
ul es</w>
rece ive</w>
immun e</w>
hear t</w>
f am
diag no
ag ed</w>
a ir
PROD UC
O p
EME A
lik ely</w>
l an
Ag ency</w>
................ ................
% .</w>
and /</w>
I U</w>
ure .</w>
su per
ne uro
micro gram
meas ure</w>
infec ted</w>
en e</w>
bodi es</w>
R o
scienti fic</w>
s ha
r ic
pres sure</w>
pow der</w>
necess ar
es tig
absor ption</w>
R ap
A m
2 7
vi g
th ough</w>
pack age</w>
ou gh
f ar</w>
c le</w>
Th ey</w>
thir d</w>
them .</w>
o id
s ity</w>
impro v
ec on
dis c
addi tional</w>
S ,</w>
On ly</w>
v en</w>
protec tion</w>
pro jec
pres sion</w>
los s</w>
h ou
de b
b ab
ve terinary</w>
v ast
procedur e</w>
o di
n ess,</w>
iti s</w>
il d
health y</w>
ha ving</w>
fact or</w>
es sion
de f
ag re
/9 8
ure ,</w>
table t</w>
provi de</w>
h is</w>
effectiv eness</w>
ca uses</w>
affec t</w>
tri als</w>
repor ts</w>
rec ogn
re main
l ac
aem ia</w>
I tal
2 1</w>
pr ac
or ding</w>
ne g
long -term</w>
intro duc
includ e</w>
g astro
do m</w>
aver age</w>
( P
% ,</w>
v ic
tis su
fac e</w>
dist rib
d ang
c irc
ati n</w>
ad ol
Th ese</w>
tech n
rec ent</w>
proble m
lim ited</w>
ed ?</w>
ca em
avir in</w>
adequ ate</w>
acc ount</w>
I D
C O
4. 4
2 8
or ig
k ed</w>
k ,</w>
ion .</w>
ev a</w>
blo c
at ten
B el
u k
respon sible</w>
recomm en
reac tion</w>
r ati
p ack</w>
on g
mu no
m an</w>
W or
B E
Author isation</w>
( E
w ant</w>
per form
form ation</w>
decis ion</w>
ag e,</w>
St at
/1 3
wh ole</w>
we igh
sup p
se ,</w>
r h
or t
occ ur</w>
maxim um</w>
m ary</w>
it ing</w>
infec tion,</w>
exam in
ech an
acc ording</w>
7 0</w>
t ub
place bo</w>
fi el
er y
d ate</w>
con comit
comple t
M an
EU/1 /00
EU/1/00 /13
8 0</w>
with dra
p ed</w>
ne w
l ist</w>
i x</w>
ation s,</w>
ar r
T a
ME D
w ell
th ink</w>
on e,</w>
m echan
/9 9
o ,</w>
m en</w>
inv estig
inf lam
fr act
dise ases</w>
al s,</w>
ac id
C an
( S
re st</w>
monit o
i e
dos age</w>
ac tivi
II I</w>
I U
sur g
in ten
ge ts</w>
en erg
d es</w>
Par liam
M P</w>
F in
us ually</w>
s '</w>
proc ess</w>
in s</w>
gener al</w>
D is
time ,</w>
ques tion</w>
or r
it ,</w>
inter feron</w>
in trav
e uro
car di
b le</w>
adol es
Wh ere</w>
mon o
ful l</w>
b ut
b or
P resid
L ond
wor l
sub cut
si x</w>
rec ept
mon th</w>
i m</w>
g /</w>
es )</w>
col l
ar th
R es
M P
King dom</w>
HI V
8 /</w>
1 ,</w>
s ;</w>
rese arch</w>
pos ed</w>
o ve</w>
moder ate</w>
ex cipi
dispos ed</w>
de tec
an .</w>
acc ess</w>
M ix
-------- --------
ti l
p ul
difficul t</w>
co -
ch ec
av oid</w>
all y,</w>
a w
S ub
O r
H B
2 ).</w>
situ ation</w>
pre par
pop ul
mit ted</w>
in ess</w>
i a.</w>
ho l</w>
he ad
en ous</w>
dru g
anti bio
ad d
P o
suspen sion</w>
recommen ded.</w>
produc ed</w>
ment al</w>
g en</w>
an y
00 /</w>
t un
mat er
b acter
U N
Nov o
C E
A t</w>
shi p</w>
pot assi
dam age</w>
bas is</w>
ad vis
S o</w>
s mo
or ,</w>
ma k
il i
f act</w>
ca u
b est</w>
ar d
P ol
O RI
vig il
us e
tail ed</w>
ser um</w>
ra z
indic ated</w>
des c
appe ar</w>
t um
s ch
posi tion</w>
lo g</w>
it y
in duc
b one</w>
at h</w>
assess ment</w>
I R
lit tle</w>
test s</w>
stand ard</w>
rit on
re ly</w>
men tion
k ey</w>
experienc ed</w>
decre ase</w>
cle ar
circ um
adul t</w>
a u
L e
+ 4
th i
t arg
sion ,</w>
se e
ide ,</w>
h ,</w>
defic i
belo w</w>
ar c
MED IC
y ro
we ak
re pe
rang e</w>
in t</w>
hy dr
fil m
en ough</w>
em ents</w>
depend ent</w>
acc ord
year .</w>
vi r</w>
v o
u red</w>
signific antly</w>
s ).</w>
pol i
cour se</w>
b an
as cular</w>
MEDIC IN
MEDICIN AL</w>
Ho w</w>
Fr ance</w>
7 )</w>
we b
su mp
sho w</w>
re li
pregn ancy</w>
o p</w>
ne ver</w>
en s</w>
2 /</w>
thro mb
ris ks</w>
par t
hol d</w>
ho e
f at
f ,</w>
ble eding</w>
al is
E C
4.4 ).</w>
3 %</w>
2 8</w>
1 %</w>
u ri
o vigil
lim it</w>
econ om
e as
d ou
an e</w>
allow ed</w>
E N
3 ,</w>
tt p
sion s</w>
resp ir
r ates</w>
r are</w>
proce du
m ou
k g</w>
im in
h ttp
grou ps</w>
eu tic</w>
edi atric</w>
concentr ations</w>
adul ts</w>
I rel
7 5</w>
2 %</w>
1 7</w>
rele ase</w>
propos ed</w>
prin ci
patient s,</w>
p ris
me ,</w>
m ot
hi st
be g
b us
achiev ed</w>
Y O
O S
2 ,</w>
/98 )</w>
ur al</w>
sp o
o .</w>
h os
h ic
fic ation</w>
ex per
compe ti
ar ch
an ,</w>
a id</w>
TI ON
Por tu
PRODUC T
th el
subjec t</w>
se .</w>
ou d
mix ed</w>
instruc tions</w>
im muno
hal f</w>
g al</w>
evid ence</w>
ever y
ab ove</w>
Hy per
3 .</w>
1 ,
tog ether</w>
tic s,</w>
t est</w>
recomm end
r o</w>
pre -
objec tive</w>
mg /
man ufacture
establish ed</w>
de ath
con sequ
clud ed</w>
ac ute</w>
5 -
( H
transp ort</w>
rec ently</w>
injec tion.</w>
gre at</w>
gly caem
disc us
am ong</w>
al fa
S U
sug g
n al</w>
me mb
fe rence</w>
ess enti
con tr
circum st
al tern
Inter ne
- up</w>
t oler
r ing</w>
od ,</w>
m y</w>
ent s,</w>
continu ed</w>
con trac
cle arly</w>
ant .</w>
YO U</w>
S I
vacc in
un c
sever al</w>
ros is</w>
r ules</w>
r at
op ath
o -
ch arg
c ris
am end
alco hol</w>
W est
O R</w>
Ne ther
L u
ro p
need ed</w>
g et
ex ten
develop ing</w>
cartridg es</w>
c rit
add res
tech nolog
subjec ts</w>
reg ard</w>
oph il
ob tained</w>
n ur
j us
issu es</w>
in suffici
bas eline</w>
b al
an ted</w>
G re
re tur
om e
f re
enc es</w>
el ev
dur ation</w>
de x
concentr ation</w>
anti bodies</w>
am ine</w>
adjust ment</w>
activi ties</w>
valu es</w>
t ed,</w>
seri ous,</w>
respir atory</w>
on e
estim ated</w>
W in
Re port
Nether land
D I
A no
2. 5</w>
year s,</w>
vie w</w>
therap eutic</w>
p ig
over all</w>
le ft</w>
kno wn.</w>
hyper ten
deter min
decre ased</w>
cl u
Lond on</w>
A S
6 .</w>
( 9
vari ous</w>
si mp
re main</w>
post -
ovigil ance</w>
o h
it al</w>
gro un
g lob
enzy me</w>
ent al</w>
enc e,</w>
devel op</w>
comm un
b ir
ag ing</w>
S e
FOR E</w>
4 /</w>
pol y
monito red</w>
l ack</w>
k id
it self</w>
inhibit ors</w>
diabet es</w>
at ed,</w>
S w
BE FORE</w>
A v
19 8
t on</w>
respec tivel
pro per
me t
m ine</w>
l act
go ver
f ish
ex tre
cl oud
ca ution</w>
c it
b ar
TH ORI
M on
He al
A b
5 6</w>
tiv es</w>
therap y.</w>
re mov
prof ession
m ol
leafle t,</w>
im plement
gu id
fail ure</w>
excre ted</w>
ev ent</w>
care fully</w>
b es
at in
a me
AU THORI
/ ww
vast atin</w>
ud ine</w>
stitu ted</w>
sol vent</w>
s tim
olog y</w>
inflam m
incre ases</w>
der iv
app lied</w>
analys is</w>
a es
O P
F ir
vi als</w>
re -
qu anti
neg ative</w>
mil k</w>
infec tions</w>
i ed</w>
fact ors</w>
con duc
alfa -2
a ff
De tailed</w>
Ano ther</w>
str ain
se par
s ),</w>
pro duce</w>
presc ri
increas ing</w>
hos pit
f ree</w>
d og
com es</w>
ag ain</w>
S um
Qu es
Bel gi
4 8</w>
v om
un i
sion .</w>
ri gh
re present
re d,</w>
ra ther</w>
pharmacokine tics</w>
p sy
li p
influ ence</w>
i um</w>
ex erc
el s</w>
demonstr ated</w>
cap sul
c op
al one</w>
5 ,</w>
( a</w>
ty pes</w>
syndro me</w>
sel ec
re stric
re fer
plac ed</w>
m bo
m al</w>
m ach
lo x
ir rit
invol ved</w>
energ y</w>
diseas e.</w>
develop ed</w>
concer n
con sul
arr hoe
ac tions</w>
V i
S lo
Medic inal</w>
wh ose</w>
us ed.</w>
prim ary</w>
breast-fe eding</w>
assi st
as ,</w>
ap ar
ag ents</w>
S af
P RE
Li pro
y our
ve hic
tw ice</w>
ti s,</w>
str y</w>
renc es</w>
qu al
pa ediatric</w>
or ity</w>
hou se
da y,</w>
at or
appear s</w>
a ut
Un iver
AUTHORI SA
2 2</w>
vacc ination</w>
ou t.</w>
mil k.</w>
le x
incid ence</w>
crit er
concomit ant</w>
ain ed</w>
affec ted</w>
C HM
si m
produc t,</w>
poin ts</w>
metabol it
me m
mak es</w>
m ph
film -
eme a.</w>
b ra
atel y.</w>
al ised</w>
P en</w>
Lipro log</w>
L im
L E
C E</w>
4 0
w in
um ,</w>
sa y</w>
rib avirin</w>
hydro x
en s
con sump
ca p</w>
Win thro
P er
M y
L et</w>
wa y.</w>
some times</w>
s oci
riton avir</w>
resul ting</w>
reg ulation</w>
pharmacokine tic</w>
meas ure
mater ial</w>
leg is
bi ological</w>
N ame</w>
AT E</w>
vol um
t or</w>
p ose</w>
iv al
h ard</w>
est i</w>
e arly</w>
cho le
bu il
addi tion</w>
S pec
Report :</w>
5 00</w>
4 00</w>
3 8
3 4
sur viv
succ ess
subcut aneous</w>
s is</w>
ro lim
pl an
p al
nam es</w>
mat eri
film- coated</w>
design ed</w>
con fir
comple te</w>
b er
Tel .</w>
St ate</w>
S ol
M any</w>
Gen eral</w>
Com mun
/9 7)</w>
’ .</w>
us h
trans fer
si z
reg ion</w>
no t,</w>
in -
http :</w>
gastro intestinal</w>
f av
defici ency</w>
Winthro p</w>
N or
N G</w>
C ar
z ap
valu e</w>
u l</w>
su ic
progres s</w>
pol ic
per at
orr ha
oper ation</w>
op a
need les</w>
l ation</w>
i k
e ar
der ly</w>
complet ely</w>
b il
accord ance</w>
Re g
O n</w>
Hol der</w>
D r</w>
1 -
you .</w>
ta x
show ed</w>
ro un
r and
ph eral</w>
od s</w>
o ffic
month s.</w>
mention ed</w>
gra du
f ec
exc es
d on
c ir
c ents</w>
am in</w>
acc ept
E esti</w>
throu gh
th re
posi tive</w>
ou ght</w>
ne um
mon ary</w>
mo di
ment s.</w>
m ag
la x
evalu ation</w>
cl ose</w>
af er
Vir afer
R om
Op ti
E l
C irc
3 /</w>
us ual</w>
tran si
st ent</w>
sec ond
produc ts.</w>
ph en
op in
o ste
mil d</w>
kid ne
in sul
ent ly,</w>
der ,</w>
con ver
at or</w>
appro ved</w>
again .</w>
ab dom
a di
T eva</w>
R A
N A
A s
200 0</w>
vit ro</w>
uc le
s -
ru p
o s</w>
initi al</w>
fin al</w>
exist ing</w>
di arrhoe
de .</w>
comm it
cle an
author ities</w>
assess ed</w>
V I
TION S</w>
R en
On ce</w>
I s
B o
- 1
y l</w>
vel y</w>
tur al</w>
tem perat
t -
spec i
s we
relev ant</w>
qu ick
proble m</w>
inter national</w>
h om
for tun
f all</w>
evalu ated</w>
em erg
bre ath
bec om
S y
I s</w>
0 7/</w>
/ww w.</w>
y ?</w>
s on
requ est</w>
na use
leg al</w>
kno w
hel d</w>
fo re
f ut
euro pa
e duc
de st
countri es.</w>
concer ned</w>
clear ance</w>
ad op
S pain</w>
Di rec
AUTHORISA TION</w>
8 00</w>
4 ,</w>
3 A
2 3</w>
( F
( EMEA
vis ual</w>
th at,</w>
parti cles</w>
meth od</w>
me .</w>
le uk
in j
ic es</w>
direc tly</w>
desc ribed</w>
de ma
d ys
ati v
a ir</w>
W ith
Mr s</w>
M ar
Ger many</w>
CHM P</w>
AC T
6 ,</w>
. ,</w>
th ,</w>
stud y,</w>
st ,</w>
remain s</w>
presc ribed</w>
pa ren
in st
improv ement</w>
hist ory</w>
gluc ose</w>
fin anc
e tic</w>
doct or.</w>
F ro
2 9
, 000</w>
(A5 -00
' ,</w>
t :</w>
star ting</w>
st atis
reg im
propor tion</w>
on in</w>
o g</w>
m es</w>
lab elling</w>
l es
inte rest
int ended</w>
house hold</w>
gu ar
equ ival
b on
arth ri
al og
Saf ety</w>
M AN
Fro m</w>
C y
36 8/</w>
1 50</w>
0. 5</w>
wh om</w>
volum e</w>
show s</w>
se x
reac hed</w>
protec t</w>
oc yt
m ed</w>
lab el</w>
iti z
is ations</w>
eu tical</w>
e red</w>
car c
c ent</w>
applic ation</w>
app ly</w>
ac e</w>
L I
wh ere
vent ed</w>
there fore,</w>
ten ance</w>
t ob
su st
st er</w>
sh ort
requ ire</w>
pers on</w>
pers on
p ic
min utes</w>
medicin e.</w>
m ut
m on</w>
ly mph
jus ti
hum an
ha ps</w>
et .</w>
drug s</w>
d en</w>
cont rib
clin ically</w>
as th
as al</w>
addi tion,</w>
a im
Com b</w>
C P
3 5</w>
tr act</w>
t ting</w>
system ic</w>
stor age</w>
intrav enous</w>
id es</w>
f ra
f ast
es :</w>
e ts</w>
com plic
ar ing</w>
adoles cents</w>
Produc ts</w>
7 .
3 9
u g
previ ous</w>
multi ple</w>
injec t</w>
fer ry</w>
dr in
con nec
chole ster
avail ability</w>
U SE</w>
T ran
P eg
Mr  
6 00</w>
zap ine</w>
z er</w>
ti de</w>
s il
ques tions</w>
pl ain
phys ici
perform ed</w>
p on
our c
nat ural</w>
for c
follow -up</w>
europa .</w>
ati ves</w>
Sub jec
SP E
Interne t</w>
1 9</w>
(EMEA )</w>
us pen
thi az
ri x</w>
rand om
op o
f ig
en ing</w>
dr y</w>
de pres
c ros
Parliam ent</w>
P e
F ur
AU C</w>
y r
web site</w>
wast e.</w>
us .</w>
therap y,</w>
th yro
sur ve
st af
staf f</w>
sa id</w>
s /</w>
ro le</w>
resist ant</w>
recon stituted</w>
r y
p ing</w>
occur red</w>
o re
n er</w>
k il
immedi ately.</w>
haem orrha
f arm
day s.</w>
contrac ep
c itiz
b ud
ang u
a king</w>
Irel and</w>
IU /</w>
EU/1 /0
Ch aracteris
Can ary</w>
B ec
2 6
ur g
through out</w>
them ,</w>
sub sequ
spec ific
sh ort</w>
reg ular</w>
pres ence</w>
oc k
lo ok</w>
hor mon
ext ent</w>
avail able.</w>
al e</w>
SPE CI
S er
In formation</w>
Hyper sensitivity</w>
HI V</w>
G u
F ren
7 %</w>
5 ).</w>
3 1</w>
ver thel
stit ution</w>
propos als</w>
og rap
necessar y.</w>
mo ve</w>
is ing</w>
hour s.</w>
follow ed</w>
fiel d</w>
f eline</w>
col our
cas es,</w>
cap ac
arm a</w>
Wh ar
West ferry</w>
V ery</w>
Ger man
00 0
( M
treat ment,</w>
ter .</w>
stim ul
st om
produc t.</w>
f all
ent er
criter ia</w>
con tain</w>
co sts</w>
U F
S .</w>
I F</w>
4 5</w>
u gh
tr on
tic o
tic ally</w>
sh ip
rolim us</w>
pregn ant</w>
pharmac ist</w>
orm one</w>
neum on
market .</w>
li g
gover n
gener ally</w>
e th
dos e.</w>
de gre
c ri
aw are</w>
al k
a c</w>
Univer sity</w>
Sum mary</w>
E 14</w>
% ),</w>
z z
t el
system .</w>
suff ering</w>
reas on</w>
re plac
pre vention</w>
possib ility</w>
pl atel
ot y
ma x</w>
it ch
inflamm ation</w>
fol d</w>
alfa-2 b</w>
ab ly</w>
a ve</w>
P l
C .</w>
A ST
2 -
x emb
ve st
t able</w>
sum an</w>
serv ice</w>
re tro
p es
p ast</w>
meas ured</w>
level .</w>
inhibit or</w>
in hal
form s</w>
comp on
ch ro
att emp
antibio tics</w>
Lu xemb
In suman</w>
In sulin</w>
I X</w>
D os
Circ us,</w>
y el
wh y</w>
train ing</w>
si d
sh e</w>
sel f-
qu e</w>
num b
mis sion</w>
fo od.</w>
enc e.</w>
de ath</w>
de ,</w>
dang er
d y
cor respon
common :</w>
be ha
b an</w>
at .</w>
Whar f,</w>
Th ir
Ta ke</w>
CYP 3A
B r
4 -
vit amin</w>
ro l
ri g
n it
li fe
impair ment.</w>
h ormone</w>
h op
h er</w>
direc t</w>
di g
bot tle</w>
bes artan</w>
aes thes
TE RI
T A
Su ch</w>
S tr
HB ,</w>
8 .</w>
4 HB,</w>
train dic
t ase</w>
rati o</w>
projec ts</w>
potassi um</w>
pl us</w>
pe g
p .</w>
mus cle</w>
l angu
in ogen
f em
essenti al</w>
equ al</w>
dri ve</w>
d ated</w>
car ry</w>
b it
ation )</w>
I ts</w>
A p
6 5</w>
2 )</w>
1. 5</w>
techn ical</w>
t ac
t ?</w>
surviv al</w>
sur face</w>
resist ance</w>
rec or
prepar ation</w>
mo ther
me an
m ig
li qu
ke ep</w>
impro ve</w>
i es.</w>
frequ ency</w>
diffe rences</w>
dem a</w>
coll ec
cloud y</w>
ap pl
al iz
ab or
U L
Ren al</w>
Produc t</w>
F e
4 %</w>
3 2</w>
( 0.
ut ri
tre x
some thing</w>
ris e</w>
oe dema
mechan ism</w>
lead ing</w>
l ess
l ar
k en</w>
introduc ed</w>
in )</w>
identi fied</w>
id al</w>
dem oc
comp ani
as h
accept able</w>
ab le,</w>
Luxemb our
2 6</w>
up per</w>
test ing</w>
studi es,</w>
st able</w>
reas ons</w>
peri pheral</w>
other s</w>
hyper sensitivity</w>
he im
difficul ty</w>
car d</w>
al f
ab ol
Th at</w>
Sw ed
SPECI AL</w>
S A</w>
P )</w>
I T
D ec
um -
ter min
su s</w>
produc ts,</w>
p ap
m id
h arm
discontinu ed</w>
cre atin
capsul es</w>
beha vi
b ul
atten tion</w>
ati c
at e)</w>
UF ACT
UFACT U
Netherland s</w>
MAN UFACTU
L o
DI SP
C ON
10 %</w>
1 ).</w>
wa ste
ti tr
targ et</w>
sto red</w>
ste p</w>
sol v
pro long
p ac
os is,</w>
o il</w>
m ac
lox ac
log ical</w>
fin d</w>
equival ent</w>
diseas e,</w>
di p
cal ci
bod y.</w>
al og</w>
L D
H OL
CYP 2
) ;</w>
withdra w
up dated</w>
un known.</w>
tissu e</w>
re ver
radi o
present ed</w>
po int
or s.</w>
op en</w>
om a</w>
frequ ently</w>
f al
ery thro
emb ol
el derly</w>
con j
co m</w>
benef its</w>
author ised</w>
administr ation.</w>
acc ep
ac tion.</w>
W AST
WAST E</w>
Th ree</w>
Sec tion</w>
OS AL</w>
MA TERI
M al
DISP OSAL</w>
3 3</w>
/200 0)</w>
( for</w>
tic le</w>
th us</w>
stat us</w>
r un
ques tions,</w>
prac tic
o S
meas uring</w>
invol v
i .</w>
ho we
equ ip
diffe rence</w>
ch aracteris
b at
atel y,</w>
MATERI AL
Inter national</w>
Hum alog</w>
DE R</w>
1 .</w>
week s.</w>
w er</w>
tox ic</w>
system s</w>
reac h</w>
pa y
ol ,</w>
inter action</w>
gly cer
fe el
exces sive</w>
e ffici
dos ing</w>
defin ed</w>
cont ent</w>
condi tion</w>
con traindic
c ep
bre ak
b ri
acc oun
ab normal</w>
UN USED</w>
S ever
PRE C
PREC AU
PRECAU TIONS</w>
E ven</w>
B ot
A f
( used</w>
sus pec
se ve
r a</w>
psy ch
p ass</w>
ir y</w>
h our</w>
el imin
ch e
cer tain
R ec
L -
7 0
w rit
under going</w>
tal k</w>
subst anc
regar ds</w>
pro mis
ph ase</w>
oc ial</w>
ner v
mo re,</w>
manufacture r
l ast
iti es.</w>
in a</w>
fol low</w>
f y</w>
et al</w>
et ,</w>
employ ment</w>
dro p
deriv ed</w>
b ed</w>
a -
Portu gal</w>
O f</w>
M et
Lim ited</w>
EU/1/00/13 1
3 -
3 ).</w>
work .</w>
us e,</w>
sub mitted</w>
s cho
mono therapy</w>
is ion</w>
fe el</w>
fe ed</w>
extre m
er ic
distrib ution</w>
der .</w>
consi der</w>
combin ed</w>
c att
b list
an t,</w>
altern ative</w>
In vented</w>
7 ,</w>
.. .</w>
v ul
uni form
trans f
tak es</w>
surg ery</w>
sul ph
star ted</w>
s ligh
rap id
propos al</w>
program me</w>
pre cau
poli tical</w>
p neumon
o pro
medicin es,</w>
main tenance</w>
ma b</w>
inu x</w>
f lo
exc ep
divi ded</w>
de d,</w>
cris is</w>
cont ents</w>
comp an
am oun
ab ine</w>
N A</w>
Man ufacture
HOL DER</w>
Fren ch</w>
ER A</w>
C V
Bec ause</w>
AN CE</w>
8 %</w>
( 1</w>
ut ro
transp l
ton n
see k</w>
require ments</w>
por te
pl es</w>
par ame
observ ed.</w>
n utri
n a</w>
microgram s</w>
medicin es.</w>
main tain</w>
giv ing</w>
exc ept</w>
er 's</w>
e ph
determin ed</w>
ag on
Wor king</w>
O c
w s</w>
ru b
reg i
pur pos
op tim
ond apar
ondapar inux</w>
n ucle
le t</w>
kin d</w>
it ary</w>
is es</w>
inter v
in spec
ib le</w>
ex ce
en h
e ve</w>
d s,</w>
d a</w>
clos ely</w>
be ta
at e
ap h
ant s,</w>
an sw
a im</w>
T ur
S ince</w>
O R
G mb
B ased</w>
8 ).</w>
6 %</w>
3 9</w>
( including</w>
( 0
vol un
un d
suff er</w>
so ft</w>
s in
refer red</w>
ras h</w>
pres su
ph as
ox y
over dose</w>
inter nal</w>
il ,</w>
i tion</w>
for me
ex posed</w>
creatin ine</w>
consump tion</w>
children .</w>
carc inogen
avi ren
al though</w>
a way</w>
TI V
Ph arma</w>
P ark
( N
y me</w>
vi ol
to p</w>
tivel y</w>
ti m</w>
th in
str a
solu tions</w>
ric ul
respon sib
re al</w>
produc tive</w>
proc ess
port un
phosph ate</w>
on az
ing ?</w>
in o
hand s</w>
hal f-
go es</w>
bin ding</w>
b ack
af t</w>
Ques tion</w>
Fir st
EU/1/00/13 2
EU R</w>
ER D
A N</w>
1 000</w>
waste water</w>
ti fic
op portun
om i
minim um</w>
mg )</w>
lan zapine</w>
in clu
ig n</w>
hi bi
f at</w>
ex tr
chec k</w>
at ors</w>
all ,</w>
P fi
O lanzapine</w>
8 ,</w>
6 9
- 1</w>
% ).</w>
v as
ter ,</w>
suffici ent</w>
su n
st ore</w>
st age</w>
so ,</w>
s tic
recommend ations</w>
ph ot
p um
oste opo
o trex
o od</w>
lab or
it able</w>
issu e</w>
invol ving</w>
infec tion.</w>
impa ired</w>
he um
har mon
form ul
fo vir</w>
er t</w>
consider ation</w>
common ly</w>
as .</w>
T ru
T rit
Stat es,</w>
RI SP
I V
D uring</w>
ver .</w>
tox icity</w>
thro mbo
them sel
st .</w>
sk in,</w>
pro per</w>
previ ously</w>
phys ical</w>
ne e
mem ber</w>
m ur
m er
m ,</w>
lo o
inte rest</w>
guid el
g /
ev ent
es ;</w>
en ol
ed ing.</w>
dog s</w>
disorder ,</w>
dec id
correc t</w>
conduc ted</w>
con cluded</w>
clean sing</w>
circumst ances</w>
cent ral</w>
bot t
act ing</w>
ac et
Slo ven
RISP ERD
PRODUCT S</w>
P u
P V
Ne w</w>
M R
D en
A ust
4. 5).</w>
ur inary</w>
um .</w>
ter ro
technolog y</w>
st re
se iz
se d,</w>
s la
ros s</w>
pharmac ovigilance</w>
pa rent</w>
ox ide</w>
out side</w>
ograp h
meth otrex
main ly</w>
le t
ini b</w>
ha z
grow ing</w>
ey el
ed :</w>
deter mine</w>
d ings</w>
com pati
bor n</w>
Un common</w>
T able</w>
S ome</w>
P r
F ol
9 0</w>
5 0%</w>
2 7</w>
x ,</w>
wor ks</w>
uniform ly</w>
u mab</w>
th .</w>
s ocial</w>
reduc ing</w>
re combin
po or</w>
on -
og lob
n ess
min or</w>
mar k</w>
m i
ism .</w>
ism ,</w>
immedi ate</w>
em s</w>
diagno sis</w>
di ure
chlor ide</w>
ar ds</w>
anc ed</w>
ag ricul
adv ice</w>
adv ant
O ffic
F RO
Ar ticle</w>
9 6/</w>
( 4
z heim
withdraw al</w>
vom it
tum our</w>
tox ic
sw elling</w>
ster oid
sh oul
sex ual</w>
s cal
s am
rel ating</w>
recombin ant</w>
quick ly</w>
placebo -
per si
n ation
n ame</w>
injec tions</w>
h ere</w>
f ron
eu tic
el ,</w>
da il
b ru
ation ?</w>
are :</w>
all y.</w>
ad ine</w>
act ually</w>
____ ____
S T</w>
MA R
M emb
Ital y</w>
Al zheim
A ID
(A4 -00
… …
wa y,</w>
w ard</w>
str ation</w>
sligh tly</w>
rap id</w>
r heum
pul monary</w>
ph y
pen s
particul ar,</w>
oc k</w>
m in</w>
m .</w>
l as
kidne y</w>
int oler
injec ted</w>
initi ated</w>
il ep
hypo glycaem
guar an
gr anted</w>
gr ad
ef aviren
docum ent</w>
cat eg
c over</w>
al y
ac u
ab norm
Subjec t:</w>
FOR MA
C )</w>
Aust ri
A B
A ,</w>
6 -
3 6</w>
' t</w>
tiv e,</w>
th ough
t ar
sw ab
sensi tive</w>
retur n</w>
replac ement</w>
relev ance</w>
p as
n i
mal ign
m od
ist s</w>
indu stri
i ro
g a
er cul
environ ment.</w>
degre e</w>
co ord
can di
calci um</w>
bal ance</w>
ad ver
ad ded</w>
P E
Ne verthel
In tro
IN FORMA
I r
Com mon
C lin
C al
C V</w>
5 /</w>
3 4</w>
wor sen
second ary</w>
sec tions</w>
s on</w>
ris k
possib le,</w>
pl an</w>
pharmac eutical</w>
per cent
le dg
le -
jo int</w>
in tr
he av
econom ic</w>
di tional</w>
decid ed</w>
conj unc
cl us
cl er
cl ass</w>
chang ed</w>
capac ity</w>
cap su
ac qu
W e
V III</w>
Th en</w>
S ch
Pre par
Heal th</w>
H ou
First ly,</w>
wat er.</w>
war ning</w>
up on</w>
ul cer
transp or
pregn anc
pat ch</w>
on set</w>
oe dema</w>
nur se</w>
mat ter</w>
ma king</w>
in de
h on
ex act
effec ts.</w>
del ay
ch lo
bus iness</w>
bio availability</w>
ant s.</w>
al isation</w>
U B
RISPERD AL</w>
O ther</w>
M M
L at
L E</w>
K E
I I</w>
8 4</w>
2 4
( the</w>
ver y
temperat ure</w>
super vision</w>
struc ture</w>
st ren
simp ly</w>
regar ding</w>
progres sive</w>
pre c
placebo .</w>
pen s</w>
n ic
le n</w>
inte gr
indu stry</w>
in stitu
fe wer</w>
f ar
excipi ents.</w>
el y.</w>
dist ur
di zz
di ff
d ?</w>
d :</w>
contraindic ated</w>
chlo ro
c ar</w>
alys is</w>
addres s</w>
ac ross</w>
V e
V al
A G
(0 )
yl ene</w>
v s</w>
ti t
thiaz ide</w>
t ou
system ,</w>
stren g
some one</w>
sit e.</w>
re ve
pol l
oglob in</w>
ob vi
metabolit es</w>
mach in
is ol
hol der</w>
har m</w>
go ti
g li
er ro
enti re</w>
des ir
der s</w>
der mal</w>
de l</w>
con ven
az one</w>
arthri tis</w>
Un fortun
S k
O ur</w>
INFORMA TION</w>
I N</w>
G -
E very
Be fore</w>
2 9</w>
- M
(C HM
ver sus</w>
vacc ines</w>
us h</w>
tub ercul
ste ps</w>
spec ies</w>
rapid ly</w>
pri v
pig s</w>
par ts</w>
or ph
loxac in</w>
k ept</w>
is e,</w>
gluc os
glob al</w>
f oc
et ine</w>
end ing</w>
em is
doct or,</w>
d s.</w>
cr im
confir med</w>
children ,</w>
ben z
assist ance</w>
a ys</w>
a red</w>
Tru dex
Pfi zer</w>
Park in
P RI
Opti S
O G
N O
Manufacture r</w>
In cre
I .</w>
EU/1/00/131 /0
Con sequ
9 ,</w>
/99 )</w>
/ 4
(CHM P)</w>
st and</w>
st -
spe aking</w>
sec re
saf e</w>
retro viral</w>
res ourc
recept or</w>
qu in
prolong ed</w>
ou s.</w>
ot e</w>
oph enol
open ia</w>
o z
o ro
ne t
materi als</w>
mark ed</w>
mal e</w>
m ob
know ledg
inform ation.</w>
inf us
in dependent</w>
if ied</w>
ide .</w>
id ov
g es
func tion
examin ed</w>
enc y
en larg
e ff
c ophenol
al most</w>
N E
J un
Fur ther
E L
Com mon</w>
9 8</w>
6 0
5. 2).</w>
( s)</w>
( 3</w>
ur ity</w>
tri al</w>
tic s.</w>
ti ous</w>
sup plement
stom ach</w>
s le
provi ding</w>
possib ly</w>
po e
peri od.</w>
ne goti
jo in
ine -
health care</w>
group .</w>
fi x
feel ing</w>
ey es</w>
extrem ely</w>
ep ilep
diseas es.</w>
cal cul
b rou
b ron
anti gen
adequ ately</w>
Parkin son
Oc tob
Neverthel ess,</w>
Ch in
A B</w>
w id
trac he
tr y</w>
th reat
sum mary</w>
si di
separ ate</w>
ro om</w>
re move</w>
re jec
pub lish
pub lic
ov ered</w>
on es</w>
maj ority</w>
liqu id</w>
li es</w>
k illed</w>
initi ation</w>
indic ate</w>
id ence</w>
hibi tion</w>
head ach
gre at
f ing
ery them
dest ro
dam aged</w>
correc tly</w>
chem o
b ate</w>
and s</w>
abdom inal</w>
Th er
St ud
S )</w>
M us
Gre ec
Gmb H</w>
E T
B er
5 8
4. 8).</w>
---------------- ----------------
(H -0
( hyper
war ds</w>
w ise</w>
up .</w>
ul c
thyro id</w>
t ex
se tting</w>
s low
ro w
rel ation
re ally</w>
pr ice</w>
percent age</w>
parame ters</w>
mou th</w>
month .</w>
m os
lim it
l un
j u
in take</w>
impro ved</w>
il .</w>
hi p</w>
func tion,</w>
fro z
financ ial</w>
dom in
conside red.</w>
consequ ences</w>
co ver
ch es</w>
ch ed</w>
c ru
att ach
ar yn
appro v
an k
act or</w>
ab sol
Wh o</w>
Re ad</w>
Ch ild
CYP3A 4</w>
B ri
4 6</w>
4 2</w>
3 )</w>
wom en,</w>
well .</w>
viv o</w>
tiv e.</w>
th ought</w>
t in
ste ad
rop in</w>
qu ite</w>
potenti ally</w>
pa y</w>
ov ascular</w>
mor tal
m om
le v
l en
import ance</w>
g al
exp lo
em ent
ell ed</w>
dr ink</w>
danger ous</w>
cophenol ate</w>
amoun ts</w>
am ide</w>
alf a</w>
al ong</w>
VE D</w>
H ung
C l
* ,</w>
wh e
vie w
ur on
til ity</w>
table t
sust ained</w>
subsequ ent</w>
sla ugh
pur pose</w>
princi ple</w>
poe tin</w>
per haps</w>
o very</w>
mar ro
insuffici ency</w>
ing s.</w>
ing ly</w>
hum ans</w>
fam ily</w>
environ mental</w>
ec h</w>
dri ving</w>
correspon ding</w>
cor tico
consum ers</w>
cl usion</w>
chem ical</w>
brou ght</w>
becom ing</w>
at eg
ari an</w>
anti body</w>
anim als.</w>
advis ed</w>
achi eve</w>
a wa
There fore</w>
Stud y</w>
R us
M erc
Luxembour g</w>
J oh
G I
FRO M</w>
Commun ity</w>
Common :</w>
C ol
C max</w>
B lo
9 .
. .</w>
vie w,</w>
th al
str ong</w>
stop ped</w>
stand ing</w>
s cre
res uspen
require ments.</w>
progres sion</w>
pro vision</w>
prescri ption</w>
pow der,</w>
orig inal</w>
onaz ole</w>
nause a,</w>
lac tic</w>
j a</w>
ing :</w>
in no
i an</w>
hi m</w>
exp iry</w>
exact ly</w>
erythro po
dos es.</w>
chlor ide,</w>
bloc k
b li
b a
at oid</w>
ag g
Trudex a</w>
T arc
PRODUCT S,</w>
P a
MATERIAL S</w>
M in
Intro n</w>
H er
F or
EU/1/00/132 /0
Coun c
Co -
Clin ical</w>
Af ter</w>
A .</w>
( B
( 5</w>
( 0)</w>
wor d</w>
t end
solu tion.</w>
s ent
reas on
re p
re ference</w>
medi an</w>
le uc
iz ed</w>
it h</w>
i es,</w>
form in</w>
e z
di lu
c all</w>
bre l</w>
b lin
am b
ac ts</w>
W ill</w>
UC H</w>
S h
S UCH</w>
RI VED</w>
RE LE
P i
En brel</w>
DE RIVED</w>
D NA</w>
CP MP</w>
C ,</w>
3 7</w>
z idov
wn ,</w>
well -
ve in</w>
v ess
tion ?</w>
tion )</w>
te red</w>
t ent</w>
studi ed.</w>
smo king</w>
serv ices</w>
ser ot
s cler
s atis
resul ted</w>
rec overy</w>
ot ox
ol s</w>
ml .</w>
mig r
ment :</w>
j ob
it 's</w>
ino trache
high -
haemorrha g
eutic als</w>
en ed</w>
dis order</w>
concentr ate</w>
car b
an u
al ed</w>
U r
Tran s
P reg
P eri
M a
AC E
A t
4 9</w>
1 00
02 2/</w>
  000</w>
wh il
w el
us sel
us ed,</w>
un used</w>
ti p</w>
t as
t a</w>
sw ell
supp ly</w>
sensi tiv
rou gh
rheum atoid</w>
requ est
reduc tase</w>
pre n
pi ec
out come</w>
our s</w>
ol d.</w>
oedema ,</w>
oc cas
neuro path
n =
mo fe
mofe til</w>
memb ers</w>
m arg
li ve</w>
iti es,</w>
is on</w>
ic ,</w>
i b</w>
hi stor
fl ec
fem ale</w>
fac il
f ru
enzy mes</w>
enc our
ed ;</w>
e ;</w>
docum ent
discontinu ation</w>
dis charg
ci al</w>
av oid
alco hol
ad ap
X X
Thir d
TIV E</w>
Peg Intron</w>
Lat vi
G lax
G M
Fin land</w>
CON ST
Br ussel
Am end
9 %</w>
37 2</w>
wor ds</w>
u ff
th is,</w>
techn i
ta st
specific ally</w>
sit es</w>
s wit
rese arch
re solution</w>
pro p
plas tic</w>
oty pe</w>
or s,</w>
ne utro
legis l
j our
high ly</w>
haem oglobin</w>
gr as
fract ure</w>
fr ic
f el
ex cluded</w>
em ent.</w>
e ar</w>
dy sp
dro p</w>
d one.</w>
com promis
com pens
cir cul
ch ar
catt le</w>
allow ing</w>
abil ity,</w>
a )</w>
Un common:</w>
SA R
S har
N T</w>
Further more,</w>
Ex peri
C or
8 .
200 6.</w>
yel low</w>
year ,</w>
weigh t.</w>
us al</w>
th ings</w>
t aneous</w>
supp lied</w>
success ful</w>
sp on
ro ut
prof ile</w>
proc ess.</w>
per man
ou ter</w>
og lit
o fovir</w>
medi a</w>
m ith
m it</w>
le ar
k g/</w>
in vest
ie ve</w>
ic s</w>
guidel ines</w>
gra m</w>
gr ant
froz en</w>
fr ag
for get</w>
embol ic</w>
ed )</w>
di et</w>
decre as
d -
ag u
ag en
With in</w>
Unfortun ately,</w>
T ra
Ro ad</w>
Rap id</w>
Preg n
P ub
Octob er</w>
Merc k</w>
K ar
In du
I B
HM G-
E ffec
E R</w>
D oc
Consequ ently,</w>
B M
20 %</w>
199 7</w>
(9 5%</w>
’ ,</w>
y cl
worl d</w>
transp a
t old</w>
t ation</w>
sub stit
st on
respectivel y.</w>
pow er</w>
pass ed</w>
osteopo rosis</w>
ob tain</w>
oS mith
mo del</w>
min ut
metabol ite</w>
m ix</w>
lo p
le d,</w>
is on
injec tions.</w>
id ,</w>
i atric</w>
g lo
g el
g ,</w>
fo od
en si
el se</w>
drin king</w>
dos e,</w>
dig ital</w>
difficul ties</w>
d op
cortico steroid
commun ic
com plain
bod y
bir th</w>
bab ly</w>
anti retroviral</w>
ang i
alog u
T r
S ept
PRO PRI
PROPRI ATE</w>
M ix</w>
M ay</w>
M ad
Jun e</w>
HMG- Co
Glax oSmith
D -
C ha
Al though</w>
Ad verse</w>
AP PROPRIATE</w>
7 6</w>
6 7</w>
2 50</w>
1 60</w>
. '</w>
( such</w>
z er
your self</w>
un less</w>
to m</w>
th ous
th is.</w>
su itable</w>
struc tion</w>
sol id</w>
so on</w>
ra rely</w>
ra ised</w>
partic ip
o si
nerv ous</w>
m mol
ion al</w>
howe ver</w>
happen s</w>
gi a,</w>
fav our</w>
f ondaparinux</w>
f ight</w>
enz a</w>
di ver
death s</w>
de grad
day )</w>
d in
cour se,</w>
cl aim
bl ad
bel ieve</w>
at es,</w>
ar y,</w>
ar di
activ ated</w>
Un der</w>
T ri
T re
T )</w>
Swed en</w>
Sever e</w>
P al
P ack
M S
M IR
Joh n
GlaxoSmith K
Fr ance,</w>
Experi ence</w>
A fric
6 )</w>
200 2.</w>
- related</w>
( as</w>
y ed</w>
week ly</w>
w ide</w>
tem por
ta x</w>
sugg est
su d
ster ile</w>
remov ed</w>
recogn ised</w>
re serv
provi des</w>
pro mot
polic y</w>
pe t
occur s</w>
o st
no thing</w>
mon ey</w>
man ufact
main tained</w>
inter pre
injec tion,</w>
ing s,</w>
fav our
emb ry
ed ly</w>
eas ily</w>
diab etic</w>
desir able</w>
de al
consi st
cholester ol</w>
chloro thiazide</w>
cartridg e</w>
c ost</w>
bacter ial</w>
amp ou
Th e
SP ON
Rus si
Reg ulation</w>
RE SPON
L ev
He pati
HMG-Co A</w>
G F
D ose</w>
C H</w>
B ar
AC R</w>
A SE</w>
9 /</w>
3 8</w>
00 2</w>
0. 0
w ron
volun te
v ice</w>
us hed</w>
te ach
struc tions</w>
st y
st ated</w>
spe ak
smo k
s co
represent ative</w>
repe ated</w>
rel ative</w>
ref ers</w>
re sol
re flec
ras h,</w>
pro vis
pend it
ou red</w>
n e</w>
mortal ity</w>
level s.</w>
her pes</w>
func tion.</w>
frequ ent</w>
fra me
expo su
es sion</w>
em ent,</w>
ell it
distrib u
d ine</w>
ch est</w>
ch ,</w>
ca using</w>
bra in</w>
att ack
ar ter
anti viral</w>
ang e</w>
al ities</w>
agre ed</w>
ag lip
ag e
T ell</w>
S tre
S al
Pro top
Novo Mix</w>
En gl
Alzheim er's</w>
ye th
x i
w all</w>
vic tim
ver te
ur it
transi ent</w>
themsel ves</w>
sup pres
sugg est</w>
si vely</w>
s qu
s !</w>
ro t
ro ad</w>
repor t,</w>
relation ship</w>
r s</w>
pro bably</w>
pri l</w>
pre fer
pol ys
physici an</w>
pes tic
opin ion</w>
nee ded.</w>
lun g</w>
lo ad
li ving</w>
le d.</w>
lam iv
k ill
ir a</w>
half- life</w>
fron t</w>
fin dings</w>
ex pendit
ex pen
enc y.</w>
do ing</w>
direc tive</w>
countri es,</w>
circumst anc
cardi ac</w>
capsu le</w>
c am
an a</w>
a uc
Y Y
T R
T A</w>
R ep
Or g
Mix 25</w>
M E</w>
In structions</w>
EX UB
B I
B AT
A /</w>
6 5
00 1</w>
( 1
vir uses</w>
val id</w>
v ascular</w>
ud e</w>
trans dermal</w>
stric t</w>
se d.</w>
sch e
ques tion
produc t
pro v
pos t</w>
pl ant</w>
peop le
pen ,</w>
pa inf
oc y
me at</w>
low ing</w>
le ak
labor atory</w>
la w</w>
in ity</w>
il ly</w>
id .</w>
heav y</w>
he ad</w>
groun d</w>
gly co
fam il
f ever</w>
elev ated</w>
diffe ren
contain ed</w>
consum er</w>
con stitu
cas e,</w>
bro ken</w>
bo x
blist er</w>
an tic
amend ment</w>
ag rap
Virafer on</w>
Third ly,</w>
T y
Rep ub
RI NG</w>
R ib
Pharmac ovigilance</w>
N eu
My cophenolate</w>
M y</w>
H ep
GlaxoSmithK line</w>
German y,</w>
F er
F ac
4 1</w>
work ers</w>
us ers</w>
up ,</w>
u tr
tubercul osis</w>
transf er</w>
stic k</w>
sor i
se ven</w>
p ir
p ed,</w>
organ is
or bate</w>
odi c</w>
o dium</w>
ne l</w>
metabol ism</w>
m other</w>
ish ed</w>
inclu de
ic k</w>
group s.</w>
gl ass</w>
fun gal</w>
enc ies</w>
emp ty</w>
el etal</w>
ef ul</w>
e ).</w>
docum ents</w>
defin ition</w>
com ing</w>
ch ing</w>
certain ly</w>
benef it
behavi our</w>
b ility</w>
amin o</w>
allow s</w>
ac ks</w>
V A
U sing</w>
SI B
SIB LE</w>
RELE ASE</w>
Pre vention</w>
P lac
N -
In tron
I ,</w>
H e</w>
H O
Ger man</w>
D es
CYP2 C
C T
BAT CH</w>
Am eric
9 0
4. 2).</w>
work ed</w>
ur y</w>
t ext</w>
sul f
ro logical</w>
repe at</w>
reac h
radi ation</w>
pre ci
pers ons</w>
patient s)</w>
our ce</w>
oc ular</w>
n 't</w>
my el
metabol ised</w>
low est</w>
iz ation</w>
investig ated</w>
in hibition</w>
ig e</w>
ic e.</w>
i er</w>
fo od,</w>
f lex
eu /
eu/ .</w>
ent ally</w>
enc y,</w>
distur b
deb ate)</w>
de pression</w>
d ar
cros s-
cr imin
coun ts</w>
consi stent</w>
conf idence</w>
compati ble</w>
cardi ovascular</w>
ar m</w>
al one,</w>
TI NG</w>
SU B
S Y
RESPON SIBLE</w>
Par ty</w>
P ri
MANUFACTU RING</w>
M ore</w>
Im port
F actor</w>
wor se</w>
w ik
ur ine</w>
ul in
tr ade</w>
syndro me,</w>
suspec ted</w>
rel ap
quanti ty</w>
pre h
par ties</w>
p ite</w>
ot al</w>
open ing</w>
necessar y,</w>
n es
medic ation</w>
m ess
loo ks</w>
lo ad</w>
li v
leuk aemia</w>
legis lation</w>
l )</w>
k et
k a</w>
il is</w>
hy p
high est</w>
harm ful</w>
haem at
h u
h es
g er</w>
fall ing</w>
fail ure,</w>
f ill</w>
ey e,</w>
excre tion</w>
e f</w>
dispos al</w>
di e</w>
dec ide</w>
de al</w>
cre di
contr ast</w>
con ges
con c
clos ed</w>
ch ance</w>
c ig
bu ild
bron ch
b ral</w>
aut om
ari es</w>
applic ations</w>
ap parent</w>
an s,</w>
Wh ile</w>
U /</w>
Res pon
Q U
O Ü</w>
O b
M ic
L illy</w>
Europe .</w>
B i
Ad mini
3 0%</w>
00 4</w>
   </w>
y c
v ag
t y.</w>
sup port
studi es.</w>
stud y.</w>
so -
sal t</w>
roun d</w>
ro ute</w>
rh inotrache
respon ses</w>
reduc es</w>
pre serv
por ts</w>
poin ted</w>
per fec
p ut
ox ib</w>
ogen ic</w>
n ight</w>
men opa
lo t
life -
la w
l ess.</w>
ion s.</w>
inhib its</w>
ide a</w>
id s</w>
i ,</w>
hospit al</w>
hap pen</w>
h ab
function ing</w>
fi br
f ish</w>
f ast</w>
ep is
efaviren z</w>
e .
dou b
dos e-
discontinu e</w>
def ec
comm er
cl ar
canc er.</w>
bacter ia</w>
at o
appro ach</w>
and /
and/ or</w>
an -
amend ments</w>
aglip tin</w>
acc um
a ?</w>
Th ro
T w
Sept ember</w>
SUB ST
S yn
S ver
S ome
S ci
Rib avirin</w>
Pack age</w>
Nov ember</w>
M il
In fec
CONST A</w>
@ m
4 7</w>
2 5%</w>
0 4/</w>
vot e</w>
vehic les</w>
u ated</w>
tri glycer
treat ing</w>
to ok</w>
titr ation</w>
swab s)</w>
subst anti
str um
spe ak</w>
so- called</w>
sim vastatin</w>
sh all</w>
serot onin</w>
sche du
require s</w>
qu ot
pre vent
pass eng
oun d
on to</w>
om et
ol ys
o ti
o int
ne tic</w>
ne ph
n ia</w>
les ions</w>
l d</w>
im ag
exerc ise</w>
ex pres
es ).</w>
el .</w>
ec u
condi tions,</w>
competi tion</w>
cl on
ch all
bel i
as pec
an rix</w>
agricul tural</w>
acqu ired</w>
ac compani
W ith</w>
Tarc eva</w>
Sver ige</w>
St ar
R em
Parkinson 's</w>
N ob
Indu stri
E E
D oh
C ent
Av oid</w>
AC TIVE</w>
8 0
6 3</w>
1 1
( n=
yeth ylene</w>
y :</w>
where as</w>
weak ness</w>
we b</w>
war n
u v
trans l
tra vel
tr ic
t oc
syring es</w>
suic ide</w>
ro ad
publish ed</w>
popul ation.</w>
po ver
persi stent</w>
ov ere
or ies</w>
or ic
open ed</w>
numb ers</w>
no ted</w>
n ess.</w>
mil k,</w>
mil est
met formin</w>
ma il
it e,</w>
in adequate</w>
ic h,</w>
gen e</w>
fun dam
every thing</w>
et h</w>
es '</w>
er ated</w>
effec t.</w>
ed s</w>
dis ast
dilu ted</w>
conver ted</w>
col our</w>
chro mos
centr e</w>
cal cit
bud get
bri dg
bod y,</w>
bel ong
av ing</w>
at s</w>
an aem
af il</w>
Virafer on
Ve terinary</w>
U p
Shar p</w>
S im
Pharmac euticals</w>
P -
A mon
200 1</w>
/99 ):</w>
( D
vis ion,</w>
ure s.</w>
tur n
tis h</w>
table .</w>
t y,</w>
t ors</w>
surve ill
sur roun
suic idal</w>
str ain</w>
sp read</w>
siz e</w>
resul t,</w>
respec t</w>
resi du
r ine</w>
procedu re.</w>
per forme
per cent</w>
pass es</w>
ol .</w>
o t</w>
n or</w>
n one</w>
mat ure</w>
low .</w>
ir besartan</w>
inhib it</w>
ing u
increas ed.</w>
in side</w>
hy poten
hou se</w>
fin ding</w>
environ ment</w>
e tr
e !</w>
diarrhoe a</w>
diabet es,</w>
coun t</w>
continu es</w>
condi tion
compar able</w>
compan ies</w>
comp any</w>
cl es.</w>
chall eng
c ust
blo od
bli ster
b s</w>
b order</w>
aryn g
ar rang
ar ily</w>
an ia</w>
ampou le</w>
adoles cent
accompani ed</w>
USE R</w>
Sk in</w>
Org an
Mix 50</w>
Memb ers</w>
Incre ased</w>
Import ant</w>
G rou
B us
B en
An d</w>
3 3
( 4</w>
zidov udine</w>
z on
z i
vomit ing,</w>
vi al
to -
ti es.</w>
syndro me
swell ing,</w>
situ ations</w>
se p
regim en</w>
re fe
psych iatric</w>
problem s,</w>
pro mo
pre sid
pr urit
po ison
pl ay
pen .</w>
par agrap
painf ul</w>
p H</w>
oun c
organ ic</w>
order s</w>
occur .</w>
o ffici
mut agen
ment s,</w>
market ,</w>
m ellit
iro n</w>
immuno deficiency</w>
im ination</w>
i or
haem ophil
gradu ally</w>
fut ure</w>
exc ess</w>
em ul
el imination</w>
educ ation</w>
e ight</w>
di oxide</w>
demonstr ate</w>
de ad
con sci
cell s.</w>
cas es.</w>
c od
br ing</w>
bot tom</w>
beg in
an aesthes
al ist</w>
ag gres
Ta king</w>
MAR KE
MARKE TING</w>
L O
L ,</w>
King dom
J e
Ir besartan</w>
H a
Characteris tics,</w>
CI :</w>
C z
C M
Author isations</w>
A pril</w>
6. 6.</w>
6. 3.</w>
5 .</w>
5 )</w>
4 4</w>
................................ ................................
( range</w>
wom an</w>
w der</w>
v e,</w>
ur o</w>
udi es</w>
ud g
u ly</w>
tri als.</w>
tiv a</w>
st ag
s /
resourc es</w>
renc y</w>
re s.</w>
profession al</w>
procedu res</w>
pre domin
porte ur</w>
pe p
or i
opath y</w>
op ha
ob lig
nat ure</w>
mother s</w>
minim is
milest one</w>
mg .</w>
meth yl
me et
m as
lo ok
lo dip
l ater</w>
in strum
in ess,</w>
ide d.</w>
hydro chlor
hop e</w>
grant ing</w>
fl ush
fac e,</w>
ech nolog
e. g.</w>
e k</w>
e ep</w>
de ep</w>
cy cle</w>
cartridg e.</w>
care ful</w>
bre ak</w>
ati vely</w>
appro ach
an xi
an aemia</w>
am ma
agre ement</w>
T RI
St udies</w>
S c
Pregn ancy</w>
Pe g</w>
P AR
L t
L abor
L )</w>
Ital y,</w>
Hepati c</w>
H aem
E r
E V
De po
Commission 's</w>
B asal</w>
B .</w>
4. 3).</w>
19 7
18 0</w>
- C
( debate)</w>
( V
( HIV
v ents</w>
tr ag
tim es.</w>
ther .</w>
th o
t al</w>
st uff
spo on</w>
sim ple
sec urity</w>
recon stitution</w>
re productive</w>
propor tion
precau tions</w>
phy lax
perman ent</w>
od y
o le
nutri tion</w>
norm ally</w>
ne utr
minimis ation)</w>
me al</w>
manufacture r</w>
m ist
li ber
lead s</w>
langu age</w>
inf ants</w>
indu str
in form</w>
ha m
h as
gal act
establish ed.</w>
epis od
e tax
dem and</w>
d re
coun ter
control .</w>
condi tions.</w>
compar ison</w>
ch ick
ch aracter
c ess
bl ack</w>
bil li
b lu
av o
at or.</w>
as is</w>
al ity.</w>
ag end
abol ism</w>
W il
T .</w>
R is
R MP</w>
Po wder</w>
H ar
EXUB ERA</w>
EU R
E m
Doh me</w>
Chin ese</w>
5. 1).</w>
4 .</w>
200 7</w>
200 0
00 3</w>
week .</w>
wat er,</w>
vot es</w>
vis ible</w>
verte bral</w>
vacc ine.</w>
un known</w>
tur n</w>
tre s</w>
th en
sy ru
su ffe
require d.</w>
rel ation</w>
reac tion,</w>
r ul
r im
post- marketing</w>
pa in
p ra
ox id
ox etine</w>
or ts</w>
on ium</w>
ogen ous</w>
nause a</w>
min d</w>
lin ked</w>
l ys
l ines</w>
l in</w>
l f
l es,</w>
invol ves</w>
inno v
inf o
individu als</w>
include :</w>
h in
h im
frame work</w>
forc ed</w>
for g
fix ed</w>
exten sion</w>
effec ts,</w>
democ r
del ay</w>
cor ne
consul t</w>
cl im
citiz ens</w>
cha in</w>
ch ol
breath ing</w>
bas ic</w>
asth ma</w>
ani um</w>
adop ted</w>
U k
The ir</w>
Pu h
Protop y</w>
Pl an</w>
P ot
P os
Le afle
LD L</w>
L U
K wik
F our
EU/1 /99
EU/1/99 /1
D an
Bot h</w>
4. 4</w>
00 6</w>
0. 00
. :</w>
(S )</w>
ï ve</w>
w ill
vi al.</w>
tain ing</w>
t ol
syru p</w>
super vis
stit ute</w>
sec tor</w>
righ ts</w>
rever sible</w>
res s</w>
recor ded</w>
rec ur
rec over
reac tions.</w>
prescri p
pos ite</w>
pers ist</w>
peop le,</w>
paren ts</w>
oper ating</w>
me eting</w>
is ed,</w>
inhal ed</w>
includ es</w>
in ated</w>
hypoglycaem ia</w>
hydr ate,</w>
group ,</w>
for ce</w>
fo ot
f ent
f .</w>
extr a</w>
excipi ents</w>
ex clu
er ation</w>
ed ed</w>
e ase</w>
di hydro
detec ted</w>
dem enti
complic ations</w>
com preh
characteris tics</w>
care ful
c overed</w>
c id
b ag
ation :</w>
at ure</w>
as one</w>
am us
al ine</w>
accid ents</w>
ac avir</w>
Viraferon Peg</w>
Uk ra
S S</w>
Re Fac
ReFac to</w>
R A</w>
J o
In jec
In f
Hy dro
Heal th
F lex
E fficacy</w>
An ti
Amon g</w>
AID S</w>
5 5</w>
( ≥</w>
( pharmacovigilance</w>
z o
yl ated</w>
y p
week )</w>
vaccin ated</w>
v ar
tion :</w>
t ure
symptom atic</w>
sty le</w>
sh or
sen s
se tt
sal e</w>
run ning</w>
random ised</w>
r am
pre dic
platel et</w>
p =
p ,</w>
orig in</w>
oglit azone</w>
objec tives</w>
o wn
nucle ar</w>
n ine</w>
men ing
memb ran
land ,</w>
l eng
it ation</w>
introduc tion</w>
induc ed</w>
in ser
implement ation</w>
im aging</w>
he pat
guaran te
gu e</w>
f ying</w>
f ri
etax el</w>
emplo ye
dou ble
diseas es,</w>
diagno sed</w>
de p
dang er</w>
concern s</w>
coll ap
cl assi
cho ose</w>
ch .</w>
ce re
b our
appe ared</w>
app li
ap hy
and .</w>
amp oul
am lodip
ag ent</w>
ag ement</w>
absor bed</w>
ab s
T rac
T N
T ,</w>
S ide</w>
P ul
P en
O s</w>
MA H</w>
Lo ok</w>
IC AL</w>
I ).</w>
EU/1/0 8
EU/1/08 /4
E ach</w>
Depo Cy
C H
Blo od</w>
9 5</w>
15 0
+ 35
your sel
y s.</w>
us er</w>
ur y,</w>
tu be</w>
tri als,</w>
treat ments</w>
tic ,</w>
thre sh
th is
termin al</w>
str ateg
sp aring</w>
sor t</w>
sm all
sc ore</w>
rough ly</w>
recept ors</w>
re ich</w>
prote in
pa id</w>
p sori
oc ardi
neutro pen
n igh
my c
methotrex ate</w>
low ering</w>
l ung
k g/
infec tious</w>
impair ment:</w>
h und
gu e,</w>
g n</w>
g est
g em
form ed</w>
fi ed.</w>
f our
f en
es opha
eph al
do wn
disorder s:</w>
dis appear
delay ed</w>
cre ate</w>
concer n</w>
co- administered</w>
chem ic
c ough
beli ev
beg in</w>
b om
ass ess</w>
al ity,</w>
adul ts.</w>
W ar
Treat y</w>
Tel z
Stat es.</w>
Presid ent</w>
Portu g
Per haps</w>
N um
Me th
Mad ri
MA O
M ost</w>
M o
Is ra
Gu id
F -
Every thing</w>
Europe ,</w>
EMEA .</w>
DepoCy te</w>
D y
Bri tish</w>
9 )</w>
200 3</w>
2 2
Ö ster
Öster reich</w>
y s,</w>
wom en.</w>
whil st</w>
ver s</w>
tre n
trans mission</w>
thromb ocyt
techni qu
te en</w>
t rou
syn thes
sus cep
subcut ane
sk á</w>
s ource</w>
s ound</w>
rub ber</w>
ris k.</w>
ri st
ri a</w>
reve aled</w>
respon d</w>
regul arly</w>
r ying</w>
por ted</w>
peg interferon</w>
p ush</w>
oun ds</w>
os ensi
optim al</w>
op e</w>
ond el
oint ment</w>
offic ial</w>
ob es
o ver,</w>
minim isation</w>
m m
is )</w>
ir ub
industri al</w>
inde ed</w>
increas ed,</w>
in ess
i es
i el
i di
har d
gly c
fer tility</w>
f um
exper im
expendit ure</w>
erythropo ie
erg ic</w>
elec tr
e /</w>
develop ment.</w>
decre ases</w>
de x</w>
de vice</w>
countr y,</w>
con vul
compe tent</w>
com for
co operation</w>
cig are
c ut</w>
blad der</w>
b iv
az ep
asth en
ar s</w>
ar dis
antic ip
al -
accid entally</w>
a meth
Y ondel
T M
T -
Slo v
S -
Rap tiva</w>
Presid ent,</w>
PRODUC T</w>
O ver
J ust</w>
J uly</w>
Intron A</w>
F ax
C ap
Bo x</w>
B as
Ar e</w>
9 00</w>
- like</w>
un likely</w>
un it</w>
un desirable</w>
tw o-
treat ment
ton .</w>
th at.</w>
th at
t an
stand ards</w>
sit e,</w>
sh oc
ser ve</w>
resul ts.</w>
restric tions</w>
ref rig
recogn ise</w>
re view</w>
predomin antly</w>
pr o</w>
pol yethylene</w>
placebo- controlled</w>
pl ans</w>
pi pet
perform ance</w>
organ isations</w>
oc lon
no ti
no te</w>
ner ve</w>
n or
n asal</w>
mmol /</w>
ml /</w>
menopa usal</w>
me t</w>
mag netic</w>
los artan</w>
li ves</w>
leak age</w>
l ost</w>
jo b</w>
inv as
intr amus
inter actions</w>
inter act</w>
ing )</w>
indic ation</w>
inc in
in ic</w>
im pl
i ble
i .
hyperten sive</w>
he par
for ward</w>
eyel id</w>
exerc ised</w>
ex ac
equip ment</w>
elec tron
dis car
depend ing</w>
de ep
cor por
concer ning</w>
con st
ca st
c iv
c ic
bo x</w>
bo ard</w>
attach ed</w>
are ,</w>
ar ia</w>
appropri ate.</w>
an s
alog ue</w>
al loc
al ism</w>
ad al
acid s</w>
acc ur
acc o</w>
Wor ld</w>
U K
Su omi
Par k</w>
M IU</w>
L y
L am
Hou se</w>
HA R
F ood</w>
EUR  
E qu
Commission ,</w>
C an</w>
C a
C CI
Belgi um</w>
B oe
Ac ute</w>
8 -
(hyper sensitiv
( 1.
y ;</w>
worl d
wh ich,</w>
we ar</w>
vom iting</w>
vir us,</w>
vir us
v e.</w>
ut ing</w>
under stand</w>
ulc ers</w>
tri c</w>
table ts,</w>
sub sidi
slow ly</w>
sh el
se ems</w>
s ess
s chem
s an
repor ted.</w>
red ness</w>
re s,</w>
r in
prof loxacin</w>
pro of</w>
pe ak</w>
over -
opath y,</w>
obvi ous</w>
o tide</w>
men tion</w>
machin es.</w>
long -
la z
l ish</w>
j udg
iz e</w>
interv als</w>
inform ed</w>
ine )</w>
in duce</w>
ific ation,</w>
id om
ia ),</w>
hel ps</w>
get ting</w>
fre e
fig ure</w>
fam ili
exam ination</w>
et y,</w>
elimin ated</w>
e poetin</w>
death .</w>
day s,</w>
com b
co st
calcit onin</w>
c u
c ro
c ame</w>
but ton</w>
bud get</w>
bro ad
blin d</w>
ble ed
belo w
avo ided.</w>
attemp ts</w>
at ropin</w>
at es.</w>
as e,</w>
ann ual</w>
ag ul
ag en</w>
act .</w>
abnorm alities</w>
Y ET
Wh ite</w>
W y
V ANCE</w>
Telz ir</w>
T e
S uspen
S ing
Ques tions</w>
P R
NA ME</w>
Fol lowing</w>
D u
D o
Belgi um,</w>
Ag ency
7. 5</w>
4 )</w>
200 8.</w>
( another</w>
( G
year s)</w>
year -
work ,</w>
week s,</w>
ver sion</w>
val s
v ac
un iver
un its</w>
ulin um</w>
tox in</w>
tig mine</w>
there by</w>
the tic</w>
ta r</w>
sust ain
sup ple
si gn</w>
ris ti
require ment</w>
re verse</w>
re :</w>
quanti ties</w>
qu ar
potassi um-
plas ma
pipet te</w>
phylax is</w>
peop le.</w>
pe ac
os is.</w>
om er
ol der</w>
off -
no e
neph ro
n ing.</w>
n al
ml ,</w>
micro biological</w>
men ,</w>
m and
m 2</w>
ly ing</w>
le ave</w>
l s</w>
l ,</w>
join ed</w>
it er
irrit ation</w>
inter vention</w>
inform ation,</w>
in ver
has n't</w>
happen ed</w>
haemorrhag e,</w>
h and</w>
gener ation</w>
g sk
g ently</w>
fish er
fast ing</w>
exper t</w>
expec t
en rol
dou ble</w>
disp la
deb ate</w>
dat ab
cy to
corne al</w>
bu y</w>
bas is.</w>
as se
am pren
am ended</w>
ad ding</w>
T lf
Suspen sion</w>
Spec ial</w>
S il
Respon se</w>
Pub lic</w>
Prepar ation</w>
OL OG
Neu pro</w>
N G
Injec tion</w>
Hum ira</w>
E ston
E F
E .</w>
Den mark</w>
Co- administration</w>
Characteris tics</w>
C R
B re
B YET
9 9
9 0%</w>
8 5</w>
7 -
6 6
4 4
3. 5</w>
10 -
00 7</w>
y a</w>
worsen ing</w>
wh at
w ent</w>
w anted</w>
transfer ase</w>
top ical</w>
ti cles</w>
ther ,</w>
te c</w>
t ures</w>
t ing
suscep ti
surroun ding</w>
ste p.</w>
st ed</w>
sp ir
si x
shoul d:</w>
short -term</w>
se ud
se min
rot ated</w>
ret in
ras h
radio active</w>
r al
psy cho
projec t</w>
parti al</w>
ot ec
os ,</w>
on going</w>
on e-
occur ring</w>
na ïve</w>
n on</w>
n ,</w>
mus cle
mg ,</w>
meth ods</w>
man ner</w>
mach ines</w>
lor at
lim its</w>
ligh t.</w>
l .</w>
inst ance,</w>
induc tion</w>
ic e,</w>
ic .</w>
hydro gen
hydr ate</w>
hab it
h ot
h ec
gl ut
g ain
forg ot
exac er
ep ide
enlarg ement</w>
enc ephal
e '</w>
double -
disp er
diarrhoe a,</w>
deter ior
des pite</w>
d le</w>
conven tional</w>
contrib ute</w>
conf us
compon ent</w>
col oured</w>
cir rh
candi di
canc er,</w>
cal ici
buil ding</w>
appl ying</w>
ap pointed</w>
ampoul es</w>
affec ting</w>
acu ity</w>
accid ental</w>
absol ute</w>
Yondel is</w>
SP C</w>
OLOG ICAL</w>
Leafle t</w>
IC H</w>
I ris
G li
G l
Fax :</w>
E -
D ub
D ev
D )</w>
Cz ech</w>
Child ren</w>
Be ta
Amend ment</w>
A F</w>
9 1</w>
4 50</w>
( 6</w>
( 1.5</w>
” .</w>
viol ence</w>
ur tic
under stand
tri g
transpl ant</w>
tog e
to day</w>
tic .</w>
thrombo embolic</w>
t ure.</w>
surveill ance</w>
statis tics</w>
sh op
scler osis</w>
scal e</w>
respon se.</w>
regul ar
re l</w>
proper ties</w>
pris on
popul ations</w>
polys orbate</w>
peri od,</w>
ody nam
minim ise</w>
me ti
m ir
m ic</w>
las tic</w>
lamiv udine</w>
lab elled</w>
l es.</w>
k er
is ed.</w>
is c
is ation.</w>
ir ing</w>
ion s,</w>
interv al</w>
inter rup
insuffici ent</w>
ing ;</w>
im pression</w>
ild agliptin</w>
il e
id es,</w>
ho od</w>
haemophil ia</w>
haem odi
ha ir</w>
great ly</w>
gras tim</w>
fut ure,</w>
fl u</w>
fact ,</w>
exclu ded.</w>
ex a</w>
et an
es p
em ia</w>
dos ing.</w>
discus sed</w>
dis appear</w>
del iv
cont amin
citiz en
carcinogen ic</w>
carb on</w>
calcul ated</w>
c ou
breast-fe eding.</w>
bil irub
becom es</w>
answ er</w>
all .</w>
ad one</w>
activ ity.</w>
abil ity.</w>
ab acavir</w>
a x</w>
V er
V acc
Tlf :</w>
T im
S ou
S an
S ON</w>
Num ber</w>
N ag
MANUFACTU RE
M A</w>
L ith
L .</w>
El i</w>
Den mark
CCI D
BI OLOGICAL</w>
B ay
@ gsk
5 5
4 9
4 2
20 ,</w>
. com</w>
(hypersensitiv e)</w>
( with</w>
ο υ</w>
ί ου</w>
y )</w>
wa iting</w>
w on
victim s</w>
vi rological</w>
v es
us eful</w>
un treated</w>
u c</w>
transpl ant
ti es,</w>
th an
ten ofovir</w>
surg er
sum m
sol id
sit y.</w>
seve re,</w>
s light</w>
re t</w>
rang ing</w>
r .</w>
prim arily</w>
porte ur
pack age.</w>
pac ks</w>
p y
oxy gen
other s.</w>
os k
oph thal
on ly.</w>
om en
ne ,</w>
mix ture</w>
mix ing</w>
malign ant</w>
m el
ly -
los por
lo t</w>
larg er</w>
l a</w>
k er</w>
issu ed</w>
im migr
ib er
hormon es</w>
h ring
gra v
g ir
for war
flu id</w>
fe ver,</w>
fe eding</w>
fe eding.</w>
f f</w>
ex pression</w>
ent an</w>
en ough
ed -
dys function</w>
de -
dam ag
cre am</w>
corticosteroid s</w>
coord ination</w>
concomit antly</w>
con currently</w>
cap it
c el
avoid ed</w>
atic ally</w>
as e.</w>
are a,</w>
any l</w>
anim als,</w>
angi ot
an alogu
am ination</w>
air cr
adv anced</w>
achiev ing</w>
a b</w>
U S</w>
R )</w>
Portug al,</w>
P an
Offic e</w>
OP TI
O ver</w>
Lith u
Kwik Pen</w>
IN I
Greec e,</w>
Ch risti
Ch ang
C HA
B y</w>
B a
Ap plic
Admini stration</w>
7 5
15 %</w>
1 A
( O
( I
( <</w>
z ,</w>
y !</w>
wh o
weigh t,</w>
w ish
urg ent</w>
un stable</w>
un it
u z
to wards</w>
ti gh
ter s.</w>
st ates</w>
s en</w>
ro ph
ris ing</w>
rhinotrache itis</w>
reli able</w>
reduc tions</w>
qual ific
purpos es</w>
pro hib
pres ents</w>
pow er
plac e,</w>
pl a
phen yl
pan cre
pal ms</w>
ous ness,</w>
ot echnolog
opro x
op raz
om s</w>
om al
oclon al</w>
o esopha
multi -
mor ning</w>
mob il
mil k
m uc
ly :</w>
ke ep
is ms</w>
invas ive</w>
il legal</w>
headach e,</w>
hand ling</w>
gen otype</w>
galact ose</w>
g ast
g as</w>
fent anyl</w>
fat al</w>
fact ory</w>
f low</w>
f la
et ary</w>
erythropoie tin</w>
ent y</w>
ent or
ens in</w>
end s</w>
elec tro
effici ent</w>
e uro</w>
drop ped,</w>
dis sol
dis oprox
di ed</w>
dex ameth
detec tion</w>
control s</w>
consul t
consider able</w>
con clus
compar t
circul ating</w>
cic lospor
character ised</w>
cha ir
ch e</w>
bur den</w>
buil d</w>
belo w.</w>
bat ter
b um
as h</w>
ar ri
ar rest
angiot ensin</w>
an i</w>
ag ree</w>
af ter
aem ia,</w>
adi ly</w>
a u</w>
With out</w>
V ,</w>
Trit anrix</w>
Trac le
Ther ap
TI N</w>
S pan
S and
R i
OPTI SON</w>
M er
I X
G astro
Ex cipi
E very</w>
E ff
Can di
CHA MP
Al l
7 4</w>
7 1</w>
6 8</w>
2. 0</w>
10 ,</w>
00 5</w>
( n</w>
( e.g.</w>
( L
( 3
' and</w>
win do
w ish</w>
vess els</w>
vacc ine,</w>
tum ours</w>
tra ditional</w>
tr ad
ter s,</w>
tas ks</w>
sur pris
subsequ ently</w>
stimul ates</w>
ste ad</w>
som no
sol d</w>
so f
si rolimus</w>
si des</w>
seri ously</w>
scho ol</w>
s ’</w>
s  
s ent</w>
ri p
retur ned</w>
respectivel y,</w>
reac t</w>
program mes</w>
profession als</w>
prin t</w>
pri or
plac e.</w>
par ty</w>
par liam
pack ag
observ ation</w>
o side</w>
n ar
n .</w>
mutagen ic</w>
mov ing</w>
mist ak
mechan isms</w>
me d
marro w</w>
mac ro
lorat adine</w>
lit er
l o</w>
l ine
it ems</w>
ist s,</w>
isol ates</w>
is tic</w>
involv ement</w>
initi ative</w>
indic ations</w>
hydro chlorothiazide</w>
health .</w>
he im</w>
govern ment</w>
giv en.</w>
fish ing</w>
fi ed,</w>
far in</w>
ex ist</w>
evalu ate</w>
end er</w>
em phas
ell a</w>
ech n
discus sion</w>
dic t
democ rac
de red</w>
cont in
con ce
clo tting</w>
circumstanc es.</w>
cess ation</w>
bus iness
bloc king</w>
bin ds</w>
behavi our
b order
avir /</w>
at ing,</w>
arg um
are as.</w>
aph ane</w>
antigen s</w>
al ert</w>
advant ages</w>
administr ative</w>
admini ster</w>
admini ste
acet yl
Y et</w>
T O</w>
Spec ification,</w>
S ur
R a
Pul monary</w>
Man agement</w>
MIR C
MANUFACTURE R</w>
M ab
Lt d</w>
J anu
In gel
H EX
G e
Fur ther</w>
F ree</w>
Dos age</w>
C am
C L
B al
B ,</w>
Ad ditional</w>
AL T</w>
AD RO
9 5%</w>
7 0%</w>
6 0%</w>
50 ,</w>
200 2</w>
( 800</w>
( 6
( 2
withdra wn</w>
wat er
vol u
vehic le</w>
under sto
un employment</w>
ty -
tric it
tion ary</w>
th ing,</w>
ten uated</w>
tempor ary</w>
t )</w>
sy m
sulph on
suffici ently</w>
sud den</w>
sa ying</w>
s y</w>
s al</w>
recur rent</w>
rec ycl
rec ru
r ation</w>
produc tion.</w>
prescrip tion.</w>
pres ent,</w>
practic e.</w>
platel ets</w>
per mitted</w>
patient 's</w>
p un
orph an</w>
on c
modi fication</w>
metabol ic</w>
low -
look ed</w>
lit ax
lif e.</w>
lif e,</w>
li ver.</w>
li fer
lab our</w>
lab el
knowledg e</w>
justi fied</w>
ingredi ent</w>
infec tions,</w>
ili ary</w>
hyperten sion.</w>
health ,</w>
h ous
gly col
giv es</w>
form er</w>
fore ign
fin ally</w>
fi b
ff ic</w>
fail ure.</w>
fact or
f if
effec tively</w>
e m</w>
contain er</w>
concern ed,</w>
commer cial</w>
chemo therapy</w>
chang es.</w>
bre ath</w>
bin d</w>
beta -
bat ch</w>
awa ren
ativ e,</w>
as is,</w>
any thing</w>
al le
affec ted.</w>
adul ts,</w>
adolescent s.</w>
achiev ed,</w>
accid ent</w>
acc ept</w>
ab le
Z i
U l
T i
SE N
S t</w>
S eri
S ).</w>
R u
R are</w>
Nag laz
MIRC ERA</w>
Kingdom .</w>
Iris h</w>
I ra
G r
Eff entor
EU/1/99/1 27
D O
Brussel s</w>
At tenuated</w>
Ac tr
8 9</w>
6 /
200 6</w>
1. 0</w>
- treated</w>
- based</w>
(9 0
( 2.
z em
y clin
v an</w>
ure auc
under taken</w>
ty p
tra ffic</w>
tra -
ti le</w>
th s</w>
sw ol
succ ess</w>
substanc es,</w>
spon taneous</w>
spe ed</w>
solv ent,</w>
sol vent
so di
sle ep
show ing</w>
sen se</w>
secon ds</w>
sa ys</w>
s ourc
s low</w>
ro c
responsib ility</w>
requ iring</w>
regim e</w>
re fu
pum ps</w>
prote ase</w>
proper ly</w>
procedur al</w>
posi tions</w>
pol ice</w>
per for
or th
opportun ity</w>
norm al.</w>
nec k</w>
ne t</w>
mot or</w>
mon oclonal</w>
mis sing</w>
minut es.</w>
meth adone</w>
medi ated</w>
lik a</w>
li x</w>
ity ?</w>
irrit ation,</w>
inter ven
insul in.</w>
in trac
if ic</w>
id og
ic in</w>
hy th
hring er</w>
go t</w>
gluc uron
gl it
gener al,</w>
fun ds</w>
fo re.</w>
fl ic
farm ers</w>
f oun
f illed</w>
experienc ing</w>
ex plain
ex hib
enti s</w>
enrol led</w>
en su
employ ed</w>
ed er
ear li
e ye
e ating</w>
direc ted</w>
da ys
connec tion</w>
con dem
comple ted</w>
col on
co ast
clo sure</w>
cle an</w>
chec k
cer tific
car ton</w>
bet a</w>
at tri
are as,</w>
ar .</w>
an tico
an s.</w>
an os
am s</w>
al te
al ise</w>
aesthes ia,</w>
acid ,</w>
V ic
SUBST ANCE</w>
ST EL
STEL AR
S te
S ain
Ris k</w>
Qu ality</w>
Pro gram
Pal est
P ax
P D
N ote</w>
N a
Met abolism</w>
Me di
M ay
K ine
Ingel heim</w>
In trav
II I
Hep B</w>
F ran
Europe ans</w>
ER S</w>
Bus iness</w>
Bot ulinum</w>
Bay er</w>
B ul
@m erc
7 3</w>
7 2</w>
6 4
6 1</w>
18 0
1 20</w>
/ Tel:</w>
-f ree</w>
youn ger</w>
w o
v es.</w>
v ary</w>
ul in</w>
trav el</w>
tr ue</w>
top otec
tissu es</w>
t ly.</w>
t elev
swol len</w>
str ong
statis tically</w>
st ages</w>
sol di
se a</w>
sa quin
ru n</w>
regul atory</w>
reg ions</w>
refrig er
reac tions,</w>
re new
problem ,</w>
pro ved</w>
pro pose</w>
priv ate</w>
pre- existing</w>
pre mature</w>
posi tion,</w>
pneumon ia,</w>
plac es</w>
piec e</w>
peg ylated</w>
patient -
pa in.</w>
p up
ou t,</w>
ot inic</w>
os in</w>
oric onazole</w>
or ally</w>
ol ab
mou th,</w>
mat ory</w>
market ed</w>
m ati
lev od
k al
j a
it ate</w>
injec tion
inhibit ors.</w>
ide ation</w>
ic on
ia )</w>
hyp oc
he at</w>
h un
guaran tee</w>
fum ar
fract ures</w>
fore ign</w>
fil ter</w>
fig ures</w>
exacer b
estab lish</w>
er n</w>
enh anc
emis sions</w>
disoprox il</w>
cul osk
cop y</w>
conjunc tion</w>
commit te
co- infected</w>
child 's</w>
bur n
bas el
bab y.</w>
b ureauc
avir ,</w>
at ur
at r
as se</w>
anaesthes ia</w>
amin o
aly se</w>
] ,</w>
W a
V IR
Trit ace</w>
Tel .:</w>
Seri ous</w>
Se biv
S a
Res e
Re duc
R -
Qu al
P I
Naglaz yme</w>
M D
L ong
L a
IN VE
IN G
II ,</w>
Health care</w>
H el
Direc tor
Con t
CV MP</w>
CHAMP IX</w>
Boe hringer</w>
Bo ard</w>
BYET TA</w>
As sess
8 00
1. 0
you ,</w>
y m
worl d.</w>
we ap
vit amin
vir tu
valu ation</w>
un fortun
tonn es</w>
toler ance</w>
thrombo tic</w>
terro ris
tac rolimus</w>
sur ge
substit utes</w>
stop ping</w>
stead y</w>
st ock</w>
st av
sp ap
somno l
some what</w>
si glit
sh are</w>
sec u
responsib il
residu es</w>
recommend ation</w>
re vision</w>
re pub
re member</w>
protec tive</w>
produc ing</w>
pro mp
pr ices</w>
possib le.</w>
ph il
ph an</w>
peri od
pen etr
paragrap h</w>
pan leuc
other .</w>
os ing</w>
organ iz
ol ed</w>
og en</w>
no t
mu nolog
mean ing
mac ular</w>
m oun
m ber</w>
lact ation.</w>
la id</w>
l um
kno wn
it ?</w>
is :</w>
ion ally</w>
involv ed.</w>
inver ted</w>
ini um</w>
in si
implement ed</w>
ill ness
identi fy</w>
i. e.</w>
i or</w>
hydrox y
hydrochlor ic</w>
hu ge</w>
hor ses</w>
guid ance</w>
glucos e-
gi es</w>
g one</w>
g el</w>
free zer</w>
fa ir</w>
f ati
ey es,</w>
eu /</w>
erythem a</w>
end point</w>
el op
el i
el ements</w>
ef ul
e at</w>
doct ors</w>
diure tics,</w>
dis ab
dexameth asone</w>
develop ments</w>
den afil</w>
dail y.</w>
cy cles</w>
culosk eletal</w>
credi t</w>
compreh en
cle ar,</w>
chromos ome</w>
categ ory</w>
car s</w>
cap able</w>
c um
c os
c .</w>
bridg e</w>
bo ok
blist ers</w>
belong s</w>
be hin
be .</w>
b y-
ant agon
analogu es</w>
alk onium</w>
al idom
administr ation,</w>
addres sed</w>
accep ted</w>
ac char
Y t
V ER
Un ion
T ox
Sy stem
Sloven ská</w>
S ign
S even</w>
Po st-
OR ACE
O ther
M ore
M B
K ap
John 's</w>
G al
F eline</w>
EU/1/99/127 /0
Dec ision</w>
Car di
C our
C -
Assess ment</w>
ADRO VANCE</w>
7 .</w>
5 2</w>
4 1%</w>
37 3/</w>
37 2/</w>
37 1/</w>
3. 0</w>
199 8.</w>
00 9</w>
/9 6)</w>
- on</w>
( called</w>
( %)</w>
wron g</w>
wor th
wh ite,</w>
week ,</w>
we g</w>
vot e)</w>
v oriconazole</w>
ure s,</w>
u d</w>
tra ffic
threat ening</w>
thre e-
tho roughly</w>
th ing.</w>
table ts.</w>
t ure,</w>
t ing,</w>
supple ments</w>
sub -
sion s,</w>
seve rely</w>
see m</w>
sec ret
s l
s es.</w>
rou s</w>
ro d
ret inal</w>
remov al</w>
re vis
qu i
problem s.</w>
pro xim
pr ic
pot ent</w>
pl ay</w>
ph aryng
pack aging</w>
p il
out com
ot h</w>
oper ative</w>
oper ate</w>
offici als</w>
offic e</w>
no w
new spap
nat ur
n el
mus cular</w>
month s,</w>
mom ent</w>
modi fied</w>
min ority</w>
meth ox
medi um</w>
mat ters</w>
malign anc
la y
l '
intramus cular</w>
inf ra
indic ating</w>
human s.</w>
her pes
hear ing</w>
he red
gen ital</w>
ge al</w>
g .,</w>
fre ed
fl av
favour able</w>
f igh
erro r</w>
er s'</w>
ent er</w>
en orm
emul sion</w>
e x</w>
disorder s,</w>
dis semin
del a
contracep tive</w>
contr act</w>
cont amination</w>
conges tion,</w>
competi tive</w>
clud e</w>
cl um
bre a
bloc ks</w>
associ ation</w>
ar tific
ann ounc
an aphy
ad a</w>
activ ity,</w>
acid osis</w>
acc el
ab sc
a :</w>
Wy eth</w>
W at
U TE
U R
Thro mbo
T o
S pain,</w>
Repub lic
R am
Qual ified</w>
Pro f
Pharmac eutical</w>
Peri odic</w>
P ack</w>
P O
Or phan</w>
OptiS et</w>
Offic ial</w>
ON AL
Novo Rapid</w>
N SA
Mab Ther
M ed
M INI
IN G</w>
HB V</w>
G 1</w>
Flex Pen</w>
Direc tive</w>
Denmark ,</w>
BM S</w>
B SE</w>
9 7</w>
8 3</w>
8 1</w>
4. 5</w>
.. ..</w>
' the</w>
…… ……
x .</w>
warn ings</w>
w ine</w>
vas cul
v es,</w>
tro p
topotec an</w>
tissu e.</w>
th ly,</w>
ten ,</w>
t am
synthes is</w>
symptom s,</w>
suspen sion.</w>
sur vi
support ing</w>
supp li
subcutane ously</w>
sub str
sp ring</w>
som atropin</w>
solu tion,</w>
sing le-
simp li
sha red</w>
ro d</w>
ri vas
ri sts</w>
resuspen d</w>
repub lika</w>
rele as
regul ated</w>
reac tion
pressu re.</w>
pregnanc y.</w>
pr an
parti cles.</w>
p seud
over weight</w>
other wise</w>
orig in
oph ob
odynam ic</w>
occur s,</w>
ocardi al</w>
nur sing</w>
no tic
nit ro
neuropath y</w>
neuro logical</w>
n y</w>
meth od
me tres</w>
man n
ly n</w>
ly mp
lung s</w>
litax el</w>
li xim
le f
land .</w>
job s</w>
inten si
inhibit or
infus ion.</w>
immuno suppres
il tr
if i
id er
i ther</w>
i ous</w>
hyperten sion</w>
hour s,</w>
hol ding</w>
hered itary</w>
he re.</w>
gl and</w>
g ent
g ate</w>
form e</w>
f os
evalu ated.</w>
et ro
est ro
enti al</w>
em o
e an</w>
e ),</w>
dr am
discharg e</w>
dihydro gen</w>
detec t</w>
def end</w>
cr ushed</w>
cough ,</w>
comp u
common .</w>
cit abine</w>
chang ing</w>
car bo
blu e</w>
bi g</w>
bec ame</w>
b y
b ov
att ack</w>
as e-
ar com
approv al</w>
antico agul
and -
analys is.</w>
an ia,</w>
ampren avir</w>
am bi
al um
ag o</w>
ad ren
ad just</w>
a e</w>
Un ion,</w>
TM Z</w>
T em
T RE
Ser vic
Sec ret
S ix</w>
RI ST
Pro tec
Ph il
Parliam ent
P el
P E</w>
P .</w>
ORACE A</w>
No s</w>
Mr s 
Mix t
Min ist
L is
Is lam
In activated</w>
I L
H ,</w>
Gastro intestinal</w>
F IR
Effec ts</w>
EX P</w>
E LI
Dy sp
Dos ing</w>
Dis orders</w>
Dev elop
D E</w>
Counc il
Candi da</w>
B ud
A S</w>
9 -
6 4</w>
5 8</w>
4. 9</w>
2 ,
0. 25</w>
/ E
- to-
+ 37
wor t</w>
vul ner
vo ice</w>
vals artan</w>
u ric</w>
tri al,</w>
tr ying</w>
to ols</w>
thous ands</w>
there af
there .</w>
th ick
surve y</w>
surg ical</w>
struc tur
stric tly</w>
speci alised</w>
soci ety</w>
siz es</w>
sit e:</w>
selec tive</w>
sec tor
se d
sam pl
sal mon</w>
s ou
s av
s '.</w>
ri al</w>
recover y.</w>
recogn ises</w>
radi olab
pro phylaxis</w>
prefer ably</w>
post s</w>
poli tic
poison ing</w>
plan ning</w>
placebo- treated</w>
pl ung
phot osensi
ph a</w>
performe d.</w>
pen s,</w>
patient .</w>
pat ent
pap er</w>
ous ly.</w>
org e</w>
open ia,</w>
op ol
op a</w>
off- white</w>
o w
nucle oside</w>
multi forme</w>
mol ec
mis s</w>
mil itary</w>
ma r</w>
m ass
limit ed.</w>
ligh ts</w>
life- threatening</w>
li ver,</w>
lam y
k s,</w>
jo int
itch ing,</w>
it ors</w>
inflam matory</w>
inf iltr
increas ingly</w>
in depend
impa ir</w>
il d</w>
ic y
ic h
i pr
i fe
hol id
he art
haemorrha ge</w>
h ome</w>
gen ic</w>
fu el</w>
formul ations</w>
forgot ten</w>
fir e</w>
f ed</w>
extre me</w>
examin ation.</w>
ev en
estim ate</w>
end ron
end ogenous</w>
electron ic</w>
el ap
ec zem
dizz iness,</w>
disorder s.</w>
del eg
def enc
day :</w>
d less</w>
cy cl
cri tic
cour ses</w>
con flic
comple x</w>
clo ts</w>
cigare tt
cas e.</w>
cam pa
c is
bloc k</w>
begin ning</w>
beg an</w>
be fore.</w>
b ,</w>
att acks</w>
asthen ia,</w>
ast a</w>
ap point
any one</w>
anti psycho
anti c</w>
ang ina</w>
ag grav
affec ts</w>
advis able</w>
addi tives</w>
ad d</w>
abs ence</w>
abdom y
a ud
Wh ether</w>
W ould</w>
W om
V AN
Ur inary</w>
Un it
Se e</w>
Sci enti
Sc ot
STELAR A</w>
S ust
S hel
Rese arch</w>
Rap porteur</w>
Pati ent</w>
Op in
Ob jec
O r</w>
Novo Let</w>
N R
M en
L eu
Irel and,</w>
In di
Im muno
H am
G ONAL
E vents</w>
E M
E D
Dec ember</w>
D ut
D 3</w>
Commission er</w>
CCID 50</w>
C N
B ur
B rit
B et
Al ways</w>
A de
A F
9 2</w>
8 6</w>
25 ,</w>
199 8</w>
1 0.
( vote)</w>
( one</w>
( T
( R
é l
  million</w>
year- old</w>
wom en
w ar</w>
volunte ers</w>
vi rosis</w>
ven ous</w>
vast at
vari ability,</w>
ure a</w>
un employ
ud in</w>
tur ning</w>
tis ing</w>
ti al</w>
thromb in</w>
ther n</w>
test ed</w>
tak e,</w>
table ,</w>
t s:</w>
t or.</w>
t ing.</w>
subjec ts.</w>
stra ight</w>
ste p
sle ep</w>
siglit azone</w>
sh ire</w>
scho ol
sch eme
sc ope</w>
s ession
s ac
rout ine</w>
ri f
rh abdomy
refe ren
ran ts</w>
quin ol
prurit us,</w>
produc tion,</w>
princi ples</w>
pre ven
pl ants</w>
ph r
panleuc openia</w>
p u
organ isation</w>
opro st</w>
on ance</w>
oc occ
ob last
ne on
n ers</w>
mov ement</w>
mot or
monito red.</w>
minim al</w>
mer cur
membran e</w>
me tr
me tast
manufacturer (s)</w>
ma de.</w>
lin k</w>
la un
l on</w>
l er</w>
known :</w>
kno wn,</w>
kil ome
kil og
k ne
k g
k ers</w>
itch y</w>
investig ation</w>
inj ury</w>
ing ly.</w>
inf lation</w>
inf ant</w>
im possible</w>
ill s</w>
h is
gen e
gast ric</w>
g am
g ain</w>
fun ding</w>
flu oro
expen sive</w>
excep tion</w>
episod es</w>
end .</w>
emerg ency</w>
eas y</w>
do wn.</w>
dis odium</w>
dis card</w>
di et.</w>
del ays</w>
datab ase</w>
dail y,</w>
consequ enc
comp ul
commit tee</w>
care .</w>
car rying</w>
c up</w>
bleed ing,</w>
b ound</w>
b ig
awaren ess</w>
ation s?</w>
arm s</w>
ar ity</w>
amma dex</w>
alk aline</w>
alis ing</w>
al bum
absol ut
a p</w>
Y ERS</w>
W IT
V enous</w>
V .</w>
U S
Tre vac
Tracle er</w>
TI C
T S</w>
Sy stem</w>
Sy mptom
Sust ained</w>
Star lix</w>
Slov ak
Sebiv o</w>
S i
S QU
SQU IB
SQUIB B</w>
Reg ul
R et
R T</w>
Plac e
P L
OL -M
OL-M YERS</w>
O x
Netherland s,</w>
More over,</w>
Meth od</w>
M ain
Li et
Kar ve
Inter action</w>
I sc
I g
Hol der.</w>
HIV -1</w>
G o
Fe bru
EU/1 /98
EU/1/98 /0
Dis ease</w>
D ,</w>
C ould</w>
C P</w>
Bul g
An y
A tri
A M
5 3</w>
4. 2</w>
36 4/</w>
35 8</w>
200 5,</w>
2 3
00 8</w>
0 4
/ 199
+4 6</w>
+ 372</w>
(A ID
( 200</w>
â nia</w>
y '</w>
ve ?</w>
under lying</w>
ulc er</w>
uc tu
transfer red</w>
tob acco</w>
thromb osis</w>
this ?</w>
ter rit
tech no
tast e</w>
tab ility</w>
t ary</w>
syring e,</w>
symptom s.</w>
suscepti bility</w>
surger y.</w>
sugg es
st ro
st oc
specif ied</w>
simp le</w>
serv ic
seiz ures</w>
sco res</w>
s n
s a</w>
s ):</w>
rou gh</w>
rivas tigmine</w>
ring ing</w>
rhabdomy olys
refer ral</w>
re view
re adily</w>
re ?</w>
rang ed</w>
ra m</w>
r at</w>
pum p</w>
provis ions</w>
pressu re,</w>
prac tical</w>
poll ution</w>
poll ut
ph al
pestic ides</w>
pay ments</w>
pan dem
pack .</w>
p iv
piv otal</w>
oti tis</w>
opa que</w>
ong st</w>
on ic</w>
on d</w>
om yc
om at
odi azep
occas ionally</w>
oc or
o dic
nic otinic</w>
ne verthel
nam ely</w>
n om
mov ements</w>
mit ting</w>
milk y.</w>
mid dle</w>
micro gram</w>
mellit us</w>
lymph ocyt
lik ely.</w>
lifer ative</w>
legisl ative</w>
lat est</w>
jour ne
iter ran
interest s</w>
inj uri
infec tion
inf lixim
inc en
in stead</w>
in es.</w>
in ).</w>
immun ity</w>
idog rel</w>
ic ial</w>
i tive</w>
i j
i e</w>
http :
hormon al</w>
ho t</w>
go od
glyco protein</w>
gl u
gen u
g ar
foc us</w>
fal len</w>
ext ended</w>
ex port</w>
ex plan
ex clus
er s?</w>
er a
epilep tic</w>
ep ider
ell ular</w>
e ti
document ation</w>
doct or
diagno s
den sity</w>
deal t</w>
cy t
cul tural</w>
countr y.</w>
cl ass
ciclospor in</w>
centr alised</w>
careful ly.</w>
car ton.</w>
c ore</w>
c m</w>
blo od.</w>
billi on</w>
benef icial</w>
behin d</w>
b ar</w>
as ked</w>
appear ance.</w>
an th
amlodip ine</w>
am ongst</w>
al pha</w>
al endron
ag ulation</w>
ag o.</w>
activ ation</w>
ab ov
ab ,</w>
a ;</w>
a 's</w>
Zi agen</w>
Wom en</w>
WIT H</w>
Un ion.</w>
T er
T as
Span ish</w>
S uc
S L
Rom ânia</w>
Re ference</w>
RIST OL-MYERS</w>
Prepar ing</w>
Pol and,</w>
ON SY
O M
No w</w>
Ne uro
NA ME
MabTher a</w>
M c
In no
IN E</w>
I ONSY
H PV
H D
GONAL -
GONAL- f</w>
Fin land,</w>
F ri
F S
El derly</w>
E valuation</w>
E con
D on
Con cer
Commission er,</w>
Col leg
Ben e
B RISTOL-MYERS</w>
An im
Al so,</w>
A ug
A -
9 6</w>
8 4
7 7</w>
6 2</w>
5 -0
37 /</w>
2 1
0 14</w>
0 10</w>
. )</w>
(A4-0 4
( U
( 12</w>
µ g</w>
° C</w>
ys el
y 's</w>
wat ch</w>
w arm
w .
ve get
ul ts</w>
ud ra
transpa rency</w>
tou ch</w>
toler ated</w>
tim es,</w>
thro at</w>
ta il</w>
t s
syndro me.</w>
swit ched</w>
suffe red</w>
suc ce
stimul ating</w>
stav udine</w>
st abil
sp a
small er</w>
sk in.</w>
sever ity</w>
se al</w>
s ely</w>
ru ption</w>
ro b
ric h
rib avir
ri t</w>
ri es</w>
resuspen ded.</w>
respec tive</w>
regar dless</w>
regar ded</w>
refu ge
reflec t</w>
referen du
re pa
put ting</w>
pur ch
prec is
phen omen
pharmac ological</w>
p el
os in
om as</w>
off er</w>
occur rence</w>
occ up
no ise</w>
muscle .</w>
min ute</w>
microgram s/</w>
mg/ day)</w>
mg/ 24</w>
measure s,</w>
mater nal</w>
mal absorption</w>
los s,</w>
li po
leng th</w>
langu ages</w>
l p</w>
intoler ance,</w>
influ enz
in som
in habit
ill ness</w>
http: /
h ur
group s,</w>
groun ds</w>
gr ap
gr an
g on
func tional</w>
flush ing</w>
fe ar</w>
fal se</w>
f le
exten sively</w>
expec t</w>
excipi ents,</w>
ex pl
ex emp
esp o</w>
ent s:</w>
econom y</w>
e u</w>
du raz
doc etaxel</w>
dizz iness</w>
diseas e)</w>
discus sions</w>
dis cre
develop ment,</w>
depres sion,</w>
de tail
de gener
d ;</w>
coord in
contracep tives</w>
comp li
communic ation</w>
col d</w>
clum ps</w>
chro me</w>
cell s,</w>
carbo hydrate</w>
bir ds</w>
benz alkonium</w>
ativ e.</w>
at a</w>
assess ing</w>
as c
artific ial</w>
ar y.</w>
anticip ated</w>
am .</w>
al op
agon ist</w>
aff inity</w>
adjust ment
accum ulation</w>
accord ingly.</w>
ac onazole</w>
a udi
Un it</w>
Ty pe</w>
T él
T ev
T c
Symptom s</w>
Sol o
Scienti fic</w>
S OL
Re member</w>
RE AC
R ev
R as
Puh /Tel:</w>
Pro me
Ph ase</w>
P 450</w>
ON AP
Ne oc
N espo</w>
Mal ta</w>
MM ONAP
MINI ST
Leu k
Kine ret</w>
K E</w>
Isc over</w>
In j
I V</w>
Fr anc
F il
F ab
F 2</w>
Ex c
Effentor a</w>
Do es</w>
De part
D ue</w>
D K
CE PRO
C ro
C at
Austri a,</w>
Al duraz
AN Y</w>
AD MINIST
A MMONAP
9 .</w>
6 6</w>
5 00
1 2.
( 5
y li
y ).</w>
x in</w>
wor th</w>
wom an.</w>
where .</w>
w al
vitamin s</w>
vi al,</w>
vaccin ation.</w>
v ildagliptin</w>
under standing</w>
un likely.</w>
un born</w>
ul tr
ul ative</w>
ub le</w>
tre mor
travel ling</w>
to s</w>
thresh old</w>
thous and</w>
though ts</w>
ter m
t ack
syring es,</w>
sup pression</w>
sup por
substanti al</w>
st ac
solvent )</w>
so il</w>
si a,</w>
ship .</w>
sh ock
sh e
sh ar
sent enc
sa y,</w>
s opraz
res c
rel atively</w>
regul ations</w>
re present</w>
psori atic</w>
promo tion</w>
prof it
process ed</w>
pre pared</w>
prac tice</w>
pol lu
peri odic
pen al
ord ination</w>
oper ation.</w>
op posite</w>
om al</w>
ol an
oblast oma</w>
obes ity</w>
no w,</w>
my ocardial</w>
my al
mo ist
men .</w>
medicin e,</w>
me et</w>
me ant</w>
marro w.</w>
m ation</w>
m ass</w>
lot inib</w>
lop idogrel</w>
loc k</w>
lan sopraz
l er
l ap
l ad
it or
it ed.</w>
ist ,</w>
ish ed.</w>
int el
instruc ted</w>
in corpor
in come</w>
in clusion</w>
ide )</w>
i od
hydrox ide,</w>
hydrogen ase</w>
howe ver.</w>
haz ard
h n
h em
go ods</w>
gli oblastoma</w>
gastro enter
fo rec
fil m</w>
f light</w>
f it
examin ations</w>
eu .</w>
et s,</w>
es sive</w>
es p</w>
era dic
epider mal</w>
environ ment
en e.</w>
el ement
eg al
effec t,</w>
du lox
do ?</w>
dissol ved</w>
di hydrate,</w>
di go
design ated</w>
decreas ing</w>
decis ions</w>
decis ion.</w>
de tailed</w>
de hydrogenase</w>
dam aging</w>
d ust</w>
d )</w>
cyto chrome</w>
con tra
con sti
con serv
ci profloxacin</w>
cholester ol,</w>
chem i
charg e</w>
c k
buil t</w>
br and</w>
bo ar
bl ur
bi otechnolog
benz odiazep
believ ed</w>
ban ned</w>
ba g</w>
at inib</w>
aspec t</w>
arthri tis,</w>
ar t</w>
anos ine</w>
an hydro
alop ec
all er
al ter</w>
al an
again ,</w>
ag ents.</w>
act ual</w>
ac tion
ac ted</w>
absolut ely</w>
ab er
a g</w>
V ol
V is
V AT
Trevac lyn</w>
Th yro
T otal</w>
T en
T al
T E</w>
Suomi /
Suomi/ Finland</w>
Spec ific</w>
Sing le</w>
SAR L</w>
S o
Re pe
R ue</w>
R econ
Pu gh</w>
Presid ent
P A
O X
Nov ar
N orge</w>
N ic
M ac
L iv
L V
K ep
K eep</w>
Jo int</w>
Isra el
In fl
I D</w>
HPV -
H CV
F ondaparinux</w>
EX J
ELI SA</w>
Counc il,</w>
Com bin
Ch lamy
C lopidogrel</w>
C i
C S
C D
Bene F
AU C
AR E</w>
A pro
A ir
1 1.
0. 2</w>
0 11</w>
/199 9)</w>
- derived</w>
+4 9</w>
(AID S).</w>
(A5-0 4
( approximately</w>
λ λ
zer o</w>
vel y,</w>
vari es</w>
un wanted</w>
u lo
tra vir
tra di
tivel y.</w>
tit anium</w>
ti te</w>
th en,</w>
test s,</w>
ter fen
t s?</w>
t etan
t ed
t ap
sym path
stop s</w>
st ress</w>
sp ra
sp er
saf e
s ession</w>
restric ted</w>
res onance</w>
rele ased</w>
regi stered</w>
recor d</w>
reac tion.</w>
re x
re placed</w>
re min
rat s</w>
r ate.</w>
program m
profession al.</w>
proc ess,</w>
pro -
prevent ing</w>
potassium- sparing</w>
pic ture</w>
physici ans</w>
phosph at
per .</w>
pay ment</w>
pat ches</w>
paren ter
pac litaxel</w>
p= 0.00
p unc
ord inary</w>
or i</w>
ophthal m
open -
on ia
on a</w>
om a,</w>
olog ically</w>
ograph ic</w>
off .</w>
oesopha g
od y</w>
ob struc
o estro
need le.</w>
nat al</w>
n ex
mor ning.</w>
monit or</w>
microgram s/
methotrex ate.</w>
measure ment</w>
marg in</w>
manufacturer s</w>
m ium</w>
m end
loc yt
lo y
lo s</w>
level s,</w>
le y</w>
le av
le agu
lar ity
larity n</w>
keep ing</w>
ir reversible</w>
ir is</w>
ip raz
ion -
inu ria</w>
intrav en
interest ed</w>
inten tion</w>
ing '</w>
inf arc
incid ences</w>
in sec
in s,</w>
in active</w>
immun isation</w>
im munolog
identi ty</w>
id ation</w>
ic ill
ic ally,</w>
headach e</w>
haemodi alysis</w>
h and,</w>
gen it
fundam ental</w>
food stuff
fo rest
fo etal</w>
fe at
exist ence</w>
ex ecu
every one</w>
et y.</w>
essenti ally</w>
er )</w>
equip ped</w>
en vis
electr icity</w>
ed rine</w>
e b
dys function,</w>
dr aft</w>
dist ance</w>
dis rup
dis h</w>
dis crimin
destro yed</w>
dec lar
de hydr
de fer
dat a.</w>
dam age.</w>
d ol
cru cial</w>
counter fe
contrib u
continu ous</w>
cont ext</w>
conjunc tivi
compon ents</w>
compart ment</w>
comm od
comit ant</w>
ci meti
carcinogen icity</w>
breath ing,</w>
bov ine</w>
b it</w>
b ad</w>
b ad
b .</w>
av en
ap preci
anti bodi
anim al
anc er</w>
anaem ia.</w>
an swe
amb ris
alidom ide</w>
al ism.</w>
aircr aft</w>
adjust ments</w>
act ,</w>
X /</w>
W )</w>
V ICH</w>
U .</w>
Tur k
TH ER</w>
Syn dro
S p
Republic ,</w>
RA TION</w>
R el
R are:</w>
R Y
Pr ad
Peg as
P ut</w>
Novar tis</w>
Nor th</w>
Neoc larityn</w>
Me an</w>
Madri d</w>
K iv
K ent</w>
Hung ary,</w>
HIV -
H igh
Grou p</w>
G D
Fol low</w>
F R
Engl ish</w>
EV RA</w>
EU ,</w>
EME NT</w>
E ,</w>
Develop ment</w>
D e</w>
Chang es</w>
CEPRO TIN</w>
B u
Al b
AS C
ADMINIST RATION</w>
AD E</w>
A Z
A VA
9 %)</w>
6- month</w>
5 1</w>
37 7/</w>
37 5/</w>
36 9/</w>
20 -
199 6</w>
14 6/</w>
1, 000
1 %)</w>
0. 3</w>
0 8
( i.</w>
ß e</w>
µ g/</w>
yl ac
year }</w>
writ ten</w>
wid ely</w>
wh en
vomit ing.</w>
ve in.</w>
ut sch
us tin</w>
trans mitted</w>
toler ated.</w>
to .</w>
thereaf ter.</w>
th um
th -
tend ency</w>
telev ision</w>
t ly,</w>
syn thetic</w>
sy mb
sw allowing</w>
sur fac
supplement s,</w>
success ful
su n</w>
su me</w>
stand ardis
sp ot
sp ent</w>
sor bit
shoc k,</w>
shi ps</w>
schem e</w>
s ick
s es,</w>
s can
s '
rub b
ro c</w>
respon ded</w>
rejec tion</w>
ref er</w>
red ness,</w>
re solv
ras tim</w>
random ized</w>
rac e
ra dic
pro spec
pris on</w>
princi ple
pres s</w>
poin ting</w>
po oled</w>
pi oglitazone</w>
person al</w>
periodic ally</w>
peri odic</w>
oxid ase</w>
onc e.</w>
ol ig
oe ph
occur ,</w>
oS tar</w>
o tic</w>
no t.</w>
ne igh
ne ar</w>
n s</w>
mo tiv
milli on.</w>
methox y</w>
meet ings</w>
me d.</w>
ma il</w>
m ysel
m s
lot ted</w>
loo king</w>
li de</w>
lat er.</w>
la red</w>
l uc
l av
l ate</w>
kno w,</w>
k y</w>
k i
iz umab</w>
is ation
intel lig
initi atives</w>
ing -
in yl</w>
in th</w>
implement ed.</w>
immuno glob
im plic
ill ness,</w>
ill ing</w>
id ity</w>
id ine</w>
i ent</w>
hyperten sion,</w>
herpes virus</w>
happen ing</w>
ha m</w>
h ence</w>
gradu al</w>
glycol -
glycer ol,</w>
gen etic</w>
fru it</w>
fro sted</w>
form ulation</w>
fo et
fing er</w>
fe ed
f are</w>
exper ts</w>
exce ed</w>
ex change</w>
ev ents,</w>
ess or</w>
erythem a,</w>
er :</w>
ent y-
ent r
end oc
eg g
e 's</w>
du ty</w>
du n
dis comfor
di c</w>
dementi a</w>
dec lared</w>
de t
d l</w>
contracep tion</w>
con v
colour less.</w>
collec ted</w>
cis pl
cho ice</w>
chang e,</w>
cha mber</w>
ch -
ca us
bro vascular</w>
bon es</w>
b ub
b is
b al</w>
avi roc</w>
at s,</w>
at ard</w>
assess ment.</w>
ar le
and ing</w>
agg reg
adv ice.</w>
a er
TA KE</w>
T RA
Subjec ts</w>
Sol oStar</w>
Sh ould</w>
SP RY
SPRY CE
S ud
S imp
RE N
R h
Peri pheral</w>
Pegas ys</w>
Pax ene</w>
Palest ini
P ,</w>
Opti C
OG EN
OGEN ATE</w>
O y</w>
N ut
N on-
M arch</w>
M ag
M S</w>
Liet uv
Latvi ja</w>
LI F
L ab
K OGENATE</w>
Inj ury,</w>
IONSY S</w>
I mp
Har mon
G a
G L
Fir st,</w>
En viron
E p
E lim
E f
E ar</w>
Dos es</w>
D el
Con tro
Con comitant</w>
Commit te
CO 2</w>
C ur
C er
Americ an</w>
? '</w>
9 7/</w>
9 7
6 7
37 6/</w>
35 /</w>
2 ),</w>
180 °</w>
15 /</w>
12 -
( MAO
λλ ά
λλά δ
η λ
Ε λλάδ
we a
w ise,</w>
vit al</w>
vir us.</w>
vi l</w>
ure ly</w>
tum our
triglycer ides</w>
tren d</w>
to day,</w>
tion ally</w>
tern al</w>
ten tion</w>
tel uk
tel eph
techno lo
ta m</w>
sug ammadex</w>
sud den
sub mit
stim ulation</w>
speci al
sp read
sp inal</w>
sp ace</w>
so .</w>
sit ting</w>
simple x,</w>
si mul
si de.</w>
sh ock</w>
seri ous
sa w</w>
s z
s cap
ru le</w>
research ,</w>
remain ing</w>
rel ates</w>
regi stration</w>
rap porteur
r is</w>
r ab
quick ly.</w>
qu ate</w>
protec ted</w>
program me,</w>
produc ers</w>
problem .</w>
pro ve</w>
pro gram</w>
pro fil
ple as
passeng ers</w>
pas sp
part ner
pa st
p ill
p ha
ov arian</w>
ophil a</w>
olog ic</w>
okine tic</w>
ograph y</w>
off spring</w>
of -
no se</w>
net work</w>
mo l</w>
mb ud
man ,</w>
main tain
ma de,</w>
m ice</w>
li br
levod opa</w>
justi fi
it sel
it ed,</w>
inter f
interf ere</w>
institu tions</w>
influ enza</w>
inf ants,</w>
in adequ
if e</w>
ib ility</w>
ib .</w>
hy gi
hund red</w>
gr ade</w>
gem citabine</w>
g ol
follow -
flu oxetine</w>
fl uctu
fil grastim</w>
fer ti
fa ec
f res
f low
ey e.</w>
experienc e.</w>
et ed</w>
est onia
es ti
es !</w>
enti t
ent ering</w>
ent ed</w>
emis sion</w>
em tricit
elec oxib</w>
el y,</w>
effici ency</w>
eff orts</w>
e str
e en</w>
duc t
double- blind</w>
dist ingu
desc ri
des er
der mati
democr acy</w>
defic it</w>
cul tiv
cre ated</w>
cover ing</w>
continu ed.</w>
continu e/</w>
confus ion,</w>
conduc t</w>
concern ed.</w>
con genital</w>
claim s</w>
cl aim</w>
civ il
child ,</w>
categ ories</w>
c ough</w>
bom b
body 's</w>
ben ec
be y
be ?</w>
b os
atten tion.</w>
at ing.</w>
ar is
ar bit
appear ance</w>
ap o</w>
ant ly.</w>
am ,</w>
al lotted</w>
al i
ag es,</w>
ad hes
accum ul
ab use</w>
ab and
a qu
a ).</w>
Vi ani</w>
Vacc ines</w>
Ukra ine</w>
Tri zi
TE NT</w>
T echn
St ock
Sand w
Sain t</w>
S we
S TI
Rom ania</w>
Rec om
R ou
Prome tax</w>
Pro t
Post- marketing</w>
Pel zon
P rac
O mbud
Med iterran
ME RI
MATERIAL S,</w>
M ul
Lietuv a</w>
Labor ato
L T
K ey</w>
Industri al</w>
IU /
Hydro chlorothiazide</w>
He ad
H u
Gl ustin</w>
G E</w>
Fran k
F ast
Equ ilis</w>
Elim ination</w>
Econ om
Dut ch</w>
D em
Cont inu
Con si
Con ference</w>
Commission .</w>
Cent re</w>
C e
C are</w>
C Y
As soci
Apro vel</w>
Ade quate</w>
A ran
A TION</w>
@merc k.</w>
9 N
9 9</w>
8 2
8 )</w>
5 9</w>
4. 6</w>
4 31</w>
18 .
12 ,</w>
10 3</w>
1, 000</w>
1 1.</w>
0. 2
0 12</w>
-------------------------------- --------------------------------
(E 17
( 50</w>
( 10</w>
( 1,000
” ).</w>
ο ς</w>
Ελλάδ α</w>
á n
{ month
y iel
wor ds,</w>
what ever</w>
we ak</w>
war farin</w>
vis its</w>
v a
up take</w>
tw are</w>
travir ine</w>
transp ort
tot ally</w>
to o,</w>
to ,</w>
thin king</w>
tex t.</w>
ta ,</w>
sus p
suggest s</w>
suc ro
su re.</w>
stom ach
statis tical</w>
sp ond
spond yli
sp as
solu tions.</w>
signific ance</w>
secre tion</w>
sec tors</w>
se x</w>
schedu le</w>
sam ples</w>
s ory</w>
s ell
s arcom
ros is,</w>
ris on
reg res
re ven
re alis
r ite</w>
pul l</w>
provi ded.</w>
produc es</w>
process ing</w>
pregn ant,</w>
practic es</w>
pr am
pover ty</w>
post menopausal</w>
popul ation,</w>
pharmac ology</w>
ph ylac
p ink</w>
p ed.</w>
oxy gen</w>
orig in.</w>
oper ational</w>
one x</w>
ol y
ol der.</w>
o ter
no se,</w>
neverthel ess</w>
neutropen ia</w>
mun ic
milli ons</w>
ment ation</w>
measure ments</w>
me rely</w>
mark s</w>
mark ets</w>
man ife
mail :</w>
lit re</w>
ligh t,</w>
lic en
li thi
leg ally</w>
lat ter</w>
larg ely</w>
l ens
l af
laf ax
iv e.</w>
itch ing</w>
ist ax
is o
invest ment</w>
infec tion)</w>
indic ated,</w>
immunolog ical</w>
imag ine</w>
im print</w>
if t</w>
identi fied,</w>
id es.</w>
id en
hec ta
h id
h an
gram s</w>
go al</w>
glycol- epoetin</w>
g ri
g ia</w>
g ender</w>
fumar ate</w>
fres h</w>
foreign 'and</w>
fer til
famil ies</w>
fa ir
f- life</w>
f end</w>
exten sive</w>
exist s</w>
ex act</w>
estonia @gsk
es ul
es pre
es is</w>
er v
enorm ous</w>
enh anced</w>
en forc
en able</w>
elec tric</w>
elec ted</w>
el s,</w>
dog s.</w>
do x
do ,</w>
distribu ted</w>
disper sible</w>
digo xin</w>
di ox
di d
des ired</w>
des ign</w>
der og
der ing</w>
de ad</w>
de ?</w>
d ophila</w>
cul ture</w>
cro ps</w>
crim inal</w>
cou ple</w>
cos me
contro ver
con current</w>
compens ation</w>
comp ly</w>
col i</w>
chick ens</w>
ch ann
cell ul
c t</w>
build ings</w>
blo od,</w>
bl ing</w>
benefit /</w>
avir .</w>
author ities.</w>
app lies</w>
ap ol
al tered</w>
aggres sive</w>
agend a</w>
ag es.</w>
ag ency</w>
administe red.</w>
accur ate</w>
acc es
ac ter</w>
ac knowledg
a .
Wh ich</w>
V fend</w>
UL N
Tim e</w>
Th ose</w>
TRI SE
TRISE NO
Some times</w>
SU TENT</w>
S ix
Rem ic
RE Y
Prad ax
Po st
Plac e</w>
Par t</w>
PV C</w>
P ent
NR TI
NO T</w>
Main tenance</w>
MS D</w>
M ast
L os
L e</w>
Karve a</w>
Intrav enous</w>
He ad</w>
H ist
H and
H amp
G over
Four thly,</w>
Febru ary</w>
Fe w</w>
Every one</w>
E g
De utsch
Chlamy dophila</w>
Cal ici
CP MP
C ub
Ber lin</w>
B AS
Av onex</w>
Ac cid
AS T</w>
AMMONAP S</w>
A z
A cl
A R</w>
A I
5 4
35 7
199 5</w>
10 ,000</w>
1 40</w>
1 /2001)</w>
+4 7</w>
(H D
(F CV</w>
(A4-0 2
( p</w>
( blood</w>
' -
yl osing</w>
x bridge</w>
wor ding</w>
vulner able</w>
vari ant</w>
val osin</w>
v ill
us u
tub ular</w>
tr u
top ic</w>
to ys</w>
tiv es.</w>
tiv al</w>
thro wn</w>
though ,</w>
th igh
ter at
tal king</w>
tak e.</w>
t us
sum ed</w>
struc tural</w>
stra ße</w>
spec tr
solu tion
sof tware</w>
so ya</w>
situ ation.</w>
sib le.</w>
sh eep</w>
scre ening</w>
sc en
satis factory</w>
s ick</w>
s cr
s anc
ri ed</w>
represent atives</w>
reg ist
reg ional</w>
reduc ed.</w>
recycl ing</w>
rec ip
reas on,</w>
re volu
re ti
psych ological</w>
propor tional</w>
princi p
pri ority</w>
presc rib
prepar ations</w>
precis ely</w>
preci pit
precau tionary</w>
por tion</w>
polic ies</w>
placebo ,</w>
peri ods</w>
pep tide</w>
out put</w>
organ ised</w>
op tic</w>
one 's</w>
on y</w>
olog y,</w>
ol d
oc ol
obvi ously</w>
ob stac
o ffe
o con
ne ed,</w>
n ia,</w>
mus cles</w>
mis sible</w>
micro -
mean ing</w>
me als</w>
mar aviroc</w>
manufact ure</w>
m es
lin .</w>
lens es.</w>
l ess,</w>
l ec
l antic</w>
jour nal
j e
ish ,</w>
ir udin</w>
ir regular</w>
invol ve</w>
inter fer
inspec tion</w>
ini stry</w>
ing !</w>
infec tions.</w>
industr y,</w>
incin er
in ev
impa i
im age</w>
il s</w>
if y</w>
icon otide</w>
ible ,</w>
i dis
hypoc ris
hypo kal
hydro lys
hospit al.</w>
haz ard</w>
h r
glycaem ic</w>
glut am
glucose- galactose</w>
glo ves</w>
for ge</w>
follow s:</w>
flo or</w>
fl ur
fin ished</w>
fi bro
f us
f ine</w>
exper ti
excep tional</w>
es cap
er up
er ship</w>
ep i
enter pris
ent ail
em ents.</w>
elimin ate</w>
elev ations</w>
el s.</w>
e ez
e dema</w>
dra w</w>
discar ded</w>
diagno sed,</w>
di min
di gn
di alysis</w>
defenc es)</w>
de vic
damag ed.</w>
d u</w>
d '
crim ination</w>
cre d
control led,</w>
contra dic
consul tation</w>
compani es.</w>
comp ut
co agulation</w>
ce f
carri es</w>
carri er</w>
cap ital</w>
cal ves</w>
cal caem
c ity</w>
c at</w>
c ab
ble .</w>
be ,</w>
bar ri
bab y</w>
b us</w>
b )</w>
az ide</w>
ation s:</w>
asse mb
arm .</w>
are a.</w>
arc el
ant ine</w>
ank ylosing</w>
anc es.</w>
alum inium</w>
alte red.</w>
aliz ation</w>
al one.</w>
al ism,</w>
al ing</w>
al es</w>
al ?</w>
ag it
adjust ed</w>
ad en
ad dic
accep table.</w>
ab sur
a ),</w>
W ed
Vir us</w>
V )</w>
U xbridge</w>
U MA
Thyro gen</w>
TE SL
TESL ASC
TE D</w>
T ac
Stre et</w>
Sever al</w>
S ta
S S
Res ults</w>
REY AT
Pol ish</w>
PE )</w>
P requ
P as
P T</w>
Opin ion</w>
O VI
O .</w>
O -
N U
N AT
Mus cle</w>
Mixt ard</w>
May be</w>
M art
Long -term</w>
L uc
L ou
Ira q
Inter feron</w>
I M
Hy po
Haem ophil
Ha arle
H is</w>
H al
Gen er
G i
G ar
G R-
G A</w>
Fir st</w>
Fast ur
F o
EU/1/0 6/
EME N
E S
E MA
D .</w>
Con stitu
CO M
C are
BAS AL</w>
B ro
B SE
B -
Austri a</w>
Anim al</w>
Alduraz yme</w>
Al most</w>
A sp
A .,</w>
9 3</w>
7 8
4 35/</w>
38 6</w>
3 5%</w>
28 00</w>
27 6/</w>
200 5.</w>
20 )</w>
199 9</w>
150 /</w>
15 1/</w>
02 6</w>
000 ,</w>
/200 2)</w>
-2 4</w>
- B
(V TE
( E</w>
! '</w>
é s</w>
ycl ine</w>
wor st</w>
withdra wn.</w>
weak ened</w>
w ood</w>
w ing</w>
w av
vo ted</w>
vis it</w>
v od
v an
up set</w>
uni form</w>
un usual</w>
un certain
un acceptable</w>
tur ned</w>
trans cri
tol cap
toge ther.</w>
to oth</w>
to o.</w>
thre at</w>
terfen adine</w>
system s.</w>
supplement ary</w>
subjec ts,</w>
su it
streng th
strain )
st ly</w>
st ations</w>
st ate,</w>
st aff
sp i
sin us
si de,</w>
sha pe</w>
selec ted</w>
sec ure</w>
se t
sci ence</w>
scheme .</w>
sc and
rop in
ropin A
ro w</w>
risk -
ri l</w>
request ed</w>
repor t.</w>
recon stitu
re place</w>
race tam</w>
ra w</w>
r ich</w>
r hyth
qual ified</w>
pun ish
provi ded,</w>
proce ed
pro b
presid ency</w>
poin t.</w>
plung er</w>
physici an.</w>
performe d,</w>
per spec
path y</w>
pat ent</w>
pat ch
p oul
p ent
ous ly,</w>
osin ophil
os por
orth opa
orthopa edi
orthopaedi c</w>
orr he
on es.</w>
on ary</w>
omi me
oeph edrine</w>
o x</w>
o th
numb ness</w>
noe a</w>
necessar ily</w>
na il</w>
mov ed</w>
mon e
modi fying</w>
mis sion
mig rants</w>
mess age</w>
measure s.</w>
meaning ful</w>
marg in
main taining</w>
ma y
m osph
m mol</w>
load ing</w>
line ar</w>
lin e.</w>
lin e,</w>
lim iting</w>
level ,</w>
leg s</w>
le gi
l ing,</w>
l -
k e.</w>
it real</w>
inter im</w>
inten sity.</w>
ing ).</w>
increas e,</w>
in s.</w>
in n</w>
in din
in activ
imp rison
im umab</w>
il it
hist amine</w>
hepati c
he ard</w>
gu n</w>
gene tically</w>
gen s</w>
gen oty
g er
g all
fract ory</w>
form al</w>
forec ast
follow ed,</w>
financ ing</w>
fiel ds</w>
famili ar</w>
fa ul
f it</w>
exce eding</w>
examin ed.</w>
ex ha
eth n
establish ment</w>
er ?</w>
er -
ent ?</w>
embry os</w>
element s:</w>
el se
e able</w>
e -</w>
drin ks</w>
do or</w>
divi de</w>
disp ose</w>
disab led</w>
dis crimination</w>
di sh
deterior ation</w>
dest in
d ing.</w>
d ates</w>
d ark
cy tar
cy an
cr ush
connec ted</w>
conc ept</w>
comput er</w>
clim ate</w>
chec ked</w>
ch el
categ or
campa ign
bro ach
bre ed
br ut
bott le.</w>
benec id</w>
be aring</w>
batter y</w>
avi an</w>
aut o
attemp t</w>
ation ).</w>
ation '</w>
ati vely,</w>
at ul
at tit
at mosph
at edly</w>
at az
ari at</w>
ar ti
anti diabetic</w>
and ed</w>
an nel</w>
an aes
ambris entan</w>
am ph
aliz ed</w>
al ter
ad es</w>
accel erated</w>
ac om
X A</w>
X -
W HO
VIR ACE
VE N</w>
V ia</w>
V el
Ul tr
UTE (S)</w>
Tem od
TESLASC AN</w>
T ηλ
T u
T or
St ar,</w>
Sou th</w>
Sloven i
Sec ond
S ad
S K
Repub lic</w>
RO UTE(S)</w>
REN CI
R ob
R AP
Pradax a</w>
Pi oglitazone</w>
Pharmac okinetic</w>
Pelzon t</w>
P ap
P ak
P L</w>
O per
O T
O RENCI
Nut ropinA
N or</w>
N one
M U/</w>
M I
Luxembour g,</w>
Laborato ire</w>
L ess</w>
Janu ary</w>
J ap
J ans
HIV /
H O</w>
H .</w>
GF R
F A
Excipi ents:</w>
Ex forge</w>
EXJ ADE</w>
Depart ment</w>
D ata</w>
D V
D RE
Ch ar
CT 13</w>
C ho
C etro
Beta feron</w>
BeneF IX</w>
BM D</w>
Atri pl
Al co
Accid ental</w>
A vi
9N J</w>
8 7
7 7
7 4
6 ).</w>
5 4</w>
200 4</w>
199 0</w>
1. 4</w>
04 6/</w>
0 13</w>
................ ........
( and</w>
( 200
( 100</w>
" .</w>
Α γ
yr inth</w>
y e</w>
writ ing</w>
we red</w>
w ip
w i
viv al</w>
virtu ally</w>
vial )</w>
ve t</w>
v oc
us i
urtic aria</w>
under tak
un necessary</w>
un commonly</w>
u x</w>
tri um</w>
train ed</w>
tr uth
ton gue,</w>
tic ul
ti tion
there ,</w>
techni que</w>
teach ing
teaching 'the</w>
sw allow
sustain able</w>
sur ance</w>
sum mar
substanc es.</w>
su m</w>
stre am</w>
ster ing</w>
stat ement</w>
squ eez
sp he
slaugh ter</w>
sit es.</w>
si de-
seri es</w>
selec tively</w>
s is,</w>
s ad
ro utes</w>
ro siglitazone</w>
reli g
re mission</w>
r um
quot a</w>
pur su
proxim al</w>
prote ins</w>
promp t</w>
promot e</w>
pro ven
pri me
pres sed</w>
pregn ant.</w>
post natal</w>
posi t</w>
pol ici
plac ing</w>
pl y.</w>
pl ate</w>
phy si
per mit</w>
pas sive</w>
pa rently</w>
p ush
p in
otox ic</w>
ot ine</w>
os is)</w>
oro dispersible</w>
or ange</w>
opin ion,</w>
open ha
of u
ococc al</w>
o le,</w>
nutri tional</w>
non -</w>
new bor
neuro toxin</w>
neigh bour
n g
n as
mo re.</w>
mis leading</w>
met al</w>
men str
me ?</w>
mass ac
market ed.</w>
manufact uring</w>
mann er.</w>
manag ed</w>
mag nit
lit res</w>
le th
le b
law y
lab ell
know s</w>
kill ing</w>
k es</w>
ju dic
j um
it y-
it !</w>
infec t</w>
induc ing</w>
inclu ded.</w>
in o</w>
in contin
im posed</w>
illness es</w>
ig u
ici an</w>
ic al
ic a</w>
ia /</w>
hypoten sion</w>
hydro chloride</w>
he re,</w>
hazard ous</w>
ha ir
g ame</w>
g ad
fla g</w>
fast er</w>
facil ities</w>
f er</w>
exposu re.</w>
exces sively</w>
ex ternal</w>
ex .</w>
ev ent,</w>
et s.</w>
est ,</w>
er lotinib</w>
environ ment,</w>
ent ary</w>
enh ance</w>
eng ine
end -
en ia</w>
en ab
earli er</w>
e travirine</w>
dop amine</w>
diure tics</w>
disp ens
del iver
de struction</w>
control s.</w>
contamin ated</w>
consump tion.</w>
const antly</w>
consci ousness,</w>
con cep
comprehen sive</w>
complain ts</w>
comp rising</w>
com prim
colour less</w>
col leagu
cimeti dine</w>
chemic als</w>
cau ght</w>
cal c
bureauc rac
budget ary</w>
bl ack
bi ofu
bey ond</w>
be ings</w>
ban k</w>
b iliary</w>
b id</w>
b att
b ann
b A
bA 1
atic s</w>
ataz an
at e-
at -
assist ant</w>
assess ments</w>
ass ay</w>
aspec ts</w>
as pir
as cul
arrang ements</w>
ari a,</w>
applic able</w>
appe tite</w>
apar t</w>
ap s</w>
anxi ety,</w>
antipsycho tic</w>
anhydro us,</w>
and a</w>
anc yt
amino transferase</w>
am ine,</w>
all -
ag on</w>
adjustment )</w>
adj uv
ad el
ac tions.</w>
aband on
ab .</w>
a ur
________ ________
] .</w>
Z im
Y or
Y es,</w>
Wed nes
VER SY
VERSY L</w>
Unit s)</w>
UL N</w>
U N</w>
Thrombo embolic</w>
Th i
Techn ical</w>
TI W)</w>
T all
Syndro me</w>
Solo Star,</w>
ST AT
S up
S tra
S en
S el
Ro y
R an
Prequ enza</w>
Pot assi
Por te</w>
Pen fill</w>
Pak ist
P res
OptiS et.</w>
NAME }</w>
N ever</w>
N erv
N ational</w>
N TED</w>
Mon t
MR L
MIR AP
MIRAP EX
M s</w>
M T
M I</w>
Lev em
L I</w>
Kiv exa</w>
K os
Im prov
INVE NTED</w>
I F
Haarle m</w>
H CV</w>
H C
Greec e</w>
GM Os</w>
Fastur tec</w>
F ,</w>
Er bit
EU .</w>
E S</w>
E P
E D</w>
Di acom
D NA
D ATE</w>
Cap su
Ca ution</w>
CO VERSYL</w>
CE L
C openha
C AR
B uc
B os
B A
Atripl a</w>
Alzheim er
AN CE
AD R
A dul
8 2</w>
7 5%</w>
7 00</w>
69 800</w>
6. 1</w>
6 9</w>
6 -0
4. 3</w>
4 5
4 3</w>
30 -2
30 -
199 7,</w>
17 4</w>
10 4</w>
1. 7</w>
1  
02 8</w>
02 7</w>
02 1</w>
0 16</w>
0 15</w>
+4 5</w>
(A L
( which</w>
( at</w>
( 2</w>
τ ρ
τρ ίου</w>
μ η
μη τρίου</w>
η μητρίου</w>
Δ ημητρίου</w>
Αγ ίου</w>
z one</w>
z lo
z in</w>
yl -
win d</w>
wid espre
whe re,</w>
wel come</w>
wel com
we re:</w>
wa it</w>
w ound</w>
w oun
w ild</w>
ur ation</w>
un ion</w>
un changed</w>
un able</w>
ul tim
transpor ted</w>
transplant ation</w>
transcri p
to l</w>
tiv es,</w>
titr ated</w>
ti s.</w>
ti d
thin k
technolo gies</w>
te trac
te am</w>
targ ets</w>
t ;</w>
swe ating,</w>
surge on</w>
sur ing</w>
sump tion</w>
studi es?</w>
streng th</w>
stat ements</w>
st y</w>
st ret
st ers</w>
spe ech</w>
sp len
sourc es</w>
smo ke</w>
slaugh tered</w>
shor ter</w>
serv ed</w>
sep tic</w>
sens ation</w>
sen ior</w>
sen -C
sen-C il
sen-Cil ag</w>
se ts</w>
sam ple</w>
s gate</w>
s at
resol ve</w>
repor ting</w>
relev ant.</w>
reg ion
red ap
recomm end</w>
reach ing</w>
re r
re production</w>
rap porteur</w>
ra ise</w>
ques tion,</w>
qual ity,</w>
present .</w>
pregnanc ies</w>
pre vented</w>
pr a</w>
point s.</w>
po or
ple ment</w>
phylac tic</w>
phr ase</w>
people 's</w>
pati on,</w>
path ogen
p yl
overe d.</w>
ou ris
otox ic
other ,</w>
orr hoe
or d</w>
opath ic</w>
on es,</w>
offe red</w>
o ts</w>
o ch
n á</w>
myal gia,</w>
muc os
mono amine</w>
mon teluk
mis artan</w>
micro sphe
metr e</w>
medicin e)</w>
man .</w>
m am
lop in
log ic</w>
liv es.</w>
lik eli
likeli hood</w>
li vest
lat er,</w>
lansopraz ole</w>
lamiv ud
lafax ine</w>
l ose</w>
kg/ week</w>
it s.</w>
it arian</w>
ist s.</w>
is -
investig ations</w>
initi s,</w>
inf ants.</w>
ine /</w>
in- line</w>
in activated</w>
im esul
im ages</w>
il y.</w>
identi fication</w>
ide as</w>
ic s,</w>
i ans</w>
hear t,</w>
hap p
gr anu
govern mental</w>
go ,</w>
glycaem ia</w>
gastro -
g ave</w>
fun g
fract ures.</w>
fo rese
flav our
fir st-
fir m</w>
fibro z
fel is</w>
fe as
fati gue,</w>
f as
exposu res</w>
explain s</w>
exce eded</w>
ex agg
es cal
es -
es ),</w>
erythropo ies
er a</w>
epide mic</w>
enough .</w>
enhanc ing</w>
end ,</w>
employe es</w>
emo tional</w>
embry o</w>
em ents,</w>
effectiv e.</w>
eas ier</w>
e k
dysp ep
dun d
dulox etine</w>
doub t</w>
discontinu ed,</w>
direc tive.</w>
differen ti
diff er</w>
di l
des per
der s.</w>
depres sive</w>
democr atic</w>
degener ative</w>
deal ing</w>
de posit</w>
dat e.</w>
dat a,</w>
cross- border</w>
cover s</w>
continu ation</w>
consider ation.</w>
con struction</w>
compul sory</w>
comp ound</w>
comp oun
commun ity</w>
comb at</w>
ci vil</w>
children 's</w>
ch os
cent res</w>
cartridg e,</w>
candidi asis,</w>
c oc
breast-fe ed.</w>
be poetin</w>
bar rel
ation ),</w>
as bour
ar ticles</w>
ar sen
approv ed?</w>
ap parently</w>
answ ers</w>
anc ial</w>
alys is,</w>
allerg y</w>
al lo
al leg
aim ed</w>
aem ic</w>
aem ia.</w>
advant age</w>
adop tion</w>
ad in</w>
achiev ed.</w>
acet ate</w>
accoun ts</w>
acchar ide</w>
ac ul
ac ne,</w>
ac i
ab at
ab ap
a ke</w>
a i</w>
YY YY
W el
V om
V en
V F
TN F</w>
T redap
T ob
T it
T ab
T AN
Str asbour
Sloveni ja</w>
SUBST ANCE
STAT EMENT</w>
ST R
SPRYCE L</w>
S odium</w>
S in
S he</w>
S ev
S ME
Russi an</w>
Rou te</w>
Rom ani
Ram sgate</w>
Pub lic
Protec tion</w>
Program me</w>
Prof essor</w>
Pos aconazole</w>
Ph ot
Pe op
Pa ediatric</w>
P ure
P M
P HAR
OptiS et,</w>
Objec tive</w>
Novo Seven</w>
None thel
Nob ilis</w>
No ,</w>
MERI AL</w>
M u
M or
Lim ited,</w>
Kep pra</w>
K no
J .</w>
In spec
In iti
In duct
II .</w>
Hand ling</w>
Gover n
Fin ancial</w>
F ung
F requ
F our</w>
F CV</w>
Europe 's</w>
Eston ia</w>
Erbit ux</w>
EU/1/06/ 357
EU/1/0 7
EU 's</w>
EC )</w>
E- mail:</w>
E spo
Deutsch land</w>
D R
Cour t</w>
Ch ange</w>
Cetro tide</w>
B raz
B arcel
B an
Ar ticles</w>
Alco hol</w>
Afric a</w>
Ab normal</w>
A si
@m s
80 ,</w>
35 8/</w>
3 /2001)</w>
200 5</w>
2 /2001)</w>
19 ,</w>
13 .
1. 25</w>
0 17</w>
-1 ),</w>
) -
(H-0 4
(C max</w>
( 2)</w>
% ;</w>
µ g/
windo w</w>
wel fare</w>
week s)</w>
war ds.</w>
w ash
w ant
ver sions</w>
vent ric
ve ter
var ic
vag inal</w>
vaccin ated.</w>
v inyl</w>
ut ed.</w>
uri a</w>
u til
tub es</w>
trans amin
trac e</w>
tr im
tr a</w>
toxic ity.</w>
ton gue</w>
tolcap one</w>
to wn</w>
tim ic
tig otine</w>
ti fication</w>
thes e,</w>
than ks</w>
temperat ures</w>
techniqu es</w>
te l</w>
t ell
t ed?</w>
t 's</w>
swe ating</w>
sup posed</w>
sub stitution</w>
stoc ks</w>
sti ff
st res
st en
st ak
squ are</w>
spo ts</w>
spo ke</w>
sol ely</w>
sk eletal</w>
sil denafil</w>
sho t</w>
sent ence</w>
seiz ure</w>
se t.</w>
se as
sal icy
salicy lic</w>
sal es</w>
saf ely</w>
s ors</w>
s ore</w>
s ell</w>
ring s</w>
ri d
retin opathy,</w>
ret ard
respon se,</w>
resist ance.</w>
repor ts,</w>
regular ly.</w>
reach es</w>
re m
re im
reim bur
re fractory</w>
re dund
re ality</w>
re act
rat es.</w>
ra ising</w>
program me.</w>
prin ted</w>
pre -</w>
pra vastatin</w>
plic ation</w>
plan ned</w>
pla ying</w>
person nel</w>
per id
parenter al</w>
p yr
ou d</w>
ot es</w>
orrhe a,</w>
organiz a
ore x
omat ous</w>
om egal
olog y.</w>
ocor tic
net works</w>
ne ur
n il
mysel f</w>
mus culoskeletal</w>
mur dered</w>
moder ate,</w>
mob ile</w>
mm H
mal a
magnit ude</w>
ma .</w>
m ing</w>
m er</w>
m Tc
m )</w>
lymphocyt es</w>
lymp h</w>
ly ?</w>
loc ation</w>
liter ature</w>
li e</w>
let ter</w>
le ast
last ing</w>
lact ation</w>
label /</w>
lab yrinth</w>
la ws</w>
la an</w>
l ingu
kilog ram</w>
kil led.</w>
k ill</w>
justi fy</w>
jus tice</w>
join ts</w>
iti es?</w>
isc haem
is ot
ir o</w>
investig ated.</w>
intoler ance</w>
instrum ents</w>
inj ure
inhal ation</w>
ing ),</w>
inflixim ab</w>
indic ators</w>
indic ator</w>
in i</w>
in es,</w>
in c</w>
in :</w>
impro ving</w>
im per
ic ul
ic idal</w>
ible .</w>
i o
hyper sensitive</w>
hydr ation</w>
hy s
high ligh
her o
hard ly</w>
ham ster</w>
h ost</w>
gu il
gr aph
gastroenter itis,</w>
g ence</w>
fut ure.</w>
fundam ent
forme d.</w>
for d</w>
fol lic
fl ushed</w>
fing er
feat ures</w>
fat ty</w>
fa ther</w>
exten d</w>
experti se</w>
example .</w>
exam ples</w>
ex trac
ex er
ex cell
ev ents.</w>
eth an
est .</w>
es tic</w>
equ ally</w>
ep tic
ent ly.</w>
ent ec
encour ag
embol ism</w>
elec tion</w>
el ines</w>
efaviren z,</w>
educ ational</w>
ec tin</w>
e go
dos e)</w>
do g</w>
diver sity</w>
distribu tion.</w>
disp lac
disp en
dig es
diffe rently</w>
di alogue</w>
detail s</w>
deriv atives</w>
der s,</w>
del to
degrad ation</w>
d i</w>
cut aneous</w>
cour t</w>
coun ted</w>
contrac ts</w>
const ant</w>
consequ ence</w>
confir m</w>
compar ator</w>
comp are</w>
com posed</w>
col um
col itis</w>
civ ili
cispl atin</w>
cirrh osis</w>
cholester ol
chol in
che ap
characteris tic</w>
cha mp
ch ances</w>
cent uri
cat s</w>
can n
c li
c hap
bronch itis,</w>
break down</w>
bo w
bi os
be ar</w>
bA1 c</w>
b ringing</w>
b on</w>
b ic
author ity</w>
author isations</w>
ation ;</w>
ati de</w>
at ine</w>
as per
ar thro
ar ise</w>
appropri ate,</w>
antibodi es.</w>
anti hypertensive</w>
an timic
an orex
al pha
al )</w>
ag o,</w>
ag ents,</w>
aff air
advis e</w>
addi tive</w>
ac tion,</w>
ab ine,</w>
a i
Z YP
XX X</w>
Wil zin</w>
Wh ere
We ight</w>
VI STI
VE R</w>
V imp
U G
Tev ag
TRISENO X</w>
Syn ag
Sur vival</w>
Stock hol
Sim ul
Servic es</w>
S prime
S et
Remic ade</w>
Rem ove</w>
REAC H</w>
R adi
Prot aphane</w>
Presid ency</w>
Prac -
Prac- tic</w>
Por c
Pol ys
P C
ORENCI A</w>
O D</w>
Ne ed
Medic al</w>
MRL s</w>
M un
M inistry</w>
Kos ov
Jans sen-Cilag</w>
J os
Infl am
IU )</w>
I f,</w>
I B</w>
H old</w>
German y.</w>
GI VEN</w>
G Y
Fung al</w>
F un
F orm
EU -
EMEN D</w>
E ast</w>
Doc etaxel</w>
DRE SS</w>
Concer ned</w>
Colleg e</w>
Christi an</w>
Cha ir
C ateg
C RI
B on
B S
Amend ments</w>
Actr aphane</w>
AD DRESS</w>
AB I
A u
8 8</w>
5 %,</w>
4 15/</w>
30 ,</w>
17 %</w>
15 2/</w>
13 4/</w>
10 .</w>
1 ),</w>
/ 2
, 200</w>
(hyper glycaem
(N =
(MAO I
(HIV -1),</w>
(A5-0 3
(90 Y
( or</w>
’ ).</w>
μ ος</w>
λ ι
λι μος</w>
Ά λιμος</w>
{ MM
z ed</w>
z e</w>
z al
ye ster
worth y</w>
with ,</w>
weap ons</w>
w rite</w>
w age</w>
volun tary</w>
ve c</w>
vastat in,</w>
v a</w>
ur ine.</w>
understo od</w>
ul l</w>
u gre
ty pe
tri ax
transpor ters</w>
transfer ring</w>
trac e
tr ack</w>
ting ling</w>
tig ec
thrombocyt open
therap ies</w>
tetan us</w>
terro rist
te z
tab ly</w>
ta p</w>
ta .</w>
t ed:</w>
system s,</w>
syndrome )</w>
sy mbo
symbo l</w>
swit ch</w>
suspec ted,</w>
subsidi es</w>
sub stitu
sub sid
strateg ic</w>
sti pul
sti g
spondyli tis</w>
spectr um</w>
sp end</w>
sib le,</w>
si ve.</w>
ship ,</w>
sha ken</w>
sal mon
s car
ro tic</w>
ro myc
ri tis,</w>
resul ts,</w>
rest aur
respon ding</w>
resol ved</w>
resi due</w>
rep lied</w>
remain ed</w>
reason s.</w>
re rs</w>
re presents</w>
re mitting</w>
re g</w>
rat s,</w>
rat es,</w>
rang e.</w>
r y,</w>
quar ter</w>
qu o
proper ly.</w>
prop ylene</w>
process es</w>
pre cur
prac tition
pr on
pneumon ia</w>
photosensi tivity</w>
phosph or
per pe
per it
peop les</w>
pen sion
pat ri
paragrap h
p a</w>
p .
out ?</w>
org ans</w>
or )</w>
opportun ities</w>
opin ions</w>
oper ation,</w>
op s</w>
omet a</w>
olan zapine</w>
oglit az
ocy tic</w>
oblig ation</w>
ob al
o v</w>
num er
newspap er</w>
neuropath y,</w>
neuro muscular</w>
nec rosis</w>
ne ither</w>
n u
n g/</w>
multi pack</w>
moun tain
month s)</w>
mon opol
ml ).</w>
mic ron
metabolit e.</w>
ment ?</w>
mening iti
mem antine</w>
mellit us,</w>
medi a,</w>
me tric</w>
me tal
me t.</w>
me als.</w>
m us</w>
m ask</w>
ly ophil
ly ).</w>
low ,</w>
loc ated</w>
lithi um</w>
legi tim
lay er</w>
k s.</w>
k o</w>
k m</w>
ju ven
joint s,</w>
iv ely</w>
ith romyc
ish .</w>
ip ex
ipex ole</w>
investig ate</w>
inv en
inten d</w>
integr ation</w>
insul in)</w>
inst all
inser ted</w>
injuri es</w>
inj ured</w>
inf ring
industr y.</w>
individu als.</w>
inadequ ate.</w>
improv ements</w>
implement ing</w>
im plement</w>
ili ation</w>
il oprost</w>
il ity,</w>
ific ation</w>
iden tical</w>
ic s.</w>
ia ).</w>
hyper calcaem
hygi ene</w>
hum an.</w>
http:/ /ww
http://ww w.
histor ical</w>
hi a</w>
haz ards</w>
h o</w>
h at
gu ard</w>
gre en</w>
gluc ocortic
fun ded</w>
formul a</w>
flo od
flex ible</w>
fl ag
fiel d,</w>
fic ations</w>
fib rosis</w>
fail s</w>
fac ed</w>
f ate</w>
es c
er o
ep istax
enti n</w>
ent ry</w>
encour age</w>
en jo
electr ical</w>
elap sed,</w>
effectiv en
ed !</w>
e ties</w>
e ous</w>
e igh
e arth
e (s)</w>
drop ped</w>
dro w
dre am
dr af
dist inc
diseas e-
discharg e,</w>
disappear .</w>
dis col
dis abil
did anosine</w>
dic ated</w>
diarrhoe a.</w>
diabet es.</w>
di pl
detec table</w>
destro y</w>
destro y
delto id</w>
de pos
days )</w>
dat e,</w>
dang ers</w>
da m</w>
d ying</w>
d res
d ental</w>
d as
cy c
cum ulative</w>
cre ation</w>
conv inc
consum ers.</w>
concentr ations.</w>
con vic
con solid
con secu
con s
con cre
compromis e</w>
compli ance</w>
complet ely.</w>
competi tiv
compati bility</w>
col i.</w>
cod e</w>
cloud y.</w>
cle are
classi fied</w>
chromos omal</w>
charg es</w>
cau ti
catt le.</w>
cat ch</w>
cat astro
catastro ph
car box
capsul es,</w>
call s</w>
ca re,</w>
breast -</w>
brea ks</w>
bre aking</w>
box .</w>
bon d</w>
bilirub in</w>
below :</w>
be tol</w>
ban ks</w>
bacter i
back ground</w>
b ase</w>
aw a</w>
avir )</w>
aven ue</w>
avail able,</w>
auto immune</w>
attri but
ati tis</w>
atazan avir</w>
at e?</w>
assist ance.</w>
arth ral
ar ial</w>
an o
altern atives</w>
allerg y,</w>
all uc
al ia</w>
al '</w>
agricul ture</w>
ag ue</w>
adv ance</w>
admini stering</w>
adel ph
ad ing</w>
acid osis,</w>
ac ept</w>
a us
Zim bab
ZYP RE
ZYPRE XA</w>
Z yr
Z ometa</w>
Yt trig
Wil son
West ern</w>
W AL</w>
Vi rological</w>
Vi read</w>
Vi et
V ascular</w>
Un less</w>
U su
U SA</w>
Tu es
Tevag rastim</w>
Temod al</w>
Tall inn</w>
TRA VAT
Swe dish</w>
Sol iris</w>
Sec urity</w>
Sandw ich</w>
SI ON</w>
S pain.</w>
S om
S it
S cal
S ar
S an</w>
S O
Ro che</w>
Res ist
Reduc tion</w>
Recom mend
Re betol</w>
R iv
R NA</w>
Puh /</w>
Pre -filled</w>
Pr im
Polys orbate</w>
Phil adelph
Parliam ent,</w>
P y
P hys
Opti sulin</w>
O ut</w>
O edema</w>
NutropinA q</w>
Nonethel ess,</w>
Ne o
Mal ign
Madri d,</w>
LI ST
K al
J ul
Israel i</w>
Inter vet</w>
In v
In stitute</w>
In din
Imp ri
HEX AL</w>
H bA1c</w>
H aving</w>
H V</w>
H )</w>
Gli vec</w>
GR- 174</w>
G ood</w>
G em
G AN
GAN FOR
G ,</w>
Frank fur
Fr ance.</w>
FS H</w>
F re
F ort</w>
F lu
F ig
F armac
Ex ta
Em sel
EMA D
EMAD INE</w>
Dis k
D ate</w>
D ar
Commission ’s</w>
Com bi
Co ordination</w>
Cl ose</w>
Child -
Child- Pugh</w>
Ch rist
Calici virosis</w>
CYP 1A
CEL SEN
C A</w>
C /</w>
B ut
B or
B R
Aug ust</w>
Ap pro
Anti -
Al pes</w>
Agency ’s</w>
Af gh
Ac tive</w>
AL T
ADR s</w>
ABI LIF
A T</w>
7 %)</w>
58 1</w>
5 9
4 0%</w>
30-2 10</w>
3 000</w>
20 .</w>
2 2%</w>
2 %)</w>
10 8</w>
1, 200</w>
0 7
0 25</w>
0 24</w>
0 19</w>
0 18</w>
0 1
/1 ,200</w>
/00 3</w>
-2 -
-------- ----
(VTE )</w>
(M RI
(E EC)</w>
(A4-0 3
(1,000 /1,200</w>
(0. 9%)</w>
(0. 2%</w>
( un
( particularly</w>
’ )</w>
ó n</w>
{month /</w>
zon is
zlo ž</w>
your s.</w>
yl ation</w>
yclin es</w>
y n</w>
y ),</w>
writ ing.</w>
world wide</w>
withdra w</w>
wh it
weak ness,</w>
war r
war ned</w>
w ife</w>
w ed</w>
vot ing</w>
volunte ers.</w>
vit ro
v enti
ut h</w>
ust ,</w>
us ?</w>
ur anium</w>
un common</w>
u xim
tu red</w>
treatment -
transi tional</w>
transcrip tase</w>
trad ing</w>
ti tle</w>
thyro idis
thro m
thes ia,</w>
ther m
them ?</w>
th ri
th in</w>
test .</w>
terat ogenic</w>
technolog y,</w>
technolog ical</w>
tablet s)</w>
t ose</w>
t ank
sz awa</w>
sympath omime
sun light</w>
sulphon yl
sudden ly</w>
strain ):</w>
ste ar
speci alist</w>
sp ort
sorbit ol</w>
somnol ence</w>
sidi c</w>
se l</w>
scen ari
sal ts</w>
s s</w>
s or</w>
s mu
smu g
s hap
shap ed</w>
s )
ro g
ri end
ri de</w>
rhinotrache itis,</w>
respon se
reg ion.</w>
re structur
re no
re a</w>
r il
r ation
r ated</w>
r .
r -
quanti t
qual ity.</w>
pseud oephedrine</w>
propos al.</w>
promot ing</w>
procedu re,</w>
pro genit
prim e</w>
prec ed
pre vents</w>
pram ipexole</w>
pow ers</w>
poin t,</w>
po t</w>
pl ays</w>
pit ting</w>
piec es</w>
pi oglitaz
phenyl but
phen y
ph ther
ph thal
perfec tly</w>
per tus
pat h</w>
pass ing</w>
par aesthesia,</w>
pap ular</w>
pancre atic</w>
pal pit
p t
p ip
p age</w>
ox one</w>
oter icin</w>
ost atic</w>
osi tion</w>
os e,</w>
orph ine</w>
organiza č</w>
org an</w>
oper ators</w>
open- label</w>
op i
op ed</w>
on om
om ,</w>
ol d,</w>
off ers</w>
of ,</w>
od en
ob ser
ob ese</w>
o Tra
new born</w>
negoti ations</w>
ne ti
natur ally</w>
n g</w>
mou th
mon ey
mol ecu
moder ately</w>
mo x
mo re
min er
mg/ ml</w>
mg/ l</w>
mercur y</w>
mem be
manufact ured</w>
m m</w>
m ad
m L</w>
m -
lo vastatin</w>
lo ose</w>
lin ed</w>
lim bs</w>
lim b</w>
less ness</w>
less ness,</w>
le p
land s</w>
lact ate</w>
l' Avi
kne e</w>
iv ac</w>
iti dine</w>
ish ing</w>
is land</w>
is ation,</w>
intrac ellular</w>
insul in,</w>
instrum ent</w>
initi s</w>
initi ated.</w>
infiltr ates,</w>
ine ;</w>
indic ated.</w>
in tim
in qu
in ner</w>
in ing</w>
in adver
impai red,</w>
if loxacin</w>
ic al,</w>
human s,</w>
hour .</w>
hor iz
histor y,</w>
her bal</w>
hepar in</w>
hel ping</w>
harmon ised</w>
harmon isation</w>
happen s,</w>
haemorrhag ic</w>
h ex
guarante ed</w>
grow th,</w>
gro w</w>
great est</w>
gr aft</w>
gover ning</w>
glyco sidic</w>
gl omer
gastro- intestinal</w>
gain .</w>
ga p</w>
g y
fru c
fri end
freed om</w>
form .</w>
fo ods</w>
flur ane</w>
flu vastatin</w>
fel t</w>
fam ous</w>
fall s</w>
facil it
fac ial</w>
f lights</w>
f iv
f ell</w>
experim ents</w>
ex port
ethn ic</w>
eth ical</w>
et c.</w>
es ’</w>
es om
erythropoies is</w>
erg ill
erg er</w>
erc ent</w>
epilep sy</w>
ent s)</w>
endoc rine</w>
encephal opathy</w>
enc ies.</w>
en vel
egg s</w>
effectiv e,</w>
effec ts:</w>
educ ation.</w>
e on</w>
dri vers</w>
dos e).</w>
don es
displa yed</w>
disp ut
discar ded.</w>
dis infec
dict ator
di alogu
di al</w>
design ation</w>
depres sed</w>
den ied</w>
dem ands</w>
deliv ered</w>
delay ed.</w>
defin it
defec ts</w>
def ence</w>
cy cle
cust om
cur rency</w>
cri tical</w>
cost s.</w>
continu ing</w>
contain ers</w>
consi sts</w>
conj ug
con struc
con stitute</w>
comple x
compani es,</w>
comm ents</w>
com posite</w>
com ment</w>
collec tion</w>
co he
cloud y,</w>
circumstanc es,</w>
chemo therapy.</w>
cha ins</w>
ch i
candidi asis</w>
c ogn
c ast</w>
c ad
c )</w>
bur den
broach ed,</w>
behaviour al</w>
bas is,</w>
back ,</w>
b rel
b les</w>
b ath
b a</w>
au ti
ati call
ath ec
at en</w>
ast ern</w>
ass a
arter ial</w>
art an
arrest ed</w>
arm y</w>
ari an
are s</w>
ar ly,</w>
ar k</w>
appe tit
antibio tics.</w>
antibio tic
anti epileptic</w>
answe red</w>
an o</w>
an n</w>
an aly
amph otericin</w>
alu )</w>
alluc in
alloc ated</w>
alle vi
all y-
aliz umab</w>
album in</w>
al arm
al :</w>
ag encies</w>
af ra
ad ,</w>
accid ent.</w>
ac e
abap entin</w>
ab r
ab duc
We ek</w>
War szawa</w>
Vom iting</w>
Vir al</w>
VISTI DE</w>
VI I</w>
V ial</w>
V R</w>
Tur key</w>
Trizi vir</w>
Tredap tive</w>
Thro mb
TH OD</w>
T AC
Stockhol m</w>
St atis
Sim il
Shel f</w>
Sci ence</w>
ST E
S on
S oci
S ha
S av
S ant
Re gi
RE NE
RENE WAL</w>
R os
R ome</w>
R ipraz
Public ations</w>
Place bo</w>
Philadelph ia</w>
Palestini an</w>
P sy
P at
P C</w>
Organ isation</w>
OS SE
Nob ivac</w>
Nerv ous</w>
Mul ti
Medi an</w>
Me ier</w>
MIRAPEX IN</w>
ME THOD</w>
MA G
M os
Levem ir</w>
L en
L ap
John son</w>
Inv estig
Inflam mation</w>
Indin avir</w>
In hib
In dones
In dividu
Impri da</w>
I cel
I S
I G</w>
I -
Harmon isation</w>
HEX AVA
HEXAVA C</w>
H ave</w>
H UMA
Guid eline</w>
F U
Exc essive</w>
Eg yp
EU/1/08/4 84
EU/1/07 /4
EU/1/07/4 25
EU RO
E pi
E S,</w>
Dub lin</w>
Du oTra
Cy an
Combin ation</w>
Cho le
Capsu le,</w>
C re
C ity</w>
C ere
C ast
C C
Bar ro
B e</w>
B alk
Aran esp</w>
Ag e</w>
AN O
AN D
A ir</w>
A Z</w>
A E
@ms d.</w>
800 ,000</w>
6. 2</w>
6 /98)</w>
50 -
5 7</w>
36 6/</w>
3 2
200 8</w>
20 7</w>
2 4-
17 ,</w>
10 9/</w>
02 3</w>
02 2</w>
0 6</w>
0 3</w>
0 20</w>
/00 2</w>
/ 3
-f riend
- site</w>
- 4
, 5</w>
(P LI</w>
(HD PE)</w>
(C N
(90Y )</w>
( under</w>
( mean</w>
( cells</w>
( 300</w>
ä r
zidov ud
z inc</w>
z a</w>
worsen ,</w>
with :</w>
will ,</w>
where by</w>
we l</w>
w ounds</w>
vi de
ve ti
valu es.</w>
val id
v ec
ur ic
under take</w>
un anim
ul a</w>
ty ros
two- year</w>
tro ph
tri ed</w>
transpa rent</w>
transi tion</w>
transf us
trag ic</w>
trag ed
tra um
tra in</w>
tou ris
toge ther,</w>
to wn
ti bi
throm bin
thro w</w>
thick ening</w>
ther s</w>
th usi
terroris t</w>
terro rists</w>
ter ?</w>
tech neti
t ext
t ask</w>
sus pic
surve ys</w>
supp lies</w>
sup ported</w>
summ er</w>
su cr
stor age,</w>
st s,</w>
st ock
speak ing,</w>
speak er</w>
sp or
somnol ence,</w>
soldi ers</w>
sol uble</w>
sol ,</w>
six -
sin us</w>
si st
si gh
shi re,</w>
sh ell</w>
sh ell
separ ated</w>
sen d</w>
see ing</w>
saquin avir</w>
s oun
s elling</w>
s ants</w>
ro n</w>
riton avir,</w>
rif amp
ri z
revis ed</w>
reve al</w>
restric tion</w>
reserv o
repor t
remov ing</w>
reli ef</w>
regul ation.</w>
red den
red ?</w>
re mind</w>
re membe
re memb
re mark
re in
rati os</w>
rash es</w>
rash )</w>
ra il
r :</w>
prurit us</w>
protec tion
prote inuria</w>
prote in.</w>
prote in)</w>
pron ounc
promot es</w>
progenit or</w>
pro ven</w>
prepar ing</w>
prec ise</w>
potassium- containing</w>
pos ing</w>
pneumon itis,</w>
pl at
pl ase</w>
phosph on
phil os
pharyng itis</w>
pharmac odynamic</w>
perfec t</w>
per mit
pen icill
pe tro
pe ace</w>
par t,</w>
par as
pandem ic</w>
packag ing.</w>
pa res
p ation</w>
p -
ox ib.</w>
ot roph
ot inib</w>
oper ations</w>
op tions</w>
op t-
op posed</w>
om ?</w>
ogen etic</w>
oc r
o king</w>
o il,</w>
o il
no w.</w>
no vel
nigh t,</w>
new ly-
n ick
n app
n M
mono hydrate,</w>
molec ules</w>
mod els</w>
mo stly</w>
mis sed</w>
min eral</w>
microsphe res</w>
me mor
man n</w>
mac ulo
ma ,</w>
loc ked</w>
loc k
load ed</w>
list at</w>
li ps</w>
let ters</w>
legisl ation.</w>
le veti
larg est</w>
kidne ys</w>
kg/ week)</w>
iv ed</w>
is ers</w>
is e.</w>
is ?</w>
ir rig
intrav itreal</w>
intr athec
inter medi
inten sity</w>
injec table</w>
inhibit ors,</w>
in a,</w>
impro ves</w>
import ant.</w>
immunoglob ulin</w>
im ports</w>
il ity.</w>
il ing</w>
ic /</w>
i vi
hypoten sion.</w>
human itarian</w>
hol ders</w>
happen ,</w>
hand .</w>
h il
groun d
gran ul
go .</w>
glyc ine,</w>
gl in
gl as
gir ls</w>
genu ine</w>
g ill
g ained</w>
fra ud</w>
fra ud
for .</w>
foodstuff s</w>
follow .</w>
fol d.</w>
fo rest</w>
fisher ies</w>
fir st
fir m
fibroz il</w>
fi re
farm er</w>
fal si
fac ing</w>
fa il</w>
ext ending</w>
exp ose</w>
exacerb ation</w>
ex ec
event s/</w>
es e,</w>
es '.</w>
erro rs</w>
enzy m
ent h</w>
en )</w>
emphas is</w>
emerg ence</w>
ement ?</w>
effec tively.</w>
ec te
e- mail</w>
e dema
e /
du mp
dom estic</w>
do reg</w>
dissemin ation</w>
dispens er</w>
disease- modifying</w>
dis ci
disci pl
di men
di ame
dem and.</w>
dela y.</w>
del iber
degre es</w>
dec om
de ple
de d
dar k</w>
dar bepoetin</w>
cy clo
crimin als</w>
cre ating</w>
cor onary</w>
controver si
contr ast
cont ent.</w>
consequenc es.</w>
conjunctivi tis,</w>
conf identi
conf id
condition s:</w>
conclus ions</w>
compar ing</w>
comp ounds</w>
comm is
combin ations</w>
co w
clos ing</w>
clo tt
claim ed</w>
chemi str
chec ks</w>
ch ur
cauti ously</w>
cast or</w>
canc ers</w>
c ure</w>
bur ic
bro ad</w>
breath ,</w>
bre eding</w>
br ad
bo ok</w>
blur red</w>
block er</w>
be fore
be ef</w>
bag s</w>
b ac
az ole</w>
az ol
autom atic</w>
ati tis,</w>
ass es</w>
ass ass
asper gill
as k
arter y</w>
arm ,</w>
ard )</w>
ar y
appli ed,</w>
appetit e,</w>
anti fungal</w>
anti d
anaphy lactic</w>
analys is,</w>
analys ed</w>
an al
ambi ent</w>
am en
allerg ies</w>
all ing</w>
alis ed.</w>
alf a.</w>
alcohol ,</w>
al together</w>
ain .</w>
ain ,</w>
ag us</w>
ag e-
ade fovir</w>
ad ox
ad mitted</w>
acetyl salicylic</w>
accep table,</w>
acc used</w>
abol ic</w>
a way.</w>
a j
[ N</w>
Zyr tec</w>
Z en
Yttrig a</w>
W ell
W I
W HO</w>
V ec
V A</w>
Ultr atard</w>
Tw enty-
Tur n</w>
Ten ofovir</w>
Tac rolimus</w>
T erro
T P</w>
System s</w>
Suomi /</w>
St ev
Sprime o</w>
Sin us
Sign ific
Sh ire</w>
SAR L,</w>
S o,</w>
S ING
SING UL
Ran exa</w>
R ules</w>
Q T</w>
Psy ch
Pro du
Pharmac ology</w>
Peop le</w>
Parliament 's</w>
P AC
OptiC lik
On going</w>
Ombud s
O THER</w>
O ,</w>
Ne utro
Ne ul
NSA ID</w>
N atur
Met alyse</w>
Mediterran ean</w>
Manufacture r:</w>
ME P
M ari
Luc entis</w>
Lithu ania,</w>
LD L-
L ong</w>
L j
L and
L a</w>
L Y
J our
Ital ian</w>
Inhib itors</w>
Incre ase</w>
In tr
In te
Improv ement</w>
IN O
I ran
I bra
Hung arian</w>
Hol dings</w>
H igh</w>
H Be
GD P</w>
G M</w>
Fil grastim</w>
FIR ST</w>
F uz
F os
F .</w>
EU /0
E udra
Diacom it</w>
D ru
D ep
D G</w>
Copenha gen</w>
Con vention</w>
Combi vir</w>
Ci profloxacin</w>
Cha mb
Ch ina</w>
Categ ory</w>
Car doreg</w>
CYP2 D
CY ST
CI AL
CI )</w>
C hi
C ).</w>
Author isation
At lantic</w>
Asp ergill
Any one</w>
Am ster
Alb ani
Agency 's</w>
Ab sol
AI R</w>
A th
6 %)</w>
5 %)</w>
40 -
4 00
4 ).</w>
3 20</w>
3 %)</w>
25 -
200 1.</w>
2. 6</w>
199 0
17 .
15 .
13 5</w>
1 37/</w>
1 30</w>
1 11</w>
000 .</w>
0. 8
/00 1</w>
.... ..</w>
- resistant</w>
- in-
- av
(E 4
(A5-0 2
( glucos
( by</w>
( N</w>
( 9</w>
( 8
( 3.
( 18
( 15</w>
é n
° C)</w>
§ ,</w>
{MM /</w>
zonis amide</w>
z iconotide</w>
worl d,</w>
won der</w>
with .</w>
wish es</w>
whil e,</w>
when ever</w>
whe ez
well ,</w>
weigh ed</w>
weak ness
weak er</w>
wea ther</w>
wa ys,</w>
w est</w>
vig en</w>
vie ws</w>
vic tim</w>
vi ro
veter in
vari able</w>
val pro
v ical</w>
v et
v ation</w>
ut in
usu al.</w>
us s</w>
us age,</w>
uri a,</w>
ur a</w>
un known,</w>
un controlled</w>
um ab,</w>
ultr as
ulcer ,</w>
ugre l</w>
u locyt
toxic ity,</w>
tor ate</w>
tonn es.</w>
tion ed</w>
ti go,</w>
thum b</w>
thrombocyt openia</w>
the ore
the -
tez omi
tezomi b</w>
territ or
ter m,</w>
te en
tak en,</w>
t te</w>
t oral</w>
t ness</w>
t ane
swe et
sulphon am
substanc e(s)</w>
submit ted:</w>
subjec t
ster ,</w>
st ory</w>
st in
st ay</w>
st ate.</w>
specific ,</w>
sp ort</w>
sp ac
sodi um,</w>
sm an</w>
sk ills</w>
siz ed</w>
sion s.</w>
single- dose</w>
sim pl
side- effects</w>
short -
shock )</w>
sho p</w>
shi el
ser otype</w>
second -
sec ut
sec tor.</w>
se vo
se g
scler osis,</w>
schedu led</w>
scal e,</w>
sc rap
safe guar
saf e,</w>
s y.</w>
s ing.</w>
s bo</w>
s ant</w>
ro se</w>
risk- benefit</w>
righ tly</w>
rib os
ri ving</w>
rh in
request s</w>
represent ed</w>
repor t?</w>
releas ing</w>
regres sion</w>
reg ion,</w>
reduc tion,</w>
reduc ed,</w>
rec y
rec ur</w>
reaction ).</w>
re ds</w>
ras buric
radio activity</w>
rac e</w>
ra y</w>
pur pur
pub er
propos ing</w>
prohib ited</w>
pro gest
priv il
privil eg
pres sing</w>
pren orphine</w>
pre filled</w>
pot -on</w>
post pon
pep ti
passeng er</w>
part ners</w>
p s.</w>
ov ary</w>
osi 's</w>
os is
os ex
oper ator</w>
op tion</w>
op position</w>
on s.</w>
om yel
om in
om as
ol ol</w>
ol ic</w>
og ly
of <</w>
od ge</w>
ob taining</w>
o ?</w>
new s</w>
negoti ating</w>
neg lig
necess ity</w>
ne uri
ne ed.</w>
ne arly</w>
n ing,</w>
mor ph
mis sions</w>
min ,</w>
mid -
microgram /
mg/ day
mg/day ),</w>
meth yl</w>
metast atic</w>
me pi
me d,</w>
may be</w>
mas sive</w>
man ual</w>
man ip
mal nutrition</w>
maj or
mag nes
m ere</w>
los ses</w>
livest ock</w>
life style</w>
lead ers</w>
le ?</w>
land fill</w>
l j
l ing.</w>
ki ren</w>
justi fication</w>
je op
j unc
iv ing</w>
iti s)</w>
it es</w>
issu e.</w>
ir respective</w>
ir ,</w>
ion ?</w>
intoler ant</w>
interrup ted</w>
interest ing</w>
inter val
insuffici ency.</w>
inspec tions</w>
inser t</w>
innov ative</w>
inhabit ants</w>
infra structure</w>
inflamm ation,</w>
inev it
indic ates</w>
incre tin</w>
in tran
in stitution</w>
in ed</w>
import ant,</w>
immunosuppres sive</w>
imesul ide</w>
im pres
im atin
ig no
ifi ed.</w>
id s,</w>
hund reds</w>
hous es</w>
hom osex
him self</w>
heim er</w>
hand ed</w>
haemat omas</w>
ha ul
h ung
h allucin
h /</w>
gradu ate</w>
gr and
gr ac
go als</w>
gli oma</w>
gi ous</w>
gen es</w>
g est</w>
fu r</w>
fruc tose</w>
fre ez
forwar d.</w>
fo ot</w>
flush ing,</w>
flu o
fibr ill
fi st
ferti lit
fe renc
fat ality,</w>
f ill
f atten
expec ted.</w>
exist s.</w>
ex en
evid ent</w>
ev ol
ev es</w>
establish ed,</w>
est er
ere d.</w>
er s;</w>
er re</w>
er ;</w>
entit led</w>
ent ation</w>
ent an
end rix</w>
en ox
em ed</w>
ell ul
electro ly
el ement</w>
eg g</w>
eczem a,</w>
e- mail
dur al</w>
dri ver</w>
dist or
discus s</w>
disast er</w>
dis colour</w>
dis colour
dis appoint
direc tor
direc tion</w>
dic ul
diagnos tic</w>
di es</w>
di es
degrad ed</w>
de vast
de d?</w>
d n
d an
cut ting</w>
cust oms</w>
cur ren
crit eri
cre sol,</w>
correspon ds</w>
conver sion</w>
contrib ution</w>
contrib utes</w>
committe es</w>
commit ted</w>
commer ci
collap se</w>
co st-
co ffe
clos er</w>
chick en
characteris tics.</w>
cha mb
cha ired</w>
ch ron
ch oler
cer vical</w>
ce phal
care rs</w>
cal ori
cal ib
c rop
c en
c elecoxib</w>
but ,</w>
business es</w>
bureaucrac y.</w>
bu ted</w>
bott le
border line</w>
bon ds</w>
bo wel</w>
biotechnolog y</w>
beta -1
be auti
barri er</w>
bal anc
auc as
attri buted</w>
atten uated</w>
ator y,</w>
ativ es.</w>
atis lav
at roph
at er
at ed?</w>
at ed)</w>
at an</w>
ash es</w>
as y
aryn geal</w>
are .</w>
applic ant</w>
appe al</w>
ap lastic</w>
anth rac
an other.</w>
an ese</w>
am ps</w>
am ples</w>
al in</w>
al /</w>
aim s</w>
af ung
aesthes ia</w>
adver tising</w>
adver sely</w>
adi ol</w>
adal imumab</w>
adal afil</w>
accoun ting</w>
ac tively</w>
ac in</w>
ac compan
abor tion</w>
ab ly.</w>
ab les</w>
a rel
________________ ____
Z e
Yt trium</w>
W ine</w>
Vic e-
Vi en
Vec tibi
V otes</w>
V it
Up date</w>
Tw o</w>
Trans fer
Tarc ev
Tab let
TR I</w>
T e</w>
T an
T ORI
Su per
Su g
Str asse</w>
Slov ak</w>
Signific ant</w>
SA .</w>
S wit
S pot-on</w>
S m
S ep
S .
Roy al</w>
Rap porteur
REYAT AZ</w>
Pro ce
Pri vigen</w>
Pi erre</w>
Parliam ent.</w>
P ost</w>
P op
P acks</w>
Other wise,</w>
Oper ation</w>
O s.</w>
O f
Neul asta</w>
Ne ed</w>
NSA ID
NAT O</w>
Mus culoskeletal</w>
Met formin</w>
MR I</w>
M is
M at
M as
M U
Lj ub
Liv er</w>
Li ke</w>
Lab elling</w>
LO G</w>
L um
L A
Kap osi's</w>
K G</w>
Je an-
Inter actions</w>
Infec tious</w>
Inf anrix</w>
In sul
IX .</w>
IV ,</w>
I A</w>
HUMA LOG</w>
HIV ,</w>
H T
Guid elines</w>
G lob
G az
Fuz eon</w>
FO SA
F ra
F endrix</w>
F IN
F C
EU/1/98/0 70
EU/1/98/0 69
EU/1/08/4 65
EU/1/08/4 64
EU/0 /00
EU/0/00 /00
EU/0/00/00 0
EU/0/00/000 /
EU/0/00/000/ 000</w>
EE IG</w>
EC U</w>
E state</w>
E or
Dub lin.</w>
Disk us</w>
Direc tor</w>
Des pite</w>
Dan mark</w>
DK -2
D uration</w>
D odge</w>
D er
Cro hn
Com pared</w>
Ch ronic</w>
Ch em
CYP1A 2,</w>
CN S</w>
CELSEN TRI</w>
C aucas
C ancer</w>
Bi o
Bal tic</w>
B la
B ir
B O
Applic ations</w>
An d
Al tern
Al ert</w>
Adul t</w>
Acl asta</w>
AL TA</w>
A ri
A SE
9 8/</w>
8 8
66 76</w>
5 1
4- 20)</w>
4 8
4 %)</w>
2000 ,</w>
20 10</w>
2 20</w>
199 3</w>
15 ,</w>
1 10</w>
/00 4</w>
- and-
- 8
+37 0</w>
+35 1</w>
(glucos e)</w>
(C YP
(A4-0 16
(4 4-20)</w>
( in</w>
( 13
' S
' (
° C.</w>
yoursel f.</w>
yl valosin</w>
year ?</w>
y ing,</w>
x en
x 1</w>
wron g
work place</w>
work load</w>
wor se,</w>
wom an,</w>
wip ed</w>
wh is
weigh ing</w>
wa ys.</w>
w ed
w as
w ants</w>
viro logic</w>
vehic les.</w>
ve j</w>
ve :</w>
valu ed</w>
vacc ine
v al</w>
ur y.</w>
ur ban</w>
up dat
unfortun ate</w>
under goes</w>
um )</w>
ultim ately</w>
typ ical</w>
tw el
tri um
tremor ,</w>
treat y</w>
tr ust</w>
to ol</w>
tiv e?</w>
ti riz
ti redness</w>
thin ks</w>
then ?</w>
themsel ves,</w>
that ?</w>
that !</w>
th o</w>
th igh</w>
test s.</w>
ten ing</w>
ten d</w>
ten .</w>
temperat ure.</w>
tax es</w>
tan ks</w>
tam per
tak en.</w>
tak e:</w>
t ory</w>
t ended</w>
t emp
syring e.</w>
susp ended</w>
sur face,</w>
supervis ion.</w>
sum mit
sulf on
sulf ate</w>
sugges tive</w>
substitu tions</w>
substit ute</w>
stop per.</w>
stop ped,</w>
ster oid</w>
star ts</w>
stand s</w>
st age.</w>
spo on
spec ially</w>
sp orts</w>
sp ok
smok ing,</w>
sk i</w>
si ve,</w>
short ness</w>
she ep
sha do
sentenc ed</w>
selec tion</w>
secre t</w>
scho ols</w>
sch eric
scheric hia</w>
sa y:</w>
s overe
s h</w>
s es
s .
rul ed</w>
ru e</w>
ros is.</w>
rol ling</w>
ro cur
risk /</w>
ris en</w>
rim on
righ t.</w>
ri go
rex ia,</w>
review ed</w>
rever sal</w>
respectivel y</w>
requ is
rep ly</w>
remov ed.</w>
regul ator</w>
refe rences</w>
recept ors,</w>
rec ently,</w>
re form</w>
ra p</w>
r ural</w>
r ate,</w>
ques tion.</w>
quar ters</w>
qualific ation</w>
prov oc
propos al,</w>
pro toc
prison er</w>
princip al</w>
preserv ed</w>
pres sion,</w>
pre lim
prelim inary</w>
potenti al.</w>
post- operative</w>
plasma ,</w>
philos oph
phen o
pheno thiaz
pertus sis</w>
per c
penetr ate</w>
pen s.</w>
pe di
partner ship</w>
particip ants</w>
par alysis</w>
pack ,</w>
pa in)</w>
p s,</w>
p im
p are</w>
p ancyt
oz yme</w>
over dose,</w>
ous ness</w>
other s,</w>
ot ene</w>
ot e
os .</w>
ord in
ophob ia,</w>
open ing.</w>
ong side</w>
on s,</w>
omal tase</w>
ol ive</w>
ol an</w>
of ten,</w>
ob lastic</w>
o ks</w>
o /E
o/E sbo</w>
noti fy</w>
noti fication</w>
no body</w>
nil otinib</w>
nic a</w>
new ly</w>
neutropen ic</w>
neum ococcal</w>
ne .</w>
myel o
mur de
mul tin
mou th.</w>
monit or
molecu le</w>
min or
microgram s,</w>
metabol ism.</w>
metabol ism,</w>
menstr ual</w>
medi um-
meas ure.</w>
me al.</w>
materi als.</w>
mand ate</w>
m- cresol,</w>
m its</w>
lo bin
lipo protein</w>
lim it.</w>
li t</w>
le ment</w>
lat ent</w>
lan -
lan- Meier</w>
la ugh
l us
l s,</w>
l ing
l /</w>
kin es
kilome tres</w>
k i</w>
juven ile</w>
j e</w>
iv ox
it ec
issu es,</w>
is omer
is omaltase</w>
introduc ing</w>
interpre tation</w>
inter ruption</w>
integr ated</w>
institu tions.</w>
inj ury,</w>
inhibitor s)</w>
info @gsk
info @
inf l
incin eration</w>
in et
in correct</w>
improv ement.</w>
imp ose</w>
im ported</w>
im migrants</w>
ile z</w>
il leg
if f</w>
hydrox y-
hot el</w>
hon our
hon ia,</w>
holid ay</w>
ho c</w>
hecta res</w>
he /</w>
hand led</w>
haem arthro
h a</w>
gon ad
gent le
g ut</w>
g as
ful .</w>
fu vir
four th</w>
forc es</w>
foc used</w>
flu or
fl ame</w>
figh ting</w>
feed ing
fat al.</w>
fail ed</w>
facil itate</w>
f ound
f eder
f ain
eye :</w>
exp an
exerc ising</w>
excre tion.</w>
excep tions</w>
exce eds</w>
ex por
es is,</w>
eri us</w>
erc ept</w>
er !</w>
epide mi
envel oped</w>
enti rely</w>
entec avir</w>
end or
enc ies,</w>
en thusi
en suring</w>
en e,</w>
eme a.
el ig
el der
ec ological</w>
e rec
e om
e br
dy nam
du oden
drow sin
dri ven</w>
dos es)</w>
don ors</w>
don or</w>
docum ents.</w>
do z
dis ability</w>
direc tive,</w>
dip ivox
di vis
di etary</w>
descri be</w>
def ine</w>
dec line</w>
dec l
de tention</w>
de pri
de part
danger ous.</w>
danger ous,</w>
d one,</w>
d ab
cytar abine</w>
cyan ide</w>
cy ste
crush ed,</w>
crim e</w>
coun ts,</w>
corticosteroid s.</w>
cop e</w>
conver ting</w>
consti pation,</w>
consider ing</w>
conjunc tival</w>
conges tion</w>
conflic t</w>
condem ned</w>
concern .</w>
con sen
con clusion</w>
con clude</w>
complic ations.</w>
comple ment
com pl
com e,</w>
com a,</w>
co ast</w>
clud ing</w>
clos por
clon ing</w>
clo thing</w>
cle ared</w>
cigarett es</w>
cigare tte</w>
chole st
chemo therapy,</w>
chang ed.</w>
chang ed,</w>
ch annel</w>
cell ular</w>
cel ebr
ce tiriz
cat abolism</w>
cartridg es.</w>
careful ly,</w>
car bon
c ub
c ov
c ock
c ile</w>
bub bles</w>
bott les</w>
bott le,</w>
blister s)</w>
bli stered</w>
bis phosphon
bet ter.</w>
bel ong</w>
be ing,</w>
be gun</w>
be d.</w>
bar bar
ban k
b ol
b id
autom atically</w>
au gh
attribut able</w>
ator s.</w>
ati o</w>
ast e</w>
as yl
as be
arri ve</w>
arr hyth
ar om
ar d.</w>
ar d,</w>
ar abine</w>
applic ation,</w>
appl y.</w>
aph an
aphan e)</w>
ap t
anxi ety</w>
anti -</w>
anaem ia,</w>
an alyse</w>
an alogue</w>
an 's</w>
amin ogly
am es</w>
alopec ia,</w>
all s</w>
alfa-2 b,</w>
alendron ate</w>
ak ed</w>
air .</w>
afra id</w>
aff in</w>
adver tis
adren aline</w>
administe red,</w>
ad ded.</w>
accompan ying</w>
aber ration</w>
X eom
X IV
Wh ite,</w>
Wh at
War farin</w>
W TO</w>
W E
Vimp at</w>
Vectibi x</w>
VIRACE PT</w>
V ari
V II
V E</w>
Ur ine</w>
US D</w>
Tηλ .:</w>
Tob acco</w>
Th us</w>
TRAVAT AN</w>
TE L
T ylvalosin</w>
T un
T W
Synag is</w>
Sum m
Sub sequ
Strasbour g</w>
So vi
Simul taneous</w>
Sil apo</w>
Sign s</w>
Shel f-life</w>
Secret ariat</w>
SU R
S or
S mo
S CH
Ro tigotine</w>
Ripraz o</w>
Resist ance</w>
Regul ations</w>
Re y
Ras ilez</w>
Pl us</w>
Phot osensi
Pharmac odynamic</w>
P ac
Other wise</w>
O EC
Netherland s.</w>
NE VER</w>
N ap
Mon o
MAG ON</w>
M el
M ann
Los artan</w>
Lond on.</w>
Ljub lj
Labor atory</w>
L et.</w>
L ane</w>
Kap lan-Meier</w>
K u
Ital ia</w>
Islam ic</w>
Ira q</w>
Ir an</w>
Inf usion</w>
Induct Os</w>
Im mun
IN C
I MP
Hung ary</w>
Hamp shire</w>
HIV .</w>
HA AR
H av
H ER
H E
H ).</w>
Gre en</w>
GANFOR T</w>
G ra
For m</w>
Fin n
Fig ure</w>
Fe L
FOR STE
FIR MAGON</w>
F- 69800</w>
F ron
F a
Ex per
Emsel ex</w>
Effec tive</w>
Effec t</w>
EMEA /
E ye</w>
E scherichia</w>
E ry
DuoTra v</w>
Doc um
Dec re
D ou
D MAR
Cyan ok
Ce pl
Cardi ac</w>
CYST AG
CYP2C 19,</w>
CRI XIV
CM V</w>
C op
C min</w>
C le
C el
Bet ween</w>
B l
Authorisation (s)</w>
Austri an</w>
Associ ation</w>
An nex
Al c
Afric an</w>
Afgh an
Ac tivel
Absol ute</w>
AUC 0
AU C)</w>
ABILIF Y</w>
A tt
A erius</w>
A V
9 5/</w>
7 9
5. 3).</w>
5- fold</w>
5 ;</w>
5 6%</w>
5 '-
42 6/</w>
4. 8.</w>
4- 91</w>
39 %</w>
37 .
3 18</w>
27 .
200 7,</w>
200 4.</w>
2 %,</w>
198 5</w>
18 4
15 1</w>
1 35
1 2.</w>
1 ):</w>
1 %).</w>
0. 9</w>
- year-old</w>
) )</w>
(E PAR
(D V
(A C
( ‘</w>
( shock)</w>
( The</w>
( 3)</w>
( "
én é
é e</w>
ä gen</w>
{ fa
{ Name</w>
z ones</w>
z an
yn ast
yl ase</w>
y me
work ?</w>
wor d
women 's</w>
wo ol</w>
who le,</w>
what so
wh o,</w>
well- known</w>
vol can
vol ati
vi d
ven lafaxine</w>
vari ations</w>
vari ation</w>
v oid</w>
v o</w>
ut e.</w>
ure th
uni que</w>
un de
um s</w>
ulcer ation</w>
typ ically</w>
tw enty</w>
tub ing</w>
tu ri
trou ble</w>
tridg es</w>
tri b
transp lan
trans mit
tra ordinary</w>
tonn es,</w>
tob acc
to day.</w>
tion s?</w>
th y</w>
ter ing</w>
ten ce</w>
tain ed.</w>
tac hy
t es</w>
t es
t !</w>
system atically</w>
survi ved</w>
summar ises</w>
sulph ur</w>
suggest ing</w>
sug ar,</w>
successful ,</w>
success fully</w>
success es</w>
subjec ted</w>
sub set</w>
sub mission</w>
stret ch</w>
strateg y</w>
str ate
stimul ate</w>
stead y-
stand ard
st s.</w>
specif i
spec ul
sp ite</w>
sol e</w>
smug gl
sm all,</w>
sk a</w>
situ ations.</w>
sit y,</w>
sit agliptin</w>
sing -
sing- remitting</w>
simul taneous</w>
sil ic
signific antly.</w>
si t</w>
si a</w>
serot on
sen se.</w>
selec tive,</w>
se ment</w>
se at</w>
scr utin
scienti fic
scap ego
sal ine</w>
saf ety,</w>
saf e.</w>
sa ve</w>
sa id
s ’.</w>
s mil
run ny</w>
rod ents</w>
rocur onium</w>
road s</w>
ro oms</w>
ris k,</w>
ris es</w>
rheum atic</w>
reti re
resul t?</w>
resolv ed.</w>
renc y,</w>
reli eve</w>
relap ses</w>
rel ax
rel atives</w>
rel ate</w>
regi str
refuge es</w>
recru ited</w>
receiv es</w>
re sto
re serve</w>
re pit
re fin
rati oph
rat s.</w>
random iz
ran ulocyt
radiolab elling</w>
ques tions.</w>
pyl ori</w>
pu ts</w>
protein s,</w>
prop ag
pronounc ed</w>
prof its</w>
prob able</w>
pro thrombin</w>
pric es.</w>
preserv ative</w>
present ations</w>
pregnanc y,</w>
prefer red</w>
pre mis
pre mi
post- menopausal</w>
possib il
por no
poor ly</w>
polys accharide</w>
play ed</w>
pl enty</w>
pioglitaz one.</w>
pig ment
phosphat ase</w>
pharmac ovigil
per version</w>
per s</w>
pen d</w>
pe ti
patient- years</w>
patient s:</w>
path way</w>
patch es.</w>
pass age</w>
part -
par oxetine</w>
pa ying</w>
p. m.</w>
p- value</w>
p uri
ox ide,</w>
otox icity</w>
ot rop
os pit
opro liferative</w>
oph ren
oph aryng
op lan
op hy
om y
om .</w>
ol s,</w>
ol ds</w>
ograph ical</w>
oedema .</w>
ob serve</w>
ob acter</w>
o fi
ofi -av
noe a,</w>
no t?</w>
neutro phil
neutr al</w>
nerv ousness,</w>
nation ally</w>
n el.</w>
mur der</w>
mouth piece</w>
modi fications</w>
moder n</w>
mo tion</w>
milli on,</w>
mg ).</w>
metabolit e,</w>
met am
ment s?</w>
mechan ical</w>
mat ter.</w>
mat rix</w>
market ?</w>
mark edly</w>
mar ri
man age</w>
malignanc ies</w>
maculo papular</w>
lymph oblastic</w>
long- acting</w>
lo ts</w>
ligh t-
les ion</w>
leg s,</w>
le ts</w>
laun ched</w>
la y</w>
kid napp
kg )</w>
k g.</w>
k et</w>
iz ophren
ity :</w>
iti c</w>
it ted</w>
it oring</w>
it ol</w>
is er</w>
ir s</w>
ir ac
involv ed,</w>
intro duce</w>
intran asal</w>
inter n
inten sive</w>
instruc tions.</w>
insom nia,</w>
initi ate</w>
initi ally</w>
ing ent</w>
infus ion
induc es</w>
induc ers</w>
individu ally</w>
indic ator.</w>
incontin ence,</w>
in tra-
in tra
in k
in ase</w>
in ?</w>
impl ants</w>
impl anted</w>
im it
ill -
ic obacter</w>
ia c</w>
i po
hypoglycaem ic</w>
hypo x
hyper uric
hyper glycaemia</w>
hospit al,</w>
hom e.</w>
highligh ted</w>
hepat omegal
hepar in)</w>
har vest
gr ant</w>
gonad otroph
glucocortic oid
gluc agon</w>
gener ate</w>
gen icity</w>
gen der,</w>
ful fi
fulfi l</w>
frag ile</w>
form ,</w>
fluoro quinol
flu ids</w>
fish ,</w>
fil tr
fif th</w>
fiel d.</w>
fibr in
fem al
fe ed.</w>
far m</w>
famil y,</w>
fail ure
fac ts</w>
f at,</w>
f adin</w>
ext ?</w>
expres s</w>
experienc es</w>
exha ust
example :</w>
ex trav
ever -
et c
estim ates</w>
equip ment,</w>
epistax is,</w>
envis aged</w>
ent re
ent ered</w>
enox apar
enoxapar in</w>
encour aging</w>
enc y?</w>
enc ed</w>
enc e?</w>
en heimer</w>
en closed</w>
emerg e.</w>
emb er,</w>
el et
el ess</w>
eff ort</w>
eczem a</w>
ear th</w>
e osinophil
e ing</w>
e .,</w>
dysp honia,</w>
drowsin ess,</w>
dri ver
dra wn</w>
dos es,</w>
dom inal</w>
doctor ’s</w>
do wn,</w>
disturb ance</w>
dist al</w>
disinfec t
dis proportion
direc tor</w>
direc tions</w>
diffe renc
diff use</w>
di phther
develop s</w>
determin ation</w>
der weg</w>
dep th</w>
dementi a.</w>
deliv er</w>
dehydr ation,</w>
defin itive</w>
deep ly</w>
decis ion-
de pend</w>
das atinib</w>
damag ed,</w>
da .</w>
d ing
cyc lic</w>
cover age</w>
countr y
coord inated</w>
contr act
consult ant</w>
consist ency</w>
consecu tive</w>
concre te</w>
con form
compu ter
compromis ed</w>
compon ents.</w>
complet e,</w>
commod ity.</w>
collec t</w>
col labor
co hes
clon ed</w>
clin ic</w>
cl es,</w>
ck enheimer</w>
circ ulation</w>
chos en</w>
cholin ergic</w>
che ap</w>
challeng es</w>
challeng e</w>
ch ocol
ch es,</w>
cetiriz ine</w>
cent ury</w>
cau tion.</w>
cat aly
carb am
car ro
cad mium</w>
c ot
but t
burn ing,</w>
bur ning</w>
bur g</w>
bri ef
breast feeding</w>
bre ad</w>
brad y
bra in,</w>
bor ne</w>
body weight</w>
blood -
bloc ked</w>
bl ame</w>
benef ici
below ).</w>
belong ing</w>
be ver
bar ome
b ought</w>
b last</w>
b h
b and
aut um
au x
au g
attit ude</w>
ativ ity</w>
ativ es,</w>
atislav a</w>
at eral</w>
at ed
at al</w>
assemb ly</w>
as part
argum ent</w>
arch itec
ar derweg</w>
apt ani
aptani b</w>
approach .</w>
ap repit
ap one</w>
antigen )</w>
antid ote</w>
antibio tics,</w>
antibio tic</w>
anti- cancer</w>
ant acids</w>
and el
anaes the
am ectin</w>
alis ation.</w>
al li
ak e,</w>
aircr af
agre ements</w>
agend a.</w>
ag ranulocyt
ag e?</w>
aer oplan
ade .</w>
add -on</w>
adap ted</w>
ad .</w>
acces sible</w>
acc ession</w>
abov e.</w>
abnorm al
ab out.</w>
a /</w>
a '</w>
XX X/</w>
XX /</w>
X ol
Wa arderweg</w>
W est</w>
W al
V ildagliptin</w>
V TE</w>
Up on</w>
Union 's</w>
UK .</w>
Transfer ring</w>
Te k
Tas ign
TORI SE
TN F
T est
T am
T Y
T V</w>
T RO
Swed en,</w>
Sw ine</w>
Summ aries</w>
Str .</w>
Sta ff</w>
Sovi et</w>
Smo king</w>
Scal e</w>
STR UC
SINGUL AIR</w>
SI FRO
S us
S ik
S HAR
SHAR P</w>
Recon cile</w>
Re productive</w>
RE F
R .</w>
Pro pos
Pol y
Pol and</w>
Place bo
Photosensi tivity</w>
Ph D</w>
PR CA</w>
P ir
P en.</w>
Or fadin</w>
Op tim
OVI ST</w>
OP TR
OP AT
O ste
O l
O B
Nor way,</w>
Nor vir</w>
No thing</w>
Ne is
N y
N ot
N orm
N as
My el
Mus lim
Multi ple</w>
Mon itoring</w>
Me eting</w>
M é
M ol
M it
M id
M ex
Ly on</w>
Lo oking</w>
Lithu ania</w>
Lis bon</w>
Latvi j
Latvi a,</w>
L ist</w>
L iber
L da</w>
K on
K a
K )</w>
Investig ations</w>
Infec tions</w>
Infec tion</w>
Indi a</w>
In vir
In c
Immuno deficiency</w>
Hep at
Hel icobacter</w>
He art</w>
HPV- 16</w>
H ospit
H as</w>
H -
Gre ek</w>
Govern ment</w>
Glob al</w>
Gli olan</w>
GI ST</w>
G y
G row
G ly
G enzyme</w>
G B
Frequ encies</w>
Fer n
FeL V</w>
Farmac ê
FIN -0
F- 9
F ed
Exta via</w>
Espo o/Esbo</w>
Epi vir</w>
Ef ex
EU/1/98/070 /00
EU/1/98/069 /00
E ur
E lev
E ckenheimer</w>
E ating</w>
E X</w>
E ID
Dis card</w>
Di ffe
Di arrhoe
DO SA
D ynast
D riving</w>
D r
D id</w>
D am
Cor por
Commun ity,</w>
Ch er
Ch echn
Care ful</w>
Cardi ovascular</w>
Car tridges</w>
CYSTAG ON</w>
CYP3A 4,</w>
CV MP
C ros
C ri
C oc
C as
C D</w>
Brit ain</w>
Beta fer
Belgi an</w>
Bel ar
Barcel ona</w>
B ou
B ond
B le
B is
B V</w>
B H</w>
B C</w>
B )</w>
As k</w>
Applic ation</w>
An t
An alysis</w>
Afghan ist
Ab dominal</w>
9 4</w>
8 5
8 0%</w>
7 9</w>
60 318</w>
6. 1.</w>
6 00
50 .</w>
5 30</w>
5 /2001)</w>
4 7%</w>
4 6
4 -0
38 6/</w>
3 /98)</w>
200 2,</w>
20 /</w>
198 7,</w>
16 %</w>
12 8</w>
11. 1%</w>
10 1</w>
10 )</w>
1, 7
1 /98)</w>
0. 9
0. 6</w>
0. 5
0 /</w>
/200 1):</w>
/00 5</w>
/ dexamethasone</w>
-- -</w>
- one</w>
- off</w>
+ 386</w>
(S een</w>
(F R)</w>
(F HV</w>
(EPAR ).</w>
(A4 -
(90 5</w>
( to</w>
( r
( itchy</w>
( alu)</w>
( Pro
( International</w>
( 23</w>
' ?</w>
' (a</w>
" )</w>
í ne
{ INVENTED</w>
zo ster</w>
ys is,</w>
yoursel ves</w>
year s),</w>
yc in</w>
y et,</w>
xen ophob
writ ing
wo od
win d
widespre ad</w>
wh om?</w>
web sites</w>
we ver</w>
we igh</w>
we al
w rec
w ine-
w ild
vis ually</w>
ves sel</w>
ventric ular</w>
ven ess</w>
var ying</w>
val dec
v or
ut ropin</w>
uron tin</w>
ur ity.</w>
univer sity</w>
understo od.</w>
un t</w>
ulcer ative</w>
u tic
u te
u pri
twel ve</w>
tur na</w>
tun a</w>
tu al</w>
tro metam
tri al.</w>
transfer ases</w>
train ing.</w>
trac es</w>
tr y,</w>
tr act.</w>
tor s.</w>
ton ,</w>
tom or
tissu es.</w>
tion !</w>
ti red</w>
ti ght</w>
ter rib
ter med</w>
ten laan</w>
ten ecte
ten der
technolog y.</w>
techn ically</w>
te ar</w>
tal ked</w>
tack le</w>
t ach
sw ine</w>
sw allow</w>
support .</w>
suppor t,</w>
supervis ory</w>
sum mit</w>
sulphonyl urea</w>
suggest ed</w>
suffici ent.</w>
sucr ase-
sucrase- isomaltase</w>
struc tures</w>
stre et</w>
stre am
strain s)
str ug
stop ped.</w>
ste el</w>
star ted.</w>
st one</w>
st atic</w>
st as
st a
squeez e</w>
spread ing</w>
sovere ign
some where</w>
solv ents</w>
solid ar
sk in).</w>
sk i
simple x</w>
sign at
sid ase</w>
si ght</w>
short com
sh ift</w>
sex ually</w>
sevo flurane</w>
session s</w>
servic es.</w>
ser s</w>
ser ia</w>
se ats</w>
se arch</w>
sch izophren
sal iv
sa id,</w>
s wa
s ought</w>
rob ial</w>
ro r</w>
ro ot</w>
risk s,</w>
rin se</w>
righ t,</w>
ribavir in,</w>
ri a,</w>
rh initis,</w>
restructur ing</w>
restric t</w>
res us
res tim
require d,</w>
renc y.</w>
ren ic
remin ded</w>
remembe red</w>
relap sing-remitting</w>
rel ations</w>
rejec t</w>
rein forced</w>
regul ation,</w>
referendu m</w>
recy cle
recor ds</w>
recept or.</w>
rec tal</w>
rec ord
rec i
reason s,</w>
reason able</w>
re tin</w>
re start</w>
re sign
re flu
random ised,</w>
ra il</w>
ra ,</w>
r s,</w>
r an</w>
r ad
r ,</w>
provi der</w>
projec ts.</w>
profil es</w>
product ),</w>
produc ed.</w>
proceed ings</w>
procedu res.</w>
pro phylactic</w>
pro benecid</w>
preven tive</w>
present ation</w>
predic ted</w>
predic table</w>
pre val
pre v
pr ud
power ful</w>
poul try</w>
posi tion.</w>
porno graph
popul ations.</w>
poli tically</w>
po x</w>
po wered</w>
plasma .</w>
plasma -derived</w>
pl en
pl ant
pil ot</w>
phosph ok
pheny to
phas e.</w>
pharmac euticals</w>
ph ar
pestic ide</w>
pers on,</w>
perfor at
pathogen s</w>
pat tern
particip ate</w>
parti ally</w>
parliam entary</w>
par alys
pap il
pal e</w>
packag ing,</w>
pa st.</w>
pa st,</w>
p t</w>
over .</w>
ov ascul
our ,</w>
oul d,</w>
otrop ic</w>
ot or</w>
orm on</w>
or listat</w>
or g</w>
or ation</w>
or -
omet er</w>
om munic
olog ist</w>
ol u
ok ed</w>
og lobin
oestro gen</w>
ocy te</w>
occ u
observ ations</w>
o j
o fo
o V
non e
none thel
nom inal</w>
no tably</w>
no des</w>
nitro gen</w>
newly- diagnosed</w>
new -
nephro tic</w>
neon ates</w>
necess itate</w>
ne y</w>
ne ts</w>
nat ure.</w>
na ive</w>
myel oma</w>
my opathy,</w>
my cophenolate</w>
mur ine</w>
muc ous</w>
mu st,</w>
mother s.</w>
month ly</w>
monteluk ast</w>
mone y.</w>
mo dul
miner als</w>
min )</w>
mil l
mil d,</w>
micron ucle
meth ane</w>
met for
met als</w>
mention ed.</w>
medium- sized</w>
medic ations</w>
mechan ism
mean ?</w>
me at,</w>
mar ine</w>
mand atory</w>
manag ement,</w>
mal es</w>
mag az
ma iz
m ap
lys is</w>
lu x
lopin avir/</w>
long .</w>
liv es,</w>
lit ropin</w>
list s</w>
list en</w>
lip id</w>
li p</w>
leveti racetam</w>
leth arg
less en</w>
lear ning</w>
lear n</w>
lead er</w>
le aving</w>
lact at
lab els</w>
kin d.</w>
kidne ys.</w>
ke ts</w>
jus tic
ja un
j ug
ity )</w>
it rac
ir regular
iod ine</w>
intrathec al</w>
interest ,</w>
insul in-
institu tional</w>
institu tion
inotrache itis</w>
injection -site</w>
inhibit ing</w>
independ ence</w>
incid ent</w>
inactiv e.</w>
in toxic
in stead
in dop
in d
in appropriate</w>
import ant
im pos
if ene</w>
if en
id s.</w>
ici ous</w>
ic um</w>
ic he
i res</w>
i re
i qu
hyper stimulation</w>
hon ey</w>
hom ocy
ho od.</w>
his tid
him .</w>
hepatic ,</w>
hepati tis,</w>
hel ped</w>
hel p.</w>
heart be
head s</w>
he ar</w>
hand le</w>
ha ve,</w>
ha m,</w>
h r</w>
h ome
h iv
h ang
grow th.</w>
gre en
gras tim
gr icul
go l</w>
gener ic</w>
gener alised</w>
g ul
g old</w>
g le</w>
g ases</w>
func tions</w>
fract ure.</w>
forme d,</w>
form at</w>
follow- up
fol litropin</w>
fol i
foet us.</w>
foc enter
focenter @msd.</w>
fo ref
fluctu ations</w>
fit ted</w>
fish .</w>
firm ly</w>
fil grastim
fibr in</w>
fe ver
fe et</w>
farm s</w>
f an
extrav as
explan ation</w>
expl ain</w>
expect ancy</w>
exerc ise,</w>
exclus ively</w>
exacerb ations</w>
ev ent.</w>
et oric
estonia@gsk .com</w>
er min</w>
ep ith
entre pre
enthusi as
encour aged</w>
en rich
en fuvir
en ?</w>
ell ite</w>
elimin ation.</w>
ec k
ec it
e udra
e po
dur e</w>
dur able</w>
drug s,</w>
drop s,</w>
dro ps</w>
drin k
don ated</w>
document ed</w>
do or
do .</w>
diure tic
distur b</w>
distribu tion,</w>
disorder s),</w>
diseas es)</w>
discontinu ed.</w>
disc overed</w>
disappear s.</w>
dis cour
dis advant
direc tives</w>
di vision</w>
devic es</w>
des loratadine</w>
des ire</w>
depend s</w>
del i
decreas ed,</w>
decis ions.</w>
dec i
deb t</w>
death s.</w>
death ,</w>
de fe
de dicated</w>
dam age,</w>
dab ig
d rough
d on</w>
d l,</w>
d is</w>
d es.</w>
cul tures</w>
cros sing</w>
critic ism</w>
cris is,</w>
cris es</w>
cr amps</w>
cr amp
counter -
correspon d</w>
correc ted</w>
correc t.</w>
convul sions,</w>
cont ent,</w>
cont acts</w>
consum ers,</w>
consider s</w>
conduc ted.</w>
con strain
con az
compens ated</w>
com pres
colum n</w>
co ol
clo su
clar ified.</w>
cl ub
cirrh osis,</w>
ci um</w>
child hood</w>
cere brovascular</w>
cef triax
cat ches</w>
cast ing</w>
car d.</w>
calori e</w>
calici virus</w>
calici virosis</w>
bur g.</w>
bu prenorphine</w>
brea the</w>
bor tezomib</w>
bor row
bo ost
blister .</w>
ble phar
blad der,</w>
bio -
bi om
ber g</w>
beauti ful</w>
basel ine.</w>
barrel s</w>
ban ning</w>
bab y,</w>
bab ies</w>
bab ies.</w>
b arg
az osin</w>
author ization</w>
atten tion,</w>
attemp ting</w>
attack ed</w>
attach es</w>
att ach</w>
atic ,</w>
at rial</w>
at om</w>
asyl um</w>
asy mptom
aspergill osis</w>
as su
arm s.</w>
arm ed</w>
arc inogen
arbit r
ar otene</w>
antimic robial</w>
anti body.</w>
and s,</w>
and in
anal ges
an omal
an e,</w>
amin e.</w>
allevi ate</w>
allerg ies.</w>
all y
alis kiren</w>
alcohol ic</w>
al ists</w>
al a</w>
air port</w>
agit ation,</w>
aggres sion,</w>
afung in</w>
adv ances</w>
adop t</w>
adj unc
acknowledg ed</w>
acid s,</w>
acid .</w>
ach ,</w>
accoun t.</w>
able ?</w>
ab rup
ab road
a use,</w>
a id,</w>
a e,</w>
a !</w>
Z O
Z I
YYYY }</w>
Y ou
Y MD
YMD D</w>
Wh y,</w>
W aste</w>
V il
V I</w>
Univer sity.</w>
UK ,</w>
Tél :</w>
Tw enty</w>
Trit azide</w>
Trans fer</w>
To o</w>
Therap eutic</w>
Th us,</w>
Tel misartan</w>
Tek turna</w>
TI N
T echnolog
Sub st
Stra uss</w>
Str ada</w>
Statis tics</w>
St and
St al
Slovak ia</w>
Slovak ia,</w>
Si rolimus</w>
Sc andin
San der
SUBSTANCE (S)</w>
SS RI
SE )</w>
S S)</w>
Rh inotracheitis</w>
Repe atedly</w>
Rec ormon</w>
RI X</w>
R it
Psych iatric</w>
Produ tos</w>
Pro gres
Prim e</w>
Potassi um</w>
Pati ents)</w>
Pan retin</w>
PHAR MA</w>
P sori
P et
P V</w>
P T
P B</w>
Or ,</w>
OptiClik .</w>
O si
O bes
O D
Nob ody</w>
Neo Recormon</w>
Neis seria</w>
Ne urontin</w>
Na use
NU MB
N plate</w>
N ig
My ozyme</w>
Minist er</w>
Mar tin</w>
Malign ant</w>
MA C
M arch
M acu
M S,</w>
Lu ver
Ljublj ana</w>
Le ave</w>
Latvij ā</w>
Land straße</w>
L et
L ast</w>
K m</w>
K en
Jour nal</w>
J er
Isra el</w>
Interne t.</w>
Inte gr
Individu al</w>
In focenter@msd.</w>
In de
IN STRUC
I l
Hyper icum</w>
Hou tenlaan</w>
Hol land</w>
Ho wever</w>
Her pes</w>
Haemophil us</w>
HM E</w>
H ard</w>
Grow th</w>
Ga ul
GM BH</w>
GI ST
G am
G ad
Frankfur t</w>
Finn ish</w>
F le
F l
Ex amples</w>
Eston ia,</w>
Engl and</w>
En ter
En sure</w>
En brel
EC ALTA</w>
E s
E mp
E duc
Dynast at</w>
DO HME</w>
D ox
D P
Cop alia</w>
Chole stag
Chechn y
Characteris tic,</w>
Cepl ene</w>
Cat al
CYP2C 9</w>
CR F</w>
CO MM
CIAL IS</w>
C reat
C ard</w>
C A
C /
Brussel s,</w>
B ol
B enz
Am ne
Ad en
AUTHORISA TION
AR S</w>
AB ,</w>
A gener
8 /2001)</w>
8 %)</w>
7 %),</w>
6 67</w>
6 ),</w>
50 1</w>
5. 2</w>
5. 0</w>
5 8%</w>
5 /97)</w>
45 61</w>
40 1</w>
40 ,</w>
4 4%</w>
35 8-
34 1/</w>
34 -
3. 3</w>
3 00
3 /
3 ),</w>
26 12</w>
200 1,</w>
2. 5
199 5.</w>
18 2</w>
13 81</w>
12 3</w>
12 %</w>
10 4.9</w>
10 2</w>
1. 3</w>
1, 0
1 1-
1 1%</w>
02 9</w>
0. 02
0 2</w>
-f at</w>
- day</w>
- containing</w>
+ 39</w>
(S D)</w>
(M M
(E C)</w>
(CN S)</w>
(A5-0 20
(0) 8</w>
( up</w>
( total</w>
( these</w>
( p=
( from</w>
( first</w>
( 7.5</w>
( 5.
( 1)</w>
' that</w>
' s.</w>
” ,</w>
–  
í n</w>
ä n
´ s</w>
} ></w>
z ation</w>
you th</w>
y st
y ing.</w>
work s.</w>
work ing.</w>
work ers,</w>
work er</w>
wor rying</w>
wn ing</w>
will ing
wh en,</w>
web site.</w>
wat ching</w>
war d
w alk
vo ters</w>
vir ap
virap ine</w>
vill age</w>
view ed</w>
vie w.</w>
vi able</w>
vehic les,</w>
vascul itis</w>
valu es,</w>
v ägen</w>
v ax</w>
v acu
us sions</w>
us eful
ur ac
under go</w>
un tary</w>
un g</w>
un certain</w>
ufact uring</w>
ud ge</w>
u ste
ty ?</w>
tw o.</w>
trou gh</w>
triglycer ides,</w>
tremor s,</w>
treat ment:</w>
treat ed.</w>
transport ation</w>
train s</w>
tr ack
tonn e</w>
tion '</w>
time ?</w>
time -
tigec ycline</w>
tic ular</w>
ti pran
ti es?</w>
thromb ocy
this :</w>
the red</w>
tex tile</w>
test ing.</w>
ter m.</w>
tend er</w>
ten ed</w>
teleph one</w>
te eth</w>
tachy cardi
tac rolim
t s)</w>
t i</w>
t g
t '</w>
system atic</w>
syn erg
symb ol
swit ching</w>
suspec t</w>
survi ve</w>
supervis ed</w>
sup pos
suff ers</w>
suff er
succ ess.</w>
substanti ally</w>
sub sc
strong er</w>
stre ets</w>
strate gies</w>
str ö
str ingent</w>
sti tial</w>
stem s</w>
standardis ation</w>
stak e
st orm
st ell
st age,</w>
st a</w>
sper m</w>
special ists</w>
spe ech
sp ar
some body</w>
sol ve</w>
sol d.</w>
sodi um
sk elet
sion )</w>
sinus itis,</w>
simil ar
sign al</w>
si ties</w>
shop s</w>
sh ir
seve re
ser t</w>
selec t</w>
secre tion.</w>
se vent
se mi
se arch
se !</w>
scienti sts</w>
sc op
satis factor
san ofi-av
saf ety.</w>
sa me.</w>
sa id.</w>
s aving</w>
s ',</w>
rimon ab
rigo rous</w>
rhyth m</w>
ret ina</w>
respec t.</w>
residu al</w>
res ource</w>
res ist</w>
renew able</w>
regim en
refriger ator</w>
reflec ted</w>
redden ing</w>
recru it
recon struction</w>
recept ors.</w>
rec overed</w>
realis tic</w>
re strain
re perc
re mot
ram s</w>
radi o</w>
ra in</w>
ra f</w>
ra .</w>
r ing.</w>
question na
qu ote</w>
qu es</w>
purpos es,</w>
purch as
public ations</w>
public .</w>
psori asis</w>
proper ty</w>
proper ly,</w>
prop yl
progres s.</w>
program me
proce ed</w>
pro test
pro drug</w>
prior ities</w>
preven tion,</w>
pressu re
prescrib ing</w>
pran dial</w>
poly ox
poly mer
pim ec
pi g</w>
phosph ate,</w>
perpe tr
perman ently</w>
perid one</w>
per cep
peac eful</w>
par affin</w>
p ure</w>
p toc
p ly</w>
p ic</w>
p )</w>
ov ul
outcom es.</w>
ot rig
ori ent
oph ane</w>
oper ated</w>
op ipr
op ing</w>
one gr
on tal</w>
on e?</w>
omyc in</w>
omet ric</w>
om ide</w>
oly tic</w>
off en
occur :</w>
occas ion</w>
oc e
observ ed,</w>
o le.</w>
o -</w>
non- clinical</w>
no se.</w>
nigh t
neutr alising</w>
neuro degenerative</w>
nar row</w>
na me
n ouris
n ity</w>
n ext?</w>
n er,</w>
mut ation</w>
munic ip
mucos al</w>
ms de
msde esti
mp tom</w>
mou se</w>
mom ent.</w>
moist ure</w>
mo od</w>
mmol )</w>
mit ot
milli on
migr ation</w>
microgram/ kg/week</w>
microgram s.</w>
mg ”</w>
meth od.</w>
metfor min,</w>
metabol iz
mepi ride</w>
mention ed,</w>
me tre
mat ter,</w>
market s.</w>
mark ing</w>
manife stations</w>
mal form
machin ery</w>
ma z
m 2)</w>
lymph ocytic</w>
los ing</w>
lor ry</w>
lo st.</w>
lo cal
list lessness,</w>
life- style</w>
li ved</w>
leuk openia</w>
leuc ine,</w>
lep tic</w>
le ;</w>
lact oid</w>
lact ase</w>
labell ing.</w>
lab el,</w>
la vi
l in,</w>
l ent
kines ia,</w>
kin ds</w>
kilome tre
k new</w>
k n
journe y</w>
ity '</w>
itsel f.</w>
ithromyc in</w>
it s,</w>
it em</w>
it e
issu e,</w>
isol ated</w>
ish ed,</w>
is ophane</w>
ir .</w>
inv est</w>
intramus cul
intensi fied</w>
instruc t</w>
inst inc
insom nia</w>
insec tic
innov ation</w>
inhibit ory</w>
inflamm ation.</w>
ine ).</w>
indin avir/</w>
in di
impl ant
immigr ation</w>
immedi ately,</w>
imatin ib
ill us
il ed</w>
igh ty</w>
ifen acin</w>
identi fied.</w>
id ase</w>
ic -
ic )</w>
i er
hypocris y</w>
hyper troph
hydrox ide</w>
hydrochlor ide)</w>
hospit als</w>
honour able</w>
histid ine,</w>
high- risk</w>
her pe
her d</w>
he ight</w>
happen ?</w>
happen .</w>
ha ve
h ort</w>
guarante es</w>
groun d.</w>
gro wn</w>
gre e</w>
granu locyt
gr and</w>
ge ographical</w>
g abapentin</w>
fun d</w>
ful ,</w>
fu els</w>
fri dg
fract ures,</w>
four -
forese en</w>
for th
foot b
follow ing:</w>
fluoro urac
flu conaz
flu -like</w>
flex ibility</w>
fisher men</w>
finger prin
fing er,</w>
fin ance</w>
fin amide</w>
filtr ation</w>
fic ation,</w>
fi es</w>
ffici ent</w>
feeding stuff
fat al
fail .</w>
fact ories</w>
f es
extre mis
exposu re,</w>
experienc e:</w>
exhib its</w>
exen atide</w>
exc use</w>
ex pi
ex clusion</w>
every body</w>
event s
evalu ating</w>
estonia@gsk .</w>
establish ing</w>
escap e</w>
es sed.</w>
erythem at
er y,</w>
epilep sy
ent ac
end- stage</w>
enab ling</w>
en ing,</w>
emtricit abine</w>
emp ty.</w>
emerg ed</w>
em ia,</w>
elec tions</w>
el in</w>
edema ,</w>
ed- release</w>
ec os
eas ily.</w>
e j
e det
e astern</w>
dyspep sia,</w>
dysp ha
dur ability</w>
dra w
discomfor t,</w>
discolour ation,</w>
dis ruption</w>
dis grac
dign ity</w>
diff user</w>
dies el</w>
diab e
di an</w>
der ).</w>
depres sion.</w>
demonstr ates</w>
democ rati
definit ely</w>
defin i
def en
decreas ed.</w>
dec entr
deb ilit
deb ate,</w>
dead ly</w>
de pre
dabig atr
dabigatr an</w>
da iry</w>
d ing,</w>
cyt ogenetic</w>
cultiv ated</w>
cub ic</w>
cru st
cros s</w>
cris is.</w>
coun ter</w>
cosme tic</w>
cop ies
conven i
contr acting</w>
cont ag
conserv ative</w>
consen sus</w>
conc iliation</w>
con su
con stituted</w>
con ference</w>
complic ations,</w>
complic ated</w>
complement ary</w>
comple ted.</w>
compar is
compan y.</w>
commis sion
comm it</w>
com e.</w>
colleagu es</w>
coast al</w>
co ws</w>
co hort</w>
clear ance.</w>
clear .</w>
citiz en</w>
cit rate</w>
cigarett es.</w>
cho ol</w>
chemi stry</w>
che w</w>
chann els</w>
chang e.</w>
cha in.</w>
cell s)</w>
cat ec
cas e-
car til
candi date</w>
call ing</w>
cal end
ca use.</w>
ca ke.</w>
c row
c od</w>
c m)</w>
c arm
c and
butt ock
but yn
but am
bru ise,</w>
bru is
bron cho
bro ther
bos entan</w>
boar d.</w>
big gest</w>
bi oc
benzodiazep ines</w>
benefit s.</w>
bec k</w>
be x
batter ies</w>
bar ometer</w>
ban an
bal lo
bal anced</w>
bad ly</w>
b ran
b one.</w>
b ile</w>
b and</w>
ax yn</w>
author ities,</w>
author isation.</w>
author is
aut onom
audi t</w>
attack .</w>
atr in</w>
ati d
at trac
as sumed</w>
as iro
as ide</w>
arrang ed</w>
are ly</w>
ard en</w>
ar ticle</w>
ar ising</w>
apol ipo
ap am
anthrac yclines</w>
animal 's</w>
ani q
anc ies</w>
analys es</w>
an ter
an g</w>
an agre
an abolic</w>
amb iti
amb igu
allow ance</w>
al s?</w>
agu e,</w>
age- related</w>
adver ti
adv oc
adolescent s,</w>
adhes in</w>
adap ter</w>
ach e</w>
acc us
ac tion?</w>
ac og</w>
ac a
absc ess,</w>
ab us
ab und
a  
a ks</w>
a id
] ).</w>
Zimbab we
Z onegr
Yor k</w>
Wor k</w>
With draw</w>
Wh il
Well ,</w>
Wat er
W as</w>
Ve hic
VAN Z</w>
V aniq
Unfortun ately</w>
Ukra ini
UL ARS</w>
UB 8</w>
U *</w>
Tran si
Tr inity</w>
Ti bet
Therap y</w>
Th rough</w>
Th re
Tarcev a.</w>
TORISE L</w>
TIC ULARS</w>
TA X
Swed en.</w>
Stre ng
Ste ad
Som atropin</w>
Sloven ia</w>
Simp ly</w>
Ser um</w>
Ser bi
Sel amectin</w>
SIFRO L</w>
S hor
S C
Rom ania,</w>
Rom a</w>
Riv as
Respon ses</w>
Repe at</w>
Regi stration</w>
Recommend ation</w>
Re view</w>
RI NG
RA ME
R ig
Qu int
QU AD
QUAD RAME
Pure vax</w>
Pro phylaxis</w>
Pregn ant</w>
Pos sible</w>
Pos ology</w>
Po int</w>
Phil ip
Pe de
Parkinson ’s</w>
Par ame
PAR TICULARS</w>
PAC K
P rec
P neumon
P P
Ox y
OSSE OR</w>
OPAT ANO
OPATANO L</w>
OEC D</w>
O pen</w>
NSAID s</w>
NO V
N imesulide</w>
N ec
N az
N ame
Mon day</w>
Mo der
Mic ardis
Mex ic
Mer z</w>
Mer ial</w>
Me et
Mast ers</w>
Man ufacturing</w>
Ma xim
MU ST</w>
MR P</w>
MR L</w>
M ug
M IX
M IU/</w>
M 184
Luver is</w>
Lou is</w>
Lond on,</w>
Le uc
Lap p</w>
L yn
L oc
L ib
Kal etr
K ur
K ir
K S</w>
J al
J EC
In sert</w>
In flu
IV .</w>
INSTRUC TIONS</w>
INO max</w>
IN VANZ</w>
II I,</w>
Hung ari
H om
Ge or
GL P
G R
G P
G E
Fin land
Fin ally,</w>
Farmacê utic
FORSTE O</w>
FOR C
F ore
F lo
F UR
F )</w>
Environ mental</w>
En erg
Egyp t</w>
Efex or</w>
EU/1/06/357 /0
EU/1/0 5
EU/1/05 /3
EU /2
EU/2 /0
Dis eas
De gree</w>
DV T</w>
Cy pr
Crohn 's</w>
Contro l
Continu ed</w>
Con stitution</w>
Con current</w>
Commun ities,</w>
Committe e,</w>
Com p
Co- Rapporteur</w>
Chair man</w>
Cam bodi
Cal cium</w>
CYP2D 6,</w>
CYP2C 9,</w>
CM L</w>
C o</w>
Brussel s.</w>
Bre ast
Br atislava</w>
Bel o
Av on
Aspergill us</w>
As sist
Amne sty</w>
All erg
Ad vag
Activel le</w>
A x
A rea</w>
A ra
A pr
A mb
A lo
A g</w>
A DE
9 3
69 007</w>
6 /97)</w>
5 ),</w>
38 3/</w>
37 3</w>
3 /97)</w>
2000 .</w>
2000 -
200 8,</w>
199 6.</w>
198 6</w>
19 76</w>
19 2</w>
18 .</w>
15 5</w>
15 -
14 8</w>
14 ,</w>
14 %</w>
1 %.</w>
0. 4
0 7</w>
0 31</w>
/ her</w>
---------------------------------------------------------------- --------------------------------
- treatment</w>
- out</w>
- induced</w>
- 5
(r DNA
(P ercent</w>
(P T)</w>
(P SUR
(MRI )</w>
(L augh
(H-0 6
(A4-0 35
(A4-0 19
(9 9
( two</w>
( not</w>
( abdom
( Mr</w>
( Invented</w>
( EU
( 400</w>
( 15
( 12
( 1-
è s</w>
{ PRODUCT</w>
z umab</w>
year s?</w>
year s).</w>
y es,</w>
y ',</w>
x ion</w>
work ers.</w>
wor sen</w>
wor se.</w>
wor ry
wor ried</w>
weak en
wav es</w>
warr ant
war ds,</w>
war ded</w>
wa ve</w>
w rap
w on</w>
w are</w>
vot e,</w>
volun tar
volum es</w>
volati le</w>
vitro ,</w>
vit re
vitre ous</w>
vi br
veterin ari
ver tigo,</w>
ver ifi
ver b</w>
vel y.</w>
ve str
ve ins</w>
ve in,</w>
vari ety</w>
vari ability</w>
valpro ate</w>
ut aneous</w>
us ers.</w>
us '</w>
uron ium</w>
urg ency</w>
ur ani
unemploy ment.</w>
un fair</w>
ug os
u ,</w>
tyros ine</w>
ture ?</w>
tu ote
tuote info@gsk
triglycer id
treat ed,</w>
transamin ases</w>
trans lation</w>
trac king</w>
tr yp
tr uth</w>
tr act
tor ture</w>
tonn es;</w>
toler ability.</w>
tin y</w>
tim olol</w>
tigh tly</w>
tig o</w>
ti li
ti fied</w>
ti er</w>
threat ened</w>
tho rough</w>
th r
tex ts</w>
territ ory</w>
termin ation</w>
ter min</w>
ten s</w>
teach ing</w>
tax pay
tar iff</w>
tain s</w>
tain ed,</w>
tack led</w>
tablet ter,</w>
tab les</w>
t elec
syndrome ).</w>
symptom s
sy mptom</w>
sw allowed</w>
suppli er</w>
sucro se,</w>
sub types</w>
sub mit</w>
su peri
struc ture,</w>
struc k</w>
strong ly</w>
strain) ................................................................
strain s.</w>
strain s):</w>
strain )</w>
stiff ness,</w>
steady- state</w>
st u
spok en</w>
spi rit</w>
speci es,</w>
speak ers</w>
sp lit</w>
sp l
sp ine</w>
sp ill
sp ending</w>
solv ent.</w>
sol ar</w>
soci ety.</w>
so il,</w>
sm ell</w>
sion :</w>
simpli fied</w>
si de
shoul d,</w>
short age</w>
shel f</w>
sha re
sh ut
sep sis</w>
secu ted</w>
sector ,</w>
secre ted</w>
se eds</w>
se e,</w>
se as</w>
scre w</w>
scre en</w>
scientific ally</w>
school s,</w>
schem es</w>
sc rap</w>
satis fac
sarcom a</w>
sampl es.</w>
said :</w>
s is.</w>
s can</w>
s ail
rul es.</w>
ru th
rol l</w>
roc k</w>
ro us
rit uxim
risk s.</w>
rip ent
ripent ol</w>
ring e</w>
rhin orrhea,</w>
reven ue</w>
retur ning</w>
rest ,</w>
responsibil ity.</w>
resol ves</w>
reserv ed</w>
research .</w>
resc ue</w>
repe ti
repa ir</w>
rep ut
rep li
reli gious</w>
rele ases</w>
reimbur sement</w>
regist er</w>
regim ens</w>
recon c
rec overed.</w>
rec over</w>
rec ep
reas on.</w>
read s</w>
read ing</w>
re tain</w>
re pro
re alise</w>
re al
ratioph arm</w>
rasburic ase</w>
rand om</w>
radiolab elled</w>
ra x
ra re:</w>
ra re
r st
r i</w>
push ing</w>
pursu ed</w>
purpos e?</w>
ptoc occ
protein ).</w>
protec tion.</w>
proper ties.</w>
prohib ited.</w>
prof en</w>
procedu res,</w>
pro tests</w>
pro pri
pro liferative</w>
prison ers</w>
prevent ative</w>
prepar ation.</w>
premis es</w>
precau tions,</w>
prec eded</w>
pre clinical</w>
pow er,</w>
pover ty.</w>
potassi um.</w>
potassi um,</w>
pos s
pop ular</w>
politic ians</w>
polici es.</w>
po sure</w>
ple te</w>
platel et
plac ement</w>
pl ates</w>
pl ann
phenomen on</w>
ph il</w>
perspec tive</w>
person 's</w>
persi sts</w>
peri ph
per sec
per hap
per form</w>
penal ties</w>
pen ny</w>
pe me
peme trex
particip ation</w>
papil lo
pack age,</w>
pack )</w>
pa rec
pa ir</w>
pa edi
pa ed
p urely</w>
p ages</w>
oxygen ase-
our .</w>
oun ce</w>
ou tr
osteopo rotic</w>
oste omyel
orrhoe a,</w>
org e
org /
ophthal mic</w>
opharyng itis,</w>
op pres
one ph
on line</w>
on in.</w>
on ed</w>
on avir</w>
om a.</w>
ograp h</w>
ofo vir
of .</w>
oesopha geal</w>
oedema )</w>
occu pati
occas ional</w>
oc rit</w>
oc clusion</w>
oblig ed</w>
oblig ations</w>
ob il
ob acter
o z</w>
o wn,</w>
o il.</w>
o eu
oeu v
now ?</w>
nonethel ess</w>
non productive</w>
no tific
no thing,</w>
no b
ni ec
ne t,</w>
nar row
n ers.</w>
n emul
nemul in</w>
month ,</w>
moder n
mod els.</w>
mob ility</w>
mo st.</w>
mis sion,</w>
min es</w>
micronucle us</w>
micro bi
metabolit es.</w>
metabol ic/</w>
mess eng
menopa use.</w>
meningiti dis</w>
medic ation.</w>
me uble</w>
me try</w>
me al
mat ters.</w>
man oeuv
man ic</w>
mam mal
magnes ium</w>
ma p</w>
ma ize</w>
ma de?</w>
ma d</w>
lymph oma</w>
lum bar</w>
lu te
loxac in,</w>
lo ve</w>
lip s,</w>
lic k</w>
lic ence</w>
li m</w>
li k</w>
leav es</w>
lead ership</w>
le  
le tt
le g</w>
lat or</w>
lar yn
lar opipr
lam otrig
lac king</w>
la ying</w>
la v</w>
l utropin</w>
kin d,</w>
kin ase</w>
ket ocon
ket o
ker atitis,</w>
justifi es</w>
jaun dic
j er
j ack
iz z
iv ast
ity ;</w>
itsel f,</w>
iti s
it em
it e.</w>
irrig ation</w>
inv ent
introduc ed.</w>
intoxic ation</w>
interpre ted</w>
interpre t
inter ference</w>
inter -
integr ate</w>
int ell
intell ec
inspec ted</w>
injection /</w>
initi ating</w>
inhibit or.</w>
inhal er</w>
ing es
inevit ably</w>
inde ed,</w>
increas e.</w>
incen tives</w>
in op
in n
in ine</w>
in ess.</w>
in ely</w>
in ation,</w>
in ability</w>
implic ations</w>
im pot
im port</w>
im peri
ill ness.</w>
il )</w>
igh ts</w>
if e,</w>
if ,</w>
id a</w>
id )</w>
ick ed</w>
ic ally.</w>
hypoten sive</w>
hypokal aemia</w>
hypo vol
hyper lactat
hur t</w>
http:/ /
hous ing</w>
hospit als,</w>
hormon e.</w>
hor se</w>
hon est
homosex u
hom es</w>
hol es</w>
ho p</w>
his /her</w>
high .</w>
her ited</w>
heal ing</w>
head ing</w>
he re
har b
happ y</w>
h ull</w>
h as,</w>
h .</w>
guidel ines.</w>
guid eline</w>
groun ds,</w>
gro ss</w>
gr atul
go od,</w>
glas s,</w>
gl arg
gir l</w>
genoty pes</w>
gen der
gad over
g p</w>
g eri
ful fil
frag il
formul a,</w>
form ing</w>
foref ing
forc e.</w>
for ce
for bid
foot -and-
food -
follow s</w>
flo ating</w>
fl ush</w>
fl un
fl atul
fir st,</w>
fin ds</w>
fif teen</w>
fi red</w>
fe ed,</w>
fe ar
fas ci
fall .</w>
fac ility</w>
f uro
f its</w>
f in</w>
ext inc
expres sing</w>
expres sed</w>
expl ained</w>
exhib it</w>
exer ts</w>
exam ine</w>
exagg erated</w>
ex ual</w>
ex traordinary</w>
events /1
events/1 ,000</w>
ethan ol</w>
et ®</w>
eradic ation</w>
epith el
episod e</w>
ep to
enzy me
environment ally</w>
ensu red</w>
enfuvir tide</w>
enforc ement</w>
end omet
ency )</w>
enc oun
enc e
en ical</w>
en em
en :</w>
emtricit abine,</w>
employe e</w>
employ ment.</w>
em esis</w>
em atics</w>
elev ating</w>
el ed</w>
ei ther.</w>
eff lu
educ ated</w>
edet ate</w>
ed- dose</w>
ecos y
ecit abine</w>
ec a</w>
e g</w>
duoden al</w>
du plic
du m
du ly</w>
dru g.</w>
down ward</w>
doub t
dose- related</w>
dos si
dol lar
doc tr
disturb ances</w>
distrib ut
dise ased</w>
disc over</w>
disast ers</w>
disabil ities</w>
dis appeared</w>
dipl om
dictator ship</w>
di f
di alys
dex .</w>
determin ing</w>
detec ted.</w>
der mat
deple ted</w>
dep loy
deliv ered.</w>
deli very</w>
dela ying</w>
del eted</w>
del e
defer asiro
dec ides</w>
deb ated</w>
de vi
de tained</w>
de struc
de pic
de par
de d:</w>
d l)</w>
cyto k
cyt es</w>
cy nic
cy clospor
cur sale</w>
cu ts</w>
criter ion</w>
cre w</w>
counterfe it</w>
cor rup
convul sion,</w>
contrib uting</w>
continu ally</w>
cont ex
consum er.</w>
constitu ency</w>
consti pation</w>
consist ed</w>
consider ably</w>
conside red,</w>
connec tions</w>
conf ron
condi tion.</w>
concentr ation.</w>
compreh ensi
complain t</w>
competitiv eness</w>
compe tence</w>
communic ations</w>
commit ments</w>
commit ment</w>
comb ine</w>
com a</w>
clo th
cle av
cleav age</w>
classi c</w>
cl am
circul atory</w>
charg ed</w>
char acter</w>
certific ates</w>
cer tification</w>
cellul itis,</w>
cartil age</w>
carri ers</w>
car ds</w>
car d
cann ab
campaign s</w>
calend ar</w>
calc ulation</w>
ca the
ca ke</w>
c z
c ure
c raz
c o</w>
c et
bul l</w>
breath .</w>
bo at</w>
bio activity</w>
be d
bann ed.</w>
bac king</w>
b ound
b one,</w>
az ac
avi ation</w>
aver age,</w>
attemp ted</w>
ator s,</w>
ator ies</w>
ation ic</w>
atid yl
ati es</w>
at ed;</w>
asymptom atic</w>
associ ations</w>
assess ment,</w>
as sumption</w>
as :</w>
arthral gia,</w>
ari es.</w>
ari es,</w>
argum ents</w>
arcinogen icity</w>
ar rog
ar rest</w>
app ing</w>
apolipo protein</w>
anticip ated.</w>
antic ancer</w>
anti depres
ans opraz
announc ed</w>
and o</w>
anc es,</w>
anagre lide</w>
an ine</w>
am ant
alopec ia</w>
allow ed.</w>
alloc ation</w>
aller genic</w>
all- cause</w>
all ed</w>
alendron ate.</w>
alarm ing</w>
al so,</w>
al ongside</w>
ail y</w>
aggrav ated</w>
age ous</w>
age ing</w>
ag h
ag glut
advis able.</w>
adop ted,</w>
ad mission</w>
ad he
ad a,</w>
activi ties.</w>
achiev ed?</w>
accumul ate</w>
accid ents.</w>
acc ess
ac idi
ac commod
absc ess
aber r
ab road</w>
ab out?</w>
ab ly,</w>
ab atrin</w>
a ire</w>
a head</w>
a eti
a '.</w>
Zonegr an</w>
Y ugos
Xeom in</w>
What ever</w>
We esp</w>
W all
Viet nam
VF EN
VE N
V ig
V ar
V H</w>
V /</w>
Usu ally,</w>
Un desirable</w>
U TION</w>
U MA</w>
Transi ent</w>
Trans dermal</w>
Tr ading</w>
Tox in</w>
Tox icity</w>
Thir d</w>
Th ink</w>
Terro ris
Tasign a</w>
Tal k</w>
T ony</w>
T og
T ).</w>
Suc cursale</w>
Stev ens</w>
St ate.</w>
St anding</w>
Son oV
Some times,</w>
Some one</w>
Se iz
Sal mon
SU S
SUS TIV
ST O
SOL UTION</w>
SEN TRE
SE -
SAR S</w>
S ul
S qu
S pe
S le
S event
S em
S atur
S ab
S Z
S VR</w>
S R
Russi a</w>
Ru le</w>
Ro Ac
RoAc tem
Rit onavir</w>
Rec ently</w>
Re ports</w>
Ras h,</w>
RELE X</w>
RE LIST
RELIST OR</w>
R ot
R ash</w>
R ),</w>
Qu ad
Q -
Psori atic</w>
Pro v
Pri est</w>
Pre ot
Pre clinical</w>
Porc ine</w>
Por to</w>
Ph en
Pent a</w>
Pede a</w>
Par is</w>
PE AR</w>
PACK AG
P é
P ur
P ens</w>
P N
P ER
Op gen
OPTR UMA</w>
ON IN</w>
OL AF</w>
O ut
O lymp
Novo Let.</w>
Nov o</w>
Nor way</w>
No w,</w>
NRTI s</w>
NG Os</w>
N ucle
N ,</w>
Mono amine</w>
Micardis Plus</w>
Mic ro
Meet ings</w>
Me as
Me an
MP S</w>
M L
M IC
M )</w>
Ly mph
Lithu ani
L eg
L ansopraz
K i
J /</w>
Ital y.</w>
Intron A.</w>
Indones ia</w>
Im meuble</w>
Ibra xion</w>
INVE GA</w>
INC RELEX</w>
IN JEC
III )</w>
ID E</w>
I t
I novel
I SENTRE
I M</w>
I L-
I GF
Hol ding</w>
Hist ory</w>
High er</w>
HD L
HB V
H ere</w>
Grou p,</w>
Gre at</w>
Ge org
GLP -1</w>
G- CS
G all
G EN
Flex Pen.</w>
Fer ring</w>
FUR THER</w>
FORC ALT
F lat
F if
F ever</w>
F ar
Excipi ents</w>
Euro st
En d
El ec
Econom ic</w>
EXUB ER
EV 1</w>
ER E</w>
EN TS</w>
E th
E l</w>
E ither</w>
E c
E arth
E C</w>
E -2
Dan ish</w>
DOSA GE</w>
DE L
D- 60318</w>
D aily</w>
D A
Cz ech
Cros s-
Council 's</w>
Counc il.</w>
Con trac
Con sum
Con st
Con f
Co hn
Cl ass</w>
Ch ild</w>
CO X
CHM P,</w>
C r
C ma
C lear
C ath
C ases</w>
C AP
Bulg aria</w>
Bond enza</w>
Bet ter</w>
Belgi um
Bas eline</w>
BI D</w>
B ure
B b</w>
B 5-0
Ath ens</w>
Ar tic
Appro ximately</w>
Ap id
Any thing</w>
Altern atively,</w>
Alo pec
All ergic</w>
Ag op
Advag raf</w>
Admini str
Ac c
AP PEAR</w>
AM UN
AL U
AID S.</w>
A sh
A lex
97 50</w>
9 /2001)</w>
8 7</w>
7 3
69 00</w>
65 4</w>
6 /2001)</w>
5- fluorourac
5 7
5 2-
5 /0
4 2%</w>
4 000</w>
36 3/</w>
30 °C.</w>
3 ml</w>
3 50</w>
3 37/</w>
3 1%</w>
3 %),</w>
29 .
28 .
27 7</w>
200 6,</w>
20 1</w>
20 10,</w>
2. 5%</w>
2 :</w>
2 2.
199 8,</w>
199 7.</w>
199 2</w>
198 8</w>
19 .</w>
18 -
18 ,</w>
17 7</w>
16 8</w>
16 ,</w>
15 %.</w>
10 5</w>
1 %),</w>
000 /</w>
00 1/</w>
0. 8</w>
0. 1</w>
0. 1%</w>
0 33</w>
0 32</w>
0 30</w>
0 20
0 %)</w>
/200 2</w>
................................ ................
.... .</w>
.... ....</w>
.. .
. org</w>
-friend ly</w>
-fe eding</w>
-f re
-2 )</w>
------------------------------------------------------------------------------------------------ ----------------
- year</w>
- associated</w>
- P
- 2</w>
- 1)</w>
+4 21</w>
+37 1</w>
+ 40</w>
+ 32</w>
* .</w>
* *</w>
(F VH</w>
(E17 1)</w>
(DV T)</w>
(A5-0 12
(A m
(99 mTc
(2. 4%</w>
( specific</w>
( mg/</w>
( inhibitors)</w>
( in
( all</w>
( SP
( Ph
( IT
( Hypericum</w>
( Child-Pugh</w>
( 10
( -
' The</w>
" ,</w>
’ t</w>
ö r
ñ a</w>
í och
é r
á n</w>
Í s
µ m</w>
  – 
{fa x
{fax }</w>
{ tel
{tel }</w>
{ e-mail
{e-mail }</w>
zo ster,</w>
zer land</w>
z be
ys :</w>
yr am
yoursel f,</w>
yl ,</w>
y g
y er</w>
y *</w>
wron g.</w>
won der
wish .</w>
win rix</w>
willing ness</w>
wh ol
wh ist
warn ing.</w>
war .</w>
want ing</w>
wal king</w>
w is
w ine,</w>
w in</w>
w as,</w>
vis ible,</w>
virus es.</w>
viol ence.</w>
vi go
vestr ant</w>
vess el
venti l
veget ables</w>
valu e
valu able</w>
valdec oxib</w>
vaccin es.</w>
vaccin ation,</w>
v niec
v ing,</w>
ust er</w>
us s
us k
us e:</w>
ur red</w>
upri ght</w>
under gone</w>
under -
und beck</w>
un clear</w>
um s,</w>
ultras ound</w>
ulcer ation,</w>
ul ence</w>
ul a
uk _
uk_ med
uk_med info@
uk_medinfo@ allerg
uk_medinfo@allerg an.</w>
uc k</w>
u ter
u itary</w>
u el</w>
tw enty-
turn s</w>
turn ing,</w>
turi tion</w>
trium ph
trig ger</w>
tri me
tren ds</w>
transpor ting</w>
transl uc
trans mucosal</w>
trans actions</w>
traged y</w>
trace ability</w>
tot al
top a
tom y</w>
toler ance.</w>
toler ability</w>
tiv ity,</w>
tis ),</w>
tion ),</w>
tin nit
tic ally,</w>
thro po
thigh .</w>
theore tical</w>
thal idom
th aw
territor ial</w>
terrib le</w>
term s,</w>
ter ri
ten tion,</w>
ten sion</w>
tech net
tar tr
tane ously</w>
table t.</w>
symb ols</w>
sw if
suspic ion</w>
surge on.</w>
sur plus</w>
super nat
summ aries</w>
sug ar
suffe rers</w>
suff oc
succe ed</w>
subsid y</w>
sub stituted</w>
sub si
su rely</w>
structur ally</w>
stri p</w>
streng th.</w>
strain s</w>
stor m</w>
sto ol</w>
ste adily</w>
standardis ed</w>
st up
st ol
st ain
spoon ful
splen ic</w>
spir it
spec tac
sp are</w>
smok e,</w>
slaugh te
sk in
situ ation,</w>
sit es,</w>
sign ed</w>
sign ature</w>
sign als</w>
si veness</w>
sho wn,</w>
sett lement</w>
serv ing</w>
serv ice.</w>
serv ice,</w>
seroton ergic</w>
seri ous.</w>
ser ve:</w>
sequ ence</w>
sensitiv ity.</w>
sensitiv ity,</w>
second s.</w>
sec tion,</w>
sec rec
se ven
se ed</w>
se aled</w>
sc eptic
sc ene</w>
sat ellit
sampl ing</w>
sal butam
sad ly</w>
s }</w>
s on,</w>
s log
s is
s in</w>
ru finamide</w>
ros is)</w>
road s,</w>
ro me
ris on</w>
rin sed</w>
rimonab ant</w>
rim al</w>
ri ver</w>
ri pro
ri dicul
ri d</w>
revolu tionary</w>
reven u
resul t.</w>
resto red.</w>
research ers</w>
require ment.</w>
repor ted,</w>
reperc ussions</w>
repe atedly</w>
ren in-
renin- angiotensin</w>
ren e</w>
remain der</w>
rem n
relig ion</w>
regul ate</w>
regimen s:</w>
reg ions,</w>
reflu x</w>
reflec ting</w>
ref used</w>
ref usal</w>
recover y,</w>
recor ded.</w>
recogn ition</w>
recogn is
recip ient</w>
receiv ed.</w>
rec re
reac ts</w>
re z</w>
re tic
re tention</w>
re solution,</w>
re plication</w>
re b
ras mus</w>
ran k
ran itidine</w>
radic al</w>
rab ies.</w>
r- Hu
r y.</w>
r s.</w>
question ed</w>
question able</w>
qualific ations</w>
qual if
qu e.</w>
py raz
purpos e,</w>
pul p</w>
pul led</w>
public ation</w>
provis ional</w>
protec tion,</w>
propos es</w>
prolong ed-release</w>
produc er</w>
problem atic</w>
pro sper
pris on.</w>
principle .</w>
prim ed</w>
pri etary</w>
prevent ed.</w>
precur sor</w>
precipit ates</w>
pre requis
pre pare</w>
pre pa
pre clude</w>
practic e,</w>
pr int
pr e</w>
pr as
pras ugrel</w>
pow der.</w>
post marketing</w>
poss ess</w>
pos is</w>
poly propylene</w>
pollut ants</w>
polic y.</w>
pol ar</w>
point s,</w>
plic or)</w>
platel ets,</w>
place ?</w>
pit uitary</w>
pigment ation,</w>
pic ture.</w>
pic ally,</w>
phenothiaz ine</w>
pharmacokine tics.</w>
ph ased</w>
person ality</w>
per technet
per indop
per ,</w>
pend ing</w>
penal ty</w>
pen sion</w>
pe l</w>
patient- years),</w>
pat ch.</w>
particul ate</w>
part ner</w>
parliam ent</w>
paren ts.</w>
par tly</w>
pap ers</w>
pap er
pan el</w>
pack s.</w>
pa int</w>
p ushed</w>
oz one</w>
ov e
out side.</w>
out comes</w>
out break</w>
oty pes</w>
os pas
orth ostatic</w>
organis ations.</w>
organis ation.</w>
organ ization</w>
organ ism</w>
organ ism
order ,</w>
or m</w>
or dered</w>
or ang
or a</w>
opportun istic</w>
open -</w>
op pon
op ic</w>
op ia,</w>
one !</w>
on- call</w>
on ly).</w>
on e:</w>
on ce
on ?</w>
om el
om ed</w>
olog ous</w>
olan zap
og s</w>
offic es</w>
ocyt es</w>
occur red.</w>
oc obal
obes ity.</w>
o- economic</w>
o thel
numer ous</w>
num ber
nouris hed</w>
nor thern</w>
non- exist
neon atal</w>
nel fin
need s.</w>
nec rol
ne gl
negl ec
name )
nal oxone</w>
n ation</w>
my ster
mus ic</w>
msdeesti @merck.</w>
mox ifloxacin</w>
mother ,</w>
mor b
morb idity</w>
mone y,</w>
mom ent,</w>
mitot ane</w>
mis understand
mir ac
mig ra
meth op
mes h</w>
mer ch
ment ed</w>
mening itis,</w>
men orrha
medic ation,</w>
mean s,</w>
me t,</w>
me at
me an,</w>
materi al.</w>
mat ter?</w>
mat ch</w>
mark ings</w>
margin ally</w>
man if
man ia</w>
man 's</w>
ma ster
m ud
m s,</w>
m erg
m atic</w>
m ari
m ant
long er.</w>
long er,</w>
lob az
lobaz am</w>
lo op
lo dg
lin ks</w>
lin k
lik e,</w>
ligh t
licen sed</w>
liber alisation</w>
less er</w>
len ses</w>
lear ned</w>
le y,</w>
le u
le m
last ed</w>
land scap
land ing</w>
lam ent
la w.</w>
l'Avi ation</w>
l up
l is
l as</w>
kil led,</w>
ker at
k land</w>
k it</w>
k ine
k e,</w>
justi fied.</w>
judic ial</w>
ju ice</w>
journal ists</w>
j ust
ity !</w>
issu es.</w>
is tic
is land
is ),</w>
irrit ability</w>
ir radi
ion- associated</w>
iod inated</w>
invol untary</w>
inv ented</w>
intraven ously</w>
intraven ously.</w>
intrac ran
interval s.</w>
interfer on-
inter stitial</w>
inter mit
inten se</w>
integr ity</w>
insul ins</w>
insul in
instruc tion</w>
inst ance</w>
inno cent</w>
injec tions,</w>
ini ,</w>
infus ion-associated</w>
influenz ae</w>
influenz a,</w>
infec ted,</w>
infarc tion.</w>
inf er
induc er</w>
incen tive</w>
inadver tent</w>
in surance</w>
in su
in stil
in herited</w>
improv ed.</w>
improv ed,</w>
imper ative</w>
impair ment,</w>
im por
im atinib</w>
im at
ill u
ill ,</w>
ie f</w>
ie bl
ide -
id osis</w>
id ine,</w>
ic al.</w>
ib ,</w>
i. e.,</w>
i re,</w>
hypoglycaem ia.</w>
hypo aesthesia,</w>
hypercalcaem ia</w>
hydrox y</w>
hydrolys is</w>
hydrogen ated</w>
hydro gen</w>
hour ,</w>
hormon e,</w>
hor ses.</w>
hom ogen
hom el
hol ds</w>
ho f
high ,</w>
hi er
hier arch
hepatomegal y,</w>
hepatic ally</w>
hepat oc
health ier</w>
he ter
he re?</w>
he ating</w>
he al</w>
have /</w>
har der</w>
haemophil iac</w>
ha el</w>
h it</w>
green house</w>
gre y</w>
gran ules</w>
govern ments</w>
go od.</w>
glyc ogen</w>
glucuron idation</w>
gl au
gen otoxic</w>
gen .</w>
gen ,</w>
gel at
ge red</w>
ga thered</w>
g on</w>
g g
g adol
g )</w>
g ).</w>
fut ure
frequ encies</w>
frag r
fract ure,</w>
fra u
forwar ded</w>
form ally</w>
fore ver.</w>
for th</w>
for d
follow s.</w>
flo ods</w>
fle et</w>
flatul ence,</w>
fla x</w>
fl at</w>
fil ms</w>
fig ure
fent an
fe rences</w>
fe ren
fatten ing</w>
fati gue</w>
fast ing,</w>
famil y.</w>
faec es.</w>
fact ors.</w>
f usion</w>
f illing</w>
f ant
fant as
f -</w>
eyel ids</w>
expen se</w>
execu tive</w>
exec ution</w>
excell ent</w>
exc it
exam pl
ex clude</w>
evi l</w>
every day</w>
ever .</w>
event s:</w>
eu ph
eti racetam</w>
et y
est er</w>
essenti al,</w>
es ',</w>
equip ment.</w>
epto termin</w>
epilep sy.</w>
epidemi ological</w>
epi dural</w>
enterpris es</w>
ent a</w>
eng ine</w>
end ang
encourag ing.</w>
en s,</w>
en ko</w>
en 's</w>
employ ment,</w>
emerg e</w>
em itted</w>
else where.</w>
elev ation</w>
electroly te</w>
elec tive</w>
el se.</w>
el on</w>
el ing</w>
el -
ej acul
eful ly</w>
ed '</w>
ecu tive</w>
ear n</w>
e ks</w>
e ffic
e e</w>
e ased</w>
e '
du s</w>
drug s.</w>
dram atically</w>
dram atic</w>
dr as
dop amine,</w>
diver ticul
disturb ance,</w>
distingu ish</w>
displa y</w>
disp osition</w>
disp ar
disorder s).</w>
discus sed.</w>
discre tion</w>
discontinu ing</w>
discomfor t</w>
discol or
disast rous</w>
dis sid
direc tiv
dipivox il</w>
diphther ia,</w>
dip lop
diame ter</w>
di methyl
deter g
det ach
dest abil
depend ence</w>
den se</w>
demonstr ations</w>
dem ic</w>
del et
degrad ing</w>
decl are</w>
decision- making</w>
dec ar
decar box
dec ades</w>
dead line</w>
de hy
de emed</w>
day -to-
day-to- day</w>
dar ifenacin</w>
da ugh
d é
d ness,</w>
d h
cyclo oxygenase-
cy tom
cul t</w>
cu lo
crim es</w>
cr ush</w>
cost ly</w>
cor tis
cor tic
cor p
control ling</w>
contribu tions</w>
continu ously</w>
consump tion,</w>
constitu tional</w>
constitu ent</w>
consist ing</w>
consequ ently,</w>
consequ ence,</w>
cons ist</w>
confir med.</w>
confid ence.</w>
conf usion</w>
conf isc
con stitution</w>
complet ed,</w>
complet e.</w>
compens ate</w>
compe t
commun ities.</w>
commit ting</w>
comb ating</w>
colon i
coll agen</w>
col og
col i
cod es</w>
co agul
co -</w>
clon ic</w>
clo sure.</w>
ci o</w>
ci di
chlor ide.</w>
chil ls</w>
chick en</w>
chem ically</w>
chec king</w>
challeng ed</w>
chair man</w>
cere bro
centuri es</w>
cent res.</w>
cell s).</w>
ce l</w>
catec hol
cataly tic</w>
cast :</w>
carc in
capsul es)</w>
capac ity.</w>
candi dates</w>
can not,</w>
can ary
canary pox</w>
can ,</w>
campa ign</w>
calici virus,</w>
calcit onin.</w>
cal m</w>
cab in</w>
ca v
ca usal</w>
ca red</w>
c ure.</w>
c lobazam</w>
c af
bur y</w>
bul l
buil t.</w>
bu prop
brut al</w>
bronch is
breast-fe ed</w>
breast -
break fast
bot tom
bo oks</w>
block ers</w>
ble ,</w>
bios et®</w>
biofu els</w>
bil ity.</w>
bex arotene</w>
beta -</w>
below )</w>
behaviour .</w>
begin ning.</w>
be half</w>
be d,</w>
bacter ia.</w>
back .</w>
b right</w>
b orders</w>
b low
b ell
avoid ing</w>
author iz
attemp t,</w>
attack s,</w>
ator y.</w>
atmosph ere</w>
ation '.</w>
ation !</w>
aticall y.</w>
atic .</w>
ati ve
ati for
ath yro
ate glin
ate ).</w>
at or,</w>
at ax
ass ays</w>
as tin</w>
as par
as es.</w>
arsen ic</w>
ari um</w>
are d.</w>
arbit ration</w>
ar s,</w>
ar i</w>
ar ding</w>
approach ,</w>
applic ation.</w>
appl ause</w>
ap olog
anticoagul ants</w>
anti- retroviral</w>
anti- eme
antagon ists</w>
ant e</w>
ann ounce</w>
anim al.</w>
an k</w>
an di
amp ut
aminogly co
am p</w>
am nes
am il
am ic</w>
am bul
altern ate</w>
all ?</w>
alis tic</w>
al ive</w>
al dehy
al caem
al ),</w>
aggreg ate</w>
ag e:</w>
adv anc
adop ted.</w>
adap t</w>
ad s</w>
acqu is
ach tar
ach el
ach e,</w>
accoun t,</w>
ac ne</w>
ac ional</w>
absc ess</w>
abov e-
abil itation</w>
aberr ations</w>
a y.</w>
a ther
a id.</w>
_ info
Z A</w>
Y ear</w>
Y EN
YEN TRE
YENTRE VE</w>
Xol air</w>
X- ray</w>
Whil st</w>
Wednes day:</w>
W i
Vir acept</w>
Vi als</w>
Vari ous</w>
V ent
V as
V AS
Un employment</w>
ULN ,</w>
U zbe
U achtar
Ty pically,</w>
Turk ey
Tran spa
Tox ic
Thir ty-
Th elin</w>
Tel ec
TM Z
TI C</w>
TH )</w>
TEL EN
TAX OT
TAXOT ERE</w>
TAN T</w>
T winrix</w>
T ech
T V
T P
T O
T B</w>
Swit zerland</w>
Sud den
Subst ances</w>
Sub sidi
Stead y</w>
Sloven ia,</w>
Simil arly,</w>
Sik los</w>
Ser vice</w>
Second ly,</w>
Second ary</w>
Sav ene</w>
Sander son</w>
Sand oz</w>
Sain t-
Sad ly,</w>
SPECI ES,</w>
SME s</w>
S top</w>
S hi
S he
S chool</w>
S H</w>
Ro siglitazone</w>
Rivas tigmine</w>
Rev atio</w>
Ret inal</w>
RE S
R ed
R G
R D
QUADRAME T</w>
Propos al</w>
Pro prietary</w>
Pro benecid</w>
Pri or</w>
Portu gu
Placebo -
Pe ter
Pax ene.</w>
Park ,</w>
PRE PAR
PREPAR ATION</w>
PO 9</w>
PE N</w>
P- gp</w>
P seud
P ra
P lan
P K</w>
P G
P F
Over dose</w>
Osi graft</w>
Or land
OptiC lik</w>
Opgen ra</w>
Obes ity</w>
OR TANT</w>
O s
O ne
O m
O ff
No tice</w>
Neu pro
Nause a,</w>
NUMB ER
N utri
N inet
N iebl
N ateglin
N at
N acional</w>
N V
N S
N L
Mixt ard)</w>
Mil os
Mart íne
Mad am</w>
Macu gen</w>
MT X</w>
MS D
MSD Belgium
MSDBelgium _info
M ü
M ur
M andel
M an</w>
Long -
Lo w</w>
Lev etiracetam</w>
L undbeck</w>
L ul
L uk
L anc
Kaletr a</w>
K y
K in
K atifor
K ab
Je an</w>
Jal ra</w>
J es
Intro duc
Interne t,</w>
Inter nation
Insul atard</w>
Inno Let</w>
Inf us
Inde ed,</w>
In tel
In cid
IT Y</w>
IN TELEN
IN FU
INFU SION</w>
IMP ORTANT</w>
IB R</w>
I cand
Hepati tis</w>
Head s</w>
HIV/ AIDS</w>
HCV -
HBe Ag</w>
HAAR T,</w>
H or
H erc
H ard
H A</w>
Gu ine
Gre en
Gr ade</w>
Gmb H,</w>
Gem fibrozil</w>
Gal ile
GF R</w>
G il
G U
G S
G A
Fos can</w>
For ste
Farmacêutic os,</w>
FOSA VANCE</w>
FORCALT ONIN</w>
F ru
F ound
F on
F IL
Ex elon</w>
Ex ecutive</w>
Ex cep
Euro barometer</w>
Engl ish,</w>
EU/2/0 5/0
EU/2/05/0 54
EU/2/05/054 /0
EN T
EID 50</w>
E vid
E st
E spa
E rasmus</w>
E in
E ch
E AC
EAC H</w>
Doc tor
Dis infect</w>
Director ate</w>
Diarrhoe a</w>
Des loratadine</w>
DP P-
DE ,</w>
D é
D ys
D izz
D iv
D ex
D ay</w>
D H</w>
Cur rently</w>
Corpor ation</w>
Contro l</w>
Constitu tional</w>
Consequ ently</w>
Conf idence</w>
Con vul
Con ven
Common ly</w>
Com plete</w>
Co Aprovel</w>
Cholestag el</w>
Chi ef</w>
Cher nob
Cere brovascular</w>
CYP2 E
CRIXIV AN</w>
CO M</w>
C elecoxib</w>
C ef
C amp
Bulg ari
Belo w</w>
BS c</w>
B one</w>
B ang
B LE
Avon ex.</w>
Av astin</w>
Au str
Artic le 
Apid ra</w>
Anti bodies</w>
An n
Americ ans</w>
Alex and
Al so</w>
Actr aphane)</w>
Ac tion</w>
Ab out</w>
AT ,</w>
AP TIV
AC T</w>
A ut
A septic</w>
A id</w>
A gricul
A ff
A dam
A /
A ).</w>
? "</w>
9 5
9 /97)</w>
8 %),</w>
75 70</w>
7 13</w>
7 00
6 13</w>
6 %.</w>
51 1).</w>
50 5).</w>
5. 17</w>
5 14
514 ).</w>
4. 8</w>
4. 6).</w>
4. 1</w>
4 70</w>
4 5,</w>
4 21</w>
4 10</w>
39 .
37. 5</w>
37 3
358- (0)
3- fold</w>
3 35
3 ,
28 5/</w>
27 )</w>
200 9</w>
200 3,</w>
20 8</w>
20 13</w>
20 ,000</w>
20 ),</w>
2- 3</w>
2  
2 NG</w>
2 5.
2 30
2 %.</w>
199 5,</w>
199 4,</w>
198 9,</w>
198 7</w>
198 0
19 0</w>
19 .
17 6</w>
16 1</w>
15 3/</w>
14 00</w>
14 -
13 8</w>
13 3</w>
13 %</w>
10 3
1. 1</w>
1,7 15</w>
1 DH</w>
1 6.
1 /97)</w>
0.2 %),</w>
0.00 1).</w>
0 8</w>
0 34</w>
0 1</w>
/200 5)</w>
/00 8</w>
/00 ):</w>
- specific</w>
- dose</w>
- agonist</w>
) ?</w>
(PSUR ).</w>
(P F
(P E
(HIV )</w>
(C HO
(Am plicor)</w>
(A5-0 35
(A5-0 16
(A DR
( v
( serious</w>
( other</w>
( non-
( low</w>
( haem
( based</w>
( 800
( 7
( 37
' no
' European</w>
' )</w>
………… …………
’ ?</w>
ö n
éné ral</w>
är v
ärv ev
ärvev ana</w>
ß -
Ó GY
ÓGY SZ
ÓGYSZ ER
ÓGYSZER KE
ÓGYSZERKE RES
ÓGYSZERKERES KE
ÓGYSZERKERESKE DEL
ÓGYSZERKERESKEDEL MI</w>
zidovud ine,</w>
zan idine</w>
z ing</w>
z a
yt tri
ys ti
youn g
yme a</w>
yiel d</w>
y ness</w>
y et.</w>
y ard
y -f
y -</w>
writing (
world 's</w>
worl d-
work s,</w>
wor ry</w>
wn ed</w>
withdraw ing</w>
with holding</w>
wit ness</w>
will ing</w>
wid er</w>
whatso ever</w>
weigh t
we aring</w>
wast e,</w>
warm ing</w>
war ran
warran ted</w>
war m</w>
wa re
w ro
w man</w>
w ine
w il
w ide,</w>
volu me.</w>
vol tra</w>
vod k
vis it
vis ible.</w>
viol ence,</w>
vig abatrin</w>
vi d</w>
ves ic
ver ify</w>
vec uronium</w>
vascul itis,</w>
varic ella</w>
vari eties</w>
valu e.</w>
vag ue</w>
vaccine ):</w>
v ine
v ed.</w>
uz ole</w>
ut z
ut ory</w>
ure tic</w>
ur ination</w>
up ward</w>
up ?</w>
up -to-
unfortun ately</w>
unemploy ment,</w>
unde restim
uncertain ty</w>
un preserved</w>
un pleas
un k</w>
um- sparing</w>
ula thro
ulathro myc
u .</w>
ty l
tyl valosin</w>
tw ist
turn ,</w>
tu ally</w>
tru e.</w>
trop in</w>
trometam ol,</w>
tro ops</w>
tricit abine</w>
tri methop
tre m
tre es</w>
transpor t,</w>
transl ations</w>
transl ated</w>
tra p</w>
tr ust
top ics</w>
ton ia,</w>
to ys.</w>
to oth
to day
to :</w>
tivel y,</w>
tis ation</w>
tipran avir</w>
tion ;</w>
ting ling,</w>
tim ing</w>
ti zanidine</w>
ti tu
ti s)</w>
ti redness,</w>
ti les</w>
ti dine</w>
thrombocyt openia,</w>
three- month</w>
though t
thiaz ol
thiazol id
thiazolid ine
thiazolidine di
tetrac yclin
terrorist s.</w>
termin ated</w>
term s.</w>
tell s</w>
telev is
techniqu es,</w>
techneti um</w>
te x</w>
te ams</w>
te al</w>
targ eted</w>
targ et.</w>
tal ks</w>
tak e-
tablet s:</w>
ta vid</w>
ta Te
t ulathromyc
t e,</w>
t ate</w>
system ically</w>
syndrome ),</w>
syn ap
synap tic</w>
symptoms ")</w>
sweet en
swe ats,</w>
swallow ing,</w>
swab )</w>
swa b</w>
sw ir
suscepti ble</w>
surfac es</w>
surfac e.</w>
supplement s.</w>
supernat ant</w>
sup pl
sum ably</w>
sulph ate</w>
sulf ide</w>
sulf ase</w>
sul fat
sul es</w>
sug ar.</w>
succ essive</w>
substr ates</w>
sub ling
sub group</w>
su it</w>
str asse</w>
str ange</w>
str ang
str a</w>
stop .</w>
stomach ,</w>
stit utes</w>
sti ripentol</w>
ster n</w>
stead ,</w>
ste in</w>
stat in
stat es
speci es.</w>
spas m</w>
sou thern</w>
sou th</w>
sol ved</w>
soci o-economic</w>
so y
so res</w>
so red</w>
smok ers.</w>
sm .</w>
slaugh ter.</w>
siz e.</w>
silic one</w>
sil ver</w>
signific ant.</w>
sib ility</w>
si mis
shortcom ings</w>
shor tly</w>
shop ping</w>
sheep ,</w>
sha me
sh ut</w>
sh aring</w>
separ ation</w>
sent ences</w>
sens ation,</w>
sen sible</w>
semi -
self- inject</w>
sel f-</w>
seiz ed</w>
see king</w>
sed ative</w>
secret arial</w>
secret ari
se wage</w>
se e?</w>
se a,</w>
scho ol.</w>
sav ed</w>
satisfac tion</w>
sanofi-av entis</w>
safeguar ds</w>
safe guard</w>
s ”</w>
s oul
s i</w>
s carc
s atur
s and
ruth less</w>
rout e,</w>
ros ace
ro ots</w>
ro li
riton avir)</w>
righ ts.</w>
rifamp ic
ribavir in)</w>
ri vers</w>
ri tis</w>
rhabdomyolys is.</w>
rhabdomyolys is,</w>
rever sible.</w>
reve als</w>
retire ment</w>
respon sive</w>
respon der
reserv es</w>
rer s.</w>
represent ing</w>
replac ing</w>
reno cortic
rememb er.</w>
reli able.</w>
rel y,</w>
rejec ting</w>
regi ste
refriger ator.</w>
refrig erated</w>
ref used.</w>
ref use</w>
recycle d.</w>
recre ational</w>
recommend s</w>
recip i
rec k
rec all</w>
re tt
re tained</w>
re stored</w>
re serve:</w>
re pres
re h
reh abilitation</w>
re bel
re ality.</w>
rapporteur ,</w>
radio therapy</w>
ra k
r-Hu EP
r-HuEP O</w>
r t
r ating</w>
qu arter
py rexia,</w>
put .</w>
purpos e.</w>
pur ple</w>
punc ture
prote in-
prospec ts</w>
propos als,</w>
prof it</w>
product s?</w>
pro state</w>
pris on,</w>
principle ,</w>
preval ence</w>
present ing</w>
prescri be</w>
pre- donated</w>
pre dispose</w>
prac tically</w>
pr ymea</w>
possibil ities</w>
posi tiv
pos aconazole</w>
por tra
por t,</w>
poly propyl
pollu tion,</w>
poll uting</w>
point :</w>
po o
po l</w>
pneumon ia
play ers</w>
pl ut
pl ur
pl ane</w>
pig s.</w>
pig ment</w>
pic tures</w>
pi pe</w>
phot ophobia,</w>
phot oc
phosphok inase</w>
phosph ate)</w>
phenyto in</w>
phenylbut yr
phenylbut y
phas e,</w>
pharmac ologically</w>
pes simis
pertechnet ate</w>
person nel.</w>
persi st
perit one
perform ance.</w>
per ver
people )</w>
patient s):</w>
passp orts</w>
parti es.</w>
parti es,</w>
paragraph s</w>
p sal
p oc
p ist
p ipraz
p ine</w>
p and
oz ol
oxygen ,</w>
oxygen )</w>
ox et
overe x
over dosage</w>
ov ist</w>
ov a</w>
out break
ou pl
ou lo
oulo u</w>
oti de.</w>
otechnolog y</w>
ot ti</w>
osteopo rosis.</w>
orph an
orig in,</w>
organis ms</w>
org e)</w>
optim isation</w>
oper ations.</w>
open ed,</w>
op t
op olys
op it
on ym
on o</w>
on ine,</w>
on al</w>
om otor</w>
olys is</w>
ol l
ol aryngeal</w>
og amma
ogamma di
ogammadi f</w>
off ,</w>
od e</w>
od a</w>
ocyt osis</w>
ocr atic</w>
ocor d</w>
occur s.</w>
occup ied</w>
oc ul
oc lo
oc ks</w>
obstac le</w>
obser vers</w>
objec tiv
ob ut
ob end
o b</w>
numb ness,</w>
numb er,</w>
notic eable</w>
norm aliz
non- governmental</w>
no str
no s
no c
no ble</w>
no -
night ma
ni fe
nife dip
ni er</w>
nex t,</w>
newbor ns</w>
neuro log
nephro path
nel arabine</w>
neighbour ing</w>
neg ativity</w>
ne w,</w>
ne o-
ne bul
nas opharyngitis,</w>
nam ed</w>
n s.</w>
n er.</w>
n ed.</w>
n an
n ail
n R
my opathy</w>
mut ual</w>
ms dn
msdn orge
mov ement,</w>
mother .</w>
mor tg
month s).</w>
money ?</w>
mon oph
mon etary</w>
molec ul
mol /</w>
mo ist</w>
ml ]</w>
ml ),</w>
mist ake</w>
minut es,</w>
min d.</w>
min ated</w>
mill ilit
micrograms/ kg/week</w>
micrograms/ kg/week)</w>
mg/ kg/
method s.</w>
metabolit es,</w>
mess ages</w>
mening itis</w>
men orrhea,</w>
memb ers.</w>
mem ory</w>
me ets</w>
me :</w>
mb er
manufacturer ,</w>
manip ul
malignanc y.</w>
malform ations</w>
macro li
mach ine</w>
ma il,</w>
m oral</w>
m ia</w>
m as</w>
m ?</w>
lymph oproliferative</w>
lymph atic</w>
ly )</w>
ly !</w>
lum irac
low -up</w>
los in</w>
long ,</w>
log o</w>
loc ally</w>
lo wered</w>
list .</w>
list ,</w>
liqu id.</w>
lip id
licen sing</w>
li gi
lev ard</w>
leuk aemia.</w>
less ons</w>
less ly</w>
len alidomide</w>
leb ogammadif</w>
leak ed</w>
leafle ts</w>
lead er
le an</w>
lat eral</w>
lamotrig ine</w>
l ude</w>
l s
l ers</w>
l ).</w>
know ing</w>
kidne ys,</w>
keto acidosis</w>
keep s</w>
k j
k inu
kinu mab</w>
k ing.</w>
k at
k .com</w>
judg ed</w>
journe ys</w>
jour n
job s.</w>
j ail
ix id
iv es</w>
it arian
ischaem ia,</w>
is a</w>
ir radiation</w>
ir in
ipr one</w>
investig ation.</w>
invest ments</w>
inven tion</w>
intermit tent</w>
intensi fy</w>
insulin- degrading</w>
instil lation</w>
inst ances</w>
inqu iry</w>
injure d,</w>
ingredi ents,</w>
ing s?</w>
ing ing</w>
influ enced</w>
infec tive</w>
inf eri
indic ations,</w>
inciner ation.</w>
in- depth</w>
in take.</w>
in sur
in stitute</w>
in k.</w>
in isation</w>
in he
in door</w>
in direc
impos ed.</w>
immuno suppression</w>
imag in
im mature</w>
im balance</w>
il legally</w>
ik a</w>
ign or
igh t,</w>
ific ations</w>
ie tic</w>
idi opathic</w>
identi fying</w>
ide ology</w>
ide ),</w>
id ol</w>
id ation.</w>
ic lo
ic e-
ia al</w>
i ri
i pril</w>
i ol
i dur
hypokal aemia,</w>
hyp o</w>
hy pe
human ity</w>
hum ane</w>
http://www. emea.
hour s)</w>
hos tility</w>
horiz ontal</w>
hon est</w>
hom e,</w>
histor ic</w>
high- level</w>
hid den</w>
hel p
heav ily</w>
head ,</w>
harmon ise</w>
harm less</w>
hand s.</w>
hand -
han dic
haemorrha ge
haemodi alysis,</w>
ha ve?</w>
h us
h an</w>
h all</w>
ground water</w>
groun d,</w>
grap es</w>
gradu ated</w>
govern ment
gover ned</w>
glycol ,</w>
glu teal</w>
glomer ular</w>
gl ands</w>
gest ation</w>
genu inely</w>
g ł
g if
g atan</w>
g ang
g anc
ganc iclo
g a</w>
fur nit
fundam entally</w>
ful vestrant</w>
fri end</w>
fre ight</w>
frag ility</w>
fr action
forbid den</w>
for ?</w>
foot-and- mouth</w>
food- producing</w>
food :</w>
follic ular</w>
fo am
fluo resc
flood ing</w>
flex ib
fiv e-
fist ul
fingerprin ts</w>
fil i
fig ures,</w>
fibr e</w>
fi bre
fi able</w>
ferti li
fem oral</w>
fem ales</w>
fel low</w>
fe ature</w>
fat s</w>
fas hi
famil ial</w>
fal se
fair ly</w>
fa ith
f od
f loxacin</w>
f ile</w>
f ab
ext ent.</w>
explo itation</w>
explo it
exper ts,</w>
expen ses</w>
exist s,</w>
excipi ent
ex ported</w>
every thing.</w>
event ually</w>
event s;</w>
euro s</w>
estr adiol</w>
escal ation</w>
es ’.</w>
es /</w>
es /
er s’</w>
er ous</w>
er al,</w>
er '</w>
equival ence</w>
equ al.</w>
enti ty</w>
ent :</w>
enough ,</w>
enh ances</w>
energ y.</w>
energ y-
energ y,</w>
end othel
end os
end a</w>
en ly</w>
en em</w>
en -
employ er</w>
emerg ent</w>
emb er.</w>
em ig
ell ose</w>
ell '
elec toral</w>
el even</w>
ef ,</w>
educ ation,</w>
econom ics</w>
ech ocardi
earth qu
e ’</w>
e re,</w>
e fl
dur ation,</w>
dul afungin</w>
drop per</w>
dr yness</w>
dose- depend
dos age.</w>
don e?</w>
don ate</w>
do ors</w>
distur bed</w>
dist res
dispos ing</w>
dish on
discontinu ations</w>
discontinu ation.</w>
dis mant
dis co
dis agreement</w>
difficul t.</w>
differen ce
diff ers</w>
diagno ses</w>
di sulfide</w>
develop ed,</w>
destro ying</w>
dest ination</w>
derog ations</w>
derog ation</w>
depri ved</w>
depres sion
depic ted</w>
depar ture</w>
den i
democrac y?</w>
deferasiro x</w>
deep ening</w>
declar ation</w>
decis ive</w>
decis ion,</w>
deci bel
dec oupl
deb ates</w>
de z</w>
de voted</w>
de trim
de pot</w>
de position</w>
de g
de duc
de af
dam ages</w>
dail y).</w>
da c</w>
d or
d l.</w>
d !</w>
cycle .</w>
curren ci
cru ci
cros s
cro p</w>
criter ia,</w>
cri ption</w>
cr yst
cr atic</w>
cour se.</w>
coun t
cop las
convinc ing</w>
conver gence</w>
control s,</w>
contain s:</w>
cont emp
consul ted</w>
connec t</w>
condem n</w>
concentr ated</w>
con gratul
compoun ds.</w>
compon ents,</w>
compon ent.</w>
compar ative</w>
colour less,</w>
colon ial</w>
cogn itive</w>
coc cidi
co ins</w>
clos ely,</w>
clos ed.</w>
clo t</w>
clo p
clean ing,</w>
cl oud</w>
cl ast
clast ogenic</w>
cl as
civili ans</w>
citizen s.</w>
cit ab
circul ation.</w>
cid ofovir</w>
cholest yr
choler a</w>
cho ice.</w>
chil ls,</w>
chil d.</w>
chicken s.</w>
chemic als,</w>
ch er</w>
ch equ
cephal ospor
cell )</w>
ce iling</w>
cat ering</w>
cat ar
care er</w>
cap ping</w>
candi da
can s</w>
cam p</w>
calib rated</w>
calcul ating</w>
c on</w>
c ement</w>
c ationic</w>
butyn in</w>
bur ned</w>
build ing.</w>
bronchis eptic
broad casting</w>
bro wn</w>
bro minated</w>
brady kin
bon es,</w>
bol us</w>
bodi es,</w>
blood y</w>
bir th.</w>
billi on.</w>
bilirub in
beta-1 b</w>
ber t</w>
ben ch
beg g
bec ause,</w>
be t</w>
be l</w>
be et</w>
be e</w>
be ans</w>
be am</w>
basel ine,</w>
b y,</w>
b red</w>
b lam
b ing</w>
b ial</w>
b /</w>
azol am</w>
aver aged</w>
autum n.</w>
attit ud
atmosph ere
ati ve?</w>
ate c</w>
at es
at ed:</w>
ast .</w>
ass ist</w>
ass essed.</w>
ass ad
as ym
as surance</w>
as king</w>
as ing</w>
artan /</w>
arr é</w>
ari pipraz
arg u
arg et</w>
ar ist</w>
ar a</w>
appli ed.</w>
appli ances</w>
appear s,</w>
app ed</w>
app alling</w>
any body</w>
anti- epileptic</w>
anti gen</w>
ant a</w>
announc ement</w>
anim al,</w>
anaphy lactoid</w>
anaesthes ia,</w>
anaesthe ti
anaes thetic</w>
an other,</w>
an a,</w>
an ?</w>
amma -
am ent</w>
am end</w>
alter ations</w>
alpha -
allow ed,</w>
alleg ed</w>
al ism
al is</w>
al g
al er
ak is</w>
air way</w>
air port
air ,</w>
agre ement,</w>
aggreg ation</w>
ag ent,</w>
ag a</w>
aff or
af ter,</w>
af en
adul ter
adox ically,</w>
adjuv anted</w>
adjust ment.</w>
addres s}</w>
addi tives,</w>
ad missible</w>
ad mis
ad ine,</w>
activi ties,</w>
activ ated)</w>
ach ing</w>
ach es</w>
ach .</w>
accid ents,</w>
accid ent,</w>
accept ed.</w>
accep table
ac y.</w>
ac tions,</w>
ac ,</w>
abs ent</w>
ab use.</w>
ab sten
ab ec
a- half</w>
a way,</w>
a il</w>
a ids</w>
_ _</w>
] -
[ ml]</w>
Zen ap
Z ocord</w>
Z ir
Z ev
Z av
Y et,</w>
Where as</w>
Wh at,</w>
W ere</w>
W T</w>
Vit amin</w>
Vehic les</w>
Vaniq a</w>
Val nemulin</w>
VIR AMUN
VE NT</w>
VE GFR
VAS OVIST</w>
V ote</w>
V oj
V all
V R)</w>
V O
Ur tic
Up psal
Up per</w>
Univer sity,</w>
UG T
UC L
U sers</w>
U g
U SA
U R</w>
U P
Turk ish</w>
Tri atec</w>
Th alidomide</w>
TY SA
TR AC
TH ER
TE K</w>
TA BLE
T á</w>
T ut
T um
T ro
T oler
T adalafil</w>
T ER
Sy ringe</w>
Super vis
Su icidal</w>
Su ic
Str uc
St om
SonoV ue</w>
Some thing</w>
Sinus itis,</w>
Sil denafil</w>
Sev o
Servic e,</w>
Ser b
Secret ary</w>
Sch ul
ST A</w>
S án
S z
S ut
S un
S hal
S exual</w>
S /</w>
Russi a,</w>
Ru a</w>
Rob ert</w>
Ro taTe
Res pir
Res i
Rec ently,</w>
RE DI
R ati
Qu ixid
Qu a
Pure gon</w>
Pro vi
Pro te
Pro portion</w>
President -in-
Presid ency.</w>
Preot act</w>
Pre pand
Pre -
Pr ice</w>
Potassi um-sparing</w>
Pot ential</w>
Porc ilis</w>
Placebo- Control
Placebo-Control led</w>
Pir ker</w>
Phys ici
Ph +</w>
Pet er</w>
Per son
Par is,</w>
Par adoxically,</w>
Pan leukopenia</w>
Pan dem
Pa ul
PRO F
PM L</w>
PE -
P ras
P om
P en,</w>
P S
P O</w>
P FO
Orland o</w>
Organ ization</w>
Ombud sman</w>
O- glycosidic</w>
O ri
O prymea</w>
O pen
O mar</w>
O )</w>
Nor thern</w>
No w
No vi
No .</w>
Niebl er</w>
Neutro phil</w>
Neuro leptic</w>
Neuro Blo
NeuroBlo c</w>
N- glycosidic</w>
N et
N ation
N P
N 1</w>
Muslim s</w>
Mu ch</w>
Mix ing</w>
Min utes</w>
Min ut
Mil d</w>
Men itor
Mediterran e
Ma j
MEP s</w>
MAO I.</w>
M ut
M ou
M ir
M -
Lum inity</w>
Lu er</w>
Lt d.</w>
Len alidomide</w>
Lam ic
L ys
L ord</w>
L ive</w>
L in
L T-
Kno b</w>
Katifor is</w>
K r
K or
K et
K F
KF T.</w>
K 103
Jos é</w>
Jean- Louis</w>
J ärvevana</w>
J en
J AN
Irel and
Iraq i</w>
Invir ase</w>
Interne t?</w>
Inno vation</w>
Initi al</w>
Infl ation</w>
Indu stry</w>
In stead,</w>
Im medi
INTELEN CE</w>
ING REDI
IN TER
ID flu</w>
IC 50</w>
I v
I so
I o
I b
I L</w>
I G
Hydro x
Hy cam
Hou se.</w>
Hospit al</w>
High -
Hav ant</w>
Hamp shire,</w>
Haem oglobin</w>
Ha iti
HPV- 18</w>
HM G</w>
HIV /</w>
HCV- RNA</w>
HC T</w>
H us
H SS)</w>
H 1</w>
Gre ater</w>
Gra du
GY ÓGYSZERKERESKEDELMI</w>
G énéral</w>
G iv
G es
G N
G .</w>
Four th
Forste o</w>
Form al</w>
Fore ign</w>
Fol low-up</w>
Flu oxetine</w>
Fer tavid</w>
FO L
F lebogammadif</w>
F is
F ax</w>
F ati
F al
F AB
F 4
Excep tional</w>
Ex ub
Ex posure</w>
Eurost at</w>
Euro pol
Eur atom</w>
Environ ment</w>
En ough</w>
Em tricitabine</w>
Educ ation</w>
EX EL
EXEL ON</w>
EU/1/08/484 /0
EU/1/07/425 /0
ER T</w>
EE A</w>
EE -1
E voltra</w>
E v
E tan
E mil
E 2</w>
Dru g</w>
Dr aft</w>
Docum ent</w>
Di fficul
De pression,</w>
DMAR D</w>
D ol
D ay
D K</w>
Cyanok it</w>
Cro ati
Consi stent</w>
Consi der
Con tr
Commun ities</w>
Com pon
Cl ass
Circ um
Cha mber</w>
Ch ur
Cel gene</w>
CYP3A 4.</w>
CO P
CL L</w>
CE N
CCID 501</w>
C hap
C arcinogenicity</w>
But ,</w>
Bud ap
Bre ast</w>
Blo kland</w>
Bas ing
BS C</w>
B y
B ren
B il
B ell
B acter
B ab
B N</w>
B -1
B-1 180</w>
Ar men
Ar ab
An aphy
Amster dam
Alc obend
Agop ton</w>
Aff air
Ad v
Actr ap
Ab adi
AZ OP
AT ED</w>
AT 1</w>
AR D</w>
AN C</w>
AID S,</w>
AID S
A zer
A y
A then
A round</w>
A part</w>
A b</w>
A X</w>
A RI
A C</w>
@merc k.com</w>
> ,</w>
99 mTc
9 40</w>
9 2%</w>
9 /98)</w>
9 /0
8 90</w>
8 9
8 48</w>
8 0)</w>
8 /97)</w>
8 ),</w>
8 %,</w>
7 8</w>
7 ).</w>
7 %.</w>
7 %,</w>
6. 0</w>
6 70</w>
6 5%</w>
500 ,</w>
50 /</w>
50 %.</w>
5. 1)</w>
5- AL
5 6.
5 %.</w>
42 1/</w>
40 5</w>
4.4 ),</w>
4. 3%</w>
4 02
4 /98)</w>
4 /2000)</w>
39 ,</w>
358-(0) 20-
358-(0)20- 7570</w>
35 4/</w>
35 1</w>
3. 0%</w>
3  
3 3)</w>
3 3%</w>
29 3/</w>
29 2/</w>
28 33</w>
28 108</w>
25 )</w>
200 4,</w>
200 3.</w>
200 2
20 10.</w>
2. 47</w>
2 3,</w>
2 25</w>
2 100</w>
2 /2000)</w>
199 9.</w>
199 2,</w>
198 6,</w>
19 5
13 14</w>
10 7</w>
1.0 -
1.0- 3.0</w>
1, 530</w>
1 14
1 12
1 );</w>
1 %,</w>
0. 7</w>
0. 000
0 5</w>
/E EC
/00 7</w>
/00 6</w>
. ”</w>
-f ed</w>
- type</w>
- 1.
- -</w>
+ )</w>
(hyperglycaem ia),</w>
(U pro
(O HSS)</w>
(N orge)</w>
(N =</w>
(M R
(HIV -1)</w>
(F AP
(E4 20),</w>
(C S
(ADR s)</w>
(AC TH)</w>
(A5 -
(A4-0 39
(A4-0 38
(A4-0 37
(A4-0 36
(A4-0 24
(A4-0 18
(A4-0 17
(A4-0 15
(A D
(99mTc )</w>
(1 0.
(0) 1</w>
(" warning</w>
( unstable</w>
( prolonged-release</w>
( predominantly</w>
( infection</w>
( every</w>
( especially</w>
( containing</w>
( activated)</w>
( about</w>
( 30
( 22
( 19
( 17
' s,</w>
‘ the</w>
α ,</w>
í cio</w>
è re</w>
ç a
Ís land</w>
µ M</w>
zi o</w>
z yme</w>
z ne
zne imit
z es</w>
z -
ys tic</w>
yram idal</w>
yp ical</w>
yl ate</w>
yg ous</w>
yester day</w>
y ards</w>
y /</w>
y '.</w>
work shops</w>
work shop</w>
work ing,</w>
wor d,</w>
with stand</w>
wik i
where ver</w>
wheez ing</w>
well- controlled</w>
weigh ted</w>
weigh s</w>
web site,</w>
we t
wat ers</w>
wat ch
warm th</w>
war far
wa ist</w>
w s,</w>
w inter
w ines</w>
w ide.</w>
w er
w and
vo virus</w>
vis itors</w>
vis ion
vis a</w>
viol ent</w>
vigo rous
vide o</w>
vic inity</w>
vi c</w>
vi ax</w>
veget able</w>
ve y</w>
vastat in.</w>
vas odi
vas ocon
vasocon stric
vals artan
valid ated</w>
vaccin es,</w>
vaccin ate</w>
va renic
v age</w>
utz fel
ut .</w>
usk as</w>
us ia,</w>
us ed?</w>
us al
us :</w>
urtic ari
ur s
ur ity,</w>
ur is
updat ing</w>
up-to- date</w>
up wards</w>
up take.</w>
up date</w>
univer sal</w>
univer s
unit s.</w>
understand s</w>
un ited</w>
un expected</w>
un avoid
um- 99
um p
um e</w>
um b
um ab.</w>
uc opolys
u tin</w>
u el
u cre
u al
type ,</w>
ty re</w>
ty ran
tun nel</w>
tun n
trou bl
troubl esom
trop ical</w>
trime ster</w>
tri oxide</w>
treat ments.</w>
transpor ter</w>
transplant ation:</w>
transplan ted</w>
transf usion</w>
trans location</w>
tran sit
traffic king</w>
tradi tionally</w>
trac ing</w>
tra w
tr is
tr aps</w>
tr ap
tr an</w>
tox oid</w>
town s</w>
tom ato
toler ate</w>
to ward</w>
to o
tissu e,</w>
tis m</w>
tion s:</w>
tion al,</w>
tion ).</w>
time !</w>
tim ely</w>
tigh tness</w>
tic k</w>
tic ity</w>
ti lit
ti ed</w>
ti ,</w>
thyroidis m</w>
thrombocy topa
thromb osis)</w>
threat en
thir ty</w>
thir st,</w>
thin k,</w>
there to.</w>
there of</w>
than k</w>
th yl</w>
th ings,</w>
tex t,</w>
test ing,</w>
test ,</w>
terroris m</w>
ter ly</w>
tend on.</w>
tem sirolimus</w>
tel misartan</w>
techneti um-99
te am
targ eting</w>
targ et
tap enem</w>
tamper ing.</w>
tak e?</w>
tablet ten
tab led</w>
t tis</w>
t s'</w>
t os
t ings</w>
t in.</w>
t ag
system ?</w>
synthes ised</w>
syn cop
sympathomime tic</w>
swell ing),</w>
swab .</w>
susp icious</w>
sur f
sun light,</w>
sulfon yl
substr ates.</w>
subst ance.</w>
subling ual</w>
subject s;</w>
sub- group</w>
sub unit</w>
su ited</w>
studi ed,</w>
stud ent</w>
stu ff</w>
struc ture.</w>
stric ter</w>
stri p
streng then</w>
streng then
strain) ................................
strain ),</w>
str ati
sto s</w>
sto ols,</w>
ste re
statis tics,</w>
star t
stag land
st yl
st ay
st ation</w>
st an
st able,</w>
spo t</w>
spec tro
spa wning</w>
sp ring.</w>
sp lit
sp end
soun d,</w>
som at
solid arity</w>
sol ic
sodi um.</w>
soci e
slow ed</w>
sit e;</w>
sing s</w>
simil arly</w>
si ve
si l</w>
shoul ders</w>
sho ot
shir ts</w>
ship s,</w>
ship ment</w>
shiel d</w>
shar p</w>
sha m</w>
sha king</w>
sh ining</w>
sh if
sh ,</w>
sex u
seve re.</w>
self- employed</w>
second s,</w>
secon d.</w>
sec tions,</w>
se t,</w>
se o</w>
se d?</w>
se aling</w>
sci enc
schedu le.</w>
scenari os</w>
scand al
sc rip
satis fied</w>
sat ellite</w>
sanc tions</w>
san itary</w>
sampl es,</w>
sal vage</w>
sa y.</w>
s. r.
s vägen</w>
s lip
s ending</w>
s cl
s artan</w>
s ants,</w>
rup ture</w>
run s</w>
rum in
rubb ish</w>
ru m</w>
rout e.</w>
rop ha
rod z
rob ust</w>
ro ta
ro mi
romi pl
romipl os
romiplos tim</w>
ris t</w>
ris ed</w>
ril uzole</w>
righ t-
ri dine</w>
rex ia</w>
review ed?</w>
retin opath
retard ants</w>
restric ting</w>
rest ore</w>
rest .</w>
respon siveness</w>
respon d
respir ation</w>
respec ted</w>
resourc es.</w>
res or
res in</w>
relap sed</w>
relap se</w>
rel ess</w>
rel ated,</w>
regul ations,</w>
regul ates</w>
regi me.</w>
reduc tion.</w>
reduc tion)</w>
red ness.</w>
reconstitu tion.</w>
rece ip
read :</w>
reac tion)</w>
re- )
re vol
re tention,</w>
re tained.</w>
re tail</w>
re r</w>
re pl
re medi
re k
rat e-
rapid ly.</w>
rang es</w>
rang e,</w>
randomiz ed,</w>
ran ous</w>
ram ipr
rac ist</w>
r ing,</w>
r ase</w>
quot as</w>
quo ted</w>
quantit ative</w>
qual it
qu il
qu ick</w>
qu e,</w>
purpur a</w>
purpur a,</w>
purpos es.</w>
puri fied</w>
purch ase</w>
pup p
pup ils</w>
public ,</w>
pub lish</w>
proven ,</w>
protec ts</w>
protec ted.</w>
prote in,</w>
propos als.</w>
proportion ality</w>
projec t,</w>
programm es.</w>
profession als,</w>
prof loxac
prof itable</w>
product s:</w>
pro ud</w>
pro stagland
pro st
pro secut
pro phylax
pro min
pro lifer
pro g
priv ati
prior ity.</w>
princip ally</w>
prin ting</w>
prim ing</w>
pri de</w>
previ ously.</w>
pressure ),</w>
prescrib es</w>
preh en
pre t
practition ers</w>
pr ag
pow er.</w>
poul try,</w>
potenti ated</w>
potenti ate</w>
potenti al,</w>
postpon ed</w>
post prandial</w>
posi tive.</w>
posi tional</w>
pos sess
port foli
popul ated</w>
polypropyl ene.</w>
pollu tion.</w>
po ster
po ore
po ol</w>
po fung
plement ation</w>
pla que</w>
pimec rolimus</w>
physi ological</w>
phthal ates</w>
phot o
phosphat ase,</w>
phosph atidyl
phenyl alan
pharmac eutic
ph os
petro l</w>
pestic ides.</w>
pers on.</w>
permit ted.</w>
perit on
periph eral,</w>
period s,</w>
peri ocular</w>
perhap s,</w>
perforat um)</w>
perfor ation</w>
perfor ation,</w>
per missible</w>
per -
people ’s</w>
pen di
pe red</w>
pe ,</w>
pay ments.</w>
patient s'
path way,</w>
path ogenic</w>
passp ort</w>
particul ars</w>
part ),</w>
parliam ent
pares thesia,</w>
paren tal</w>
paren t.</w>
parec oxib</w>
parame ters.</w>
par t.</w>
par athyro
par adox
pandem ic.</w>
pancre atitis</w>
pal mit
pal ivi
painf ul
pain /</w>
paedi atr
pack ed</w>
pack ages</w>
pa y,</w>
p ins</w>
p ile</w>
p assi
p ace</w>
oz ygous</w>
ow ing</w>
over come</w>
ov y
ov an</w>
out breaks</w>
our ing</w>
oun d.</w>
otoxic ity.</w>
oste oc
osph ate</w>
organis ational</w>
organ s.</w>
organ s,</w>
organ ise</w>
order .</w>
or b
opt- out</w>
opit ant</w>
oph armac
oph arma</w>
oper idol</w>
on ly:</w>
on i
on e)</w>
on colog
on a,</w>
on :</w>
omy r</w>
omel atine</w>
omas ti
om o
om emb
omemb ranous</w>
om arist</w>
olog ists</w>
ol )</w>
ok ,</w>
ogen esis,</w>
og rastim</w>
off ences</w>
oesophag us</w>
odi um,</w>
od ec
occup ation</w>
occas ions</w>
oc ur</w>
oc a
obstruc tion
obser ver
objec tions</w>
objec t</w>
o yl
o stat
o oz
o ily</w>
o a</w>
o 's</w>
now ad
notific ations</w>
notic ed</w>
norm al,</w>
nor th</w>
nor adrenaline</w>
non- linear</w>
no se
no ise,</w>
neuro transmit
neglig ence</w>
neg ative.</w>
nee ded,</w>
necrol ysis,</w>
nec rosis,</w>
ne virapine</w>
ne tt
nation ality</w>
nar co
name) ®</w>
nam es:</w>
na m</w>
na ec
n y
n ings</w>
n g/
n ations</w>
myel ogenous</w>
muscle ,</w>
multin ational</w>
mucos a</w>
mu til
moun tain</w>
more over,</w>
mono hydrate</w>
mono hydr
mod es</w>
mod el.</w>
mobil isation</w>
mmH g,</w>
mistak es</w>
mir ta
minut e,</w>
minim um.</w>
minim ize</w>
mini ster
min ors</w>
min ing</w>
min ded</w>
milli metres</w>
milli gram
mil it
mid d
mg/ kg</w>
mg ),</w>
methotrex ate,</w>
meth aem
medic ated</w>
me ters</w>
materi als,</w>
mater nity</w>
mark er</w>
mari time</w>
manufacturer s.</w>
manif est</w>
manag ement.</w>
mala ise</w>
mala ise,</w>
mak ing.</w>
maintain ed,</w>
macro gol</w>
machin ery,</w>
mac ropha
m o</w>
m iti
m ia,</w>
m erc
lute in
los s.</w>
lor ries</w>
long -</w>
log is
lob by
lo v
lo pri
lo os
lit t
liqu id,</w>
lingu istic</w>
lin king</w>
lin es.</w>
lim it,</w>
lik e.</w>
ligh tly</w>
lif ted</w>
lif t</w>
lif esp
lifesp an</w>
li tis,</w>
li d</w>
li ability</w>
li a
leu kin
leth al</w>
les ions.</w>
les ion
lent un
len alidom
lenalidom ide
legitim ate</w>
legisl ation,</w>
lef t.</w>
least ,</w>
le ague</w>
le a
lawy ers</w>
lat ter,</w>
last s</w>
lap se.</w>
lact one</w>
labell ing,</w>
lab ility,</w>
la w,</w>
la m</w>
la di
l'Avi ation,</w>
l s.</w>
l ack
kil le
kat ell
k r
k g,</w>
k ers,</w>
ja w</w>
j ok
j es
j erg
jerg vej</w>
ivast atin</w>
ival irudin</w>
iv et</w>
ity ),</w>
itrac onaz
iti es)</w>
it um
it inib</w>
it es.</w>
it en
it age</w>
issu ing</w>
isomer ase.</w>
is tic.</w>
is lands</w>
irrit ation.</w>
irrit ated</w>
irradi ated</w>
ip el
ion '</w>
invol ve?</w>
introduc ed,</w>
intramuscul arly</w>
interpre ting</w>
interpre t</w>
interfer ing</w>
inter governmental</w>
inten tional</w>
intellig ent</w>
intellec tual</w>
int act</w>
insuffici ency)</w>
inspec tor</w>
insi st
insi c</w>
injure d.</w>
injec ted,</w>
injec t.</w>
infring ement</w>
infra red</w>
inform ation
inf used</w>
inf ul</w>
inf requ
inf la
inf ant.</w>
inev itable</w>
ine- treated</w>
ine a</w>
ine ),</w>
ine 's</w>
industri es</w>
individu als,</w>
indic ations.</w>
inde x</w>
increas ing,</w>
incin erated</w>
incid ents</w>
inadver t
in take,</w>
in sp
in s
in ococc
in formed,</w>
in effective</w>
in effective.</w>
in dul
in cur
in comprehen
in ating</w>
in ate</w>
impot ence,</w>
imp act.</w>
imat oprost</w>
im perfec
im idine</w>
im id
illness es,</w>
ill iter
ilep sy</w>
igh ting</w>
ig i</w>
ide ological</w>
ide /</w>
id a,</w>
ic yl
ic ity,</w>
ic es,</w>
ic eb
iceb erg
ic ate</w>
ic am</w>
ic als</w>
ib u
i me
i dulafungin</w>
i dium</w>
i ans.</w>
hypertroph y</w>
hyperlactat emia</w>
hypercalcaem ia.</w>
hyper therm
hyper plas
hy bri
hung er</w>
hun ting</w>
hum ili
http://www.emea. europa
http://www.emea.europa .
hour )</w>
hop es</w>
homocy ste
holid ay
hi ther
hes itate</w>
herpe tic
hec k
hear t.</w>
he res
he at
hard t</w>
har d.</w>
happen ed?</w>
hal operidol</w>
ha v
ha den
h t
h n</w>
h C
gr af
glutam ic</w>
glucos e-</w>
glucos amine</w>
glucocorticoid s,</w>
glo ttis</w>
glarg ine</w>
gl asses</w>
gl ass
gent le</w>
gastroenter itis</w>
gall bladder</w>
ga ther</w>
ga ther
g un
g es</w>
g ed</w>
g e,</w>
g a,</w>
ful l-
fre ely</w>
frau dul
fraction ated</w>
foun ded</w>
foun d.</w>
fos sil</w>
form ation.</w>
form aldehy
forest ation</w>
for :</w>
for ,</w>
foc al</w>
fo ster</w>
fo ol
flu ,</w>
fish ery</w>
first- pass</w>
fing ers</w>
financ ed</w>
fin ished.</w>
fil iaal</w>
fibrin ogen</w>
fever ),</w>
fertilit y.</w>
fertilit y,</w>
fe e</w>
fe ars</w>
fast -
farm ers,</w>
far -
famili es,</w>
falsi fied</w>
fail ures.</w>
fact or.</w>
fact or,</w>
fac es</w>
fa ke</w>
f ed
eyel ids,</w>
extravas ation</w>
extr apol
expen sive.</w>
expect ations</w>
exhib iting</w>
exhaust ed</w>
exemp tions</w>
exc ise</w>
examin ing</w>
ex posing</w>
ex pos
even ly</w>
eu tics</w>
estim ates,</w>
ester ase</w>
essenti al.</w>
esc a</w>
erythro myc
erythro cytes</w>
eri es,</w>
er o</w>
er ies</w>
er ate</w>
er ).</w>
er ),</w>
ept acog</w>
epide mic
epi phys
enter tain
entail ed</w>
ent -to-
ens -
enlarg ement.</w>
enlarg ement,</w>
enjo y</w>
enhanc ement</w>
endomet rial</w>
encephal opath
enc i
en o
en de
ende av
emerg ing</w>
embol ism
emb arr
embarr ass
elig ible</w>
el li
effici ently</w>
effectiven ess.</w>
efaviren z
ef alizumab</w>
ed itor
ed ge</w>
ed es</w>
ed ),</w>
econom ies</w>
ec o-
eb jergvej</w>
eas i
e/ discontinue</w>
e es</w>
e ases</w>
e arm
earm ark
e '.</w>
e ".</w>
dyspha gia,</w>
dys function.</w>
dulox et
du es</w>
du bi
dri ed</w>
dre ams</w>
dou bling</w>
dos ing,</w>
don ations</w>
dom ain
dol ph
divi ding</w>
distrib uted.</w>
dist ress</w>
dissol ve</w>
disproportion ate</w>
disp ute</w>
disinfect ant</w>
dis solv
dis odium,</w>
dis missed</w>
differenti ated</w>
differen tly.</w>
differen t,</w>
dif ício</w>
di vor
di verse</w>
di tions</w>
di t</w>
di r
di ed.</w>
di e.</w>
di az
develop mental</w>
develop ed.</w>
detec ted,</w>
destroy ed,</w>
deser ve</w>
desc rib
deriv atives,</w>
depre otide</w>
den omin
den af
democrac y,</w>
dem ographic</w>
deliber ate</w>
deleg ates</w>
del avir
defin ite</w>
defin ed.</w>
defici encies</w>
defic its</w>
defec tive</w>
deep -
decreas e,</w>
decom mission
declar ations</w>
decis iv
dec ad
death s,</w>
dead lines</w>
de tain
de tail</w>
de al.</w>
day -
dar a</w>
d y</w>
d enti
d .
cytok ine</w>
cr ack
cour ts</w>
correc tly.</w>
correc tion</w>
cor related</w>
cor d</w>
copies /
cop ic</w>
convul sant</w>
conv ince</w>
controversi al</w>
contribu ted</w>
contrast ,</w>
continu ity</w>
continu e/discontinue</w>
consum ers?</w>
consum er
consul ted.</w>
conjunctivi tis</w>
conges tive</w>
conform ity</w>
confir mation</w>
confidenti ality</w>
conf using</w>
conf use</w>
condi tional</w>
concomit antly.</w>
concep ts</w>
concentr ation
conce iv
con tra-
con sume</w>
con clu
compromis ed.</w>
compromis e.</w>
comprim é
compres se</w>
comple ment</w>
compe te</w>
compan y,</w>
commun ity.</w>
commission ed</w>
comm odi
com pa
com ed</w>
collap se.</w>
collabor ation</w>
col leg
cohe rent</w>
cogn i
coffe e</w>
cod ing</w>
co- administration</w>
co w</w>
co operation.</w>
co di
clos ely.</w>
clin ical
clean ing</w>
class es</w>
clar ify</w>
cl uster</w>
cl ic
cl a
civili an</w>
civil isation</w>
chol ine</w>
chol ine,</w>
chol ec
child care</w>
chemistr y,</w>
chemic als.</w>
check ed,</w>
champ ag
chamb ers</w>
chair man
ch op
ch ing,</w>
ch er
certific ate</w>
certain ty</w>
cere als</w>
cent ,</w>
cat alogue</w>
cas h</w>
cardi ovascul
carcinogen ic,</w>
car d,</w>
car ,</w>
capit al,</w>
cap ecitabine</w>
cannab is</w>
can al.</w>
calci um-
c yl
c uri
c up
c obal
c m
c ited</w>
c if
c ade</w>
c -
bureauc r
bur n</w>
buprop ion</w>
bul k</w>
buil ds</w>
bub bl
bru ises</w>
bru ised,</w>
bronch itis</w>
bra in.</w>
br ile</w>
boost ed</w>
boar ding</w>
bo ats</w>
bo ard
blur red,</w>
blister ing</w>
blephar itis,</w>
bir ths</w>
bio diversity</w>
bilirub in,</w>
big ger</w>
bi olog
benefit -
benefit- risk</w>
believ es</w>
bel t</w>
be ing.</w>
be ar
batt le</w>
banan as</w>
bag s,</w>
ba ij
b rings</w>
b ill
b ak
azac itidine</w>
az ole,</w>
az ak
aviren z</w>
avi a</w>
aux iliary</w>
author s</w>
aus e)</w>
au er</w>
attack ,</w>
att ended</w>
ation s)</w>
ate- General</w>
ate ;</w>
at ypical</w>
at ra
at o</w>
at es-
at enol
at e:</w>
at ch</w>
astro cytom
asth ma,</w>
ast ric</w>
asbe stos</w>
as ma</w>
as es,</w>
as ep
as ?</w>
arri ved</w>
arrest ed,</w>
arm s,</w>
aris e.</w>
ar y-
ar s.</w>
ar ises</w>
appropri ations</w>
appropri ately.</w>
approach ing</w>
appro xim
applic ator</w>
applic ations,</w>
appl y,</w>
appl ause)</w>
apam ulin</w>
ap noea</w>
ap art
any where</w>
any where.</w>
any way,</w>
anti histamine</w>
answ er.</w>
anorex ia,</w>
anomal ies</w>
ann u
ang le</w>
anc ient</w>
anc e?</w>
anc a</w>
an aplastic</w>
amino transferases</w>
am ous</w>
alum ini
allow ances</w>
aliz ing</w>
aliz e</w>
alis ed,</w>
alcohol .</w>
al d</w>
air ways</w>
agre ement.</w>
aggrav ation</w>
agg ing</w>
ag o
ag n
ag itation</w>
ag e)</w>
after wards.</w>
affair s</w>
aff ord
aff ir
advis ed.</w>
adjust ing</w>
adhe red</w>
addres sing</w>
adap tation</w>
adal ix</w>
activ e.</w>
accumul ates</w>
accept ance</w>
ac y,</w>
ac ulation</w>
ac rome
ac lopri
absur d
absor p
abr adine</w>
above- mentioned</w>
abnorm ally</w>
abil ities</w>
abduc ted</w>
abat to
ab utin</w>
ab ac
a- treated</w>
a- like</w>
a w</w>
a h</w>
a be</w>
____________________ __
______________________ _</w>
] )</w>
Zav esca</w>
Z omarist</w>
Z iconotide</w>
Yor k
Y trac
Y TRAC
YTRAC IS</w>
X a</w>
Wor l
Wilson 's</w>
We eks</w>
WI K
WIK PEN</w>
W ater</w>
W all</w>
W ales</w>
W P</w>
W P
Voj vod
Virafer on,</w>
Vir tually</w>
Viet nam</w>
Val sartan</w>
Val dox
VFEN D</w>
VAN CE
V id
V LDL</w>
Un til</w>
Un its</w>
Uachtar á
UL OX
ULOX E
ULOXE TIN
ULOXETIN E</w>
U s
U V
U ,</w>
Tηλ :</w>
Tél /Tel:</w>
Tur ke
Trizi vir
Treat y.</w>
Trans lation</w>
Tra katell
Tra ining</w>
Tr act
Thromb in</w>
Thir d,</w>
Thi azide</w>
Thi az
There after,</w>
Th urs
Terroris m</w>
Ter m</w>
Technolog y</w>
Tal c</w>
Tablet ten</w>
Ta p</w>
TI S</w>
TE VA</w>
TAN ZA</w>
T arget</w>
T ar
T ake,</w>
T 2</w>
T 1</w>
System ic</w>
Sup port</w>
Sum mit</w>
Sub oxone</w>
Struc tural</w>
Stat ale</w>
St ore</w>
St ate,</w>
Sor bit
Solo Star
Sol lentun
Sinus itis</w>
Sim vastatin</w>
Sha ke</w>
Set up</w>
Sch mid
SUBSTANCE S</w>
SU R</w>
SOL VENT</w>
S. A.</w>
S urely</w>
S ter
S tability</w>
S par
S ocial</w>
S how</w>
S et</w>
S ell
S am
S IS</w>
Resi dues</w>
Report ing</w>
Reg arding</w>
Re present
RO B
RING ER</w>
RI S</w>
RI LU
RILU TEK</w>
REYAT AZ
REYATAZ /</w>
REF ER
REFER R
R iver
R ights</w>
R ed</w>
Qua est
Pul l</w>
Progres sion</w>
Proce dure</w>
Pro phylactic</w>
Pro ble
President-in- Office</w>
Presid ency,</w>
Prepand rix</w>
Pre vi
Pl atel
Pl ads</w>
Par agrap
Pandem rix</w>
PRO TE
PN R</w>
PG N</w>
PF S</w>
PACKAG ING</w>
P- value</w>
P neumococcal</w>
P lat
P ig
P er</w>
P SUR</w>
Optim ark</w>
On sen
Of ten</w>
Of ten,</w>
O h</w>
O de</w>
O U
O MP
Nor th-
No  
Nateglin ide</w>
Name :</w>
NUMBER (S)</w>
NE VAN
NE CE
NECE S
N one</w>
N L-
N H
N EU
My oc
Mug abe</w>
Mr  Barro
Mil k</w>
Mer ci
Mc C
Maxim um</w>
Martíne z</w>
Ma ke</w>
MS c</w>
MED I
ME N
MA O</w>
M ov
M i
M Y
M T-
M ON
Lul ling</w>
Lu igi</w>
Lo wer</w>
Lev viax</w>
Leuk oS
Lamic tal</w>
LV -1
LV-1 004</w>
LIST ER</w>
LE S</w>
LE D</w>
L ange</w>
L ang
L Y</w>
L ),</w>
Ket ek</w>
K103 N</w>
K el
K at
K WIKPEN</w>
Jer usal
Jap anese</w>
Janu via</w>
J ak
Ital i
Introduc ing</w>
Infec tion
Industri a</w>
In stit
In fra
Immun e</w>
Im munolog
Icel and,</w>
Icand ra</w>
IX ,</w>
IV ):</w>
ISENTRE SS</w>
IR A</w>
ING EL
INGEL HE
INGELHE IM</w>
IN TANZA</w>
II )</w>
Hou se,</w>
Hol oca
Heal th,</w>
Hard ly</w>
Hal ocur</w>
HB V)</w>
H ut
H en
H au
H ann
H RINGER</w>
H P
H G
H 5
Gu ill
Gu adalix</w>
Greec e.</w>
Go og
Giv en</w>
Georg ia</w>
Gener ally,</w>
Gen etic</w>
Gal v
Gad ovist</w>
G ros
G au
G )</w>
Fru ebjergvej</w>
Fra me
Flat ulence</w>
FR ANCE</w>
FIN-0 2
F ib
F act
F L
F IC
F I
F EV1</w>
F E
F AR
Evid ence</w>
Euro pa
Etan ercept</w>
Equ ally</w>
Ep ilepsy</w>
Enbrel ,</w>
Ef avirenz</w>
Ech inococc
EU/1/99/1 07
EU/1/05/3 29
EN A</w>
EN -
EF SA</w>
EE-1 1314</w>
EC 50</w>
E uro</w>
E ucre
E ri
E poetin</w>
E difício</w>
E ast
E PAR
E N</w>
E HRINGER</w>
Dysp ep
Dub lin,</w>
Dru g
Dos e-
Don 't</w>
Director ate-General</w>
Di ovan</w>
Des cription</w>
Denmark .</w>
De fin
DPP- 4</w>
D un
D res
D om
D ogs</w>
D id
D ic
D eg
D ULOXETINE</w>
D AS</w>
D ).</w>
Cypr us,</w>
Cross- resistance</w>
Cre utzfel
Cor rec
Con traindic
Con sti
Con ditions</w>
Commission ers</w>
Co -</w>
Class ical</w>
Circum st
Christi ans</w>
Chin a,</w>
Chang ing</w>
Chamb er,</w>
Ch urg
Ch arg
Ch annel</w>
Care fully</w>
CYP2 B
CR F.</w>
CPMP /</w>
CPMP /
CON CEN
CONCEN TR
CI ,</w>
CAR T.</w>
C yt
C u
C old</w>
C anc
C I</w>
C AM
Bure au</w>
Bur sal</w>
Bulg aria,</w>
Bud dh
Buc ure
Buc ha
Bu iten
Breast -feeding</w>
Braz il</w>
Br un
Ble eding</w>
Bi otechnology</w>
Ber lin.</w>
Bar on
Bar ac
Balk ans</w>
Ba uskas</w>
BYET TA
BSE ,</w>
BR I</w>
BO EHRINGER</w>
B ra
B es
B erg
B achel
B TP</w>
B LISTER</w>
B IC
B E</w>
Azer baij
Az omyr</w>
Austr al
Assist ant</w>
Ar c
Ar af
Annex es</w>
An idulafungin</w>
An gi
Amster dam</w>
Am es</w>
Allerg an</w>
Al low</w>
Al dara</w>
Agener ase</w>
Afric a.</w>
Ad d
Ac tos</w>
Ac ti
Ab rax
Ab acavir</w>
AZOP T</w>
ASE M</w>
AN E</w>
AL S</w>
AL ,</w>
AG ,</w>
AF .</w>
AE s</w>
AC S</w>
AC E</w>
A ven
A gre
A M</w>
A 77
A77 17
@ emea.</w>
9 9%</w>
9 7%</w>
9 6
9 2-
9 %.</w>
8 6/
8 10</w>
8 006</w>
8 /2000)</w>
74 14</w>
70 73</w>
7 4%</w>
7 2,</w>
7 1
7 /98)</w>
7 /9
7 /2001)</w>
6. 6).</w>
6 26</w>
6 2%</w>
50 x1</w>
50 %,</w>
5-fluorourac il</w>
5 67</w>
5 500</w>
5 ,000</w>
5 ,
5 %).</w>
4. 6%</w>
4. 5)</w>
4 50
4 3
4 25</w>
4 /
37 1-
371- 7</w>
36 0</w>
34- 91</w>
34 3/</w>
335 5</w>
30 %.</w>
3. 1%</w>
3 80</w>
3 2%</w>
28 7</w>
26 -
200 7.</w>
200 7)</w>
20 2</w>
20 20.</w>
2. 5-fold</w>
2. 4</w>
2- fold</w>
2 C
2 B
2 4,</w>
2 30</w>
2 300</w>
2 15
2 1%</w>
2 /98)</w>
199 4</w>
199 1</w>
19 9</w>
19 70
18 5</w>
18 )</w>
18 %</w>
16 9</w>
100 -
100 ,</w>
100 %</w>
10. 7%</w>
10 6</w>
1. 0%</w>
1 st</w>
1 25</w>
1 13</w>
1 12</w>
1 1,</w>
1 -2
08 6/</w>
08 5/</w>
0.0 3%</w>
0 9</w>
0 5
0 ,</w>
0 %),</w>
/E C</w>
/00 9</w>
................ ....</w>
. "</w>
-2 ,</w>
-0 52-
- proof</w>
- R
- 0.
, 000
, '</w>
+4 8
+4 4</w>
) /</w>
) *</w>
) ).</w>
(rDNA ).</w>
(p= 0.0
(S VR)</w>
(MAOI s),</w>
(HIV ),</w>
(CHO )</w>
(C OX
(C OM
(C M
(C E
(B 5-0
(A5-00 9
(A5-0 34
(A5-0 28
(A5-0 25
(A5-0 19
(A5-0 18
(A5-0 17
(A5-0 15
(A4-0 27
(A 6-0
(A -0
(A )</w>
(3 %)</w>
(1 1.
(0. 3%</w>
(0) 10</w>
( usually</w>
( shoul
( saquin
( re-)
( patients</w>
( pH</w>
( more</w>
( liver</w>
( insulin)</w>
( ex
( equivalent</w>
( either</w>
( deep</w>
( WHO
( SE)</w>
( MA
( HBV)</w>
( 7.
( 60</w>
( 6.
( *
' A</w>
' :</w>
% ].</w>
” )</w>
“ Pfi
“Pfi zer
“Pfizer ”</w>
“ PGN</w>
π ρ
ö ld</w>
ç o</w>
ä l
ã o</w>
µg/ kg/week)</w>
{month /
{month/ year}</w>
zo on
zal citab
za ar</w>
z k
z e
yttri um-
you :</w>
yn thes
yl alan
yel low
year 's</w>
y ’s</w>
y right</w>
y mid
ymid ine</w>
y lo
x iv
xiv an</w>
wrec k</w>
worsen s,</w>
work place,</w>
work -
work !</w>
wor n</w>
wor ds.</w>
wit ness
win ter</w>
whe at</w>
wh el
welcom ed</w>
weigh t-
weigh t)</w>
week s).</w>
week ;</w>
wed en)</w>
weakness es</w>
weak ening</w>
we re,</w>
wash ing</w>
wal k</w>
w s.</w>
w ol
w oh
w ant.</w>
w alls</w>
w -
vot e.</w>
volunte ers,</w>
voc ate</w>
vo ice,</w>
viv o.</w>
virus )</w>
view ?</w>
vial :</w>
veterinari an.</w>
vessel ).</w>
vess el,</w>
verifi able</w>
ver tigo</w>
ver ified</w>
vel l
vehic le.</w>
vehic le,</w>
van ish
valu e,</w>
v ast</w>
v .</w>
utro ph
util ised</w>
ut e,</w>
uste kin
ust ín</w>
ust oms</w>
uss ée</w>
us ep
usep pe</w>
ur s</w>
ur ine,</w>
ur al,</w>
up op
undertak ings</w>
understand able</w>
un safe</w>
un ity</w>
un intended</w>
un il
un fractionated</w>
un equal</w>
un acceptable.</w>
ul f
ugh es</w>
ud ine,</w>
u tility</w>
u n</w>
u le</w>
u al.</w>
tw o
tuoteinfo@gsk .com</w>
tub ules</w>
tu be
tryp t
truth .</w>
tru e,</w>
trimethop rim
trig gered</w>
tri phosphate</w>
tri az
treatment- experienced</w>
treatment ?</w>
treatment )</w>
treat ed)</w>
tre e</w>
tre aties</w>
transpor t.</w>
transplant ation.</w>
transpl ant.</w>
transpa rency.</w>
transpa ren
transluc ent</w>
transi t</w>
transfus ions.</w>
trans missible</w>
train ing,</w>
trag edi
traffic kers</w>
trad ed</w>
tr uc
tr il
tr e</w>
tr am
tr actor</w>
tor s,</w>
tor ,</w>
ton in</w>
toler ated,</w>
toc og</w>
tobacc o,</w>
to rem
to k
to il
tiv eness</w>
titr e</w>
titr ating</w>
tion ally,</w>
tim ul
til l</w>
tigec yclin
tic ket</w>
tic al.</w>
ti p.</w>
thyroidis m
thyro tropin</w>
thrombocytopa enia</w>
thrombin .</w>
thromb osis,</w>
thri tis</w>
thresh old.</w>
though .</w>
thir st</w>
thir ds</w>
thir d-
themsel ves.</w>
the at
theat re</w>
th ral
th ing
th ank
tetrac ycline</w>
termin ate</w>
ter i
tenecte plase</w>
ten e
ten able.</w>
tempor arily</w>
tel ematics</w>
ted in</w>
techniqu es.</w>
tec hi
teach ers</w>
teach er</w>
te ur</w>
te m</w>
te am.</w>
te ach</w>
tal ity</w>
tal ent</w>
tak e
tacrolim us.</w>
tac apone</w>
tabletten /</w>
tab ly,</w>
tab ility.</w>
ta g</w>
t ough</w>
t od
t elling</w>
t an</w>
t adalafil</w>
system ).</w>
syndrome :</w>
syncop e,</w>
swe at
suspen sion:</w>
surviv al.</w>
surveill ance.</w>
surpris e</w>
surpris e.</w>
surger y,</w>
sur pl
suppres sants</w>
suppos es</w>
support ed.</w>
suppor ters</w>
super market</w>
super fic
sup ports</w>
sup ine</w>
sun ,</w>
sugges tion</w>
suff er.</w>
succe eded</w>
succ ess,</w>
substr ate,</w>
substit uting</w>
substit ut
substanc es:</w>
subst ance,</w>
subsidi arity</w>
subsi dis
subsc ri
su ms</w>
su ch.</w>
su ch,</w>
studi ed?</w>
stud ents</w>
strö m</w>
strug gle</w>
stro mal</w>
stri dium</w>
strength ened</w>
stra Zen
str adiol</w>
stor ies</w>
stop per</w>
stomach .</w>
sto ke</w>
stit uting</w>
stiff ness</w>
stic king</w>
stas y</w>
star ch</w>
standard s,</w>
staff ,</w>
st uck</w>
st ones</w>
st ays</w>
st amp
st ad
st ability</w>
spor ting</w>
spo ons</w>
spec im
sor ts</w>
solu tions,</w>
solu tion?</w>
soldi ers.</w>
soci eties</w>
soci et
so y</w>
so on
sn ap
smok ers</w>
smo oth</w>
small est</w>
sligh test</w>
slaugh ter
sk i,</w>
siz e,</w>
six- month</w>
six th</w>
six teen</w>
simpl y,</w>
sil icon
silicon ised</w>
sil ent</w>
sil ence</w>
sign s.</w>
sick ness</w>
shor t,</w>
shoc king</w>
sho es.</w>
she et</w>
shame ful</w>
sha ky</w>
sh ore</w>
sh ed</w>
sett ling</w>
set amide</w>
serv ants</w>
serious ness</w>
seri ou
seriou s)</w>
ser y</w>
separ ately</w>
sep sis,</w>
sell er</w>
self- injection,</w>
self- employ
selec tivity</w>
seiz ures.</w>
seiz ures,</w>
secret ariat</w>
sec urity.</w>
se t-
se mb
se m
se a.</w>
sco re
scienti st</w>
school s.</w>
sch i
schi öld</w>
scarc ely</w>
sc ru
sc ep
sav ings</w>
sarcom a,</w>
saquin avir)</w>
salmon ella</w>
saliv ation,</w>
sal icyl
sa ys:</w>
sa ys,</w>
s ounds</w>
s nee
s lower</w>
s inc
s cars</w>
s ca
s ation</w>
rub ble</w>
rub bed</w>
ru z</w>
rout es,</w>
roli done</w>
rodz ka</w>
roc tocog</w>
ro ws</w>
ro ot
ro les</w>
ro le.</w>
rifamp icin</w>
ric ane</w>
rib itol</w>
rhabdomyolys is</w>
rh et
rhet or
retin opathy</w>
rest ing</w>
responsibil ity,</w>
respectivel y),</w>
respec ted,</w>
respec t?</w>
resourc es,</w>
resid ence</w>
reservo ir</w>
rese tt
res ).</w>
require ments,</w>
request ing</w>
repe at
renocortic otropic</w>
renew al</w>
ren der</w>
ren al,</w>
remn ants</w>
reli eves</w>
relev ant,</w>
releas ed.</w>
releas e:</w>
relap sing</w>
regul ating</w>
reg ret
reg en
refer ring</w>
red ness
recruit ment</w>
recon struc
recommend ations.</w>
recommen ded:</w>
recogn ized</w>
recept or
rec tile</w>
reach ed.</w>
reac tive</w>
re y</w>
re uptake</w>
re tic</w>
re sume</w>
re sec
re produc
re patri
re mun
re marks</w>
re form
re distribution</w>
re bound</w>
re assessed</w>
re ar</w>
re act.</w>
re '</w>
raz ole</w>
rare ’,</w>
rap e</w>
ra is
ra d</w>
r- h
r ine,</w>
r ice</w>
r ack
question :</w>
qu it
qu id</w>
qu eu
qu ad
pyr rolidone</w>
pyr imidine</w>
pupp ies</w>
pup s</w>
punish ment</w>
punc tate</w>
pun ished</w>
pum p.</w>
protec ting</w>
propag ation</w>
promo ted</w>
progres s,</w>
programm ing</w>
produc tivity</w>
pro ver
pro ton</w>
pro st</w>
pro long</w>
privileg ed</w>
prev ail
predic t</w>
precur sors</w>
pre- dispen
pre mium</w>
pre mat
pre disposed</w>
pover ty,</w>
poten sion,</w>
pot ato
post s,</w>
post -</w>
port al</w>
poo rest</w>
polyox yl</w>
poly posis</w>
polici es,</w>
polic y,</w>
polic em
polic e,</w>
poli tics</w>
pol ye
poison ed</w>
pofung in</w>
plic ity</w>
ple uro
platelet s).</w>
plan t,</w>
placebo /dexamethasone</w>
pl ants.</w>
pin ching</w>
pil ot
pig mentation</w>
philosoph y</w>
phenylbuty rate</w>
pharyng olaryngeal</w>
pharyng itis,</w>
pharmacovigil ance,</w>
ph ob
ph ases</w>
pestic ides,</w>
person ally</w>
percep tion</w>
per su
per secuted</w>
per mits</w>
per mission</w>
per fus
peg filgrastim
peg aptanib</w>
pe techi
past a).</w>
passeng ers,</w>
particul ates</w>
part y.</w>
paren ts,</w>
parame ter</w>
par vovirus</w>
par ts.</w>
par os
par king</w>
par ate</w>
par alysis,</w>
par alle
paralle l</w>
par all
papillo edema,</w>
pancyt openia</w>
pancre as</w>
palpit ations</w>
pal m</w>
paediatr ician</w>
paed ophil
p ock
p neumococcal</w>
p lo
p icked</w>
ozol omide</w>
oxy butynin</w>
own er</w>
over whel
over weight.</w>
over doses</w>
ov sk
ov ,</w>
outcom e.</w>
out weighs</w>
out weigh</w>
out standing</w>
ough t,</w>
ou tw
ou ts</w>
ou red.</w>
ou l</w>
other ?</w>
osi a</w>
os es</w>
os cler
oro c
origin ating</w>
ori ented</w>
organis ed.</w>
organis ations,</w>
ore m
orem ifene</w>
or s'</w>
or al,</w>
optim ised</w>
opo Target</w>
opin ion.</w>
opi oid
ophy l
ophthalm ologic</w>
oper ation?</w>
oper ates</w>
open ed.</w>
op ted</w>
op sia,</w>
op positional</w>
op position,</w>
op pos
op lastic</w>
ooz ing</w>
once -
onc e,</w>
on wards</w>
on ucle
on t
on gue</w>
omyc osis</w>
omyc in,</w>
om y</w>
om es</w>
olu tion:</w>
ol ac
olac rimal</w>
ol a
ol -
oglob inuria</w>
og rodzka</w>
og ,</w>
offic er</w>
off ering</w>
oesophag iti
ocobal amin</w>
och ond
oce an.</w>
oc ile</w>
oc ean</w>
oc cult</w>
oc al</w>
obstac les</w>
o to</w>
o ster
o let</w>
o be
nur sery</w>
not es.</w>
not e,</w>
nor th-
non- union</w>
non- hormonal</w>
non- enveloped</w>
no table</w>
no ,</w>
new- born</w>
neuropath y*</w>
nephropath y,</w>
nephro toxic</w>
need le,</w>
nec ro
ne uron
ne ar
nat ure,</w>
nM ,</w>
n ˚</w>
n ing
n ia
n a,</w>
myelo suppression</w>
myelo suppres
myel oid</w>
mut ations</w>
mus e
multin ation
multi ply</w>
multi plicity</w>
multi ple
mu ch,</w>
mountain s</w>
motor cycle</w>
motiv ated</w>
mor ning,</w>
monteluk ast.</w>
monoph osphate</w>
mono therapy.</w>
mon um
mom ent
molec ular</w>
moist ure.</w>
mod est</w>
mo roctocog</w>
mm 3)</w>
mis sing.</w>
mis sil
mis led</w>
minim ising</w>
mini ster</w>
min us</w>
min i</w>
mil len
migra ine,</w>
mid azolam</w>
micro tubules</w>
mg/kg/ day</w>
mg ”.</w>
mg /1
method s,</w>
method ology</w>
metabol isers</w>
menstr u
menorrha gia,</w>
mening ococcal</w>
men tions</w>
membran es.</w>
mel phal
mel an
meet ings.</w>
meet ing.</w>
medicin es)</w>
medicin es
medicin e
medi um.</w>
mechan ism.</w>
meas les</w>
me tro
me ter
me l</w>
mb H</w>
mat ter
market ing.</w>
manag ing</w>
man y,</w>
mammal ian</w>
mal aria</w>
mal ari
maiz e,</w>
maintain s</w>
maintain ed.</w>
mail @emea.</w>
mag ne
mag lob
maglob ulin
ma il.</w>
m ighty</w>
lyophil ised</w>
lutein ising</w>
lup us</w>
local ised</w>
loc k.</w>
lob by</w>
lo o</w>
list ing</w>
lin es,</w>
lic ences</w>
libr ary</w>
li x,</w>
lenalidomide /dexamethasone</w>
lef t,</w>
lear n,</w>
le flun
le )</w>
le '</w>
laun ch</w>
lat e-
lat ch</w>
larg e,</w>
lansopraz ole.</w>
land s.</w>
land fill
lam in
lad es
lact am
lac tic
lab el.</w>
la p</w>
l ou
l er,</w>
l ate.</w>
l P</w>
l /
knowledg e.</w>
know -
ke e
k ing
k ey
k es,</w>
job s,</w>
job .</w>
j aculation</w>
iv udine</w>
ity- based</w>
ity '.</w>
ithromyc in,</w>
it é</w>
it tle</w>
it ting</w>
it an</w>
issu e?</w>
isol ation</w>
is s</w>
is pan
is n't</w>
is k
is e
irin otec
ir s,</w>
ir responsib
ir re
ir a,</w>
investig ator</w>
inv ited</w>
intracran ial</w>
intra ocular</w>
intest ine</w>
intest ine.</w>
intest ine,</w>
intest in
interven tions</w>
interven e</w>
intermedi ate</w>
interest .</w>
inter nation
inter leukin
intellig ence</w>
integr al</w>
insuffici ency,</w>
institu tions,</w>
install ed</w>
inst ance.</w>
insec t</w>
injuri es,</w>
initi ative?</w>
inhibit or,</w>
inhe rent</w>
ingredi ents.</w>
ing er</w>
infus ions.</w>
infus ion,</w>
inflixim ab.</w>
inflam ed</w>
infarc tion</w>
ine phr
ine ffici
industri alised</w>
independ ently</w>
increas ing.</w>
incorpor ated</w>
in yl
in visible</w>
in qui
in put
in na</w>
in formed.</w>
in en</w>
in emia</w>
in em
in disput
in diges
in dex.</w>
in consist
in capable</w>
in appropriate.</w>
in -</w>
imprison ment</w>
imp act,</w>
immunoglob ulin
im printed</w>
im parti
im bal
illu str
ill um
ill a</w>
ill :</w>
ik e.</w>
igu el</w>
ign ed</w>
igh t
ific ation.</w>
idov udine</w>
idog rel
id os</w>
id h</w>
id es;</w>
icy cle</w>
ic op
ic it</w>
ic in,</w>
ib ri
ib af
ia :</w>
i re.</w>
i en
i -
hypo es
hyper triglycerid
hyper hid
hyper aesthesia,</w>
hyp no
hydrox ylation</w>
hydrox ylated</w>
human ised</w>
howe ver
hot ,</w>
hospit als.</w>
hor ror</w>
hol e</w>
hol ding.</w>
ho arsen
hil ard
hilard otti</w>
high -fat</w>
hic s</w>
hibi tions</w>
hi de?</w>
herpetic um
her ds</w>
hel icop
heartbe at</w>
hear ing.</w>
hear ing,</w>
hear d,</w>
health y,</w>
head ed</w>
head .</w>
he ts</w>
he ade
hav n</w>
har den
hand s,</w>
hand ling,</w>
hand ful</w>
ham mad</w>
hallucin ations,</w>
half- lives</w>
hal ves.</w>
haemat ological</w>
haemarthro ses,</w>
h ire</w>
h Eor
guil ty</w>
guar dian</w>
grow ing.</w>
grant ed,</w>
gra ve</w>
gr at
govern ment,</w>
gover is</w>
gol den</w>
go ?</w>
glyc os
glyc ogen
glutam ate</w>
glucuron ide</w>
glucuron idation.</w>
glob ulin</w>
glo ves,</w>
gli a</w>
gl os
gi form</w>
gest ational</w>
gem fibrozil</w>
gadover setamide</w>
gadol inium</w>
g ing
g il
g ation</w>
g amma-
furnit ure</w>
fur ther.</w>
fron ti
fro m.</w>
fre ed</w>
fraud .</w>
fragil e)</w>
frag ment
fr anc
fos car
forecast s</w>
forecast s,</w>
for um</w>
for t
follow ed.</w>
foam ing.</w>
fluor ide</w>
flex ible,</w>
flavour ings</w>
fl ying</w>
fl ud
fl am
fix ed-dose</w>
first ly,</w>
fir st.</w>
fir ms</w>
fin ish</w>
fil ter.</w>
fiel ds,</w>
fibrill ation</w>
fi res,</w>
fertil isation</w>
fertil is
feedingstuff s</w>
feas ibility</w>
fe et,</w>
faul t</w>
fat alities</w>
fat .</w>
fast ed</w>
fan atic
fail ed.</w>
faec al</w>
facilit ating</w>
fab ric
fa x</w>
fa thers</w>
fa ther
f righ
f et
f ers</w>
f asc
f ar,</w>
ey es
extr ap
explo sive</w>
expendit ure.</w>
expan sion</w>
exp ul
exp anded</w>
exhib ited</w>
exemp tion</w>
execu ted</w>
excep tion.</w>
exce e
exacer bate</w>
ex propri
ex plic
ex av
evid ence.</w>
evi c</w>
every where,</w>
every one.</w>
event u
ev acu
euro .</w>
euph or
eu r</w>
eth yl</w>
etc .)</w>
etan ercept</w>
est a</w>
es p.</w>
es k
erythropoie tic</w>
erythro id</w>
erythemat ous</w>
eric s</w>
er s:</w>
er ol</w>
er ing,</w>
ep tin</w>
ep razole</w>
ep inephr
enzy l</w>
entrepre neur
entit le
entail s</w>
entac apone</w>
ent ;</w>
ent )</w>
ensu res</w>
enrich ment</w>
eng agement</w>
enforc ement.</w>
energ e
endothel ial</w>
end ants</w>
enc ing</w>
enc es.</w>
enc ap
encap sul
en ess,</w>
en al
enal ap
en a</w>
employe es,</w>
emphas ised</w>
emis sions.</w>
emis sions,</w>
ement '</w>
em it</w>
em in
em ic</w>
em esis,</w>
em .</w>
ell o</w>
ell i</w>
elimin ated.</w>
electro magnetic</w>
electro cardi
elder ly.</w>
el led.</w>
el eph
ejacul ation,</w>
eigh teen</w>
ei ther,</w>
eg o</w>
eg ation</w>
efflu x</w>
eff or
ef .</w>
eder schiöld</w>
ed e</w>
econom ically</w>
ec tomy</w>
ear ned</w>
e o</w>
e aten</w>
dubi ous</w>
du plication</w>
du m</w>
dra wing</w>
dra in</w>
dr yn
dr on
dox azosin</w>
doubt edly</w>
double- blin
doub t,</w>
dossi er</w>
dop ing</w>
dop a</w>
dog 's</w>
docum ents,</w>
divi ded.</w>
diver g
diuretic s:</w>
diure tic</w>
distrib uting</w>
dissemin ated</w>
disrup ting</w>
dispos al.</w>
displac ed</w>
disast er,</w>
dis til
dis orient
dis advantages</w>
din bur
diges tive</w>
difficul ties.</w>
dic tability</w>
dic ation</w>
diagnos is,</w>
di str
di re</w>
di et,</w>
di d,</w>
dex ,</w>
deterior ation.</w>
destroy ed.</w>
desir able,</w>
des pair</w>
dermati tis</w>
deriv ative</w>
der :</w>
depos its</w>
depos its.</w>
depend ency</w>
dep lo
den y</w>
demonstr ation</w>
demonstr ated.</w>
democrac y.</w>
dem anding</w>
dem anded</w>
dem and
deleg ation</w>
delavir d
degrad es</w>
defici ency,</w>
defici ency
defer iprone</w>
defec t,</w>
decarbox ylase</w>
dec ide
dec ep
debilit ated</w>
de void</w>
de methyl
de d;</w>
days ).</w>
day ;</w>
day ).</w>
dark er</w>
dan az
d read
d odec
d ings,</w>
d ell</w>
d al
d ).</w>
cyl in
cy cles.</w>
cust ody</w>
cul ture.</w>
cruci al.</w>
cru el</w>
criteri a.</w>
cri me.</w>
credi bility</w>
creatin ine.</w>
cre atine</w>
cre ated.</w>
cre am.</w>
cr y.</w>
cr aft</w>
countri es?</w>
coun ting</w>
coun c
cou mar
corticosteroid s,</w>
cortico steroid</w>
corpor ate</w>
cor rid
cor n</w>
coplas ma</w>
cop per</w>
cool ing</w>
conver ts</w>
control ,</w>
control )</w>
contracep tion,</w>
contrac tions</w>
contrac ted</w>
contr ary,</w>
contemp t</w>
contain er:</w>
contain er.</w>
cont ents.</w>
consum er,</w>
consum ed</w>
consider ations</w>
consci ousness</w>
cons ent.</w>
conjug ated</w>
conce ived</w>
conce al</w>
con stitutes</w>
con dom
compu ters</w>
comprimé s/</w>
complic ation</w>
comple tion</w>
comple ting</w>
complain ing</w>
comp rised</w>
comp as
common ,</w>
com ment
com bus
colour s</w>
collec ted.</w>
collap sed</w>
col lo
co virus</w>
co ok
co hor
co ff
co agu
coagu lo
clud es</w>
clop idogrel
clo thing.</w>
clim atic</w>
cleare r</w>
clean ed</w>
classi fication</w>
class ical</w>
cl ause</w>
civil isation.</w>
citizen s,</w>
citiz en,</w>
cirrh osis)</w>
circ u
cig ar
ci profloxac
chro mium</w>
cholestyr amine</w>
chocol ate</w>
child bearing</w>
chi p</w>
charg ing</w>
chap ter</w>
chang e
cha in,</w>
ch t</w>
ch ief</w>
ch i</w>
ch et</w>
cerebro spinal</w>
cent res,</w>
cell s/</w>
ceftriax one</w>
ce real</w>
cau tioned</w>
catastroph ic</w>
cat onin</w>
cat ch
case- by-
cas e?</w>
carm ellose</w>
cardiovascul ar,</w>
card board</w>
car to
car inic</w>
car ing</w>
capsu le.</w>
cal ories</w>
cal or
ca reg
c ystic</w>
c ogen
c lock</w>
c lip
c G
budget .</w>
budget ,</w>
bu ys</w>
bu ying</w>
bu ff
broad ca
bri ef</w>
breast -fed</w>
break through</w>
break through
break fast</w>
box es</w>
bow els</w>
bott len
bot ulinum</w>
borrow ers</w>
border .</w>
bom bs</w>
bodi es.</w>
boar d,</w>
block ade
blister s,</w>
ble ed</w>
black ,</w>
bl ank
bir th,</w>
bir th
bir ds,</w>
bir d</w>
bios ynthes
biom ass</w>
bioc idal</w>
bin ders</w>
bin .</w>
beta- blocker</w>
beta ine</w>
beta *.</w>
benef ited</w>
bel ge</w>
beg ins</w>
before hand.</w>
be fore,</w>
be ating</w>
bas ically</w>
bar rel</w>
bag .</w>
bag ,</w>
bacter aemia</w>
b uses</w>
b und
b lowing</w>
b ivalirudin</w>
b ing,</w>
b an.</w>
b :</w>
awa re,</w>
avo ide
avir /
autom ated</w>
author ity.</w>
aut y</w>
attack ),</w>
att end
ator vastatin</w>
ator i
atis ation</w>
ation *</w>
aticall y,</w>
ati sed</w>
atax ia,</w>
at z
at titu
at tained</w>
at opic</w>
at lantic</w>
at ard)</w>
asym metric</w>
asthen ia</w>
asth ma.</w>
ast om
assu red</w>
assemb led</w>
ash ing
ash es,</w>
asep tic</w>
asbe st
as sume</w>
as is.</w>
as il
art ate</w>
arrhyth mi
arm y.</w>
arg ue</w>
arch iving</w>
arch ipel
arc in
ar is</w>
appro ve</w>
appoint ments</w>
applic ants</w>
appl es</w>
appear ing</w>
ap ple</w>
antimic ro
antigen ic</w>
anticoagul ant</w>
anticoagul ant
anti- allergic</w>
anti rheumatic</w>
antagon ists,</w>
ant us</w>
answe red.</w>
ani ,</w>
and- a-half</w>
and ro
anc e:</w>
anaphy lactic
an z
an them</w>
an s?</w>
an onym
an num
an no
an ing</w>
an e.</w>
an -M
amnes ia,</w>
amend ments.</w>
amant adine,</w>
am mon
am ines</w>
am ide.</w>
am )</w>
all !</w>
alis ation,</w>
ali en
alcohol :</w>
alcaem ia</w>
al ive.</w>
al ition</w>
al ists,</w>
al imumab</w>
al ga
al ent</w>
ak in
ak i</w>
aircraf t.</w>
air ports</w>
ain e,</w>
aggres sion</w>
ag inal</w>
ag her</w>
ag ed.</w>
affec ted,</w>
afen ib</w>
af iel
aeti ology</w>
aes ia,</w>
aer os
adren ergic</w>
adjustment ),</w>
adjunc t</w>
adhes iv
aden omatous</w>
addic tion</w>
adap ter.</w>
ad mir
ad ed</w>
act u
acquis ition</w>
aclopri d</w>
acid osis.</w>
achiev ements</w>
ach no
acet am
accord ingly</w>
acchar idosis</w>
acc ess,</w>
ac tion:</w>
ac resol
absur d</w>
absor ber</w>
abnorm al,</w>
abec tedin</w>
ab str
a warded</w>
a h
____________________ _</w>
Zimbab we</w>
Ze al
ZO ST
ZOST AVA
Z idovudine</w>
Z ar
Z Y
Z A
Y oun
X AC
XAC IN</w>
Wilson ”</w>
Wh ite
We ar</w>
Water loo</w>
WHO ,</w>
W o
W ij
W ay</w>
W ashing
W V
WV 16
Vol ib
Vis ud
Vien na</w>
Vi ol
Ven lafaxine</w>
Vacc ine</w>
VIRAMUN E</w>
VII a</w>
VI ,</w>
VE TERI
VETERI N
VETERIN AR
VETERINAR Y</w>
VE L
VAT E,</w>
VA X
VA T</w>
V a
V TE
V IT</w>
V III
V II,</w>
V ATE</w>
V .,</w>
Usu al</w>
Un screw</w>
Un der
UTE R</w>
U C</w>
Tél /</w>
Ty verb</w>
Tur ner</w>
Tues day</w>
Tues day:</w>
Tri est
Tre ati
Tract ocile</w>
Tr ade</w>
Tr abectedin</w>
Toler ance</w>
Thrombo embolism</w>
Thromb ocyt
Th en,</w>
Tev a.</w>
Telec ommunic
Tas mar</w>
Tan dem
TYSA BRI</w>
TMZ ,</w>
TE X
TE R</w>
TE C</w>
TA IN
TA C</w>
T s
T oremifene</w>
T opoTarget</w>
T est</w>
T Y</w>
T C</w>
Sw elling</w>
Sug ar</w>
Sudden ly,</w>
Subsequ ently,</w>
Subsequ ent</w>
Su fficient</w>
Stat us</w>
Star t</w>
St ocks</w>
Sorbit an</w>
Sm all</w>
Sit tings</w>
Sing le-
Simp li
Ser otype</w>
Ser bs</w>
Sept ember,</w>
Sell afiel
Seiz ures</w>
Sec tor</w>
Scot tish</w>
Scot land</w>
Scandin avian</w>
Sant a</w>
Sandw ich,</w>
San it
Sal mon</w>
SU L
SP C,</w>
SP A</w>
SOL VIT</w>
SO MA
SOMA VER
SA IN
S é
S timul
S omal
S co
S ave</w>
S at
S WE
S SE
S C</w>
RotaTe q</w>
Rot ter
Rel eased</w>
Reg im
Recon stituted</w>
Rec ept
Re ver
Re stric
Re flud
RO )</w>
RG 24</w>
REFERR AL</w>
RE V</w>
R é
R od
R oc
R ating</w>
R S
R C</w>
Quixid ar</w>
Quint a</w>
Qu ite</w>
Q Tc
Pé rez</w>
Protop ic</w>
Pre dictability</w>
Post bus</w>
Portugu ese</w>
Portug al.</w>
Phys ician</w>
Ph aryng
Per s
Per goveris</w>
Peg aptanib</w>
Pat ri
Pas eo</w>
Paragrap h</w>
Par ticul
Par is.</w>
Pa ren
PV C/</w>
PROTE LO
PROTELO S</w>
PROF LO
PROFLO XACIN</w>
PRI E
PRIE ST</w>
PR O</w>
PI s.</w>
PA TI
P lavi
P ere
P au
P ancyt
P ain</w>
Ox idase</w>
Over all</w>
Organ on</w>
Onsen al</w>
Off -
Off- white</w>
OS CE</w>
OP INI
OPINI ON</w>
O t
O S</w>
O ME
Ny comed</w>
Nucle oside</w>
Now ogrodzka</w>
Novi ana</w>
Nor way.</w>
Nor dic</w>
Nor d</w>
No -one</w>
Neverthel ess</w>
Neutro pen
Need le-
Ne upop
Ne ph
Na ïve</w>
NEVAN AC</w>
NECES SAR
N on
N ik
N asal</w>
N ames</w>
N T
N I
N C</w>
N =
Mü l
Myoc et</w>
Mus culo
Mor tality</w>
Mon tene
Mon san
Mix 25,</w>
Milos evic</w>
Mid dle</w>
Mic hel
Medi a</w>
Mas ivet</w>
Mark et</w>
Mann itol</w>
Man uel</w>
Mal ta,</w>
Mag netic</w>
MR F
ME T
MD S/</w>
MAN AG
MANAG EMENT</w>
MAC EU
MACEU TIC
M yl
M um
M ucopolys
M iguel</w>
M ess
M en</w>
M e</w>
M S)</w>
M RI
M ON</w>
M Cy
M ,</w>
Lys od
Los s</w>
Long- Term</w>
Liv ens
Le ban
Le ar
LI M</w>
LA BE
L or
L ip
L ight</w>
L ef
L ater</w>
L ar
L antus</w>
L angu
L ane,</w>
L act
L S</w>
L ING</w>
L H</w>
Kosov o</w>
Kno dell</w>
Kingdom ,</w>
Kar ad
K ore
K oh
K h
K ay</w>
K are
K R
K L
John ’s</w>
Je ws</w>
Je an-M
JAN SSE
J us
J acqu
Is lam</w>
Inter nal</w>
Inovel on</w>
Influ enza</w>
Indi an</w>
Inc idence</w>
In st
In c.</w>
Immuno suppressants</w>
Im proved</w>
Im plementation</w>
Im pa
Ig E</w>
IV ).</w>
IM MEDI
II I.</w>
I gn
Hypo glycaemia</w>
Hy potension,</w>
Herc eptin</w>
Hel m
Heal th.</w>
Har rison</w>
Haem at
HIV- 2</w>
HCV .</w>
HA Q</w>
H ughes</w>
H ud
H op
H on
H it
H ence,</w>
H an
H 2
Guid ance</w>
Gly c
Gi useppe</w>
German ,</w>
Geor gi
Gar nier</w>
Galile o</w>
GM O</w>
GM O
G-CS F</w>
G or
G od
G hilardotti</w>
G ently</w>
G arg
G T
G I</w>
G G
Fun d</w>
Fri day:</w>
Fren ch.</w>
Fren ch,</w>
Franc o</w>
For cal
Fis kers</w>
Finland .
Finland. tuoteinfo@gsk.com</w>
Fin land.</w>
Fern ando</w>
Fer ripro
FAB LY
FA P</w>
F unc
F lor
F ish
F at
F ar</w>
F P
Ex tre
Europe ?</w>
Europe '</w>
Europe !</w>
Euro pol</w>
Espa ña</w>
Eri ka</w>
Er lotinib</w>
Engl ish
Energ y</w>
End ogenous</w>
En tacapone</w>
Emil -
El les</w>
Effentor a.</w>
EU/1/08/465 /0
EU/1/08/464 /0
EPAR s</w>
EMEA /</w>
EMEA ,</w>
EE C</w>
EC B</w>
E stim
E specially</w>
E rit
E rectile</w>
E jaculation</w>
E ffici
E dinbur
E arly</w>
E ar
E P</w>
Dé fen
Dysp noea</w>
Dy b
Dres den</w>
Dizz iness,</w>
Dis eases</w>
Director -
Director- General</w>
Del egation</w>
Decre ased</w>
Decre ase</w>
De pression</w>
D ist
D ell'
D ef
D al
D af
D a
D S</w>
D RA
D D</w>
D A</w>
Cur ren
Cub an</w>
Cri xivan</w>
Creutzfel d
Creat inine</w>
Contrac ts</w>
Contr ast</w>
Consider ation</w>
Con nec
Con gres
Compon ent</w>
Committe e.</w>
Combin ed</w>
Co zaar</w>
Co x</w>
Co sta</w>
Co operation</w>
Clin ically</w>
Clear ly,</w>
Circumst anc
Circ adin</w>
Child ren
Char les</w>
Chap ter</w>
Cha ussée</w>
Ch es
Cer ivastatin</w>
Cent ral</w>
Cap sules</w>
CYP2C 9
CP 97
CO MP</w>
CN V</w>
CI PROFLOXACIN</w>
CI BIC
CIBIC -
CD 4
CD4 +</w>
C ustoms</w>
C ul
C ry
C ou
C ell
C ederschiöld</w>
C K</w>
C FC
C F
C B
Bus il
Buddh ist</w>
Bou levard</w>
Boe ing</w>
Betafer on
Beta -
Belgi qu
Baron ess</w>
Barac lude</w>
Bang lades
Bachel or</w>
BSE .</w>
B ov
B in
B enzyl</w>
B ay</w>
B ad</w>
B P
Av da.</w>
Aug ust
Au jes
Asp artate</w>
Asi an</w>
Ari x
Aran esp.</w>
Ar zneimit
Ar thral
Ar ter
Ar co
Anti body</w>
Ann ual</w>
Alzheimer ´s</w>
Alopec ia,</w>
Al im
Al -
Ag ustín</w>
Ag omelatine</w>
Ag ency,</w>
Ag ence</w>
Afric a,</w>
Affair s</w>
Ad vocate</w>
Ad alimumab</w>
Acl ast
Ac tivity</w>
Ac qu
AUTHORISATION /</w>
AU C.</w>
AD VATE</w>
AD VATE,</w>
AD AS
AC -052-
A tor
A straZen
A h
A 6,</w>
A )</w>
> .</w>
90 %.</w>
9. 5</w>
9 9/</w>
9 /2000)</w>
87 50</w>
86/ PB</w>
8. 3%</w>
8 70</w>
8 6%</w>
8 5%</w>
8 2%</w>
70 -
7. 5%</w>
7 9,</w>
7 75</w>
7 30</w>
60 3</w>
6. 6</w>
6 3%</w>
6 3
6 -</w>
5. 1</w>
5. 0%</w>
5-AL A</w>
5 5,</w>
5 5%</w>
5 3%</w>
5 3
5 000</w>
4/ 27
4/27 9/0
4. 5%</w>
4. 0</w>
4- pack)</w>
4 th</w>
4 5-
4 5%</w>
4 00/</w>
4 /97)</w>
4 /2001)</w>
3A A</w>
38 7/</w>
38 .
36 4000</w>
34 4/</w>
34 %</w>
3. 75</w>
3- month</w>
3 17</w>
3 -</w>
27 5</w>
25 .</w>
24 .</w>
200 9)</w>
20 58</w>
20 50.</w>
20 31</w>
20 15</w>
20 11</w>
2. 3%</w>
2 60</w>
2 45</w>
2 4%</w>
2 3%</w>
2 1,</w>
2 /97)</w>
2 ,000</w>
199 9,</w>
199 4-
198 9</w>
19 80</w>
19 %</w>
18 1</w>
18 /</w>
17 2</w>
16 6</w>
150 3</w>
15 .</w>
14 9</w>
14 0
13 /</w>
13 )</w>
12 6</w>
12 1</w>
10 3.5</w>
1. 75</w>
1. 2%</w>
1- 9
1- 3</w>
1,0 71</w>
1 ;</w>
1 19
1 17
1 15
1 14</w>
1 135</w>
1 /2000)</w>
020 80)</w>
02 -</w>
0. 8%</w>
0. 75</w>
0. 50</w>
0. 4%</w>
0. 3%),</w>
0 ,5</w>
/200 1</w>
/ RENEWAL</w>
................................................................ ........................
................................ ........................
. org/
-1 9</w>
-1 .</w>
---------------------------------------------------------------------------------------------------------------- --------
------------ -</w>
-- -
- style</w>
- of-
- line</w>
- dependent</w>
- Strauss</w>
- Strasse</w>
- 7
, 1</w>
, ,</w>
+48 (0)
+48(0) 22</w>
+35 8</w>
* *
(v CP97
(un boosted</w>
(abdom en
(S weden)</w>
(S D</w>
(P 02080)</w>
(N L)</w>
(MM SE</w>
(B )</w>
(AL T</w>
(A5-0 39
(A5-0 27
(A4-0 40
(A4-0 34
(A4-0 20
(A4-0 10
(A CE
(5 7%)</w>
(22 %)</w>
(1,000 /</w>
(1 -</w>
(0) 810</w>
(0) 69</w>
(- )</w>
(* )</w>
( viral</w>
( valsartan
( pulmonary</w>
( p=0.00
( baseline</w>
( antibiotic
( an</w>
( affects</w>
( RO)</w>
( LD
( IU/</w>
( GIST
( 27
( 199
' un
' of</w>
' a</w>
' If</w>
% ?</w>
≤ 1</w>
…………………… …</w>
‘ no
ύ πρ
σ ί
Κ ύπρ
ī ba</w>
ā vniec
āvniec ība</w>
ā rst
ārst āvniecība</w>
ú pa</w>
ø ben
øben havn</w>
í os</w>
ë /</w>
é n</w>
æ r</w>
° C,</w>
} .</w>
zz le</w>
z ol
z ide</w>
z ar
yt trium</w>
yr gy
young sters</w>
youn g,</w>
yn e</w>
yl ribitol</w>
yiel ded</w>
yeth yl
yel oneph
year- olds</w>
year s’</w>
year s:</w>
year ly</w>
y og
y o</w>
y ar
xim e</w>
x x
wro te</w>
woun d,</w>
work force</w>
women ’s</w>
woh l</w>
with held</w>
wip ing</w>
windo ws</w>
windo w,</w>
will :</w>
widespre ad.</w>
who oping</w>
who le.</w>
wheez ing,</w>
welcom ed.</w>
welcom e.</w>
weight- bearing</w>
weap on
weaken ed)</w>
we stern</w>
we re.</w>
we ,</w>
wat ering</w>
wast ed</w>
wash out</w>
warrant ed.</w>
warr ant</w>
war d.</w>
want ?</w>
wa it
wa ist.</w>
w z
w ould,</w>
w ished</w>
w all,</w>
w ag
w ?</w>
voc ab
vocab ul
vit rel
vitrel le</w>
vis ited</w>
virus ).</w>
vir als</w>
vigorous ly</w>
vic tory</w>
vic tor
vess els,</w>
ver -
vast atin
vari ants</w>
varenic line</w>
vag initis,</w>
vac izumab</w>
v s.</w>
v ing.</w>
v ap
utr amine</w>
uth en
ut op
ut most</w>
ut ed,</w>
ut ,</w>
ust ular</w>
us es.</w>
us e)</w>
us age</w>
us able</w>
us )</w>
us ),</w>
urtic arial</w>
urtic aria,</w>
uro xime</w>
uri l</w>
urg ently</w>
ure mber
urember g</w>
ur ge</w>
ur g</w>
up take,</w>
univer sities</w>
unfortun ately,</w>
under taking</w>
under min
under ground</w>
un tenable.</w>
un t
un resec
unresec table</w>
un related</w>
un realis
un preced
un loading</w>
un ified</w>
un healthy</w>
un equ
un doubtedly</w>
un detectable</w>
un ch</w>
un aware</w>
un affected</w>
un acceptable,</w>
um bil
ultr avi
ultravi olet</w>
ulcer ation.</w>
ul ty</w>
ul tra-
ul monary</w>
ul i
ud ine-
uc k
uc c
ub ach</w>
u zz
u ve
u pro
u es</w>
u an</w>
turn out</w>
tunn els</w>
tumour .</w>
tum my
tulathromyc in.</w>
tubercul osis,</w>
tub ulo
tub ing,</w>
truth ,</w>
troublesom e,</w>
trou ble
trimethoprim .</w>
triglycer ides.</w>
trig g
tri es</w>
treatment- emergent</w>
treatment ).</w>
treat y,</w>
treat .</w>
tre mend
tre as
travel .</w>
traum a</w>
transplan t,</w>
transpa rency,</w>
transp osition</w>
transp os
transi ent,</w>
transfer .</w>
transf ers</w>
trans mit</w>
trans mission,</w>
trans genic</w>
tran eous</w>
tradi tion</w>
tra de.</w>
tra de
tr uly</w>
tr ick
tox oid
touris m</w>
tou rists</w>
tou ch,</w>
total itarian
tot y
tot al,</w>
tor tured</w>
tor is</w>
ton ic-
ton gu
toler ance,</w>
tol l</w>
toc il
to ys,</w>
tis ed</w>
tinnit us,</w>
tic s)</w>
tic oll
tic asone</w>
ti um</w>
ti f
thrombocytopen ic</w>
thrombocytopen ia.</w>
thrombin ,</w>
thro at,</w>
thresh ol
threat s</w>
thir d
thiazolidinedi ones,</w>
thes e.</w>
thereaf ter,</w>
there ?</w>
ther mal</w>
then burg.</w>
the or
th ymidine</w>
th oud
thoud t-
thoudt- Ro
thoudt-Ro wohl</w>
th ose,</w>
th ing!</w>
th ick</w>
th aesia,</w>
tex tiles</w>
tetan us,</w>
test ed.</w>
test ed,</w>
test )</w>
terrorist s,</w>
terroris m.</w>
terro r</w>
termin als</w>
teri par
ter a</w>
tenecte plas
tender ness,</w>
tend on</w>
ten sions</w>
telec ommunic
teen age</w>
technetium-99 m</w>
tax ed</w>
tax ation</w>
tartr ate</w>
tam per</w>
tal i
tach ograph</w>
tac tics</w>
ta -
ta- analysis</w>
t ude</w>
t su
tsu nam
t ford
t esti
t are</w>
t ant
t ang
syn th
sympathomime tics,</w>
sym metr
symmetr ical</w>
sy rup
sweeten ers</w>
sweet ened</w>
swallow ing.</w>
sw im</w>
sustain able.</w>
survi ving</w>
surve y,</w>
surroun ds</w>
suppres s</w>
suppli es.</w>
supplement ation</w>
supple ment</w>
superi or</w>
super markets</w>
super -
sun sh
sun light.</w>
sulph ate,</w>
sulfat ase</w>
sul fa
sul esom
suic ide.</w>
sucro se.</w>
suc k</w>
substanti ated</w>
subcutane ously.</w>
sub type</w>
su vastatin</w>
su ria</w>
su re,</w>
su pre
su pran
studi es)</w>
stres sed</w>
strengthen ed.</w>
streng th,</w>
stre ptococc
str aw
str at
sto m</w>
stic k.</w>
steroid s</w>
sten ol</w>
stell ung</w>
stell as</w>
stear ate,</w>
stat us,</w>
stat in,</w>
stand ,</w>
stake holders</w>
stag n
st um
st ub
st roph
st ovy
st ine</w>
st ating</w>
st ar</w>
spot s
spoonful )</w>
spon sors</w>
spon giform</w>
spon ge</w>
spir its</w>
specif ying</w>
special ists,</w>
sp ine,</w>
sp in
sp ic
sp ark
sp are:</w>
sovereign ty</w>
sor ry</w>
sor afenib</w>
solution s:</w>
sol es</w>
sodium -fre
socie ties.</w>
soci ety,</w>
so res
so on,</w>
so ?</w>
snee z
sn ack</w>
smok ing.</w>
sleep y,</w>
sleep ing</w>
sl udge</w>
sl av
ski ego</w>
skelet on</w>
sk y
sk im
sk ill
situ ations,</w>
situ ation?</w>
sion ate</w>
sinus itis</w>
simul taneously</w>
simple .</w>
simple ,</w>
similar ities</w>
sil litis,</w>
sil ica</w>
sil denaf
sid es.</w>
sid es,</w>
sib ly</w>
sib an</w>
si rolim
si fied</w>
short- acting</w>
sho es</w>
ship s.</w>
ship ?</w>
shi po
shipo wn
shel ves</w>
shel f-life</w>
sha ke</w>
sh ack
sett ing.</w>
set- aside</w>
session ,</w>
serious ;</w>
seri es.</w>
ser ological</w>
separ ately.</w>
sensi o</w>
sel eg
seleg il
sed ation,</w>
secrec y</w>
second- class</w>
sec uri
sec ure
seas on</w>
se es</w>
se at
se a
scrutin y</w>
scru pul
score board</w>
scop e,</w>
sco op</w>
scl eral</w>
sci ence,</w>
scapego at</w>
scal y</w>
sc ar</w>
salmon ell
salbutam ol</w>
saf et
saf er</w>
sa y
s y,</w>
s wee
s lip</w>
s k</w>
s cour
s at</w>
s ak
s ain
rul ing</w>
ru le.</w>
rop ini
ro w.</w>
ro w,</w>
ro om
ro of</w>
ro of
ro le,</w>
ro l</w>
ris e.</w>
rip tions</w>
rip ped</w>
rim ation</w>
righ t
ric ular</w>
ric k</w>
ribos ylribitol</w>
ri x,</w>
ri m</w>
ri fic
ri es,</w>
ri ed,</w>
ri de,</w>
ri an</w>
retro grade</w>
resul t:</w>
restric tive</w>
restaur ants</w>
responsibil ities</w>
respon s
respectivel y;</w>
respectivel y).</w>
resolv ed,</w>
resid es</w>
resid ential</w>
resid ent</w>
reserv ation</w>
res cu
rer ,</w>
repor ts.</w>
repor t:</w>
repeti tion</w>
repe ated.</w>
renew al:</w>
renc e,</w>
remin der</w>
remark able</w>
reli es</w>
reli ability</w>
rel y.</w>
rel l
reimbur sed</w>
regular ly
regul ations.</w>
regul ated.</w>
regar d.</w>
reflec ts</w>
redund ant</w>
recycl ed</w>
recru it</w>
reconstitu tion,</w>
recommend ing</w>
recogn ize</w>
recogn iz
reci proc
recept or,</w>
receip t</w>
rec ording</w>
read ings</w>
re- data</w>
re views</w>
re vi
re vel
re vaccinated</w>
re ts</w>
re tali
re prehen
re ply.</w>
re osinophil
reosinophil ic</w>
re ments</w>
re med
re forms</w>
re forestation</w>
re assessment</w>
re aring</w>
re ared</w>
re ap</w>
re actor</w>
re a,</w>
rati o.</w>
rapporteur s</w>
ram s.</w>
radio therapy.</w>
radio iodine</w>
radi ation.</w>
rac es</w>
ra ises</w>
ra in.</w>
r d
r ant</w>
r amp
qui rements</w>
qualif ying</w>
qual ities.</w>
q .</w>
push -
pup il
pum p,</w>
publish ing</w>
publish ed.</w>
pt ospor
psych omotor</w>
proxim ity</w>
provis ion
provi ders</w>
prov inc
protoc ol</w>
propos ed,</w>
propos als?</w>
prophylax is.</w>
prop ter
promis ed</w>
prolong ation</w>
projec t.</w>
prohib it</w>
progres sively</w>
progres sion
progest ogen</w>
profit s.</w>
profit e
prof ound</w>
prof it.</w>
prof ession</w>
product s;</w>
produc ers,</w>
procedu res
problem s:</w>
pro ves</w>
pro toty
pro t
pro stenol</w>
pro lac
prolac tin</w>
pris ons</w>
prior ities?</w>
princi pl
pric es,</w>
pret ty</w>
pressu re-
pres ently</w>
prepar atory</w>
prepar ation,</w>
premi ums</w>
pregnanc ies.</w>
pre- treatment</w>
pre supposes</w>
pre sumed</w>
pre serve</w>
pre dn
pre dec
pre caution</w>
pot ency</w>
poster ior</w>
post- oper
port able</w>
por ph
porph yr
popul ation
pon atra
poly my
pollut er</w>
politic ian</w>
poison ing,</w>
po ker</w>
po ison</w>
pneumon itis
ple ural</w>
plac enta</w>
pl er</w>
pl ain</w>
pill ar</w>
pig s,</w>
pig meat</w>
pic k</w>
pi pe
phen ol,</w>
phas ing-
phas ic</w>
pharmaceutic als,</w>
pharmac y</w>
pharmac ology,</w>
ph one</w>
ph leb
ph en</w>
pet act</w>
person s.</w>
persec ution</w>
perpetr ators</w>
perpe tu
period ;</w>
perindop ril
per mis
per fum
per ce
pepti des</w>
pep tic</w>
pension ers</w>
penetr ation</w>
pendi x</w>
pen sions</w>
pen alise</w>
pel li
pec toris</w>
pe ts</w>
pe gn
pegn a</w>
pe at</w>
patient- years)</w>
pat ents</w>
passp or
pas sed,</w>
particip ated</w>
partic le</w>
parti cles,</w>
par ts,</w>
par k</w>
par aph
paraph rase</w>
pap er,</w>
pan itum
pan ic</w>
pan els</w>
palpit ations,</w>
pain kill
pack s,</w>
pac if
pac e.</w>
pa ys</w>
pa use</w>
p o</w>
p it</w>
oxid ative</w>
ox in</w>
own ers</w>
own ers,</w>
own ed</w>
overe d,</w>
over weight,</w>
over night</w>
over capacity</w>
over active</w>
ov á
ov is
ov an
outr age
out lined</w>
ous ?</w>
ous !</w>
our sel
our se</w>
ou tri
ou ri
ou red,</w>
ou los</w>
oty pic</w>
otox in</w>
ot te</w>
ot ech
os yl
os omal</w>
os ity</w>
origin ally</w>
org as
orb ital</w>
or um</w>
optim ism</w>
opo rosis</w>
opo ietic</w>
ophyl line</w>
oph ili
ophili ac
oper ations,</w>
oper ation
open ia.</w>
opa /</w>
op tion.</w>
op t</w>
op pression</w>
op pose</w>
op oulos</w>
op oe
one- off</w>
onaz ole
on- going</w>
on- board</w>
on ia</w>
on i</w>
on ermin</w>
omo dul
omen cl
ome ters</w>
omasti a,</w>
om eprazole</w>
om e.</w>
olys is,</w>
olog ist.</w>
olig os
ole dr
oledr onic</w>
ole ate</w>
old est</w>
olanzap ine.</w>
ol ution</w>
ol s.</w>
ol ip
ol ),</w>
ograph s</w>
ograp hy
og ram</w>
offici ally</w>
offic es.</w>
offic ers</w>
offic e.</w>
offic e,</w>
off ence.</w>
of ten.</w>
of ?</w>
oestro gens</w>
odi p
od ox</w>
od ds</w>
od )</w>
ocul ar,</w>
oclon ic</w>
ochond rial</w>
occur red,</w>
oc clus
oc arcin
objec tive.</w>
objec tive,</w>
ob ile</w>
o- biliary</w>
o wn.</w>
o ted</w>
o str
o qu
o ime
oime er</w>
o i</w>
o ate</w>
nur ses</w>
nur se,</w>
notic e
noti fied</w>
nos tic</w>
normaliz ed)</w>
non- blistered</w>
non- Q-
non- EU</w>
non sense.</w>
nom inated</w>
no where</w>
no thing.</w>
no ted.</w>
no dul
no d
nitro glycer
nigh t.</w>
nick el</w>
ng/ ml</w>
newspap ers</w>
new- onset</w>
neutrophil s,</w>
ness )</w>
negoti ation</w>
neg atively</w>
neg ative,</w>
necess it
ne w.</w>
ne po
nation al
na ubach</w>
n st</w>
n ith
n ia.</w>
n i</w>
n es</w>
n avi
n af
my oclonic</w>
my dri
mus carinic</w>
mur ders</w>
municip al</w>
multi ply.</w>
mul tiv
mul sion</w>
mu st.</w>
mu co
muco si
mountain s,</w>
mother s,</w>
more )</w>
mor ,</w>
month s;</w>
monopol y</w>
mono therapy,</w>
monitor ing.</w>
monitor ing,</w>
monito red,</w>
mon ome
mol lus
mollus c
modi fied.</w>
moder ation</w>
mo st,</w>
mo re?</w>
mo on</w>
mmol .</w>
mm 3</w>
mix ing.</w>
mistak e.</w>
mis sed,</w>
mis er
mirac le</w>
mini sters</w>
mini -
min ute
min /</w>
milli grams</w>
micrograms/ 0.5</w>
methyl -
methaem oglobin
metast ases</w>
metast ases.</w>
metaboliz ers</w>
met :</w>
mercur y,</w>
mel ting</w>
medi ators</w>
measure s?</w>
meas ur
me ter</w>
me ta-analysis</w>
me ga
me al,</w>
me !</w>
materi al,</w>
mat ched</w>
massac res</w>
marro w,</w>
market s,</w>
mark s,</w>
mark ,</w>
marg ins</w>
manufacturer .</w>
manife sted</w>
man ual.</w>
man ner
man -
mam m
malignanc ies,</w>
mal nutri
mal nourished</w>
mag ic</w>
macro lide</w>
machin es:</w>
m id</w>
m erger</w>
m L)</w>
lyophil ized</w>
lyophil is
lyophilis ate</w>
lymph omatous</w>
ly n
ly ;</w>
ly -</w>
lux ury</w>
lu gg
low ers</w>
long ?</w>
loc y
loc ation,</w>
loc ate</w>
lob b
liter ally</w>
link ed.</w>
lingu is
lim ycin</w>
lik es</w>
lik ened</w>
ligi ble</w>
light- heade
life time</w>
libr aries</w>
li pop
li ance</w>
levod op
leuk aemic</w>
leuk aemia,</w>
lett a</w>
letharg y</w>
less on</w>
leflun om
lef to
leav e,</w>
le te</w>
le e
le as
le aking</w>
le !</w>
last .</w>
las go
las er</w>
larg e-
langu age?</w>
langu age.</w>
langu age,</w>
lamin ate)</w>
lact ating</w>
l u</w>
l oud</w>
l ing)</w>
l ate,</w>
l ar</w>
l ),</w>
knowledg e,</w>
kj ær</w>
kin d
kilog rams</w>
kille d)</w>
kidnapp ed</w>
ketocon azole,</w>
ket ones</w>
kal aemia</w>
k m,</w>
k m
k ist
k a,</w>
justifi able</w>
judg ment</w>
judg es</w>
ju ice,</w>
journal ist,</w>
journ alist</w>
jour nal</w>
join ing</w>
jo in</w>
jeop ardis
jaundic e,</w>
j uris
j ung
j udge</w>
j k
j i</w>
j ams</w>
iver s</w>
itraconaz ole,</w>
it or</w>
isot ope</w>
isot op
isot onic</w>
island s,</w>
ish es</w>
isc al</w>
is ón</w>
is thoudt-Rowohl</w>
is s
is om
is ch</w>
irrit ability,</w>
ir rever
ir responsible</w>
ir bes
ion isation</w>
ion :</w>
invest ment
inver t</w>
inv al
intrav ascular</w>
intrav ascul
intrac ellul
intr insic</w>
intr ad
intrad er
intoler able.</w>
interven tion.</w>
interrup t</w>
inter view</w>
inter connec
int /</w>
instruc tions,</w>
inspec tors</w>
inop ril</w>
innov ation,</w>
inno c
inn ate</w>
injec ting</w>
inj ury.</w>
ing ly,</w>
ing est
ing en</w>
ing -up</w>
ing *</w>
ing 's</w>
infusion )</w>
influenz a-like</w>
inferi or</w>
infection ),</w>
ine- resistant</w>
indic ator
inde ed!</w>
incre di
incorpor ation</w>
incorpor ate</w>
incontin ence</w>
inc it
inc ision</w>
inadvert ently</w>
in- use</w>
in spir
in put</w>
in definit
in complete.</w>
in comes</w>
imprison ed</w>
important ?</w>
import ation</w>
impor ter</w>
implant ation.</w>
imperfec tions</w>
impair ment
impai red.</w>
imp ul
immunosuppres sants</w>
immuno genicity</w>
immigr ants.</w>
immigr ants,</w>
im plant</w>
im men
ill icit</w>
il y,</w>
il le,</w>
il ance</w>
igno red</w>
ign ore</w>
igh t.</w>
if :</w>
idur on
ide ation,</w>
ide ).</w>
id ron
id ated</w>
id -
icill in</w>
iceberg .</w>
ic e
ic c
ic ardi
ibu profen</w>
ib an</w>
i for
i et
i bi
i as</w>
hypovol aemic</w>
hypoglycaem ia)</w>
hypoes thesia,</w>
hypo gam
hypogam maglobulin
hypo .</w>
hypertriglycerid aemia</w>
hyper sensitivity,</w>
hyper calci
hyper aemia,</w>
hydroxy- ibaf
hydro chloro
hydrochloro thiaz
hy pos
hun t</w>
hun gr
hon our</w>
homocyste ine</w>
hom ologous</w>
hol ders.</w>
hof o</w>
ho w.</w>
ho w,</w>
histor y.</w>
his tidine</w>
high- density</w>
high light</w>
hi stop
hes it
hero in</w>
her bic
hepatoc ellular</w>
hec tare</w>
health y.</w>
headach e.</w>
he v
he pt
hat red</w>
hat red.</w>
harmon ised,</w>
harm ing</w>
harb our</w>
har bour
har an</w>
happen ing?</w>
happen ed.</w>
haemodi alys
haemat oma,</w>
ha st
ha ke</w>
h one
h ob
h ide</w>
h i</w>
h ell</w>
h ed
gy naec
gu ard
grow ers</w>
group s?</w>
group s:</w>
gre en.</w>
granul omat
granu locy
grant ed.</w>
grad ed</w>
gra vir</w>
gr ass
good s,</w>
glycaem ia,</w>
glu con
glucon e
glu co
glob alisation</w>
gli oma,</w>
gli mepiride</w>
glau coma</w>
gl es</w>
giv en,</w>
gi ant</w>
gh t,</w>
get ,</w>
gener alized</w>
gener 's</w>
gen ous</w>
gen es.</w>
gast ritis,</w>
gam ma</w>
gam es</w>
gain s</w>
gain ed.</w>
g ust
g us</w>
g ums,</w>
g st</w>
g rubb
g out
g old.</w>
g ing</w>
g ently,</w>
g e.</w>
g ame
fun d
ful ness</w>
ful filled</w>
fu il</w>
fru str
froz en.</w>
frequ ency,</w>
fre e-
fragr ances</w>
fr ame</w>
found ations</w>
foun d,</w>
forwar d,</w>
forth coming</w>
forgot ten.</w>
forest s</w>
forefing er.</w>
forec ast</w>
fore stry</w>
forc es.</w>
forc e,</w>
for -
footb all</w>
follow- up,</w>
fol d,</w>
fod der.</w>
fo x
fo am</w>
flu oxet
flo or.</w>
flo od</w>
flex ic
flag ,</w>
fl are</w>
fix ing</w>
fit ting</w>
fist ula</w>
fisher men,</w>
first -</w>
fir med</w>
film s,</w>
fill er</w>
fil tered</w>
fil es</w>
fil ed</w>
fig ures.</w>
fic ation.</w>
fer mentation</w>
feel ings</w>
fed eral</w>
fec tin</w>
fe w.</w>
fe et.</w>
fe es</w>
fe eds</w>
fe brile</w>
faul ty</w>
farm ing</w>
fail ures</w>
fail ing</w>
fact ors,</w>
fact .</w>
facil ities.</w>
f ran
f ought</w>
f on
f low.</w>
f lip
f law
f iscal</w>
f ice</w>
f armac
farmac ev
eyes ight</w>
eyel ashes</w>
extremis m</w>
extrap yramidal</w>
extrac tion</w>
extr ad
extinc tion</w>
exten sions</w>
ext ent,</w>
expres sion,</w>
explo sion</w>
experim ental</w>
experim ent</w>
experim ent
expendit ure,</w>
exp on
exp elled</w>
exha us
exerc is
exemp t</w>
exclu ded,</w>
excep tionally</w>
examin ations.</w>
exact ly?</w>
ex ports</w>
ex ist.</w>
ex -
evid ently</w>
evid ent.</w>
ever- increasing</w>
ev o</w>
ev a,</w>
euro -
euro ,</w>
etro reli
etoric oxib.</w>
ethan ol.</w>
eth yl
eth ov
et ta</w>
et t</w>
et ongue</w>
et gens</w>
est s</w>
est o</w>
ession al</w>
esopha geal</w>
es- Car
es-Car pegna</w>
es ’,</w>
es el
es e.</w>
es '
ero sion,</w>
erec tile</w>
eradic ate</w>
er tapenem</w>
er s
er o,</w>
er ic</w>
equ i
equ als</w>
epo prostenol</w>
epithel ium</w>
epiphys es.</w>
epinephr ine,</w>
ep tide</w>
ep ti
ep irudin</w>
enz a,</w>
enter o
entan il</w>
ent ery</w>
ent an.</w>
engine ering</w>
eng en</w>
eng aged</w>
end points.</w>
end ocardi
encephal opathy,</w>
encephal itis</w>
enab led</w>
en s.</w>
en force</w>
en ed,</w>
en comp
en ;</w>
employ ers</w>
emp ty,</w>
emp ire</w>
emin ent</w>
emerg es</w>
embry onic</w>
emb arg
embarg o</w>
em its</w>
em ak
em ,</w>
else where</w>
ell ing.</w>
elec tric
elec tions.</w>
elec tions,</w>
elec tion.</w>
elap se</w>
el ite</w>
el er
el abor
ei ther
ei j
eg ,</w>
effici ent,</w>
effici ency.</w>
effectiven ess,</w>
effec t
eff ort
ed y</w>
ed rine,</w>
ed ing,</w>
ed ).</w>
econom y,</w>
echocardi ography</w>
ech in
ec k</w>
ear s,</w>
ear ly-
e utroph
e j</w>
e *</w>
dys function
duloxet ine-treated</w>
du ty
du le</w>
du al</w>
dryn ess,</w>
drug -
drug ,</w>
drough t,</w>
drin k,</w>
dri ve,</w>
dri p
dri f
dream s,</w>
dre w</w>
draf ted</w>
dr y.</w>
dr y,</w>
dr un
doz ens</w>
double-blin d,</w>
doub ts</w>
dose- finding</w>
dose- dependent</w>
dos es).</w>
don ation</w>
don 't</w>
dom ain</w>
dollar s</w>
dodec a
doct ors.</w>
do or.</w>
do ing?</w>
dizz y</w>
dizz iness.</w>
diverticul itis</w>
disturb ing</w>
distribut or</w>
distrib ute</w>
distingu ished</w>
distinc tion</w>
distinc t</w>
dist ant</w>
dist ances.</w>
disper sion</w>
disper se</w>
dispen se</w>
diseas es:</w>
diseas e).</w>
discus sing</w>
discre p
discolor ation,</w>
discol oured.</w>
discharg es</w>
disc .</w>
disast er.</w>
disab led.</w>
dis cover
dis coloured</w>
diplop ia,</w>
diox ins</w>
ding ly,</w>
dilu tion.</w>
dihydro pyrimidine</w>
dign ity.</w>
difficul t,</w>
difference ?</w>
differenc e.</w>
differen tial</w>
diff ering</w>
dict ated</w>
diaz oxide</w>
diarrhoe a)</w>
di stric
di es,</w>
di chloro
di am
destin ed</w>
desper ately</w>
design ,</w>
descri ption</w>
des i
des ert</w>
dermati tis,</w>
der y
deploy ment</w>
depend ent.</w>
depend ence.</w>
democrac y!</w>
dementi a,</w>
deliver s</w>
deleg ations</w>
dele tion</w>
delay ed,</w>
del ta.</w>
dehydr ated,</w>
defini tions</w>
defin ing</w>
deficiency ).</w>
defec ts.</w>
defe at</w>
decom pens
decis ions,</w>
decibel s</w>
dec ided.</w>
dec ent</w>
dec ency</w>
dead .</w>
de generation</w>
de form
de flec
de als</w>
de )</w>
day time</w>
dat e?</w>
danaz ol.</w>
d ness</w>
d al</w>
cyste amine</w>
cycl am
cut .</w>
cut ,</w>
cur rency.</w>
cum ber
cryst all
crust ing,</w>
cru el
cros sed</w>
cros carmellose</w>
crop s.</w>
cris is?</w>
cre ative</w>
cre ates</w>
cre ated,</w>
cre at
cr af
cow s,</w>
cour t.</w>
cour t,</w>
coumar in</w>
cost s,</w>
correspon d
cor tex</w>
cor ner</w>
copies/ ml</w>
cop yright</w>
conven ient</w>
contracep tiv
contra- indicated</w>
contr ary</w>
continu ous.</w>
continu es.</w>
continu e.</w>
contex t,</w>
contamin ation,</w>
contain ers.</w>
contain ?</w>
contag ious</w>
cont em
consu med.</w>
consist ently</w>
consider ation,</w>
conserv ation</w>
consequ ent</w>
consci ence</w>
connec tive</w>
conflic t.</w>
confir ms</w>
conf used</w>
conduc tion</w>
condi tion,</w>
concentr ations,</w>
conce aled</w>
con sent</w>
con i</w>
con ferenc
computer ised</w>
compul sive</w>
comprim idos</w>
comple x,</w>
competi tion?</w>
competi tion.</w>
compens atory</w>
compati bil
comparis ons</w>
comp ound
comp iled</w>
committe e,</w>
comfor t</w>
com pression</w>
com es.</w>
com bat
colour ings</w>
colour ing</w>
colour .</w>
colour ,</w>
collec ting</w>
collec ted,</w>
col d,</w>
cohes ion</w>
cogni tive,</w>
cod ed</w>
cod ec
cock tail</w>
co- ordination</w>
co- ordin
co re-data</w>
co operative</w>
co ating</w>
co at</w>
co ,</w>
clott ing.</w>
clinical '
clic king</w>
cli ent</w>
cleare d.</w>
clear ing</w>
cle an,</w>
clar ification</w>
cl ones</w>
cir covirus</w>
cimeti d
cid ofovir
chron ically</w>
cholesterol ),</w>
chlor ine</w>
chemistr y;</w>
cheap est</w>
cheap er</w>
che z</w>
characteris tics,</w>
chang es,</w>
cet uxim
cess ful</w>
cere bral</w>
cer tified</w>
cent ury,</w>
cent re,</w>
cent age</w>
catt le,</w>
categor ised</w>
catechol -
catechol- O-
cat ch-
cat abol
case-by- case</w>
cas ual
cas es?</w>
carro ts</w>
careg ivers</w>
carc asses</w>
carbox y-
carbox y
carbam azep
car s.</w>
car go</w>
capsu le
capit a</w>
cap .</w>
canc ers,</w>
calici vi
calcul ate</w>
ca ,</w>
c overed.</w>
c ould,</w>
c etroreli
c ed</w>
c ages</w>
c a</w>
bureaucr atic</w>
burden .</w>
bul bs</w>
budget ?</w>
bud gets</w>
bu y
bru ising</w>
bronchiseptic a</w>
bronch ospas
broad er</w>
bro k
bridg ing</w>
bridg es</w>
breed s)</w>
breed ers</w>
breakfast .</w>
bran ch</w>
bra ke</w>
br ush</w>
bott les.</w>
bot t</w>
bor g</w>
bomb s.</w>
body ).</w>
blu etongue</w>
block ed.</w>
block ed,</w>
biotechnolog ical</w>
bio degrad
billi ons</w>
bi phasic</w>
bi ometric</w>
bi ome
bi og
bh fuil</w>
bever ages</w>
beta- lactam
beta *</w>
bes ides</w>
benz yl</w>
benef it.</w>
ben ser
belong ed</w>
behaviour ,</w>
be vacizumab</w>
be st,</w>
be it</w>
be iro</w>
be ings,</w>
be have</w>
be es</w>
be auty</w>
bath ing</w>
bar s</w>
bar -
bar- code</w>
bank rup
ban kno
bal lot</w>
bal ance.</w>
bacteri ostatic</w>
bacteri al,</w>
back ground.</w>
back ;</w>
b other</w>
b la
b ish
b if</w>
b ath</w>
b arely</w>
b ans</w>
b agg
awa iting</w>
aw k
avir/ ritonavir)</w>
avir -treated</w>
avi d</w>
av el</w>
av al</w>
autom obile</w>
authoris ations.</w>
author iti
aut oc
aut o-
aut ala</w>
audi ovis
attach ed.</w>
att le</w>
atroph y</w>
ato siban</w>
ation ary</w>
ation /</w>
at á</w>
at stovy
at ro
at om
ast s</w>
ast on
assist ed</w>
assist ance,</w>
assa y.</w>
assa y,</w>
aspart ame</w>
asil inna</w>
asc o</w>
as sump
as ha
arti cles.</w>
arthri tis)</w>
arthral gi
arth y</w>
arter ies</w>
arri ves</w>
arrang ements,</w>
arrang ement</w>
ark er</w>
ark ,</w>
argu ed</w>
arel a</w>
are lix</w>
are d,</w>
are a?</w>
arcom a</w>
ar ticular</w>
ar t,</w>
ar row
ar naubach</w>
ar isation</w>
ar dise
ar cha
aqu eous</w>
aqu acul
approv ed.</w>
appropri ately</w>
appear .</w>
appear ,</w>
aphy loc
ap s,</w>
ap lex
ap ler
ap heres
anz es-Carpegna</w>
anxi ous</w>
antimicro bi
anticoagul ants,</w>
anticip ate</w>
anti- tuberculosis</w>
anti- rheumatic</w>
anti- diabetes</w>
anti hist
anti convulsant</w>
ant ly,</w>
ant acid</w>
ant :</w>
ann ually</w>
anim ity</w>
angi ography</w>
ang er)</w>
ane x</w>
anc y,</w>
anc ing</w>
an- speaking</w>
an s'</w>
an ch
an alog
an :</w>
amlodip ine/</w>
amlodip ine,</w>
amlodip ine)</w>
amend ments,</w>
amend ment,</w>
amend ing</w>
amen hofo</w>
amb assad
am un
am ide,</w>
am er</w>
altern atives.</w>
alter ation</w>
alis ation'</w>
ali pride</w>
alfa-2 a
alf entanil</w>
album in:</w>
album in.</w>
alan ine</w>
al ways,</w>
al igned</w>
al ib
al gia</w>
al gia,</w>
al cif
al beit</w>
al as</w>
ak es</w>
air lines</w>
agricul ture,</w>
agon ists</w>
agon ist,</w>
aglip tin.</w>
agh d
agen icity</w>
ag es?</w>
ag ency,</w>
ag en.</w>
after no
after -
affor ded</w>
aff ord</w>
af arnaubach</w>
aeroplan e</w>
aem ia)</w>
advis ers</w>
advertis ing.</w>
adverti se
adv enti
adv ance.</w>
adren al,</w>
adop ting</w>
adop ted
administr ation:</w>
adjust ments.</w>
adjunc tive</w>
adj u
adi es</w>
adi an</w>
aden ocarcin
addres ses</w>
ad sor
ad o</w>
ad mits</w>
ad mit
ad here</w>
act s)</w>
act ?</w>
acrome gal
acresol ,</w>
achiev ement</w>
acetyl choline</w>
accur acy</w>
accoun ted</w>
accep ting</w>
ac ity</w>
ac ep
ac compl
ac .</w>
abund ant</w>
absten tion
absor b
abrup t</w>
abroad :</w>
abor tions</w>
abor tion,</w>
abol ished.</w>
abnormal ities,</w>
abandon ment</w>
ab used</w>
ab use,</w>
ab out
a íoch
a ine</w>
ZY ME</w>
Z ap
Z amenhofo</w>
Z al
Z E
Youn g</w>
York shire</w>
Y em
Y .</w>
X enical</w>
X .</w>
Wy e</w>
White hall</w>
Where ver</w>
Wh o
Wel sh</w>
Wednes day</w>
We gener's</w>
Wal es.</w>
Wa y,</w>
W ol
W ie
Viraferon Peg
Vir us,</w>
Vir lix,</w>
Vien na,</w>
Vic tim
Vent av
Vel meti
Val trop
Val ley</w>
Val letta</w>
Val idation</w>
VIRACE P
VIRACEP T.</w>
VI STA</w>
VE GF
VAX PRO</w>
V inc
V ie
V asco</w>
V arela</w>
V L</w>
V AL
Uzbe kist
Urtic aria,</w>
Uppsal a</w>
Un it,</w>
Ukraini an</w>
Ukra ine,</w>
UR B
UN H
UGT 1A
UCL AF</w>
U sed</w>
U VI
U EF
Treat y,</w>
Tre mor,</w>
Tre deg
Tran sport</w>
Trakatell is</w>
Tracle er.</w>
Tra vo
To wards</w>
Tit anium</w>
Ti etgens</w>
Ti bet</w>
Thre onine,</w>
Third ly:</w>
Therap ies</w>
Th y
Th in
Th ail
Test ing</w>
Terro rists</w>
Tandem act</w>
Tal iban</w>
Tablet ten,</w>
TRI TAC
TRITAC E</w>
TRE L
TNF α</w>
TN F-
TIC LE</w>
TH RO
TE S</w>
TABLE T</w>
T ub
T op
T ok
T ex
T c</w>
T ak
T afarnaubach</w>
T SS</w>
T HAT</w>
Sán chez</w>
Swit ching</w>
Sw allow</w>
Sug ammadex</w>
Suc cessful</w>
Subsidi es</w>
Subjec t</w>
Su anzes-Carpegna</w>
Streng th</w>
Str ateg
Squ are</w>
Spec i
Sp inal</w>
Sp enc
Sol na</w>
Sle ep
Sk eletal</w>
Six ty-
Simpli fied</w>
Simil ar</w>
Shi p
Shar on</w>
Sh ort</w>
Sevent y</w>
Ser ot
Sep sis,</w>
Sec tions</w>
Scot land,</w>
Sch um
Sch engen</w>
Sant é</w>
Sal v
Sal om
Sal am
Sa haran</w>
SUSTIV A</w>
STI T
SPRYCE L.</w>
SOMAVER T</w>
SK -8
SI L
SE- 169</w>
SE R
S- AD
S Ø</w>
S ure
S ten
S reb
S pon
S oil</w>
S of
S ic
S ib
S ere
S ME</w>
S D</w>
S -</w>
Rom an</w>
Ro ad,</w>
Riv er</w>
Ri beiro</w>
Ret ac
Respir atory</w>
Res olution:</w>
Report .</w>
Rel ative</w>
Regul atory</w>
Reduc ed</w>
Rec ord</w>
Re quirements</w>
Re production</w>
Re gre
Re bif</w>
Rati ograstim</w>
Rap amun
ROB ERT</w>
RI C</w>
RE N</w>
R ī
R ul
R if
R ic
R est
R and
R ace</w>
R T,</w>
Qu isthoudt-Rowohl</w>
Qu e
Prote in</w>
Program me.</w>
Program me,</w>
Prof ender</w>
Proce du
Proble ms</w>
Pro por
Pro liferative</w>
Previ ous</w>
Presid ents.</w>
Pres sure</w>
Prepar atory</w>
Pras ugrel</w>
Pr urit
Pr am
Pot ters</w>
Portu gal
Pop ulation</w>
Pom pe</w>
Pol ic
Po or</w>
Po in
Pneumon ia,</w>
Plavi x</w>
Platel et</w>
Pl asma</w>
Philip p
Phen ylalan
Ph ar
Person nel</w>
Pers ons</w>
Per centage</w>
Pent agon</w>
Pe ace</w>
Pau l</w>
Parliament ’s</w>
Parame ters</w>
Par que</w>
Palestini ans</w>
Pal aci
Pakist an</w>
Pac litaxel</w>
Pac ific</w>
Pa ço</w>
Pa ste
Pa inful</w>
Pa asilinna</w>
PV D
PRO T
PRE -
PRE- FIL
PRE-FIL LED</w>
PD T</w>
PATI ENTS</w>
PAR γ</w>
P ru
P ress</w>
P oc
P iro</w>
P im
P ic
P es
P ercent</w>
P ain,</w>
P ag
P S</w>
P PE</w>
P PARγ</w>
P HA
P -2
Ox ford</w>
Over all,</w>
Oste oporosis</w>
Organ isation,</w>
Org alu
On sets</w>
Ombuds man.</w>
OP HAR
ON E</w>
OM IX</w>
O vitrelle</w>
O ost
O ne,</w>
O dense</w>
O UTER</w>
O P</w>
O I
O H
O AT
Novo Nor
NovoNor m</w>
Nov ember.</w>
Not ting
Ninet y-
Nig eri
Nic otinic</w>
Nic osia</w>
Ne opharma</w>
Natur ally,</w>
Natur a</w>
Nat ural</w>
NS CL
NOV OMIX</w>
N- des
N- CI
N-CI LA
N-CILA G</w>
N uremberg</w>
N ord
N et</w>
N NRTIs</w>
N L</w>
N .</w>
N -</w>
Myel oma</w>
My c
Mut agenicity</w>
Musculo -</w>
Mun ich</w>
Mont pelli
Mon th</w>
Mo tion</w>
Mix ed</w>
Mil an,</w>
Mic turition</w>
Mic hael</w>
Menitor ix</w>
Memb ers.</w>
McC arthy</w>
Mark ov</w>
Mari o</w>
Mar low</w>
Mal ay
Mac ro
Mac ed
MS ).</w>
MP D</w>
MM -00
MM-00 9</w>
MM -0
MI G
MIG AN</w>
ME D</w>
MCy R</w>
MAN Y</w>
M other</w>
M oroc
M ill
M ight</w>
M ig
M arg
M are
M ang
M O
M G</w>
M 1</w>
Lysod ren</w>
Lyn g
Luk ash
Livens a</w>
Li ver
Li quid</w>
Li po
Li ke
LeukoS can</w>
Leuk aemia</w>
Leuc ine,</w>
Lef t</w>
Le on
Le inen</w>
Lat via</w>
Labor atories</w>
LU MIGAN</w>
LT- 44
LT-44 287</w>
LI TA
LE R</w>
L- Phenylalan
L- Leucine,</w>
L- Iso
L-Iso leucine,</w>
L opin
L ittle</w>
L au
L atin</w>
L arg
L /</w>
L ).</w>
Ky oto</w>
Ken ya</w>
Karve zide</w>
K øbenhavn</w>
K yrgy
K oz
K han
K er
K enter
K au
K am
K IN
K I
Jul y.</w>
Jul i
Joh ann
JANSSE N-CILAG</w>
J am
J ac
J ,</w>
Iv abradine</w>
Is le</w>
Is ):</w>
Irel and.</w>
Intrav itreal</w>
Intrav ascular</w>
Intr on.</w>
Internation al,</w>
Inter pre
Intel lig
Infus at</w>
Induct Os.</w>
In ten
In adequate</w>
Impa ired</w>
Imp act</w>
Immedi ate</w>
Im aging</w>
Ig G
Icel and</w>
IV )
IU/ ml</w>
IN FA
INFA I</w>
IGF -
IC H
I stan
I sol
I denti
I )</w>
Hycam tin</w>
Holoca ust</w>
Her tford
Her stellung</w>
He in
Hau g</w>
Ham burg.</w>
Ham as</w>
Hal f</w>
HT 2
HIV- infected</w>
HBe Ag
HBV -
HB VAXPRO</w>
HA C
HA ),</w>
H5 N
H ur
H ere
H er</w>
H ell
H az
H autala</w>
H ANE</w>
H AND
HAND LING</w>
H ),</w>
Gu ant
Go thenburg.</w>
Go oimeer</w>
Gli mepiride</w>
Gil ad</w>
Ger hard</w>
Gen erics</w>
Gaz a</w>
Gau cher</w>
Garg ani</w>
Gall agher</w>
GM Os.</w>
GI P</w>
GEN ER
GB P</w>
G ö
G went</w>
G ul
G oe
G nR
G lasgo
G iving</w>
G abapentin</w>
G T)</w>
G O
G ER
G AT
G AD
G AB
Further more</w>
Func tional</w>
Fron ti
Fri ed
Frame work</w>
Fourth ly:</w>
Four th,</w>
Forcal tonin</w>
For um</w>
For ce</w>
Flo or</w>
Fil m</w>
Fe wer</w>
Fab ry</w>
Fab raz
Fa ther</w>
FR ,</w>
FOL LO
FO IL</w>
F us
F inal</w>
F entan
F el
F at</w>
F ast</w>
F arma</w>
F arm
F VIIa</w>
F L</w>
F F</w>
Ex port</w>
Ex p
Europe ’s</w>
Euro -
Eucre as</w>
Er nst</w>
Ep istax
Enter opathy</w>
En d</w>
Elev ations</w>
Econom ics</w>
Echinococc us</w>
Earth qu
EXUBER A
EXJ ADE
EXJADE .</w>
EU/1/0 4/279/0
EU/1/0 3/
EU/1/03/ 26
EU- wide</w>
ER G</w>
EN- C,</w>
EN T</w>
EN 6</w>
ED T
EC HO</w>
E thi
E mulsion</w>
E le
E ight</w>
E fectin</w>
E co
E astern</w>
E T</w>
E SA</w>
E RE
E IT</w>
E GFR
E E</w>
Défen se</w>
Dysp noea,</w>
Dyb kjær</w>
Dox azosin</w>
Div ision</w>
Diseas e.</w>
Direc tive.</w>
Direc tive,</w>
Diffe rent</w>
Di pl
Di ag
Dev ice</w>
Depart ments</w>
Dep ending</w>
Dem ocratic</w>
Dell' Alb
Dan dery
DMAR D
DK -5
DK-5 220</w>
DE X</w>
D- 90
D-90 4
D op
D ig
D anu
D TP
D M</w>
D IC
D HA</w>
Cy clo
Cy cle</w>
Curren tly,</w>
Cur rent</w>
Cry ptospor
Creutzfeld t-
Convul sions</w>
Continu e</w>
Consum er</w>
Concer ning</w>
Con sumption</w>
Con firmed</w>
Con centr
Comp any</w>
Commun ity.</w>
Commun ist</w>
Com peti
Com petact</w>
Colleg e,</w>
Col om
Cohn -B
Cohn-B end
Co- Rapporteur
Co el
Cma x.</w>
Churg -Strauss</w>
Christi an
Christ od
Christ mas</w>
Chin a.</w>
Char ter</w>
Chair man
Ch ine
Cere zyme</w>
Cell C
CellC ept</w>
Cef triax
Cath ol
Car bag
Car b
Cam isón</w>
Cal ifor
Cal cit
CYP2E 1,</w>
CYP2C9 *
CYP2 A6,</w>
CYP 450</w>
CT C
CPMP/ CVMP</w>
COP D</w>
CONST A,</w>
CONCENTR ATE</w>
COMM UN
CO MP
CO 2
CM O</w>
CL AI
CLAI M</w>
CA P</w>
C- urea</w>
C od</w>
C iv
C he
C ant
C S-AD
C R</w>
C HI
C 24
C ),</w>
Budap est</w>
Bud gets</w>
Bucha rest</w>
Bri di
Bren ner</w>
Bon dron
Bl urred</w>
Bl ack
Bin ocrit</w>
Betafer on.</w>
Beta- blockers</w>
Ber ès</w>
Ber om
Benz alkonium</w>
Belgiqu e/</w>
Belgi ë/</w>
Be ethov
Basing stoke</w>
Bas que</w>
Barcel ona,</w>
Ban k</w>
BE N
B org
B ody</w>
B imatoprost</w>
B erger</w>
B aghd
B RO
B 19.</w>
Author ity</w>
Ator vastatin</w>
AstraZen eca</w>
Asi a</w>
As then
As th
Arix tra</w>
Arco s</w>
Ar thritis</w>
Ar g
Ar ch
Apr il
Ap proxim
And al
Anaphy lactic</w>
An ton
An sw
An glia</w>
An g
An dr
An aemia</w>
Amon gst</w>
Americ a</w>
Amend ment
Am pren
Alzheimer 's,</w>
Alcobend as,</w>
Albani an</w>
Al stom</w>
Al pine</w>
Al is
Al geri
Air port</w>
Agricul ture</w>
Afghanist an</w>
Af ter
Adul ts</w>
Ade fovir</w>
Ad vis
Ad junc
Ad d</w>
Accor dingly,</w>
Abrax ane</w>
Ab bott</w>
AV ON
AUTHORISATION /RENEWAL</w>
AUC0 -24</w>
AUC0 -
ARI CLAIM</w>
AR TICLE</w>
AR -
AN .</w>
AL U</w>
AID S-
AG E</w>
AF ,</w>
AC R),</w>
AC P</w>
A- I</w>
A ud
A stellas</w>
A sk
A sensio</w>
A res</w>
A iv
A er
A ce
A MP
A II
A 4-0
? ’</w>
90 .</w>
9. 7%</w>
9 8-
9 8%</w>
9 5-
8 EP</w>
8 6
8 /99):</w>
8 /98)</w>
8 ,000</w>
70 1</w>
7. 2</w>
7 50</w>
69 ,</w>
60 .</w>
6. 9%</w>
6. 6%</w>
6. 2).</w>
6- 10-
6 ;</w>
6 76</w>
58 6</w>
5- hydroxy</w>
5- hydroxy
5  
5 99</w>
5 600</w>
5 /98)</w>
5 /2000)</w>
402 3000</w>
40 7</w>
4. 8)</w>
4 103</w>
4 ,
4 ),</w>
4 %.</w>
4 %,</w>
39 8/</w>
39 0
39 /</w>
373 20
37320 603</w>
37 8
37 ,</w>
36 7/</w>
36 0
36 ,</w>
35 0
34 7/</w>
30 /</w>
3. 9</w>
3. 6</w>
3. 6%</w>
3. 1</w>
3 ;</w>
3 28</w>
3 26
3 15</w>
29 ,</w>
28 7
28 2</w>
28 %</w>
26 %</w>
25 °C</w>
25 2</w>
24- hour</w>
21 -2
200 9
200 1
2. 7</w>
2. 4%</w>
2. 3</w>
2 6.
2 34</w>
2 33</w>
2 19</w>
2 16</w>
2 14</w>
2 1.
2 0.6</w>
2 /9
199 2.</w>
198 3</w>
198 2</w>
19 68</w>
19 4</w>
19 3
19 1</w>
17 8</w>
17 1),</w>
16 .</w>
15 6</w>
15 5/</w>
14 4</w>
14 1</w>
13 4
13 -
12 )</w>
10. 0</w>
10 9</w>
10 3.0</w>
1. 6
1 16</w>
1 1/</w>
1 000/</w>
1 /99)</w>
1 /96)</w>
02 -
0.0 1</w>
0. 5%</w>
0 36</w>
0 /97)</w>
/98 ,</w>
/200 7</w>
................................................................ ....................</w>
................................ ........
.... ...</w>
. ’</w>
-2- 3355</w>
-2 5
-2 1</w>
-1 00
------------ ---
--------------- Study</w>
- fold</w>
- depreotide</w>
+4 2</w>
+4 21
+ 31</w>
+ 3
) ]</w>
(shoul der).</w>
(saquin avir/ritonavir)</w>
(re-) vaccination</w>
(in %</w>
(hyperglycaem ia).</w>
(WHO )</w>
(Upro ar</w>
(U ACR),</w>
(Pro tests</w>
(P -
(O J</w>
(MAO Is):</w>
(Laugh ter,</w>
(H eck
(FAP ),</w>
(EU )</w>
(CYP 1A
(COX -2)</w>
(B 6-0
(ACE )</w>
(A5-0 38
(A5-0 37
(A5-0 26
(A5-0 10
(A4-0 29
(6 %)</w>
(4 )</w>
(1- pack</w>
( ≤</w>
( weakened)</w>
( tummy
( swelling</w>
( side</w>
( s).</w>
( rhabdomyolys
( results</w>
( reduction</w>
( platelets</w>
( persistent</w>
( pancyt
( over</w>
( occurring</w>
( less</w>
( laminate)</w>
( killed)</w>
( infla
( if</w>
( hypoglycaemia)</w>
( high</w>
( hazard</w>
( dose-
( below</w>
( amlodipine)</w>
( alendronate</w>
( age</w>
( adopted</w>
( acute</w>
( Table</w>
( 75</w>
( 500</w>
( 5%</w>
( 35
( 30</w>
( 29.
( 16</w>
( 16
( 10,000</w>
' re</w>
' public</w>
' non-
' from</w>
' all</w>
' You</w>
' What</w>
' Europe</w>
' A
… …</w>
’ ;</w>
’ :</w>
‘ Do</w>
θ ή
θή ν
β ,</w>
Κύπρ ος</w>
ü r</w>
ü r
ú n</w>
í a</w>
é -
ça ise</w>
å rd
än en</w>
ä parate</w>
É ire
µg/ kg/</w>
µ m.</w>
  000.</w>
} <</w>
zi o-
zi al
zial pr
zialpr äparate</w>
zer w
zerw ane
zerwane j</w>
z ur</w>
z st
z one.</w>
z icon
zicon otide.</w>
z er,</w>
z am</w>
z .</w>
yttrium- 90</w>
ysti tis,</w>
ys abr
ysabr i</w>
yoursel ves.</w>
your s</w>
you ’
yester day
yar bak
y-f our</w>
y- related</w>
y ’</w>
y h
y en</w>
y '(
y'( mmH
y'(mmH g).</w>
x a</w>
x -
x )</w>
wz now
wznow ien
wznowien ie</w>
wron g,</w>
writ er</w>
worry ing.</w>
world- wide</w>
work place.</w>
work ed.</w>
word ing:</w>
wor se
wonder ful</w>
won dering</w>
wom b.</w>
wish ,</w>
win ners</w>
win es,</w>
win ds</w>
whol ly</w>
whol es
who ?</w>
whit e.</w>
whist le</w>
whis ky</w>
when ?</w>
whe el
well- being</w>
well ?</w>
weigh ts</w>
week s),</w>
weap ons.</w>
weal th</w>
weak ness.</w>
weak est</w>
we tt
we gi
wav es,</w>
water -like</w>
wat ers.</w>
was hed</w>
war te
war ,</w>
wa y?</w>
wa ke</w>
w- D3</w>
w y</w>
w ine.</w>
w ife,</w>
w ife
w iel
w elling</w>
w ash</w>
w all.</w>
w all
w age.</w>
w )</w>
vot ing:</w>
vot es,</w>
vom it</w>
voluntar y.</w>
volcan o</w>
volcan ic</w>
vol t
vod ka</w>
vocabul ary</w>
vo start
vo ices</w>
vo ic
vitro .</w>
vit an</w>
vis u
vis iting</w>
virtu e</w>
vir ,</w>
vine yards</w>
vill ages</w>
vigil ant</w>
view ing</w>
vide ocon
vic el</w>
vial s)</w>
vi als.</w>
vi als,</w>
vet ovan
vetovan je</w>
vest ment</w>
vess el.</w>
ves et</w>
verte bra
ver y,</w>
ver tical</w>
ver ification</w>
ver dic
ver alipride</w>
ventric le</w>
ventil ated</w>
vent ing</w>
vel i
vel .</w>
ve z</w>
vasodi lat
vari ations,</w>
vari ables</w>
var denafil</w>
vanish es.</w>
val ve</w>
val idation</w>
vaccin ations.</w>
v y</w>
v ity</w>
v is</w>
v axyn</w>
v agu
util isation</w>
ut ting</w>
ut amic</w>
uste kinumab</w>
useful ness</w>
us h,</w>
us es,</w>
us ers,</w>
us e?</w>
us *</w>
us ):</w>
us ).</w>
urg ency.</w>
ureth ra</w>
ure l
urel la</w>
ure a,</w>
urani um,</w>
up stream</w>
unpreced ented</w>
unpleas ant</w>
unit s,</w>
unit s)</w>
unit inib</w>
unil ateral</w>
undertak ings.</w>
understand ing.</w>
unanim ous</w>
un ting</w>
un justified</w>
un it,</w>
un intentional</w>
un infected</w>
un ha</w>
un explained</w>
un deni
un control
un avir</w>
un .</w>
um brel
um ab
um -</w>
ulf an</w>
ulcer s.</w>
ulcer ations</w>
ul ins</w>
ul ated</w>
ul air</w>
ug in
ud a
uc t
ub ric
u vo
u ted</w>
u ph
u no
u g</w>
ty res</w>
ty ph
two- thirds</w>
tw o,</w>
tur nal</w>
tur bin
turbin es</w>
tur bid</w>
tubercul in</w>
tub ule</w>
tub ul
tub al</w>
ts ke</w>
tro pic
tro op
triaz eno
triazeno imid
triazenoimid azole</w>
tri ple</w>
tri p</w>
tri azol
tri ang
tri alogu
tremend ous</w>
trem or</w>
treat y.</w>
treat ments,</w>
trav oprost</w>
traum atic</w>
transpor ted.</w>
transplant ation,</w>
transp osi
transl ations.</w>
transl ates</w>
transl ated.</w>
transf used</w>
transamin ase</w>
trans formed</w>
train ed.</w>
traged y,</w>
traffic .</w>
traffic ,</w>
tract ors</w>
trace able.</w>
tra- indication</w>
tra de,</w>
tr ast
trast uz
tr active</w>
toxic ,</w>
tou ched</w>
tot ox
totox ic</w>
tor ture
tor ticoll
top o
topo isomer
tonic- clonic</w>
ton -</w>
tomor row
tomato es</w>
tod d
tocil izumab</w>
to es</w>
to ?</w>
tivi ties</w>
tiv a,</w>
tit ude</w>
tis /</w>
tis ).</w>
tion ing</w>
tion al.</w>
tion -related</w>
tin ent</w>
time table</w>
time table
tim es)</w>
tim ber</w>
tigecyclin e.</w>
tig li
tic a</w>
tic a,</w>
ti te
ti es;</w>
ti es
thyro globulin</w>
thropo ie
thropoie tin</w>
thrombocytopen ia)</w>
thrombo embolism</w>
thromb oph
thromboph leb
three- year</w>
threaten ing.</w>
threat en</w>
thre e,</w>
third ly,</w>
thir d.</w>
think ing,</w>
think ?</w>
thin ning</w>
thigh s</w>
thick ened,</w>
therap ies.</w>
them !</w>
that :</w>
th or
th ings.</w>
th en.</w>
th ar</w>
tex til
tetracyclin es,</w>
tetrac yclines</w>
termin ology</w>
teripar atide</w>
ter n</w>
ter ious</w>
ter ing,</w>
ten ofovir
ten ing.</w>
ten der,</w>
ten b
tempor ary,</w>
tempor ar
temperat ures.</w>
temp t
tem ozolomide</w>
teluk ast</w>
teen ag
technolo gi
techniqu e,</w>
techniqu e)</w>
tec avir</w>
teach ing.</w>
te plase</w>
te enth</w>
te en.</w>
te au
te ars</w>
te :</w>
te -
tax i</w>
tax .</w>
tas k.</w>
tas e,</w>
targ o</w>
tant amount</w>
tank ers</w>
tan k</w>
tamper -
tamper- evident</w>
tam i
tal low</w>
tal k,</w>
tachycardi a.</w>
tablet )</w>
ta ire</w>
t á</w>
t ros
t ons</w>
t n</w>
t enth</w>
t e.</w>
synerg istic</w>
syn cope</w>
sy non
sy no
sy l
swit ch
swif tly</w>
swee ts</w>
swe et</w>
swe at</w>
suspen sions</w>
suspen sion,</w>
surpris ing</w>
surg ery
sur ge</w>
sur fact
suppos edly</w>
suppor tive</w>
suppl ying</w>
superfic ial</w>
super numer
supernumer ary</w>
sun .</w>
summit .</w>
summ er,</w>
summ ari
sum ing</w>
sulphonyl ure
sulphonam ides</w>
sulph one,</w>
sulph ide</w>
sulfon am
sulfa methox
suit ably</w>
suit able.</w>
suic ides</w>
suic ide,</w>
sug ary</w>
suffici ency</w>
suffe rers.</w>
successful .</w>
succe ed.</w>
succ um
substr ate</w>
subsidi es,</w>
subsid y.</w>
subscri ption</w>
sub missions</w>
sub jug
sty le.</w>
stum bling</w>
stuff .</w>
stud y).</w>
struc ture
stro ke</w>
stro ke.</w>
stric ture</w>
stri king</w>
stri kes</w>
stri ke</w>
streng ths</w>
straw ber
strati fied</w>
strateg y.</w>
strains) ........................................................................................
strain s),</w>
stra w</w>
stra at</w>
str o</w>
stor age.</w>
stock pile</w>
stoc k,</w>
sto len</w>
stipul ated</w>
stic ker</w>
sti f
sti ,</w>
ster s,</w>
step wise</w>
step ped</w>
statis tics.</w>
stat es,</w>
stat e-
stand ard,</w>
stain ing,</w>
stag es.</w>
staff ing</w>
staff .</w>
stabil ised</w>
sta ying</w>
st un
st one,</w>
st ing</w>
st ing
st ed
sted t</w>
st ations.</w>
st amp</w>
st agg
st able.</w>
st ab
squeez ing</w>
spra ying</w>
spra y</w>
spot ted</w>
sport sm
sportsm en</w>
spor t.</w>
spondyli tis,</w>
splen did</w>
spl inter
spirit ual</w>
spi ke</w>
specific ations</w>
specific ally,</w>
specific .</w>
specifi ed.</w>
speak ers,</w>
spe eds</w>
spe aks</w>
sp p.</w>
sp here</w>
sp ared</w>
sor ption</w>
som nam
somnam bul
solution s/
solutions/ drugs</w>
soldi er</w>
sodium-fre e".</w>
sodium -</w>
soci ally</w>
soci alism.</w>
so w</w>
so ren
so rely</w>
so lem
snap -off</w>
smo ked</w>
small .</w>
slog an</w>
sleep ing,</w>
skin ),</w>
skim med</w>
sk o</w>
sk ip
sk info
sk ,</w>
situ ated</w>
sit agliptin.</w>
sion al</w>
single- hull</w>
sing ing</w>
simpli fied.</w>
simpli fication</w>
simp lif
simil ar,</w>
sim vastatin,</w>
signific ant,</w>
sign ing</w>
sign atory</w>
sign als.</w>
si tis,</w>
si ster</w>
si ology</w>
si fication</w>
show ed:</w>
short ages</w>
shop s.</w>
shoc ked</w>
sho wn.</w>
ship ping</w>
shel ves.</w>
share holders</w>
shado ws</w>
shado wed</w>
sh unt</w>
sh ot
sh as
sevent h</w>
sett led</w>
sett le</w>
set ê
session .</w>
ses ji</w>
serv es</w>
serv er</w>
ser um.</w>
ser o
ser a</w>
separ ating</w>
separ ati
sep sis.</w>
sensi tisation</w>
sen se,</w>
sen be
senbe ek</w>
selegil ine</w>
selec ting</w>
sel f.</w>
seg ment</w>
sector s.</w>
sector s,</w>
second ly,</w>
sec uring</w>
sec toral</w>
search ing</w>
se in
se en,</w>
se emed</w>
se ed
se /</w>
scrutin y.</w>
scrupul ous</w>
scre ening,</w>
scre ened</w>
scrap ie</w>
sco ops</w>
scienti sts,</w>
schedu le,</w>
sche dul
scandal ous</w>
scand al.</w>
scan ning</w>
scan .</w>
scal e.</w>
sc ha
scha ft</w>
sc ab
satis fied.</w>
satellit es</w>
sarcom a.</w>
sal e.</w>
sac red</w>
sac hets</w>
sac .</w>
sa y?</w>
sa me,</w>
sa ke</w>
sa -
s- European</w>
s vetovanje</w>
s son</w>
s s)</w>
s oph
soph istic
s now</w>
s ly</w>
s lo
s ic
s er</w>
s ends</w>
s coli
s ch</w>
s ati
s ans</w>
s ad</w>
s ab
s *,</w>
s 'and</w>
s "</w>
run .</w>
rul es,</w>
rubb ish.</w>
ru le,</w>
ru it</w>
ru ins</w>
ru ined</w>
ru b</w>
rt v</w>
ron y
roc ket
road s.</w>
ro y
ro tigotine</w>
ro le?</w>
risk ?</w>
ris peridone</w>
ris perid
ris ol</w>
rich est</w>
rib ine</w>
ri uretic</w>
ri st,</w>
ri ots</w>
ri a.</w>
rh initis</w>
rever sed</w>
retur ns</w>
retro spec
retro peritone
retinopath ies</w>
retard ant</w>
ret ino
ret initis</w>
resuspen sion</w>
resuspen sion.</w>
resul t
rest s</w>
rest oration</w>
responsib le,</w>
response :</w>
respond ents</w>
respectivel y
respec ted.</w>
respec t,</w>
resourc es?</w>
reserv es.</w>
rese mb
resc rib
res ent
resent ment</w>
require ment
request ,</w>
represent ed.</w>
represent ation</w>
repres sive</w>
repli ed.</w>
renew ed</w>
ren tin
remov ed,</w>
reli ev
relev ance.</w>
relap ses,</w>
rel uct
rel im
relim inary</w>
rejec ted.</w>
regul ations?</w>
regul ation?</w>
regul ar,</w>
registr ation.</w>
reg rett
refriger ate.</w>
referendu ms</w>
refe renc
ref lex
redund ancies</w>
redund anc
reduc tions.</w>
red ;</w>
red -
recur rence</w>
recommen ded,</w>
recogn ised.</w>
recogn ised,</w>
recipi ents</w>
reci pe</w>
receiv e.</w>
rec ourse</w>
rec ap
rebel li
reason ably</w>
read ing:</w>
read ers</w>
react ors</w>
re- start</w>
re- evaluation</w>
re used.</w>
re teplase</w>
re tail
re t.</w>
re sumed</w>
re public
re production,</w>
re plic
re organisation</w>
re m</w>
re located</w>
re affir
rati fied</w>
rati fication</w>
rap ed</w>
rank osk
rang e)</w>
random ization</w>
ran king</w>
ran k</w>
ramipr il
ramipril ),</w>
ral te
rail way</w>
radi ological</w>
radi ographic</w>
rac ing</w>
rac ial</w>
rac emic</w>
ra re.</w>
ra ised.</w>
ra ised,</w>
ra in,</w>
ra in
r ö
r as</w>
quinol ones.</w>
quinol one</w>
quick ly,</w>
qui et</w>
questionna ire</w>
quantit ation*</w>
quanti ty.</w>
quanti ties,</w>
qualific ations.</w>
qualific ations,</w>
qu it</w>
qu e
pyr am
py ridine</w>
purchas er</w>
purch ased</w>
pur se</w>
pur in
punish able</w>
puncture -proof</w>
punc ture</w>
pul ling</w>
puber ty,</w>
prurit us.</w>
prud ence</w>
provi der.</w>
proven /</w>
prov oked</w>
prov ince</w>
prototy pe</w>
protein s.</w>
prospec tively.</w>
prospec t</w>
propter in</w>
propos ed.</w>
proportion ately</w>
proportion ate</w>
proportion ally</w>
propor tions</w>
promp tly</w>
promo tional</w>
promo tion.</w>
promis ing</w>
promis es</w>
promis e</w>
projec ted</w>
prohib its</w>
progres sed</w>
programm es,</w>
program me?</w>
prog nostic</w>
prof essor</w>
product s'</w>
produc e.</w>
process ?</w>
proceed ings.</w>
problem s)</w>
pro ving</w>
pro of.</w>
pro maz
pro m
pro hibition</w>
pro hept
prohept adine</w>
prison s.</w>
preven tion.</w>
prev ent,</w>
pressu res</w>
presid ent</w>
presid ency.</w>
presid ency,</w>
preserv atives</w>
preserv ative,</w>
prescrip tion)</w>
prefer able</w>
predic tive</w>
predec ess
preci ous</w>
pre-dispen sed</w>
pre- specified</w>
pre- haemodialysis</w>
pre text</w>
pre term</w>
pre sume</w>
pre sumably</w>
pre medication</w>
pre judic
pre feren
pre disposition</w>
pre disposing</w>
pre dat
pre car
pre -term</w>
prag matic</w>
pra ise
pr zerwanej</w>
pr one</w>
pr ice.</w>
pr ice,</w>
pot ently</w>
post- treatment</w>
post –</w>
post ure</w>
post p
postp one</w>
post ed</w>
possib le?</w>
posi tive,</w>
posi tions,</w>
portfoli o</w>
pornograph y</w>
popul ations,</w>
poore r</w>
pon ds</w>
polye ster</w>
poly sty
poly ribosylribitol</w>
poly ole
pollu ted</w>
poli tics,</w>
pol ox
polox amer</w>
poison ing.</w>
point s?</w>
po le
po dru
podru ž</w>
po dro
podro č</w>
plen ary</w>
ple .</w>
play er</w>
plat form</w>
plann ed.</w>
plan s.</w>
plan et.</w>
pl ed</w>
pl ants,</w>
pir acy</w>
pip eline</w>
pip el
pil ed</w>
piec es.</w>
piec es,</w>
pi erc
physi ologic</w>
photosensi tivity,</w>
phot opsia,</w>
phosphor ib
phosphorib os
phosphatidyl choline,</w>
phosph odi
phosph ates</w>
phenylbutyr ate,</w>
phas ing</w>
pharmacovigil anc
ph ras
ph aryngeal</w>
persi st,</w>
perform ing</w>
perce ived</w>
per pen
perpen dicul
perpendicul arly</w>
per mitting</w>
per cutaneous</w>
people ?</w>
people !</w>
penicill ins,</w>
penicill in</w>
penetr able</w>
pen stedt</w>
pemetrex ed</w>
pemetrex ed.</w>
peac efully</w>
peac e.</w>
peac e,</w>
pe t</w>
pe an
pean ut</w>
pay ments,</w>
pattern s,</w>
path ophy
pathophy siology</w>
path ogen</w>
path ic</w>
patent ing</w>
pat tern</w>
past e</w>
particip ants,</w>
pares thaesia,</w>
parenter ally.</w>
paras ite</w>
paralys ed</w>
parall el,</w>
paragraph  
par v
par in</w>
par acetam
par able</w>
pancre as.</w>
palmit oyl
pain ted</w>
pac litax
pa int
pa ins</w>
pa id.</w>
pa enia</w>
pa di
p=0.00 23,</w>
p= 0.02
p änen</w>
p up</w>
p ud
p rus</w>
p ru
p oured</w>
p lot</w>
p d
p ages.</w>
oxygen ase</w>
oxid ation</w>
ox ides</w>
ox icam</w>
ox ib,</w>
ox afil</w>
ovul atory</w>
over ly</w>
over look
over lap</w>
over l
over come.</w>
ov a,</w>
outw ard</w>
outri ght</w>
out set.</w>
out put.</w>
out -of-
our s.</w>
our s,</w>
ough ts</w>
ou se</w>
ou ch
otoxic ity,</w>
otox ic,</w>
otech no
otechno lo
ot to</w>
osteomyel itis</w>
osteoc last</w>
oste o
ost atin</w>
ost asis</w>
osis ),</w>
os yn
os veset</w>
os us,</w>
os el
osel tami
os e.</w>
os amine</w>
os a</w>
orrhoe a</w>
organiz ations</w>
organism s.</w>
or ance</w>
or 's</w>
optim um</w>
opt- out.</w>
opt ysis,</w>
opportun ity,</w>
opportun ities.</w>
oppon ents</w>
ophob ia</w>
ophiliac s</w>
opha gus</w>
oper ation),</w>
oper ability</w>
open s</w>
open .</w>
opath y.</w>
opa que.</w>
opa enia</w>
op tions.</w>
op or
op hi
op ers</w>
ond a</w>
onazole /</w>
on- treatment</w>
on wards.</w>
on ol
onol act
on g.</w>
on do</w>
on )</w>
on '
on !</w>
omal ac
om is
olog ical,</w>
oligos accharide</w>
olig arch
ole )</w>
ol ini</w>
ol der).</w>
ol a</w>
ol ).</w>
ok ed,</w>
off ence</w>
of- the-
of osveset</w>
of i</w>
oedema ),</w>
odynam ics</w>
ody sp
od y.</w>
od ru
od or
od one</w>
od g
od es</w>
oclo be
oclobe m
oc utaneous</w>
oc ide</w>
obvi ous.</w>
obstruc tion,</w>
objec ts,</w>
objec tives.</w>
ob tained.</w>
ob so
ob ses
ob li
ob iliary</w>
o virus</w>
o vi
o therapy</w>
o rest
o on</w>
o ils</w>
o fe
ofe l</w>
o der
o :</w>
ny com
nycom ed
nutri ents</w>
nur se/</w>
notic e,</w>
norm alised</w>
norm al)</w>
non-exist ent</w>
non-Q- wave</w>
non- vertebral</w>
non- serious</w>
non- selective</w>
non- pharmacological</w>
non selective,</w>
nom in
nolog ic
nologic o</w>
no tion</w>
no ted,</w>
no sti,</w>
nifedip ine</w>
newbor ns.</w>
newbor n.</w>
new s
neutrophil s</w>
neutro paenia</w>
neurotransmit ter</w>
neuropath y.</w>
neuri tis</w>
neuri tis,</w>
nerv ousness</w>
neo- coloni
nelfin avir</w>
neigh b
negoti ations.</w>
negoti ations,</w>
negoti ated</w>
negoti ate</w>
need s,</w>
need les.</w>
need les,</w>
nee ded
nec rosis)</w>
ne ovascul
ne h
neh men</w>
ne are
nat riuretic</w>
nam es,</w>
nam es)</w>
nail s</w>
naf arel
na p</w>
na me,</w>
na ecological</w>
nM )</w>
n íos</w>
n ip
n inet
n ice</w>
n ical</w>
n ell</w>
n ell
n :</w>
mydri asis,</w>
my oglobinuria</w>
mutagen icity</w>
mut ually</w>
mut ation.</w>
mut ated</w>
mus cles.</w>
murde red.</w>
mur der,</w>
multiple -dose</w>
multi tude</w>
multi for
mul tic
mu ch-
mu ch
msdnorge @msd.</w>
mp haden
mox if
mot e</w>
mos quit
mos ques</w>
mortal ity.</w>
month s?</w>
month s'</w>
monome thyl</w>
mon o</w>
mon d</w>
molecul es,</w>
moder ate)</w>
mod el,</w>
mod el
mod e</w>
mobil ity.</w>
mo tion.</w>
mo od)</w>
mo dule</w>
mix tures</w>
mix ed,</w>
mit .</w>
mistak enly</w>
mission ?</w>
minut es)</w>
minut e.</w>
minim is</w>
min e.</w>
min ds</w>
millilit res).</w>
milk y</w>
mil es</w>
mil d
midd le-
micron s</w>
microbi ologically</w>
micro n</w>
micro liter
microliter )</w>
micro bial</w>
mic ros
mg/ 25</w>
mg /0
mg/0 ,1</w>
meti con
meticon e</w>
meth an
metal s,</w>
metabol ising</w>
messeng er</w>
mess ag
mercur y'(mmHg).</w>
mer it</w>
mention ed:</w>
melphal an</w>
mellit us:</w>
mel at
mega wat
medicin skinfo
medi ator</w>
medi a.</w>
mechan ism,</w>
measure d.</w>
meas ure,</w>
mean s.</w>
me to
me at.</w>
mat ur
massac re</w>
massac re,</w>
mas ked</w>
mas k,</w>
mas cul
marri age</w>
mark .</w>
marg inal</w>
mar ,</w>
manip ulation</w>
manag er,</w>
manag ement
man y.</w>
man ure</w>
man nit
man kind.</w>
malignanc y,</w>
malign ancy</w>
mak ers</w>
major ity:</w>
major ity,</w>
main stream
macropha ge</w>
macro -
mach ine.</w>
ma y,</w>
m ó
m um
m oul
m oclobem
m ite</w>
m ing
m ers</w>
m ec
m art
m T
m 2).</w>
lys osomal</w>
lymphocyt es,</w>
lymph oid</w>
ly- nafarel
lung s.</w>
lumirac oxib</w>
luc k</w>
luc k
low er.</w>
long- distance</w>
long standing</w>
lon glin
logis tical</w>
lodg ed</w>
lock stop</w>
loc ks</w>
lob act
lobact ell</w>
load .</w>
lo ve,</w>
lo stridium</w>
lo st,</w>
lo ans</w>
lo ,</w>
liv e.</w>
litt le,</w>
lit re,</w>
list ed,</w>
lipo atroph
lip ids</w>
lin is
linis che</w>
lin ing</w>
lin ed.</w>
limit s.</w>
limit s,</w>
limit ed,</w>
limit ations.</w>
lim b
lim ate</w>
ligh ts,</w>
ligh t)</w>
life time.</w>
lif ting</w>
lic ence.</w>
lic ence,</w>
lia ison</w>
li veli
li b
lib eral</w>
levodop a,</w>
levod opa/</w>
lev y</w>
leuk openia,</w>
leuk opaenia</w>
leuk apheres
les ions,</w>
les ion.</w>
leng th.</w>
legis lator</w>
leg s.</w>
lef t)</w>
lec t</w>
lec ith
le um</w>
le t,</w>
le pir
le is
leis ure</w>
le ap
le ak</w>
lay ers</w>
late- onset</w>
laryn x</w>
large- scale</w>
lar k</w>
lamivud ine.</w>
lament u</w>
lac rimation</w>
label s.</w>
lab our.</w>
lab our,</w>
la ur
la h</w>
la dies</w>
l es)</w>
l er.</w>
kne y</w>
kine tics.</w>
kin inase</w>
kin 's</w>
kilometre s,</w>
kilome tre</w>
ket osis,</w>
ker ato
kerato conjunctivitis</w>
k u</w>
k m.</w>
k linische</w>
k it
k i,</w>
k hope</w>
k et.</w>
justi fic
jum ping</w>
judg ement</w>
ju v
job ,</w>
jer k</w>
j ust,</w>
j unk</w>
j skiego</w>
j av
jav nosti,</w>
j am
iz ing</w>
iz ed.</w>
iz ation,</w>
iv ance</w>
iv al</w>
ity 's</w>
iti s.</w>
iti es:</w>
iterran ean</w>
item s,</w>
it es,</w>
issu es?</w>
isol ate</w>
is ely</w>
is ed;</w>
irrit ate</w>
irregular ities</w>
ir on
ir ch
ir a.</w>
iqu im
iquim od</w>
ion ship</w>
ion ic</w>
ion ),</w>
io virus</w>
invest ment.</w>
inv itation</w>
inv ent</w>
intra- patient</w>
intestin al,</w>
interpre ters</w>
interest s,</w>
inter change
insul t</w>
insuffici ently</w>
instrum ents.</w>
instead ?</w>
install ation</w>
inspec t</w>
insp ired</w>
ins ist</w>
inqui ries</w>
injuri es.</w>
injection ;</w>
injec tor</w>
injec tion?</w>
injec tion:</w>
inhibitor )</w>
inhabit ants,</w>
inges tion</w>
infring ements</w>
infrequ ent</w>
inform ation?</w>
info _
infiltr ates
infer tile</w>
inf in
inf est
ine- like</w>
ine- gu
ine-gu anine</w>
ine ?</w>
ine :</w>
ine -</w>
industr y?</w>
indul gence</w>
induc tion.</w>
indin avir.</w>
indiges tion,</w>
indi go</w>
indi genous</w>
indefinit ely.</w>
increas es.</w>
increas e:</w>
include d).</w>
inclu ded,</w>
inciner ators</w>
incid ent
incid ence.</w>
incen tives.</w>
inc ub
inadequ ate,</w>
in transi
in stig
in significant.</w>
in s'</w>
in os</w>
in justic
in ety</w>
in eration</w>
in er</w>
in directly</w>
in different</w>
in compatible</w>
in compatibility</w>
in clin
inclin ed</w>
in activation</w>
in ;</w>
imprison ed,</w>
impres sive</w>
important ly,</w>
import ing</w>
import ance.</w>
implic ations.</w>
imp lies</w>
imp lied</w>
immuno compromised</w>
immuno compromised.</w>
immun ise</w>
immen se</w>
imag ination</w>
im possible.</w>
im possible,</w>
im penetrable</w>
im iquimod</w>
im er</w>
illustr ated</w>
illness es.</w>
ill o</w>
ill ary</w>
ill .</w>
ill )</w>
ili an</w>
il ys
il t</w>
il li
il le</w>
il ities</w>
il ding</w>
ign oring</w>
ifi ed,</w>
idi r</w>
identi fiable</w>
ide :</w>
id acloprid</w>
ici an
iche ver</w>
iche l</w>
ich tenb
icardi al</w>
ic ks</w>
ic i</w>
ic ;</w>
ia ?</w>
ia ;</w>
i č
i ously</w>
i os
i k</w>
i ers</w>
i en</w>
hypox anth
hypoxanth ine-guanine</w>
hypovol aemia</w>
hypos padi
hypoglycaem ia,</w>
hypo thyroidism</w>
hypo activity,</w>
hypertherm ia,</w>
hypercalci uria</w>
hyper aemia</w>
hype reosinophilic</w>
hydr ated</w>
hy prom
hy ponatra
hy d
hyd rous</w>
hung er.</w>
hund red
hun ted</w>
hu is</w>
http://www. eudra
hr úpa</w>
however :</w>
hous es,</w>
hormon es.</w>
hormon es,</w>
horiz on.</w>
hor se
hop ed.</w>
hone y,</w>
homosex ual</w>
homogen e
homocy st
home opathic</w>
hom e-
holid ay.</w>
hol dings</w>
hoarsen ess,</w>
hiv es)</w>
hin der</w>
him ,</w>
high- quality</w>
high -f
hes itation</w>
herpes virus,</w>
her itage</w>
hepat otoxic</w>
hem p</w>
hear ings.</w>
health ?</w>
health -
he w-D3</w>
he re:</w>
he l</w>
he irs</w>
he avi
harvest ing</w>
hard ship.</w>
harbour ing</w>
har d-
har ass
happen s?</w>
happen ed,</w>
han g</w>
ham pered</w>
hal ving</w>
hal of
haemorrhag e.</w>
haemorrha ges
haemodialys is.</w>
haemat uria,</w>
haemat opoietic</w>
haem olytic</w>
habit s.</w>
ha ven
ha ve.</w>
hEor pa</w>
hC G</w>
h r.</w>
h ne</w>
h m</w>
h irudin</w>
h ens</w>
h ate</w>
h as.</w>
h -
h )</w>
gł as
głas zam</w>
gul let</w>
guidel ines,</w>
guarante eing</w>
guarante ed.</w>
gu r</w>
gu inea</w>
gu er</w>
gu anosine</w>
grow er</w>
group )</w>
gro tes
gres sive</w>
great er.</w>
gre n</w>
gras p</w>
graph y</w>
grap h</w>
grap e</w>
granulocyt es</w>
granulocy te</w>
grand mother</w>
gram s.</w>
gradu ates</w>
gradu ally.</w>
gra in</w>
gr in
gr ass</w>
gr ants</w>
govern ment.</w>
gol d,</w>
go s</w>
go ing.</w>
glycer ol</w>
glucose- dependent</w>
glucos e,</w>
glucocortic oid</w>
gluco sidase</w>
glob in</w>
glo be.</w>
glas s.</w>
gl aring</w>
gl ands,</w>
gir l,</w>
ging ival</w>
gi a),</w>
gh .</w>
get ?</w>
gentle men,</w>
genoty pic</w>
gener ous</w>
gener ous.</w>
gener ated</w>
gender -
gen ocide</w>
gen oci
gelat in,</w>
gel atine</w>
gather ing</w>
gastro duodenal</w>
gas es,</w>
ganciclo vir</w>
gamma- glutam
gain ing</w>
g p)</w>
g m</w>
g avel</w>
g ated</w>
g ate
gate way</w>
g arden</w>
g ap
g aller
g ac
furo sem
fur ther
fur n
fung al,</w>
func tions.</w>
fun ds.</w>
ful l,</w>
ful !</w>
fu el,</w>
fru it
fron tal</w>
fro m?</w>
fridg es</w>
fri ends</w>
freed om
fre ely.</w>
fraudul ent</w>
franc s</w>
fr action</w>
fos amprenavir</w>
fos ampren
formul a:</w>
form s.</w>
forefing er;</w>
for k.</w>
footb all
food s.</w>
follow-up :</w>
follow- up.</w>
follow ing,</w>
follow -</w>
fol inate</w>
fol ic</w>
fluoroquinol one</w>
fluoresc ence</w>
fluconaz ole,</w>
flav our</w>
fl ouris
fish ing,</w>
fire -f
finger print
fing er.</w>
financ ially</w>
fin ished,</w>
fin dings,</w>
fin ally,</w>
fin alised</w>
fin alised.</w>
film -</w>
fil ters</w>
figh ts</w>
fig ure.</w>
fiel ds.</w>
fiel d?</w>
fibre s</w>
fi re.</w>
fi re-
fi re,</w>
ff .</w>
fes tival</w>
fertili zation</w>
fer ries</w>
femal es.</w>
feel ing,</w>
feas ible.</w>
feas ible,</w>
favour ite</w>
favour able,</w>
fati gu
farmacev tske</w>
farm s.</w>
farm ed</w>
fall ,</w>
fail ,</w>
fact s.</w>
facil ity,</w>
fac es.</w>
f ür</w>
f y.</w>
f oul</w>
f lowing</w>
f lower</w>
f ?</w>
f )</w>
ez uel
eyel id,</w>
eyel ashes,</w>
extrem ities</w>
expres sly</w>
expor ter</w>
explo si
explo red</w>
explo ited</w>
explo ded</w>
explan ations</w>
explain ed.</w>
experim ents.</w>
experienc e;</w>
expect ed
exp and</w>
exist ed</w>
exist ed.</w>
exist ?</w>
exist ,</w>
exer tional</w>
execu tions</w>
exclus ive</w>
exclus iv
excipi ent</w>
excipi ent.</w>
exc iting</w>
exampl es,</w>
examin ed,</w>
ex or
ex in</w>
ex il
ex hibition</w>
evid ence,</w>
every where</w>
every one's</w>
evalu ations</w>
evalu ation,</w>
evacu ation</w>
ev ic
ev axyn</w>
ev al</w>
ev ,</w>
eth inyl</w>
eth in
et ric</w>
et ce
et 's</w>
esk á</w>
es po
es *</w>
erythropo iet
eric k</w>
erg ot
ere ne.</w>
er ’s</w>
er on</w>
er ly</w>
er i</w>
er a.</w>
er a,</w>
epithel ial</w>
episod es,</w>
epis o
epilepsy )</w>
epilep tic
eph edrine</w>
eosinophil ic</w>
eosinophil ia,</w>
enzym es.</w>
envis age</w>
enti ally</w>
enterpris e</w>
enter ocol
entail s.</w>
ent-to- treat</w>
ent ricular</w>
ensu ing</w>
ensu es,</w>
enough !</w>
endor se</w>
end- of-
end ophthalm
end less</w>
end ?</w>
encourag ed,</w>
enc e)</w>
enalap ril</w>
en tion</w>
en ligh
en demic</w>
en anti
enanti om
en ant</w>
employe es.</w>
employ ment?</w>
emphas ise</w>
emerg ency,</w>
eme tics</w>
eme tic</w>
embolism )</w>
em ia.</w>
ellul ar,</w>
ell schaft</w>
electroly tes</w>
elec tor
elap sed</w>
el oqu
el led,</w>
el ement,</w>
el bo
el as
egal ovirus</w>
effic ac
effectiven ess
effec tively,</w>
effec t?</w>
eff us
ef ruit</w>
ed us
ed mon
ed a</w>
ecosy stems</w>
econom y.</w>
ec ul
ec stasy</w>
ec nologico</w>
earmark ed</w>
earli est</w>
e ’.</w>
e w
e uth
e pl
e iner</w>
e enth</w>
e ast</w>
e ag
e ach,</w>
dyspep si
dysp noea,</w>
dys menorrhea,</w>
dys ge
dynam ic</w>
dy es</w>
dump ed</w>
duct us</w>
du st,</w>
du ous</w>
drop ping</w>
drop per,</w>
drin ks,</w>
drin k.</w>
dre dg
dre am</w>
dras tic</w>
draf ting</w>
dra wn.</w>
down stream</w>
down -
dose- proportional</w>
dose- limiting</w>
dos ages</w>
don ors.</w>
dom ain.</w>
dodeca hydrate,</w>
docum ent,</w>
doctor /
doct ors,</w>
do omed</w>
do ing.</w>
do es,</w>
do es
dizz iness
divis ions</w>
divi ded,</w>
diver sity.</w>
disturb anc
distric ts</w>
distor ted</w>
dist en
dissolv ed.</w>
dissid ents</w>
disput ed,</w>
displac ement</w>
displa ying</w>
dismant ling</w>
diseas e?</w>
diseas e:</w>
discrimin ation.</w>
discrimin ation,</w>
discre d
discipl inary</w>
disc overed,</w>
disappoint ment.</w>
disappoint ed.</w>
disappear ance</w>
disadvant aged</w>
dis closure</w>
dis c</w>
dis arm
dis appears</w>
dis ap
direc tives,</w>
direc tion.</w>
diplom atic</w>
dipl oma</w>
diox ins,</w>
diox ide.</w>
dimin ished</w>
difficul ty,</w>
difficul ties,</w>
differenti ation</w>
diff usion</w>
dict ory</w>
dichloro methane</w>
dialogu e.</w>
dialogu e,</w>
diabe tic,</w>
diabe tic
di lig
di et
di e,</w>
di ast
di alysis,</w>
di a</w>
dexameth as
devic es,</w>
develop ment
develop .</w>
develop ,</w>
detrim ental</w>
deterg ents.</w>
detec ting</w>
desper ate</w>
desir able.</w>
design ed,</w>
deser ves</w>
describ ing</w>
dermati tis.</w>
depart ments</w>
den ying</w>
den .</w>
den ,</w>
demonstr ating</w>
dem ograp
dem ia</w>
dem arc
deliver ing</w>
delet ed.</w>
dele terious</w>
degre e.</w>
defin ed,</w>
defici ent</w>
defen sive</w>
def ending</w>
def ended</w>
def ence.</w>
decompens ated</w>
dec ay</w>
debilit ating</w>
deb ate?</w>
deb ate.</w>
dead ,</w>
de vis
de vastat
de regulation</w>
de ported</w>
de port
de oxy
de javnosti,</w>
de faul
de alk
day /
dat ing</w>
dat a?</w>
dark ening</w>
dang ers.</w>
dang er,</w>
dail y)</w>
da ,</w>
d or</w>
d one
d est</w>
d are</w>
d F
dF d
cz warte
cytar ab
cyclospor ine,</w>
cyclooxygenase- 2</w>
cycle ,</w>
cycl ine</w>
cy totoxic</w>
cy proheptadine</w>
cy ber</w>
custom ers</w>
currenci es.</w>
cur rency,</w>
cur ité</w>
cum enical</w>
cul ture
crush ed.</w>
cross- linking</w>
crop ,</w>
cri me,</w>
credi ble</w>
credi bility.</w>
craz y</w>
cramp s,</w>
cr ying</w>
cr y</w>
cr as
cr an
cov ari
cour ses.</w>
cour age.</w>
countr y;</w>
countr y's</w>
counterfe ited</w>
coun ts.</w>
coun t.</w>
coun t,</w>
cost ing</w>
cosme tics</w>
corpor ation</w>
cor ri
cop ies</w>
coordin ator</w>
convul sion
conven tions</w>
controversi al.</w>
control ?</w>
contrib utory</w>
contraindic ations</w>
contradic t</w>
contract s,</w>
contracep tives.</w>
continu es,</w>
continu ations</w>
contin ent</w>
contamin ation.</w>
consum ing</w>
consult ations</w>
construc tive.</w>
consist ent,</w>
consist ency.</w>
consider ably.</w>
conside red
consi gn
consequenc es?</w>
consequenc es,</w>
consci ous.</w>
conjug ates</w>
conflic ts</w>
confir med,</w>
confidenti al</w>
conf ig
condition s?</w>
condition ing</w>
concep tion</w>
concentr ation,</w>
conc ession</w>
conc ept
con stric
con ferences</w>
compul sor
compu ter,</w>
compromis es</w>
compoun ds,</w>
complic ated.</w>
complain ts,</w>
complain ant,</w>
competi tors.</w>
competi tor</w>
competi tion,</w>
compatibil ities</w>
comparis on,</w>
compa res</w>
comp lied</w>
comp any
commun ist</w>
common ly,</w>
commodi ties</w>
combin ations.</w>
combin ation,</w>
com yc
com position</w>
com position.</w>
com position,</w>
com pos
com ing.</w>
com ial</w>
colon y</w>
collo idal</w>
colleg e</w>
collec tive</w>
collap se,</w>
col on.</w>
col d-
coffe e,</w>
coccidi oid
cobal amin
coast line</w>
coast ,</w>
coagulo pathy</w>
co- administering</w>
co st.</w>
co ol</w>
co ins,</w>
co in</w>
co de.</w>
co de,</w>
co alition</w>
co ach</w>
co .</w>
club s</w>
clott ing)</w>
closu res</w>
closu re,</w>
clon ing,</w>
clin ics</w>
clim b</w>
cle ver</w>
class es.</w>
clas s.</w>
clar ithromycin,</w>
claim s.</w>
cl it
citizen s'</w>
cit rate.</w>
cir cle
cic hew-D3</w>
ci a</w>
chur ches</w>
chron ic
cholin esterase</w>
cholester ol.</w>
cho ro
cho ices</w>
cho a</w>
chlor inated</w>
chlor ide)</w>
chlor ic</w>
children ’s</w>
chil les</w>
chemic al,</w>
chel ating</w>
che e
charg e.</w>
chap ter,</w>
chann elled</w>
chairman ship</w>
ch est,</w>
ch ed.</w>
ch ase</w>
ch as</w>
cere als.</w>
cer amide</w>
centuri es,</w>
cen sored</w>
cellul ose</w>
cell ).</w>
ce il
ce ann</w>
caus ally</w>
cau tious</w>
cathe ter
categor y.</w>
catch- the-
catar act</w>
cat ching</w>
cas pofungin</w>
cas ing</w>
cas cade</w>
carro t</w>
carri er)</w>
carm ine</w>
care s</w>
care rs,</w>
cardi ology</w>
carbox amide</w>
carbamazep ine.</w>
car tel
capsul ar</w>
capsu le,</w>
cap ,</w>
cann ula</w>
canc elled</w>
canc ell
cam era</w>
calicivi rosis,</w>
calcul ation,</w>
calcium- channel</w>
cal ves,</w>
cal f</w>
cab in
ca th
ca ffe
cG MP
c ite</w>
c ession</w>
c enti
c amp
by pass</w>
but toc
but ter</w>
business man</w>
burn t</w>
burn s,</w>
bur i</w>
bul lf
bul let</w>
build ings.</w>
build ings,</w>
build -up</w>
bubbl es,</w>
bu ried</w>
broncho di
bronch iol
broad cast</w>
brief ly</w>
breath lessness</w>
breast- milk</w>
break s,</w>
bre ad,</w>
bradykin in.</w>
brady cardi
br in
bound aries</w>
bottlen ec
bott les,</w>
bor n.</w>
bor n,</w>
book s,</w>
bon es.</w>
bon eme
bomb ers</w>
bo y</w>
bo x,</w>
bo th.</w>
bo at
blow s</w>
blood sh
blood ),</w>
blo w</w>
ble ed,</w>
blam ed</w>
black mail,</w>
bl unt</w>
bl ess
bl ended</w>
biv udine</w>
biotechnolog y.</w>
bio equivalent</w>
bio chemical</w>
billi on,</w>
bi ologically</w>
bever age</w>
beta-1 b.</w>
beta- sympathomimetics,</w>
beta- block
bet ter,</w>
bet ter
bes ide</w>
ber t-
benzodiazep ines.</w>
benz ene</w>
benefici aries</w>
benef iting</w>
ben ign</w>
bel ts</w>
be st
be g</w>
be ef
be aten</w>
be at,</w>
bat ches</w>
bas is?</w>
barri ers</w>
barome ter,</w>
barg ain
ban ana</w>
ban ,</w>
ballo on</w>
balanc e?</w>
bacter ium</w>
bacter icidal</w>
ba thro
b á
b reach</w>
b ond
b on,</w>
b old</w>
b old
b led</w>
b in</w>
b ill</w>
b ands</w>
b and,</w>
b all</w>
b ail
azep ine</w>
az ine</w>
ax is</w>
ax -treated</w>
avail able?</w>
aux -
autom obil
author ized</w>
author ities?</w>
author ised,</w>
aug mentation</w>
aud its</w>
au tions</w>
atten d</w>
att ending</w>
ator vastatin,</w>
ator ies.</w>
atmosphere .</w>
atis m</w>
ati vis
ati de,</w>
ather oscler
ath ing</w>
atenol ol),</w>
ate ur
ate /</w>
at tractive</w>
at tained,</w>
at tain
at ric
at on</w>
at ing?</w>
at acept</w>
asth ma
assess ment
asse ts</w>
asse t.</w>
assass ins</w>
assass in
ass ing</w>
ass ay
aspart ate</w>
as sur
as ser
as phal
as le
as e/
as e)</w>
arrest ed.</w>
arom atised</w>
arian ship</w>
ar vitan</w>
ar ith
ar achno
ar a-
aqu atic</w>
aprepit ant.</w>
aprepit ant,</w>
approach ed</w>
appreci ate</w>
appli es.</w>
appe tite
appe ared,</w>
apolog ised</w>
aplex y</w>
apler min</w>
aphyloc occ
aph ne</w>
apar the
apar t.</w>
ap parent.</w>
antipsycho tics,</w>
antibodi es,</w>
anti- tumour</w>
anti- hypertensive</w>
anti- coagul
anti -f
anter ior</w>
ant s'</w>
ant i</w>
answ er:</w>
answ er,</w>
annum ,</w>
annu ally.</w>
ann ex
anhydro us.</w>
ang er</w>
ang er.</w>
ang ,</w>
andro genic</w>
anc ell
analys es.</w>
analges ic</w>
anaem ia),</w>
an- treated</w>
an y.</w>
an o,</w>
an nex</w>
an ion</w>
an ic</w>
an hydrous</w>
an ese,</w>
an dering</w>
an astom
an a
an '</w>
amput ations</w>
amp edus
amoun t.</w>
amoun t,</w>
amin o-
amin ate</w>
ameth asone</w>
ambul ance</w>
ambiti ous.</w>
am ylase</w>
am ox
am azepine</w>
am az
am ag
altern ating</w>
alter ing</w>
ally -friendly</w>
alloc ated.</w>
allo purin
allerg ies,</w>
alle e</w>
all y?</w>
alk al
alga e</w>
alcohol ism</w>
alcohol ism,</w>
al together.</w>
al s:</w>
al ists.</w>
al bin
al arm</w>
airport .</w>
air -
ain -B
ain-B arré</w>
aim ing</w>
agranulocyt osis,</w>
agg ed</w>
agend a,</w>
ag ri
ag ly-nafarel
ag am</w>
aff orest
advoc ate</w>
advertis ing,</w>
adventi tious</w>
adv ent
adulter ated</w>
adoles cent</w>
adjuv ant
adjust ed.</w>
adju dicated</w>
adi c</w>
adequ ate.</w>
adequ acy</w>
ade ,</w>
ad ribine</w>
ad renocorticotropic</w>
ad or</w>
ad mit</w>
ad ine-
ad a.</w>
activi ties?</w>
activ e,</w>
activ ation.</w>
activ ates</w>
acidi fication</w>
ach t</w>
ach ers</w>
ach ed</w>
acet ate.</w>
acet ate,</w>
accoun table</w>
accoun tability</w>
accommod ation</w>
acces sible.</w>
accept ed,</w>
accep ts</w>
ac ry
ac rony
ac r
ac oxib</w>
ac knowledge</w>
ac ill
ac complic
abund ance</w>
absorp tion,</w>
abor tions.</w>
abor tion.</w>
abnorm ality</w>
able ;</w>
able :</w>
abdom en</w>
abandon ed</w>
abandon ed,</w>
ab used.</w>
ab ras
ab l
a z</w>
a uthen
a ul
a is</w>
a f</w>
a dis
[ 95%</w>
Zev alin</w>
Zeal and</w>
Zar zio</w>
ZOSTAVA X</w>
Z one</w>
Z oledronic</w>
Z erene.</w>
Yugos lavi
Ytrac is</w>
You ,</w>
YYYY }.</w>
Y es.</w>
Y ear
Y arvitan</w>
Y an
Y L-
Y HA
X ,</w>
Wor kers</w>
Win d
Wij senbeek</w>
Who ever</w>
West er
West ,</w>
Wat son</w>
Wat ch</w>
Washing ton</w>
Wa ke</w>
WV16 24
WP ),</w>
W ort</w>
W alter</w>
W T
W ING</w>
W IL
Volib ris</w>
Vojvod ina</w>
Visud yne</w>
Virafer on.</w>
Vir rankosk
Vir g
Vimp at,</w>
Vig ilance</w>
Vic tor</w>
Vic econ
Ver tigo,</w>
Valdox an</w>
VE L</w>
V ia
V and
V an</w>
V aginal</w>
V AC
Un it.</w>
Un ified</w>
Un changed</w>
Un animity</w>
Ukraini ans</w>
Ug anda</w>
Uachtará in,</w>
UVI N</w>
URB AN</w>
UR E</w>
ULN )</w>
UL T
UF H</w>
U se
U S.</w>
U RE
U EN
UEN .</w>
U D</w>
Ty gac
Tut sis</w>
Turke y.</w>
Tun is
Triest e</w>
Tri als</w>
Tredeg ar</w>
Travo prost</w>
Transpa rency</w>
Trans fers</w>
Tran s-European</w>
Tra k</w>
Tr ag
Toxic ology</w>
Tog ether</w>
Tibet an</w>
Thy man
Thir teen</w>
Thin k,</w>
Th ys
Th omas</w>
Th is,</w>
Th ank</w>
Test s</w>
Telecommunic ations</w>
Tel eph
Technolog ical</w>
Tam pe
TRO UVIN</w>
TN FR
TION AL</w>
TIC ).</w>
THER AP
TEX T</w>
TE N
TAIN ING</w>
T ysabri</w>
T ry</w>
T ris
T res</w>
T ou
T ig
T el</w>
T ecnologico</w>
T ax
T at
T T
T ON</w>
T FC
TFC ),</w>
T F
T :</w>
Sé curité</w>
Sy ria</w>
Sw iss</w>
Sus tiva</w>
Sur rey</w>
Supervis or</w>
Sup plement
Suic ide</w>
Su vaxyn</w>
Stre ptococc
Stre et,</w>
Stre am</w>
Stimul ates</w>
Ste p</w>
Stat es'</w>
St or
St and</w>
Spe zialpräparate</w>
Sp in
Sou th.</w>
SoloStar .</w>
Sollentun a</w>
Sol id
Sit u
Single- dose</w>
Sing ulair</w>
Simp son</w>
Sib utramine</w>
Shor t
Sevo flurane</w>
Sever o</w>
Serot onin</w>
Ser ono</w>
Sep pänen</w>
Sel f-
Sec chi</w>
Se a.</w>
Sch rö
Sch nell
Sch mid</w>
Scandin avia</w>
Satur day</w>
Sat ellite</w>
Sar aj
Sanit aire</w>
Salom one</w>
Salam anca</w>
Saint- Priest</w>
Saf e</w>
Sad ly</w>
Sad dam</w>
SWE DI
SWEDI SH</w>
SUSTIV A.</w>
ST OP
ST )</w>
SSRI s</w>
SP C
SI -1
SI-1 000</w>
SE S</w>
SE N</w>
SCH -
SCH- 30
S í
S ä
S v
S unitinib</w>
S per
S mar
S ite</w>
S even
S ens
S eg
S ak
Russi ans</w>
Rotter dam
Rom ano</w>
RoActem ra.</w>
Ro suvastatin</w>
Ro on
Retac rit</w>
Ret apamulin</w>
Res olution</w>
Ren als</w>
Rem eron</w>
Regul ation,</w>
Regre t
Regim en</w>
Reduc tase</w>
Rec ital</w>
Rec ent</w>
Re place</w>
Re memb
Re fer
Re as
Rapporteur :</w>
Rapamun e</w>
Rap port</w>
Rap ilys
Rap id,</w>
Rand zio-
Ra he
RISPERD AL
RI N</w>
RESPON SES</w>
RE GIST
REGIST ER</w>
RAP EX</w>
RA DE
RADE NAME
RADENAME )</w>
R wand
R ix
R ies</w>
R heum
R emission</w>
R arely</w>
R ang
R ain
R X
R P
R 07
R07 64
R0764 7
R07647 7-
R076477- SCH-30
R -</w>
Quad risol</w>
Qu ick
Q Tc</w>
Q R
Py lobactell</w>
Pseud oephedrine</w>
Pru ban</w>
Provi ding</w>
Prot aphane)</w>
Prof essional</w>
Pro test
Pro secut
Presid ency?</w>
Prec autions</w>
Pre ven
Pram ace</w>
Pra vastatin</w>
Pr ague,</w>
Poly vinyl</w>
Pol iovirus</w>
Pol ice</w>
Pol and.</w>
Po oled</w>
Po et
Plat h</w>
Pi edmon
Physici an's</w>
Pharmac ist</w>
Pfi zer,</w>
Peter buri</w>
Pent ofel</w>
Pen n</w>
Peg Intron.</w>
Paul -
Pati ent
Paste urella</w>
Pas sive</w>
Particul arly</w>
Parame ter</w>
Par ties</w>
Par lamentu</w>
Palest ine</w>
Pag et's</w>
PS ORI
PRO MP
PROMP T,</w>
PRE ZI
PR T</w>
PR T)</w>
PI D</w>
PHA N</w>
PFO S</w>
PE R</w>
PE G</w>
PD GF
P  
P ro</w>
P rescrib
P reliminary</w>
P ort</w>
P odru
P is
P ear
P act</w>
P PE-
P OL
P H
P GA</w>
P G</w>
P D)</w>
P B
Oxy globin</w>
Over weight</w>
Other s</w>
Or kney</w>
Or der</w>
Opti Pen</w>
Opin ions</w>
Ombuds man,</w>
Ob vi
OS CE
OR PHAN</w>
OP -1</w>
OME P</w>
O zone</w>
O il</w>
O h,</w>
O głaszam</w>
O choa</w>
O ce
O Y</w>
Nutri tion</w>
Nov a</w>
Notting ham</w>
Nor wegi
Neupop eg</w>
Net work</w>
Neo Spec
Needle- Pro</w>
Need les</w>
Need le</w>
Nas olacrimal</w>
NV 17
NV17 317</w>
NU RIC</w>
NSCL C</w>
NP 22</w>
NH L</w>
NECESSAR Y</w>
NA TIONAL</w>
N- linked</w>
N- acetyl
N oxafil</w>
N ice</w>
N i
N exav
N eves</w>
N espo
N el
N eder
N av
N P)</w>
N MS</w>
N EURO
N =</w>
N +
My coplasma</w>
My an
Mus lim</w>
Mun ich
Mucopolys accharidosis</w>
Mu chas</w>
Mos cow</w>
Montpelli er,</w>
Monsan to</w>
Mon telukast</w>
Mon day,</w>
Moder ate</w>
Mo ha
Mix 50,</w>
Minist ers</w>
Mil ton</w>
Mexic an</w>
Meth adone</w>
Merci er</w>
Merc edes</w>
Men rad</w>
Memb ers,</w>
Memb er.</w>
Med a</w>
Mean while,</w>
Mc Don
Mast er</w>
Mart ine
Mark et
Mar x
Mar se
Mar sa</w>
Mar opitant</w>
Mar ia</w>
Man ch
Macro gol</w>
MS ),</w>
MR A</w>
MET AL
METAL Y
MERI AL,</w>
MED IA</w>
MAR K</w>
MAO Is</w>
MA RA
MA H
MA B
M184 V</w>
M ount</w>
M odi
M ist
M em
M ec
M ax
M ary</w>
M achi
Ly on,</w>
Ly mphaden
Lukash enko</w>
Lopin avir/</w>
Loc ati
Lo ok,</w>
Liver pool</w>
Lithuani an</w>
Lipo atrophy</w>
Lim erick</w>
Liet uvo
Lev od
Lev el</w>
Let 's</w>
Leg is
Le wy</w>
Lam y</w>
Labor atori
La w</w>
La ke</w>
LV AP
LO C
LDL- C</w>
L- Threonine,</w>
L- Gl
L-Gl utamic</w>
L ov
L loy
L ison
L ine</w>
L ife</w>
L ichtenb
L evi
L es
L epirudin</w>
L aw
L ast
L ampedus
L age</w>
L adies</w>
L ack</w>
L ac
L AST
LAST A</w>
L 1</w>
Kyrgy zst
Kwik Pens</w>
Koz lo
Kir khope</w>
Kin shas
Kep ivance</w>
Kar l</w>
KR K
K la
K id
K ha
K ash
K all
K T
K IU/</w>
K IU)</w>
K .</w>
K ,</w>
Jun e,</w>
Johann es
Jean-M ichel</w>
Jacqu es</w>
J ob
J i
J ames</w>
J IC
Isra el,</w>
Iran ,</w>
Ir respective</w>
Invir ase/
Inter val</w>
Integr ation</w>
Insul atard)</w>
Inspec torate</w>
Initi ative</w>
Infra red</w>
Industri el
Individu als</w>
Inc ineration</w>
In tif
In sufficient</w>
In stead</w>
In hibition</w>
In hal
In duc
In dex</w>
Improv ements</w>
Immuno genicity</w>
Im idacloprid</w>
Il legal</w>
Ign orance</w>
Ig G</w>
Ib af
IV AX</w>
IU ,</w>
IT T</w>
IT -
INGREDI ENT
INGREDIENT (S)</w>
IN H</w>
IN .</w>
IL- 2</w>
III -
IGF- I</w>
IC ES</w>
IC E
IC C
I de
I an</w>
I P</w>
Hyper kinesia,</w>
Hydrox y
Hydro chloric</w>
Hy poc
Hut us</w>
Hud son</w>
Hop penstedt</w>
Hol land.</w>
Hist or
Her z
Her bal</w>
Hepat o-biliary</w>
Head ache</w>
He a
Ham burg</w>
Haemophil ia</w>
HO W</w>
HM R</w>
HIV/ A
HIV- positive</w>
HER 2</w>
HD L</w>
HD L-
H ul
H RT</w>
H R</w>
Gul f</w>
Guill ain-Barré</w>
Gu er
Grou p
Gros setê
Gr ö
Gr and</w>
Goog le</w>
Gl uc
Gi an
Ges ellschaft</w>
German y?</w>
Geor gia,</w>
Gen otypic</w>
Gaul le</w>
GF R)</w>
GER MANY</w>
GE RIX</w>
GAD OVIST</w>
G ård
G ron
G reat
G ram
G ot
G org
G hrúpa</w>
G et</w>
G astric</w>
G ab
G V
G P</w>
G MP</w>
G H
Fre ib
Fran çaise</w>
Fr ass
Found ation</w>
Fos av
For ty-
Fon te</w>
Fo etal</w>
First ly:</w>
Fin ance</w>
Fif teen</w>
Fer tility</w>
Fed eration</w>
Fed eral</w>
Febru ary,</w>
Fac ulty</w>
Fabraz yme</w>
Fab lyn</w>
FOLLO WING</w>
FIN-0 22
F-9 2058</w>
F ull</w>
F org
F oc
F lan
F ive</w>
F ill</w>
F evaxyn</w>
F ay
F an
F air
F ail
F VF
F HV</w>
Exub era</w>
Exta vi
Exper t,</w>
Excipi ent:</w>
Exc ise</w>
Europe jskiego</w>
Europe ans,</w>
Europe ana</w>
Europe an-
Euro stat
Euro pa</w>
Euro dac</w>
Eudra Vigilance</w>
Eudra Net</w>
Eston ian</w>
Ery thropoietin</w>
En tecavir</w>
En cephal
Emp loy
Em tri
Em erg
Elev ation</w>
El der
Ein nehmen</w>
Edinbur gh.</w>
Econ or</w>
Earthqu ake</w>
EX P
EV RA
EURO PE
EU/1/99/1 16
EU ’s</w>
EU /
ET OMEP</w>
EN GERIX</w>
EMEA/ MB
EMEA/ CVMP</w>
EM U</w>
EGFR .</w>
EF F
E-2 8750</w>
E vicel</w>
E valu
E ric</w>
E ighty</w>
E cumenical</w>
E chel
E bi
E VISTA</w>
E O
E AS
Dyspep sia</w>
Dys entery</w>
Dut ch,</w>
Drug s</w>
Don ’t</w>
Doc torate</w>
Doc tor</w>
Do y
Dist rib
Dis continuations</w>
Director ates-
Direc teur</w>
Dipl oma</w>
Difficul ty</w>
Did anosine</w>
Dic ural</w>
Di yarbak
Di rek
Di meticone</w>
Dex amethasone</w>
Des irudin</w>
Des ign
Dep ut
Dem oc
Deg arelix</w>
Defin ed</w>
Dec lar
Dec ember,</w>
De ath</w>
Dam asc
Daf iro</w>
DNA -derived</w>
DE PO
D ro
D or
D ip
D imit
D i</w>
D avid</w>
D av
D aphne</w>
D RO
D 23</w>
D 1,</w>
D -2
Cy prus</w>
Cub icin</w>
Cub a</w>
Cryptospor idium</w>
Creutzfeldt- Jak
Cour to
Cour t's</w>
Council ’s</w>
Correc tion</w>
Continu ous</w>
Cont act</w>
Connec t</w>
Con tra-indication</w>
Con junc
Con flic
Con ditional</w>
Commun ities.</w>
Com pens
Col um
Col lect</w>
Cohn -
Cohn- Ben
Cohn-Ben dit</w>
Coel ho</w>
Coc a</w>
Co- A</w>
Co ws</w>
Co administration</w>
Ci vil</w>
Chur ch</w>
Christod oulou</w>
Chine ham,</w>
Chernob yl</w>
Ch est</w>
Ch ech
Ceftriax one</w>
Cat ania</w>
Cardi ff</w>
Carbag lu</w>
Carb amazepine</w>
Cant os,</w>
Can adian</w>
Can ada</w>
Cal le</w>
Cal cichew-D3</w>
CYP3A 4)</w>
CYP2C 8</w>
CRIXIV AN
CR ,</w>
CP C
COMMUN ITY</w>
COM T</w>
COM /
CM L,</w>
CL AS
CLAS SI
CH R</w>
CE N</w>
CE LVAP
C unha</w>
C ruz</w>
C ough
C os
C lockstop</w>
C limate</w>
C itiz
C ir
C astro
C ab
C RE
C J
C HO
C 5-0
Buiten weg</w>
Bu ilding</w>
Brit ain,</w>
Bridi on</w>
Bov ine</w>
Bos nia</w>
Bos nia
Bon viv
Bol ivi
Bo ard.</w>
Bla ir,</w>
Bis hop</w>
Bir g
Betaferon ’).</w>
Bes ides</w>
BeneF IX.</w>
Belgi en</w>
Be ing</w>
Be au
Ban ning</w>
Bacter ial</w>
BR .
B- type</w>
B ö
B ron
B ring</w>
B rac
B ound
B lu
B lack</w>
B inger</w>
B ed
B av
B aden
B V,</w>
B ON
B H
B :</w>
B /</w>
B ).</w>
Ay ala</w>
Av entis</w>
Av andi
Av am
Austri ans</w>
Austri a.</w>
Austral ia.</w>
Aug ust,</w>
Atri ance</w>
Athen s.</w>
At lan
Asi an,</w>
As semb
Arzneimit tel</w>
Arter ial</w>
Ara va</w>
Ar gent
Approxim ate</w>
Applic ants</w>
Ap pendix</w>
Ant acids</w>
Ano rexia</w>
Anim als</w>
An der
All er
Albani ans</w>
Al targo</w>
Al le
Aiv losin</w>
Air bus</w>
Ag ents</w>
Ag ency.</w>
Ag ain
Afghanist an,</w>
Administr ative</w>
Admini ster</w>
Aden omatous</w>
Ad juv
Acti Trak</w>
Acqu ired</w>
Ac tivities</w>
Ac et
Ab sorption</w>
Ab atacept</w>
AVON EX</w>
AS S</w>
AR T</w>
AN TI
AIDS- KS</w>
ADE NURIC</w>
AD UL
AD R</w>
AD P</w>
ACT RAP
ACE -
AB .</w>
A vostart
A min
A gu
A ffec
A VEN
A U</w>
A MED</w>
A IR
A G</w>
A ),</w>
A 's</w>
9. 9
9. 4</w>
9 /9
85 4)</w>
8. 9
8- hydroxy-ibaf
8 6,</w>
8 ,
8 %).</w>
7. 3</w>
7- 16</w>
7 90
7 5-
7 37</w>
7 378
7378 800</w>
7 2%</w>
7 /97)</w>
7 /2000)</w>
66 6</w>
64 3</w>
60 6-10-
606-10- 50</w>
60 ,</w>
6- phosphate</w>
6 70
6 7%</w>
6 5,</w>
6 40</w>
6 38</w>
6 30</w>
6 25</w>
6 21</w>
6 000</w>
6 /2000)</w>
6 ,000</w>
6 %,</w>
6 %).</w>
58 a</w>
58 1,</w>
55 3
50  000</w>
5- F
5'- triphosphate</w>
5'- D
5 ml</w>
5 b</w>
5 80</w>
5 60</w>
5 50</w>
5 4,</w>
5 2%</w>
5 2
5 17</w>
5 -00
5 %
49 600</w>
49 2</w>
49 %.</w>
42 7/</w>
42 1
400 ,</w>
40 %.</w>
4.4 .</w>
4. 7%</w>
4. 7
4-0 4
4- hydroxy
4 9%</w>
4 8,</w>
4 7
4 49</w>
4 25
4 14</w>
4 1
4 -</w>
4 ,5</w>
4 %),</w>
39 7</w>
37 530</w>
37 1</w>
36 .</w>
36 .
35 -
34 ;</w>
300 ,</w>
30 1</w>
3  000</w>
3 27
3 25</w>
3 22</w>
3 %,</w>
2C 8</w>
29 85</w>
28 -day</w>
26 7</w>
26 4</w>
26 49600</w>
25 %,</w>
24 6</w>
230 9/</w>
23 -24</w>
23 ),</w>
21-2 2</w>
200 9,</w>
200 7-
200 5-
200 4
200 3-
200 /</w>
20- week</w>
20 mg</w>
20 5</w>
20 3</w>
20 10
20 %,</w>
2. 9</w>
2. 7%</w>
2. 6%</w>
2. 2%</w>
2- 5</w>
2 ”</w>
2 C,</w>
2 4.
2 3-
2 17</w>
2 15</w>
2 +</w>
1  200</w>
1990 s.</w>
199 7-
199 6,</w>
199 3,</w>
199 1.</w>
198 1</w>
197 8</w>
197 7</w>
197 4,</w>
197 3</w>
197 2</w>
19 70</w>
19 5</w>
19 56</w>
18 9
18 5
17 3</w>
16 5</w>
16 3</w>
15 3</w>
15 3
15 2</w>
15 00</w>
14 7</w>
14 6</w>
14 5</w>
13. 5</w>
13 9
13 7</w>
13 2),</w>
13 .</w>
12- 16</w>
12 2</w>
12 00</w>
12 /</w>
11 a</w>
11 ),</w>
11 %).</w>
100 %,</w>
10 50</w>
10 %.</w>
10 %,</w>
1. 9</w>
1. 6</w>
1. 2</w>
1- 5</w>
1- 4
1  000</w>
1 g</w>
1 E</w>
1 :</w>
1 :
1 19</w>
1 18</w>
00 3/</w>
0.0 8%</w>
0. 22</w>
0. 19</w>
0 9
0 55</w>
0 4</w>
0 35</w>
0 -
0 %,</w>
/200 3,</w>
/ mm
/ kg</w>
/ EEC</w>
/ EC
................................................................ ................................................
.. .'</w>
. ]</w>
. ).</w>
-f il
-M RA
-2 4
------------------------------------------------------------------------------------------------------------------------ ---</w>
- mediated</w>
- enhanced</w>
- 401</w>
- 1,200</w>
- ,</w>
+421 -2-3355</w>
+4 20</w>
+35 6</w>
+35 3</w>
+ 33</w>
* Lipoatrophy</w>
* :</w>
) *,</w>
(valsartan ),</w>
(tummy ),</w>
(n= 6
(n= 28
(hyperglycaem ia)</w>
(dose- normalized)</w>
(antibiotic ),</w>
(abdomen );</w>
(T RADENAME)</w>
(S ee</w>
(S S
(S L)</w>
(S K)</w>
(R P</w>
(P- gp)</w>
(P w)</w>
(P en
(P D
(P CV</w>
(O TFC),</w>
(MRI ).</w>
(M ad
(M TIC).</w>
(Laugh ter</w>
(L oud</w>
(H-0 5
(H-0 16
(F AS
(F ACT
(F 2</w>
(E17 2),</w>
(D MAR
(D ),</w>
(CS F
(CE -MRA
(C OP
(C D
(B NP)</w>
(A5-00 0
(A5-0 36
(A5-0 30
(A5-0 29
(A5-0 14
(A UC
(A ST</w>
(800 -</w>
(800 -1,200</w>
(4 99/</w>
(4 31</w>
(4 3.3</w>
(4 0.1</w>
(37 %</w>
(30 %)</w>
(3 ),</w>
(29. 8</w>
(18 /</w>
(18 %)</w>
(15 %)</w>
(1. 3</w>
(1 1/</w>
(1 ),</w>
(0. 7%</w>
(0. 5%</w>
(0) 89</w>
(0) 21</w>
(0 -
( “</w>
( using</w>
( urticari
( this</w>
( statin
( sp
( range)</w>
( ramipril),</w>
( pneumon
( once</w>
( maintenance</w>
( life-threatening</w>
( kg)</w>
( infected</w>
( ile
( i.e.</w>
( herpes</w>
( heart</w>
( facial</w>
( extremely</w>
( excessive</w>
( erythema</w>
( equal</w>
( eg</w>
( eg,</w>
( continuation</w>
( cancer</w>
( buttock
( both</w>
( benzalkonium</w>
( b
( atenolol),</w>
( assessed</w>
( also</w>
( agranulocyt
( adul
( W
( TNF
( Needles</w>
( Ki
( K
( IB
( ></w>
( 600</w>
( 50
( 5)</w>
( 29
( 20</w>
( 20,000</w>
( 2.5</w>
( 1000</w>
( 100
( +)</w>
' y
' not</w>
' no</w>
' Ode</w>
' No</w>
' In</w>
' I</w>
' H
' EU</w>
" sodium-free".</w>
" .
! "</w>
………… ……
……………… ……</w>
“ How</w>
‘no ’</w>
‘ Women</w>
‘ Week</w>
‘ The</w>
‘ If</w>
φ ι
φι σί
φισί α
φισία ς</w>
ρ ο
ρ ι
θήν α</w>
η φισίας</w>
Λ Λ
Κ ηφισίας</w>
š k
ă lean</w>
ü t
ön n
önn gren</w>
ó ł
éné fice</w>
é s.</w>
é ,</w>
è res</w>
ç o
är d
ärd vägen</w>
â t
á nam
ß- cell</w>
º C</w>
º C.</w>
µg/ week)</w>
µ l</w>
µ g.</w>
µ M,</w>
© EMEA</w>
  2005.</w>
  000,</w>
{fa x</w>
{ tel</w>
{ e-mail</w>
zoon oses</w>
zon es.</w>
zo res</w>
zk y's</w>
zem bow
zalcitab ine)</w>
zal epl
z umab,</w>
z um</w>
z ky</w>
z ia</w>
z el</w>
yt os
yt olu
ysti tis</w>
you ?</w>
you /
you/ your</w>
you !</w>
ym us</w>
ym osis</w>
yl ation.</w>
yl ase,</w>
yiel ds</w>
yel lowing</w>
year s;</w>
year s'</w>
year )</w>
year ).</w>
y  
y ri
y rem</w>
y me,</w>
y es</w>
y clo
y '
xenophob ia</w>
x il
x anth
x /</w>
ww w.
wrong ly</w>
writing( 2).</w>
wrap ped</w>
woun ded</w>
worth y.</w>
worsen .</w>
worry ing,</w>
worl d?</w>
wor t,</w>
wood en</w>
won ders</w>
women ?</w>
wom b)</w>
wn ?</w>
wn -
witness ed</w>
withdraw als</w>
with standing</w>
winter .</w>
wine- based</w>
wind pipe</w>
win ning</w>
win d,</w>
wild life</w>
wild -type</w>
wiki pedi
wikipedi a.
wikipedia. org/
wikipedia.org/ wiki
wikipedia.org/wiki /
wi reless</w>
wi pe</w>
where as,</w>
where ?</w>
whe el</w>
whe at,</w>
whatso ever.</w>
wh iti
whiti sh</w>
wh ichever</w>
wh at,</w>
well :</w>
wel f
welf are.</w>
weight ).</w>
weal thy</w>
weakness es.</w>
wea ther
we ar
was :</w>
warn ing,</w>
warfar in.</w>
war s</w>
war s.</w>
war rants</w>
war n</w>
walk ing,</w>
wal ked</w>
wal d
wald allee</w>
wa iv
w rot
w rist</w>
w ives</w>
w ic
w ery</w>
w andering</w>
w alle
w ages</w>
w '</w>
vot es:</w>
vom it,</w>
volunte er</w>
volt age</w>
vo y
vo ke</w>
vniec ī</w>
vit al.</w>
vision )</w>
vis ion.</w>
virus -like</w>
virus -1</w>
vir .</w>
viol ent,</w>
videocon ferenc
videoconferenc ing</w>
victim s.</w>
victim .</w>
vic e-
vial ;</w>
vi x</w>
vi ra
vi e</w>
vi ability</w>
veterin arian</w>
vet 's</w>
vess els.</w>
vesic les</w>
ves tite</w>
vertebra e</w>
ver sion,</w>
venti lat
ven lafax
veget ab
ve to</w>
vasoconstric tion</w>
vas ive</w>
varic elli
varicelli form</w>
vari ed</w>
van ity</w>
value ”</w>
vals art
valpro ate.</w>
val ’.</w>
val idity</w>
vag ina,</w>
vacc ine)</w>
v on-
von- Be
von-Be hring
v oid
v inc
v ex.</w>
v end
v ation.</w>
v ain.</w>
v ):</w>
ut ure</w>
ut terly</w>
ut ter</w>
usu al,</w>
ust .</w>
ush ing</w>
ush .</w>
useful .</w>
use ),</w>
us z</w>
us sa
us ing.</w>
us ia</w>
us er
user -friend
us ei
us ed:</w>
us ;</w>
us -
uri fied</w>
urg ,</w>
ureth ral</w>
ureth ane</w>
ure ase</w>
ure ?</w>
ure )</w>
ur ine;</w>
ur in</w>
ur in
ur ate</w>
up s</w>
up p
unit -dose</w>
unequ iv
unequiv ocal</w>
unemploy ed.</w>
undertak ing.</w>
understo od,</w>
understand ,</w>
under went</w>
under mine</w>
under developed</w>
und i</w>
uncertain ty,</w>
uncertain .</w>
unavoid able.</w>
un willingness</w>
un well,</w>
un usually</w>
un think
un sustainable</w>
un solic
unsolic ited</w>
un sch
un reported</w>
un reliable.</w>
un like</w>
un le
un justified.</w>
un identified</w>
un for
un er</w>
un employed</w>
un des
un common
un clear.</w>
un authorised</w>
un answered</w>
un accompanied</w>
un acceptable
ump teenth</w>
umbrel la</w>
umbil ical</w>
um ulative</w>
um alin</w>
um :</w>
um ),</w>
um '</w>
ultim ate</w>
ulcer s,</w>
ul ties</w>
uk ov
uk oral</w>
ugin one</w>
udi ce</w>
ud .</w>
uctu ations</w>
uc id
u x
u tili
u ous</w>
u k</w>
u ght</w>
u de.</w>
u a</w>
tyros inemia</w>
typ es,</w>
ty losin</w>
ty -f
ty-f our</w>
two- way</w>
twist ing</w>
tw ist</w>
tw ice-
twice- daily</w>
tw er
twer p</w>
turn .</w>
tur ke
tuoteinfo@gsk .</w>
tun nel.</w>
tumour s.</w>
tubulo path
tub ing.</w>
tt l</w>
trypt oph
truc ks</w>
tros copy</w>
tris odium</w>
trim ox
trim ers,</w>
trib un
triazol am)</w>
tri vi
treat s</w>
tre s
tre otide</w>
tre n</w>
tre mb
tre hal
tre es,</w>
transpl ants</w>
transl ate</w>
transit .</w>
transfus ions</w>
transfer s,</w>
transfer ase,</w>
transfer ,</w>
trans national</w>
trans lat
trans formation</w>
trans -f
trans -
track ed</w>
trac ks</w>
tra u
tra il</w>
tr um
tr ick</w>
tr alising</w>
tr act,</w>
toxic ological</w>
toxic ities.</w>
touris m,</w>
tot alled</w>
tot al.</w>
torem ifene</w>
tor sional</w>
topoisomer ase-
topoisomerase- I,</w>
top ho
topho retic</w>
top .</w>
tonn age</w>
ton e.</w>
tomor row</w>
tom y.</w>
toler ated;</w>
tol izumab</w>
tol it
tok en,</w>
toil et</w>
today 's</w>
toc oph
tocoph erol</w>
toc ida,</w>
tobacc o.</w>
to y</w>
to ols.</w>
to o?</w>
tiv e)</w>
titr ation.</w>
tion s)</w>
tion ed.</w>
tion '.</w>
tinnit us</w>
timetable ?</w>
time- action</w>
time tables</w>
time frame</w>
tilit y.</w>
til ting</w>
tigh tening</w>
tigh tened</w>
tigh t
tic s:</w>
tic kets</w>
tic ip
tic ally.</w>
ti tre
ti sm.</w>
ti sh,</w>
ti r</w>
ti of
ti gious</w>
ti ero</w>
ti e</w>
ti b
ti an</w>
ti a</w>
thyroidism §,</w>
thum ber
thrombocy th
thrombocyth aemia</w>
thromb us</w>
thromb osis.</w>
thro ats</w>
thresh olds</w>
threat ens</w>
thre w</w>
thr ush
tho rough
third- country</w>
thir ty-
thir teen</w>
thir sty</w>
thigh ,</w>
there fore.</w>
there !</w>
themsel v
them e</w>
them ;</w>
the ory</w>
the ories</w>
the ophylline</w>
the ft</w>
the f
the .</w>
thaw ing</w>
thalidom ide</w>
thalidom ide.</w>
th us,</w>
th aw</w>
test s)</w>
test oster
territor y.</w>
terri ble.</w>
ter s:</w>
ter in
ter )</w>
tenofovir /</w>
tenecteplas e.</w>
tend s</w>
tend ons</w>
ten sion,</w>
tempor ary.</w>
tempor al</w>
temperat ure
tem plates</w>
ted ness</w>
techno cratic</w>
tec h</w>
te tra
te e
te as
teas po
taxpay ers</w>
tax es,</w>
tas k
tartr ate)</w>
tar ry</w>
tank s,</w>
tank er</w>
tane ously,</w>
tan ning</w>
tam ide,</w>
tal k
tal c
take- up</w>
tain ted</w>
tail or-
tailor- made</w>
tail o
tailo red</w>
tachycardi a,</w>
tablet ter</w>
table t,</w>
tab o
tab les.</w>
ta í</w>
ta ught</w>
ta is</w>
t ö
t wit
t ures.</w>
t ough
t one</w>
t ner
t ents</w>
t ed;</w>
t c
t ari
t all</w>
t agging</w>
system atically.</w>
system )</w>
syring es.</w>
syring e:</w>
synon ym
syno vial</w>
symptom s).</w>
symbol ised</w>
sy st
syst olic</w>
swir ling</w>
swe ets.</w>
sw ift</w>
sust ain</w>
suspic ion.</w>
suspen ded,</w>
surviv ed.</w>
surveill ance,</w>
surgery :</w>
surger ies</w>
surg eries,</w>
surg ence</w>
surf ing</w>
sur ro
surro gate</w>
sur passed</w>
sur -C
sur-C is
supran ational</w>
supplement ed</w>
suppl y,</w>
supp ose</w>
sup pur
suppur ative</w>
sup ply.</w>
sun k</w>
sun di</w>
sun burn</w>
summit ,</w>
summari zed</w>
sulphonam ides.</w>
sulphon amide</w>
sulfonyl urea</w>
sulf ate,</w>
sul fin
sulfin pyraz
sulfinpyraz one</w>
suit case</w>
suit ability</w>
suggest ed,</w>
sugges tions</w>
suffici ently.</w>
suffer ing.</w>
suffer ing,</w>
sucro se</w>
sucro se
success or</w>
succe ed,</w>
substanc es
submit ted.</w>
subjec t.</w>
sub- Saharan</w>
sub type,</w>
sub sist
subsist ence</w>
sub mitting</w>
sub group,</w>
sub f
subf ove
subfove al</w>
sub contract
su ria,</w>
su r</w>
su ffic
styl es</w>
stud ents.</w>
strug gl
structur ing</w>
struc tive</w>
strong er.</w>
stro ke,</w>
stres s.</w>
stres s,</w>
streptococc al</w>
strength ening</w>
stre ets.</w>
stre ams</w>
stre am.</w>
strat um</w>
strains) ........................
strain)................................ .....</w>
strain)................................ ......</w>
strain) 4</w>
str ada</w>
storm s</w>
stop p
ston ing</w>
ston ed</w>
stomach )</w>
stock s,</w>
sto res</w>
sto ol
stool );</w>
sto l</w>
stipul ates</w>
sting ing,</w>
stimul i</w>
stimul ation.</w>
stil l.</w>
stic k
sti r
stere oty
ster s.</w>
step s?</w>
step s,</w>
stear yl</w>
stear ate</w>
ste rec
ste p,</w>
ste kinumab</w>
ste at
ste am</w>
stay ed</w>
stav udine,</w>
state- of-the-
stat utory</w>
stat in.</w>
stat es.</w>
stat ement?</w>
star vation</w>
star ting.</w>
star t?</w>
star t.</w>
standard s.</w>
stand ing,</w>
stand ard.</w>
stand .</w>
stag es,</w>
stag e?</w>
sta y,</w>
st oring</w>
st ok
st o</w>
st ations,</w>
st ated.</w>
squeez ed</w>
spra yed</w>
spra y,</w>
spots §</w>
spot ting</w>
sport sman</w>
spo il</w>
spir onolact
spir it.</w>
spir al</w>
spill age.</w>
speech ,</w>
specul ators</w>
spectac les</w>
specim ens</w>
specific ation</w>
specifi ed,</w>
speci es-
speci es*</w>
speci alising</w>
speci alis
speak .</w>
spas ms,</w>
spark ling</w>
spar floxacin</w>
sp ut
sp p
spp .,</w>
sp iro
sp ira</w>
sp ill</w>
sp ark</w>
sp an
sourc es.</w>
sourc e,</w>
sou l</w>
sores ],</w>
sorbit an</w>
sor ivudine</w>
sophistic ated</w>
soon er</w>
son ia</w>
somno graphy</w>
somnambul ism,</w>
some times,</w>
some thing,</w>
somat ostatin</w>
som nia,</w>
som e.</w>
som atic</w>
solidar ity.</w>
solem n</w>
sol ving</w>
sol ub
sol id.</w>
sof t,</w>
societ y?</w>
so ws</w>
so il.</w>
so far</w>
so comial</w>
smuggl ing</w>
smok es</w>
smo o
smil e</w>
small -
sm ell
sm acks</w>
slow .</w>
sleep ,</w>
sle eve</w>
slaughte red.</w>
slaughte red,</w>
sl urred</w>
sit u</w>
sit tac
sion ?</w>
single- dose)</w>
sing le,</w>
sinc e,</w>
sin ce
simpli fied,</w>
sildenaf il.</w>
sil ent.</w>
sign s,</w>
siglit az
sigh ted</w>
sigh t.</w>
sigh t,</w>
side ;</w>
si vity</w>
si del
si ded</w>
show ,</w>
shoul der</w>
shoul der.</w>
shoul d.</w>
shor tening</w>
shoot ing</w>
shock ing.</w>
shoc ks</w>
ship ped</w>
ship ments</w>
sheep .</w>
sha v
sha res</w>
sha m
sha k
sh uff
sh rim
sh ing
sh ed
sh at
sh allow</w>
sex es</w>
sex .</w>
severe );</w>
sevent y</w>
sett le
session s.</w>
servic es,</w>
serv ation</w>
ser otypes</w>
ser og
serog rou
serogrou p</w>
sequ el
sep tic
sentenc es.</w>
sent ence.</w>
sensi ti
sens ory</w>
sens ations,</w>
sen tim
sen ic</w>
sen ,</w>
semi- synthetic</w>
sell ers</w>
self- criticism</w>
sel fish
sel dom</w>
seiz ure,</w>
seiz ure
seiz ed,</w>
see ks</w>
sed entary</w>
secret ?</w>
second- generation</w>
secon d,</w>
sec ution</w>
sec urity,</w>
sec urely</w>
sec ured</w>
seas ons</w>
seas onal</w>
se y</w>
se v):</w>
se tamide,</w>
se e.</w>
se at.</w>
se al
se a-
scrip ted</w>
scoli osis.</w>
sco re.</w>
scienti sts.</w>
sci ence.</w>
schizophren ia.</w>
sceptic ism</w>
scenari o</w>
scar red</w>
scapego at.</w>
scand al</w>
scal es</w>
scal e).</w>
sc i</w>
satur ation</w>
satisfactor y.</w>
satis fy</w>
san it
salmon .</w>
saliv a,</w>
salicyl ates</w>
sal ts.</w>
sal meter
salmeter ol</w>
sain t</w>
sa- Ts
sa-Ts ag
sa-Tsag ar
sa-Tsagar op
s.r. o</w>
s.r. o.</w>
s- related</w>
s- (
s ”.</w>
s ’,</w>
s é</w>
s ound
s ough
s ong</w>
s nap</w>
s lide</w>
s ink</w>
s ing,</w>
s ent.</w>
s cent
s ake,</w>
s A</w>
s ..</w>
s 's</w>
rumin ant</w>
rum ours</w>
ru st
rst ā</w>
roy al</w>
row ing.</w>
rout ine.</w>
rout es.</w>
roun d
